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Abstract	  Inefficient	  intracellular	  drug	  delivery	  is	  a	  significant	  limiting	  factor	  to	  success	  in	  cancer	   therapeutics.	   Photochemical	   internalisation	   (PCI)	   utilises	   the	  fundamental	   principles	   of	   photodynamic	   therapy	   (PDT):	   photosensitiser	   plus	  light	   and	   oxygen,	   at	   sub-­‐lethal	   level	   to	   facilitate	   targeted	   intracellular	   drug	  delivery.	   This	   effect	   is	  mediated	   by	   reactive	   oxygen	   species	   (ROS).	   This	   thesis	  investigates	   the	   mechanisms	   underpinning	   sulfonated	   meso-­‐tetraphenylporphine	   (TPPS2a)	   mediated	   PCI	   to	   enhance	   the	   delivery	   of	   two	  cytotoxins,	  saporin	  or	  mitoxantrone,	  and	  a	  novel	  Small	  Molecule	  Carrier	  (SMoC)	  
in	  vitro.	  PCI	  of	  saporin	  was	  also	  assessed	  in	  a	  3D-­‐tumour	  model.	  	  
In	   vitro	   experiments	   using	   4T1	   murine	   breast	   adenocarcinoma	   cells	   were	  performed	  to	  investigate	  which	  factors	  determined	  the	  likelihood	  of	  PDT	  versus	  PCI	  predominant	  cytotoxicity.	  The	  role	  of	  the	  intracellular	  REDOX	  environment	  in	   PDT/PCI	  was	   assessed	   using	   a	   free	   radical	   potentiator	   and	   quenchers.	   The	  results	  suggested	  that	  the	  localisation	  and	  total	  amount	  of	  ROS	  produced	  exerts	  the	  greatest	   influence	  in	  determining	  the	   likelihood	  of	  PDT	  versus	  PCI	   induced	  cell	  kill.	  In	  addition,	  PCI	  further	  enhanced	  SMoC-­‐aided	  delivery	  of	  siRNA	  in	  MCF7	  human	  breast	  cancer	  cells.	  	  A	   compressed	   collagen	   scaffold,	   embedded	   with	   4T1	   cells,	   was	   used	   to	  investigate	  TPPS2a-­‐mediated	  PCI	  of	  saporin	  in	  a	  3D	  tumour	  model.	   	  The	  results	  indicated	  that	  a	  3D-­‐model	  is	  potentially	  a	  useful	  tool	  for	  pre-­‐clinical	  assessment	  of	  PCI.	  	  Bioluminescent	   PDT	   studies	   were	   also	   carried	   out	   on	   MCF7	   cells	   transduced	  with	   luciferase	   and	   the	   4T1-­‐luc2	   cell	   line,	   which	   is	   stably	   transfected	   with	  luciferase.	   These	   studies	   demonstrated	   that	   bioluminescence	   can	   be	   used	   to	  activate	  a	  photosensitiser	  for	  a	  cytotoxic	  effect	  (PDT).	  	  Overall,	  this	  thesis	  demonstrated	  that	  by	  further	  understanding	  the	  mechanisms	  that	  underpin	  PCI	  it	  is	  possible	  to	  further	  enhance	  its	  facilitative	  effects	  for	  drug	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1.1	  HISTORY	  OF	  PHOTOSENSITISERS	  AND	  PHOTODYNAMIC	  THERAPY.	  Photodynamic	   therapy	   (PDT)	   is	   a	   cytotoxic	   treatment	   modality,	   which	   is	  dependent	   on	   the	   presence	   of	   a	   photosensitiser,	   molecular	   oxygen	   and	   light.	  Under	  such	  conditions	  reactive	  oxygen	  species	  are	  generated(1),	  which	  in	  a	  time	  and	   distance	   dependent	   manner	   can	   cause	   localised	   damage	   to	   cellular	  organelles	  resulting	  in	  irreparable	  damage	  and	  cell	  death(2).	  	  The	  medicinal	  use	  of	  photosensitive	  compounds	  can	  trace	  their	  origins	  back	  to	  ancient	   Egyptian	   and	   Indian	   civilizations	   for	   the	   treatment	   of	   simple	  dermatological	   complaints.	   The	   turn	   of	   the	   century	   saw	   the	   pioneering	   work	  performed	   by	   Niels	   Finsen	   on	   the	   use	   of	   red-­‐light	   and	   UV	   exposure	   for	   the	  treatment	  of	  smallpox	  pustules(3)	  and	  cutaneous	   tuberculosis(4),	   respectively.	  Finsen’s	  work	  ushered	  in	  the	  era	  of	  modern	  light	  therapy,	  and,	  in	  1903,	  his	  work	  on	  the	   ’therapeutic	  use	  of	  concentrated	   light’	  was	  awarded	  the	  Nobel	  Prize	   for	  Physiology	   or	   Medicine.	   Subsequently,	   the	   discovery	   of	   the	   toxic	   effects	   of	  photosensitising	  dyes,	  such	  as	  eosin,	  by	  Raab	  and	  von	  Tappeiner	  led	  to	  a	  clinical	  trial	   using	   1%	   eosin	   (topical)	   +/-­‐	   light	   on	   6	   patients	   with	   skin	   carcinoma.	   4	  patients	   showed	   evidence	   of	   tumour	   resolution	   at	   12	   months(5).	   In	   1907,	  following	  work	  by	  von	  Tappeiner	  and	  Jodlbauer	  the	  term	  ‘photodynamic	  action’	  was	  first	  coined.	  	  	  The	   discovery	   of	   the	   photosensitising	   properties	   of	   the	   porphyrin-­‐based	  compounds	   marked	   an	   important	   step	   in	   the	   development	   of	   modern	   day	  photosensitisers	  and	  PDT.	  	  In	  1911,	  W.	  Hausmann	  described	  the	  photosensitive	  and	   phototoxic	   effects	   of	   haematoporphyrin	   on	   the	   skin	   of	   mice	   following	  exposure	   to	   light(6).	   Porphyrins	   are	   the	  main	   precursors	   of	   haem,	  which	   is	   a	  vital	   component	   of	   naturally	   occurring	   structural	   and	   enzymatic	   proteins	  including	   haemoglobin,	   myoglobin,	   catalase	   and	   the	   P450	   liver	   cytochromes.	  Clinically,	   the	   disordered	   synthesis/metabolism	   of	   haemoglobin	   can	   result	   in	  porphyria,	  a	  group	  of	  diseases	  that	  can	  affect	  multiple	  organ	  systems	  including	  liver,	  heart	  and	  skin.	   Interestingly,	   acute	  attacks	  of	  porphyria	   can	  be	   triggered	  by	  excessive	  exposure	  to	  sunlight.	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Porphyrins	   comprise	   a	   porphine	   tetrapyrrolic	   structure	  based	  on	   four	  pyrrole	  rings	   connected	   in	   most	   cases	   by	   one-­‐carbon	   bridges	   in	   a	   cyclical	  configuration(4),	   and	   often	   with	   central	   metal	   coordination	   such	   as	   iron	   in	  haem.	   In	   1913,	   Friedrich	   Mayer-­‐Betz	   applied	   haematoporphyrin,	   topically,	   on	  his	  own	  skin(7).	  Following	   light	  exposure	  he	  observed	  swelling	  and	  pain.	  This	  work	  also	  demonstrated	   the	   selective	  properties	  of	  PDT,	  as	   the	  photo-­‐induced	  dermatological	  reactions	  were	  restricted	  to	  light-­‐exposed	  areas.	  	  	  In	  1955,	  crude	  haematoporphyrin	  was	  purified	  by	  Schwartz	  et	  al.	  (8)	  into	  a	  form	  named	   ‘haematoporphyrin-­‐derivative’	   (HpD).	   Richard	   Lipson	   and	   colleagues,	  based	   at	   the	   Mayo	   Clinic,	   used	   HpD	   in	   a	   range	   of	   studies	   that	   heralded	   the	  modern	   era	   of	   PDT,	   for	   example	   the	   use	   of	   HpD	   to	   image	   tumours(9).	  Independent	   in	   vivo	   studies	   by	   Dougherty	   and	   Kelly	   in	   1975	   showed	   the	  translational	  potential	  of	  PDT	  by	  demonstrating	   the	  antitumor	  efficacy	  of	  HpD	  plus	   red-­‐light(10,	   11).	   Kelly	   and	   colleagues	   would	   subsequently	   commence	  clinical	   trials	   in	   humans	   using	   HpD-­‐based	   PDT	   to	   treat	   bladder	   cancer(12).	  Further	   development	   and	   purification	   of	   HpD	   resulted	   in	   the	   synthesis	   of	  Photofrin®	   (Porfimer	   sodium),	  which,	   in	   1993,	  was	   approved	   for	   treatment	   of	  bladder	  cancer	   in	  Canada(2).	  This	   followed	  decades	  of	  research	  into	  the	  use	  of	  PDT	   to	   treat,	   often	   advanced-­‐stage,	   cancers	   including	   oesophageal(13)	   and	  gastric	  (14)	  carcinomas.	  Despite	  its	  approval	  for	  use	  in	  humans,	  Photofrin®	  was	  found	   to	  have	  a	  number	  of	   limitations	   that	  have	  stifled	   its	  use.	  Firstly,	  being	  a	  mixture	   of	   monomers,	   dimers	   and	   oligomers(15)	   it	   is	   difficult	   to	   synthesize	  identical	   batches	   of	   Photofrin®.	   In	   addition,	   the	   relatively	   low	   extinction	  coefficient	   (ε)	   at	   the	   red	   end	   of	   the	   spectrum,	   which	   limits	   tissue	  penetration(16),	  and	  prolonged	  photosensitivity	  have	  further	  limited	  its	  clinical	  application(2).	  However,	  the	  potential	  benefits	  of	  PDT	  within	  the	  clinical	  sphere,	  for	  example,	  the	  potential	  for	  repeated	  exposure	  to	  non-­‐ionising	  light	  confers	  a	  theoretically	   protective	   effect	   on	   tissue	   surrounding	   a	   lesion	   compared	   to	  radiotherapy(17).	  	  	  Nevertheless,	  the	  need	  for	  more	  suitable	  agents	  for	  clinical	  application	  resulted	  in	   the	   development	   of	   the	   so-­‐called	   second-­‐generation	   photosensitisers	   based	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on	   porphyrin/chlorophyll	   analogues	   such	   as	   chlorins,	   bacteriochlorins	   and	  phthalocyanines	  within	  the	  basic	  structure.	  The	  second-­‐generation	  agents	  were	  designed	   to	  exhibit	  greater	  absorbance	   in	   the	  red-­‐spectrum	  for	  example	  meso-­‐tetrahydroxyphenyl	  chlorin	  (652	  nm)	  and	  sulfonated	  aluminium	  phthalocyanine	  (675	   nm)(2),	   enhanced	   tumour	   selectivity,	   reduced	   skin	   photosensitivity	   and	  increased	   chemical	   purity.	   The	   development	   of	   these	   agents	   has	   been	   the	  catalyst	  for	  the	  increased	  investigation	  into	  PDT	  within	  the	  last	  twenty	  years.	  	  	  Both	  the	  first	  and	  second	  generation	  photosensitisers	  have	  representation,	  albeit	  limited,	  within	  the	  clinical	  arena.	  Despite	  the	  highlighted	  limitations	  of	  Photofrin®,	  it	  is	  currently	  licensed	  in	  Canada,	  Japan	  and	  the	  USA	  for	  the	  treatment	  of	  both	  premalignant	  (Barrett's	  oesophagus)	  and	  malignant	  (bladder	  and	  lung	  cancer)	  lesions.	  	  	  Visudyne®	  (benzoporphyrin	  derivative	  monoacid/verteporfin)	  is	  a	  newer	  porphyrin-­‐based	  photosensitiser	  that	  is	  licensed	  for	  the	  treatment	  of	  wet	  macular	  degeneration	  (a	  not	  uncommon	  cause	  of	  significant	  visual	  impairment	  in	  the	  elderly	  population)	  in	  the	  USA,	  Canada,	  European	  Union	  (2000)	  and	  Japan	  (2003).	  Verteporfin	  benefits	  from	  a	  red-­‐shifted	  absorption	  peak	  at	  689	  nm	  wavelength(18)	  enabling	  better	  tissue	  penetration	  of	  the	  photosensitiser-­‐activating	  laser.	  It	  has	  been	  found	  to	  cause	  selective	  damage	  to	  neovascular	  endothelial	  cells	  found	  in	  choroidal	  vessels.	  This	  results	  in	  thrombosis	  and	  the	  occlusion	  of	  subfoveal	  lesions	  patients	  with	  age-­‐related	  macular	  degeneration.	  This	  example	  is	  particular	  important	  as	  it	  demonstrates	  the	  versatility	  of	  PDT	  as	  a	  treatment	  modality	  for	  non-­‐malignant	  lesion.	  	  m-­‐THPC	  (Foscan®)	  is	  a	  chlorin	  based	  photosensitiser	  that	  is	  licensed	  within	  the	  European	  Union	  for	  the	  palliative	  treatment	  of	  Head	  &	  Neck	  Squamous	  cell	  carcinoma(19).	  Foscan	  is	  given	  by	  intravenous	  injection	  prior	  to	  laser	  treatment	  (652	  nm)(2)	  and	  was	  licensed	  due	  to	  its	  beneficial	  effects	  on	  patient	  morbidity	  (28	  (22%)	  of	  128	  patients	  assessed	  in	  a	  study	  found	  that	  treatment	  with	  foscan	  significantly	  improved	  their	  most	  troubling	  symptom	  in	  addition	  to	  approximately	  1	  in	  5	  patients	  experiencing	  a	  reduction	  in	  tumour	  size)(19).	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Sulfonated	  Aluminium	  Phthalocyanine	  (AlPcS2a)	  is	  currently	  licensed	  in	  Russia	  (2001)	  for	  the	  treatment	  of	  various	  malignant	  tumours	  (Photosense®)(2).	  Despite	  demonstrating	  good	  red-­‐shifted	  light	  absorption	  at	  670	  nm	  wavelength,	  the	  use	  of	  this	  photosensitiser	  has	  mainly	  been	  limited	  to	  preclinical	  studies(20).	  In	  addition,	  owing	  to	  a	  the	  large	  number	  of	  isomers	  formed	  during	  its	  synthesis	  AlPcS2a	  has	  an	  unfortunate	  relatively	  high	  level	  of	  batch	  to	  batch	  variation(21,	  22),	  which	  has	  contributed	  to	  stifling	  its	  use	  beyond	  pre-­‐clinical	  applications.	  	  The	  development	  of	  new	  photosensitisers	  over	  the	  past	  20	  years	  has	  resulted	  in	  the	   development	   of	   a	   range	   of	   amphiphilic	   compounds,	   which	   owing	   to	   the	  presence	  of	  1-­‐2	  carboxyl	  groups	  on	  the	  side	  of	  the	  compound	  enable	  it	  to	  retain	  enough	   hydrophobicity	   to	   facilitate	   penetration	   of	   the	   cell	  membrane(20,	   23).	  This	  confers	  three	  advantages	  as	  described	  by	  Berg	  et	  al.	  (2011)(20):	  1. Sufficient	  solubility	  in	  biocompatible	  solutions.	  2. Good	   cell	  membrane	   penetrability	   secondary	   to	   the	   relatively	   high	   pKa	  values	  generated	  by	  the	  carboxyl	  groups.	  3. Intercalation	   within	   phospholipid	   membranes	   where	   the	   life-­‐time	   and	  cytotoxicity	  of	  singlet	  oxygen	  is	  enhanced,	  compared	  to	  aqueous	  solution.	  Another	  strategy	  that	  is	  of	  particular	  importance	  to	  PCI	  is	  the	  substitution	  of	  carboxyl	  groups	  with	  sulfonate	  groups.	  This	  reduces	  the	  penetrating	  potential	  of	  photosensitisers	  across	  a	  cell	  membrane,	  particularly	  when	  2	  sulfonate	  groups	  are	  present(24);	  and	  the	  associated	  low	  pKa	  of	  the	  sulfonate	  groups	  prevents	  protonation	  of	  the	  compounds	  even	  in	  acidic	  environments	  such	  as	  lysosomes(20).	  Consequently,	  disulfonated	  photosensitisers	  including	  AlPcS2a	  and	  disulfonated	  tetraphenylprophin	  (TPPS2a)	  the	  latter	  is	  the	  main	  photosensitiser	  used	  in	  this	  thesis,	  are	  taken	  up	  by	  adsorptive	  endocytosis	  and	  reside	  within	  the	  inner	  leaflet	  of	  endocytic	  vesicles	  making	  them	  potentially	  suitable	  for	  photochemical	  internalisation	  (PCI)(20).	  Other	  chemical	  modifications	  have	  been	  made	  to	  photosensitisers	  to	  enhance	  their	  suitability	  for	  clinical	  application.	  For	  example,	  the	  development	  of	  nanoformulations,	  which	  has	  been	  particularly	  useful	  with	  verteporfin	  that	  is	  complexed	  with	  liposomes	  to	  improve	  cellular	  uptake.	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1.2	  CHALLENGES	  ASSOCIATED	  WITH	  DRUG	  DELIVERY	  The	   bulk	   of	   conventional	   chemotherapeutic	   agents,	   such	   as	   taxanes	   and	  alkylating	   agents,	   exert	   their	   cytotoxic	   effects	   by	   gaining	   access	   to	   DNA	   in	   a	  replication-­‐selective	   manner	   and	   this	   requires	   access	   to	   the	   cytosol(25).	  Endocytosis	   is	   a	   cellular	   uptake	   process	   whereby	   mammalian	   cells	   can	  internalise	  hydrophilic	  molecules	  larger	  than	  1	  kDa	  (fig.	  1.1a)(26).	  Endocytosis	  initiates	   with	   interaction,	   including	   cell	   surface	   receptors,	   between	   the	   cell	  membrane	   and	   the	   molecule	   to	   be	   internalised.	   Consequently,	   there	   is	  invagination	   of	   the	   phospholipid	   membrane	   of	   the	   cell	   and	   subsequent	  formation	  of	  endocytic	  vesicles(27).	  In	  order	  for	  a	  therapeutic	  cytotoxin	  to	  reach	  its	  final	   intracellular	  target,	   it	  must	   ‘escape’	  from	  these	  vesicles	  and	  any	  others	  that	   may	   have	   formed	   via	   fusion,	   such	   as	   lysosomes.	   Photochemical	  internalisation	   (PCI)	   spawned	   from	   PDT	   and	   utilises	   the	   fundamental	  mechanisms	  of	  photoactivation	  and	  production	  of	  reactive	  oxygen	  species	  (ROS)	  to	  facilitate	  the	  release	  of	  endocytosed	  molecules	   into	  the	  cytosol	  (fig	  1.1)(26).	  As	  a	  result	  of	  this	  PCI	  acts	  as	  an	  enabling	  mechanism	  to	  enhance	  the	  delivery	  of	  therapeutic	  agents	  to	  their	  site	  of	  action.	  In	  doing	  so	  PCI	  can	  be	  considered	  as	  a	  novel	  intracellular	  delivery	  tool	  for	  macromolecules.	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Figure	  1.1	  -­‐	  Endocytic	  mechanism	  of	  drug	  uptake	  and	  destruction/efflux.	  	  
(a)	  Depicts	  the	  uptake	  of	  a	  macromolecule	  by	  endocytosis,	  packaging	  within	  endosomes	  and	  subsequent	  enzymatic	  degradation	  within	  lysosomes	  or	  efflux	  from	  the	  cell	  via	  cell	  membrane	  pumps.	  Such	  a	  mechanism	  may	  be	  up-­‐regulated	  in	  the	  multidrug	  resistance	  phenotype	  expressed	  by	  many	  cancers.	  (b)	  Illustrates	  the	  incorporation	  of	  amphiphilic	  photosensitisers	   within	   the	   phospholipid	   bi-­‐layer.	   Following	   the	   formation	   of	  endo/lysosomes,	  the	  photosensitiser	  is	  retained	  within	  the	  membrane	  of	  the	  organelle.	  (Image	  and	  legend	  first	  published	  in	  Adigbli	  DK	  et	  al.,	  2012)(26).	  
1.3	  MECHANISMS	  OF	  PCI	  PCI	  employs	  the	  basic	  mechanisms	  that	  underpin	  PDT	  but	  at	  a	  sub-­‐cellular	  level	  with	   the	   aim	   to	   enhance	   the	   intracellular	  delivery	  of	   endocytosed,	   biologically	  active	   macromolecules,	   including	   cytotoxic	   chemotherapeutic	   agents(25,	   28,	  29).	   In	   PDT	   the	   ROS	   produced,	   principally	   singlet	   oxygen	   (1O2),	   but	   also	  superoxide	  	  	  (O2-­‐)	  to	  induce	  non-­‐site	  specific	  cytotoxic	  damage	  with	  the	  ultimate	  aim	  of	  inducing	  cell	  death.	  In	  slight	  contrast,	  PCI	  utilises	  ROS	  production	  that	  is	  localized	   to	   the	  membranes	   of	   vesicles	   that	   enclose	   the	   endocytosed	  molecule	  (drug).	   This	   localized	   effect	   is	  made	  possible	   via	   the	   selective	   localisation	  of	   a	  photosensitiser	   to	   the	   phospholipid	   membrane.	   Compounds	   with	   amphiphilic	  properties	   are	   able	   interact	   with	   hydrophilic	   (water-­‐loving)	   and	   hydrophobic	  (water-­‐intolerant)	   environments.	   If	   one	   end	   of	   the	   molecule	   is	   more	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hydrophobic	   the	   molecule	   can	   then	   partition	   to	   phospholipid	   membranes	  without	  fully	  crossing	  into	  the	  cytosol(30).	  The	  hydrophobic	  end	  interacts	  with	  the	   lipid	   bilayer	   of	   the	  membrane	  whereas	   the	   hydrophilic	   end	   interacts	  with	  the	   ionized	   surface	   of	   the	   lipid	   bilayer.	   Therefore,	   any	   molecule	   that	   is	  subsequently	   endocytosed	  will	   reside	   in	   vesicles	   (endosomes	   and	   lysosomes),	  where	   the	  photosensitiser	   is	   localized	  preferentially	  within	   their	   phospholipid	  membranes	   instead	   of	   the	   central	   aqueous	   compartment.	   This	   localised	  distribution	  of	  the	  photosensitiser	  coupled	  with	  the	  short-­‐range	  and	  survival	  of	  ROS	   such	   as	   singlet	   oxygen,	   results	   in	   restricted	   phototoxic	   damage	   to	   and	  consequent	   rupture	   of	   endo-­‐lysosomal	   membranes.	   The	   attenuated	   and	  restricted	   nature	   of	   this	   process	   negates	   the	   direct	   photo/ROS-­‐mediated	  cytotoxicity(31-­‐33)	  (see	  fig.	  1.1b).	  This	  relatively	  ‘controlled’	  production	  of	  ROS	  is	   essential	   for	   ‘true’	   PCI	   as	   the	   technique	   aims	   to	   enhance	   the	   delivery	  therapeutic	  molecules	  without	   damaging/modifying	   the	   co-­‐delivered	   bioactive	  agent	   within	   the	   central	   aqueous	   compartment	   or	   lethally	   damaging	   the	   cell.	  This	  may	  be	  particularly	  relevant	  when	  delivering	  non-­‐stable	  and	  primarily	  non-­‐toxic	  molecules	  such	  as	  siRNA	  and	  other	  genetic	  material.	  The	  principal	  protocol	  for	   PCI	   involves	   activating	   the	   photosensitiser	   after	   pre-­‐incubating	   cells	   with	  photosensitiser	  and	  the	  molecule	  to	  be	  internalised,	  however,	  a	  second	  protocol	  exists	   whereby	   the	   cells	   are	   photochemically	   treated	   prior	   to	   delivery	   of	   the	  molecule	  of	  choice(34).	  The	  latter	  mechanism	  is	  postulated	  to	  involve	  the	  fusion	  of	   newly	   formed	   endosomes	   with	   previously	   ruptured	   (PCI)	   endocytic	  membranes(30).	  
1.4	  IN	  VITRO	  PCI	  The	  body	  of	  evidence	  to	  support	  PCI-­‐induced	  cell	  death	   in	  vitro	   is	  already	  well	  established.	   The	   two	   main	   classes	   of	   photosensitiser	   used	   for	   PCI	   are	   the	  amphiphilic	   disulfonated	   porphyrin(20,	   35)	   and	   phthalocyanine(30)	  photosensitisers,	  which	   can	   be	   activated	   using	   red	   light.	   The	   benefit	   of	   this	   is	  that	   red	   light	   can	   penetrate	   tissues	   to	   greater	   depths	   than	   green	   and	   blue	  light(36),	   thus	   are	   likely	   to	   be	  more	   relevant	   to	   potential	   clinical	   applications.	  However,	  other	  photosensitisers	  such	  as	  hypericin	  have	  also	  been	  demonstrated	  to	   be	   effective(25).	   PCI	   has	   been	   used	   to	   enhance/facilitate	   the	   intracellular	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delivery	   of	   a	   variety	   of	   different	   compounds	   including;	   cytotoxic	  chemotherapeutics(20,	   25),	   immunotoxins(37-­‐39),	   immune	   therapies(39)	   and	  genes(20).	  The	  diversity	  of	   compounds	  utilised	  demonstrates	   the	  versatility	  of	  PCI	  as	  a	  delivery	  tool.	  The	  type	  II	  topoisomerase	  inhibitor	  (mitoxantrone,	  MTX)	  is	   used	   for	   the	   treatment	   cancer	   including	   haematological	   (Acute	   Myeloid	  Leukemia	   (AML)	   and	   refractory	   Acute	   Lymphoblastic	   Leukaemia	   (ALL)),	   and	  metastatic	  solid	  tumours	  (breast	  and	  prostate).	  The	  success	  of	  MTX	  is	  limited	  by	  the	  multidrug	  resistant	  phenotype	  (MDR),	  which	  attenuates	  the	  efficacy	  of	  many	  other	  chemotherapeutic	  agents.	  In	  addition	  to	  MDR,	  narrow	  therapeutic	  indices	  and	   intolerable	   systemic	   toxicity	   e.g.	   myelosuppression	   are	   also	   factors	   that	  significantly	   reduce	   the	   success	   rates	  of	   conventional	   anticancer	   cytotoxins.	   In	  
vitro,	   MDR	   expressing	   breast	   and	   bladder	   cancer	   cell	   lines	   (MCF7/R	   and	  MGHU1/R,	   respectively)	   are	   known	   to	   express	   dose	   dependent	   resistance	   to	  mitoxantrone,	   amongst	   other	   chemotherapeutics(25).	   Following	   endocytic	  uptake	   of	   a	   drug,	   the	   MDR	   phenotype	   can	   manifest	   in	   multiple	   mechanisms	  including	   the	   fusion	   of	   endosomes	  with	   enzymatic	   lysosomes	   and/or	   efflux	   of	  the	  drug	  via	  cell	  membrane	  pumps	  e.g.	  P-­‐glycoprotein	  pumps	  (PgP).	  PCI,	  using	  the	  St	  John’s	  Wort	  extract	  hypericin	  as	  a	  photosensitiser,	  was	  shown	  to	  reverse	  this	  MDR	  phenotype	  in	  both	  cancer	  cell	   lines	  with	  up	  to	  38	  %	  increased	  killing	  (p<0.05)(25).	  	  	  Although	   hypericin	   has	   membrane-­‐localising	   properties,	   newer	   amphiphilic	  porphyrin	  based	  photosensitisers	  such	  as	  meso-­‐tetraphenyl	  chlorin	  disulfonate	  (TPCS2a,)	   have	   been	   designed	   to	   selectively	   target	   endosomal	   and	   lysosomal	  membranes(20).	  Such	  drugs	  are	  consequently	  optimised	   for	  PCI	  as	  opposed	  to	  PDT.	  In	  the	  latter,	  non-­‐selective	  sub-­‐cellular	  localisation	  may	  be	  advantageous	  in	  order	   to	   maximise	   cell	   kill(37).	   Disulfonated	   meso-­‐tetraphenyl	   porphine	  (TPPS2a)	  has	  been	  used	  to	  facilitate	  the	  delivery	  of	  an	  endothelial	  growth	  factor	  (EGF)-­‐saporin	  chimera	  into	  an	  EGF	  resistant	  EGFR-­‐positive	  rat	  epithelial	  ovarian	  cancer	  cell	  line	  (NuTu-­‐19)(40).	  Saporin	  is	  a	  Type	  I	  ribosome-­‐inactivating	  protein	  (RIP)	   that	   exerts	   its	   cytotoxicity	   by	   disrupting	   protein	   synthesis.	   However,	  unlike	  type	  II	  RIPs,	  such	  as	  ricin,	  saporin	  has	  relatively	  poor	  cytotoxicity	  since	  it	  lacks	  the	  necessary	  cell-­‐binding	  domain	  and	  is	  not	  efficiently	  taken	  up/retained	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by	   the	   cell	   following	   endocytosis.	   Consequently,	   saporin	   is	   a	   good	   candidate	  molecule	  for	  PCI	  potentiated	  delivery(41).	  	  	  EGFR	  positivity	  is	  not	  an	  uncommon	  occurrence	  in	  carcinomas,	  therefore	  such	  a	  receptor	   is	   a	   good	   target	   for	   selective	   cancer	   chemotherapy.	  A	   previous	   study	  demonstrated	   that	   following	   exposure	   to	   light;	   the	   viability	   of	   NuTu-­‐19	   cells	  treated	  with	  both	  TPPS2a	   and	   the	  EGF-­‐saporin	   chimera	  was	   reduced	  by	  50	  %;	  this	   is	   consistent	   with	   PCI(40).	   Furthermore,	   the	   LD96	   required	   to	   achieve	  approximately	  a	  50	  %	  reduction	  in	  cell	  viability	  was	  ∼10	  nM	  for	  PCI	  of	  saporin	  alone,	  compared	  to	  ∼10	  pM	  for	  PCI	  of	  the	  EGF-­‐saporin	  chimera.	  This	   indicates	  that	   by	   targeting	   PCI,	   it	   is	   possible	   to	   attain	   even	   greater	   selectivity	   and	  consequently	   widen	   the	   therapeutic	   index	   of	   a	   drug.	   These	   findings	   were	  supported	  by	  Yip	  et	  al.	  who	  used	  PCI	  to	  deliver	  cetuximab-­‐saporin	  chimera	  into	  colorectal	  (HCT-­‐116);	  prostate	  (DU-­‐145)	  and	  epidermal	  (A-­‐431)	  carcinoma	  cell	  lines(41).	   TPCS2a	   has	   been	   used	   to	  mediate	   the	   PCI	   of	   gelonin	   (Type	   I	   RIP)	   in	  WiDr	  (human	  colorectal	  adenocarcinoma	  cell	  line)(20).	  The	  same	  group	  went	  on	  to	   demonstrate	   the	   versatility	   of	   PCI	   by	   using	   it	   to	   increase	   the	   transfection	  efficiency	  of	  enhanced	  green	  fluorescence	  protein	  (EGFP)-­‐encoding	  plasmid	  and	  also	  induce	  gene	  silencing	  using	  siRNA.	  Other	  groups	  have	  also	  reported	  success	  in	   photochemically	   internalising	   silencing	   RNA	   and	   also	   showed	   that	   delayed	  PCI	   on	   cells	   previously	   transfected	   with	   siRNA	   significantly	   prolonged	   the	  knockdown	   of	   the	   target	   protein	   when	   siRNA	   was	   carried	   by	   nanogels(42).	  These	   findings	   demonstrate	   the	   use	   of	   PCI	   as	   a	   versatile	   delivery	   tool	   for	  macromolecules.	   Although	   not	   currently	   established	   as	   anti-­‐cancer	   therapies,	  both	  gene	  silencing	  and	  gene	   transfection	  may	  play	  a	   significant	   role	   in	   future	  cancer	  therapy	  and	  PCI	  may	  provide	  a	  means	  of	  enhancing	  selective	  delivery	  of	  such	  compounds	  into	  cancer	  cells.	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1.5	  IN	  VIVO	  PCI	  The	   development	   of	   in	   vivo	   PCI	   models	   has	   aided	   the	   acquisition	   of	   further	  understanding	   of	   the	   technique,	   its	   strengths	   and	   weaknesses,	   including	  significant	   direct	   cytotoxicity	   in	   whole	   organisms(43).	   An	   additional	   effect,	  which	   could	   not	   be	   modeled	   using	   current	   in	   vitro	   techniques,	   is	   vascular	  starvation(44).	   In	   addition,	   an	   immune	   mediated	   component	   has	   been	  postulated	   (Norum	   O.J.	   and	   Berg	   K.,	   unpublished	   data).	   Given	   the	   important	  roles	   that	   angiogenesis	   and	   the	   immune	   system	   play	   in	   carcinogenesis,	   any	  potential	  beneficial	  effects	  of	  PCI	  on	  these	  factors	  is	  promising.	  Nevertheless,	  far	  more	   work	   is	   required	   to	   truly	   understand	   these	   findings	   as	   paradoxically,	  vascular	  damage	  may	  blunt	   the	  delivery	  of	   therapeutic	  molecules	   to	   a	   tumour	  bed,	   thus	   there	  may	   be	   implications	   for	   repeated	   therapies.	   In	   vivo	   work	   has	  included	  both	  local	  injection	  of	  drugs	  directly	  into	  a	  tumour	  mass	  and	  systemic	  administration	   with	   positive	   observations(26).	   Subcutaneous	   human	  adenocarcinoma	   (WiDr)	   tumours	  have	  been	  grown	   in	  athymic	  nude	  mice.	  The	  mice	   were	   treated	   with	   the	   photosensitiser	   aluminium	   phthalocyanine	  disulfonate	   (AlPcS2a),	   via	   intraperitoneal	   (i.p.)	   injection,	   48h	   prior	   to	  illumination.	   The	   cytotoxin,	   gelonin,	   was	   given	   intratumorally	   6h	   before	   light	  therapy.	   The	   group	   observed	   complete	   remission	   in	   6	   of	   9	   treated	   mice(43).	  Significantly,	  tumour	  growth	  was	  unaffected	  by	  treatment	  with	  AlPcS2a,	  gelonin	  or	  a	  combination	  of	   the	  two	  compounds	   in	  the	  absence	  of	   light,	   indicating	  that	  photoactivation	   and	   ROS	   generation	   are	   likely	   to	   play	   important	   roles	   in	   PCI.	  Furthermore,	  PDT	  alone	  was	  not	  as	  effective	  as	  PCI	  in	  opposing	  tumour	  growth.	  The	   study	  also	  managed	   to	  demonstrate	  PCI	   induced	   re-­‐localisation	  of	  AlPcS2a	  from	   a	   granular	   pattern	   (indicating	   endosomal	   targeting)	   prior	   to	   light,	   to	   a	  diffuse	   pattern	   in	   the	   cytoplasm	   following	   light	   treatment.	   Such	   a	   finding	   is	  important	  when	   considering	   the	   potential	  mechanisms	   the	   underpin	   PCI,	   thus	  the	   release	   of	   endocytosed	   molecules	   from	   cytosolic	   vesicles	   would	   be	  consistent	   with	   a	   change	   in	   distribution	   from	   granular	   (vesicular)	   to	   diffuse	  (cytosolic).	   This	   is	   supported	   by	   in	   vitro	   studies	   that	   report	   re-­‐localisation	   of	  both	  photosensitiser	  and	  cytotoxin	  following	  PCI(25).	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AlPcS2a	  has	  also	  been	  used	  to	  sensitise	  the	  effect	  of	  bleomycin	  on	  orthotopically	  implanted	  HT1080	   fibrosarcoma	   cells(44).	  This	  was	  one	  of	   the	   first	   studies	   to	  look	  at	  the	  effect	  of	  PCI	  on	  deep-­‐lying	  tumours	  in	  vivo.	  The	  tumours	  were	  grown	  in	   the	  gastrocnemius	  (calf)	  muscle	  of	  nude	  mice.	  Treatment	  was	   initiated	  with	  i.p.	   administration	   of	   AlPcS2a	   (10	  mg	   kg-­‐1)	   once	   tumours	  were	   80-­‐150	  mm3	   in	  volume.	  48	  h	  following	  injection	  with	  AlPcS2a	  bleomycin	  (1500	  IU)	  was	  given	  i.p.	  prior	  to	  illumination	  with	  a	  670	  nm	  diode	  laser,	  30	  minutes	  later.	  Tumour	  size	  was	   subsequently	   measured	   five	   times	   per	   week.	   The	   study	   found	   that	   PDT	  (AlPcS2a)	   alone	   delayed	   tumour	   growth	   by	   5	   days,	   which	   was	   more	   effective	  than	  light	  or	  bleomycin	  alone.	  However,	  PCI	  treated	  tumours	  had	  a	  mean	  growth	  delay	   of	   21	   days	   compared	   to	   control	   and	   15	   days	   compared	   to	   PDT	   alone	  (p<0.001).	   Histological	   examination	   of	   the	   tumours	   demonstrated	   that	   7-­‐days	  post	   treatment	  with	   PDT	   alone	   there	  was	   evidence	   of	   central	   necrosis	  with	   a	  relatively	  spared	  tumour	  periphery	  whereas	  PCI	  showed	  more	  extensive	  central	  necrosis	  with	  only	  a	  thin	  layer	  of	  spared	  periphery	  in	  the	  deep	  layer.	  	  This	  study	  not	  only	  demonstrated	  that	  PCI	  of	  bleomycin	  increased	  the	  selective	  toxicity	  of	  the	   chemotherapeutic	   agent	   in	   vivo	   but	   also	   that	   it	   was	   superior	   to	   PDT	   in	  delaying	   tumour	   regrowth,	   with	   enhanced	   tumour	   damage	   at	   the	   periphery.	  Bleomycin	   has	   also	   been	   used	   in	   combination	   with	   TPCS2a	   for	   in	   vivo	   PCI	   in	  athymic	   mice,	   subcutaneously	   inoculated	   with	   CT26.CL25	   cells	   (metastatic	  colorectal	  cancer)	  (20).	  In	  this	  study,	  Berg	  et	  al.	  reported	  that	  bleomycin-­‐TPCS2a	  PCI	   was	   superior	   to	   PDT	   with	   the	   photosensitiser	   meso-­‐tetraphenyl	   chlorin	  (mTHPC)	  in	  inhibiting	  tumour	  growth.	  	  	  Although	   still	   at	   a	   relatively	   early	   stage	   of	   technical	   development	   and	  refinement,	  the	  in	  vivo	  findings	  highlighted	  above	  do	  indicate	  the	  potential	  use	  of	  PCI	   in	   live	   multicellular	   organisms	   and	   are	   an	   important	   step	   in	   the	  development	   of	   protocols	   that	   could	   lead	   to	   clinical	   application.	   	   Work	   by	  Woodhams	   et	   al.	   (45)	   provided	   further	   evidence	   of	   the	   mechanisms	   that	  underpin	  PCI	  mediated	  cytotoxicity,	   in	  vivo.	  Using	  AlPcS2a	   in	  a	  normal	   rat	   liver	  model,	   the	   group	   demonstrated	   in	   vivo	   that	   gelonin,	   following	   endocytosis,	   is	  trapped	   in	   lysosomes	   but	   can	   be	   released	   into	   the	   cytosol	   following	   PCI	  treatment.	  Furthermore,	  they	  also	  observed	  that	  the	  depth	  of	  necrosis	  post	  PCI	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was	  greater	  than	  that	  achieved	  with	  PDT	  alone	  in	  keeping	  with	  the	  reports	  from	  other	  groups(44).	  
1.6	  POTENTIAL	  LIMITATIONS	  OF	  PCI	  Despite	  the	  promising	  results	  of	  PCI	  in	  both	  in	  vitro	  and	  in	  vivo	  studies	  there	  are	  limitations.	   The	   first	   is	   the	   issue	   of	   tissue	   light	   penetration.	   The	   benefit	   of	  selective	  cell	  killing,	  concentrated	  to	  areas	  exposed	  to	  light	  and	  drugs,	  forms	  the	  basis	  of	  one	  of	  PCI’s	  drawbacks.	  Given	  that	  non-­‐ionising	  light	  will	  only	  penetrate	  superficial	   tissue	   layers	   the	   photodynamic	   component	   of	   PCI	   will	   only	   be	  utilised	  in	  superficial	  lesions	  on	  skin	  or	  the	  apical	  surface	  of	  luminal	  or	  tubular	  organs.	   This	   hurdle	   has	   already	   been	   encountered	   in	   clinically	   applied	   PDT;	  where	  the	  use	  of	  novel	  light	  sources	  including	  fiber	  optics	  has	  enabled	  access	  to	  deeper	   lesions.	   Linked	   to	   this	   would	   be	   the	   limited	   access	   in	  disseminated/metastatic	  disease.	  Another	  problem	  encountered	   in	  PCI	   studies	  is	  the	  time	  taken	  to	  determine	  the	  optimal	  doses	  of	  photosensitiser,	  which	  may	  vary	  significantly	  in	  different	  cell/tumour	  types.	  However,	  as	  PCI	  continues	  to	  be	  developed,	   the	   library	   of	   available	   amphiphilic	   photosensitisers	   continues	   to	  grow.	   TPCS2a	   is	   an	   example	   of	   this,	   being	   an	   optimised	   variant	   of	   AlPcS2a	  specifically	  designed	  for	  clinical	  application.	  	  	  
1.7	  UK	  BASED	  CLINICAL	  TRIAL	  FOR	  PCI	  	  A	   clinical	   trial,	   evaluating	   the	   use	   of	   TPCS2a-­‐bleomycin	   PCI	   in	   head	   and	   neck	  cancers	  is	  currently	  taking	  place	  at	  University	  College	  London	  Hospital,	  London,	  UK.	   Following	   promising	   results	   from	   a	   Phase	   I	   study(46),	   Phase	   II	   trials	   are	  now	  in	  progress.	  This	  pioneering	  trial	  is	  vital	  for	  the	  development	  of	  PCI	  into	  a	  safe	  and	  economically	  viable	  treatment	  modality	  in	  oncology.	  	  
1.8	  INTRODUCTION	  TO	  SMALL-­‐MOLECULE	  CARRIERS	  (SMOCS)	  	  Small	  molecule	   carriers	   are	   a	   class	   of	   transporter	   that	   can	   ferry	   biomolecules	  across	   phospholipid	   bilayers	   into	   and	   within	   the	   cell.	   They	   are	   based	   on	   the	  third	   helix	   of	   drosophila	   PTD	   Antennapedia	   homeodomain(47).	   These	   SMoCs	  essentially	  mimic	   the	   amphipathic	   helix	   of	   PTDs(48)	   enabling	   them	   to	   readily	  interact	  with	  both	  hydrophobic	  and	  hydrophilic	   regions	  of	   the	   cell	  membrane.	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SMoCs	   present	   an	   interesting	   tool	   for	   enhanced	   cellular	   drug	   and	   therapeutic	  delivery.	   Of	   particular	   interest	   are	   the	   variable	   routes	   of	   uptake,	   including	  endocytosis,	   which	   opens	   up	   the	   possibility	   of	   combining	   SMoCs	   and	  photochemical	    internalisation	  (PCI)	  with	  possible	  additive	  effects.	  
1.9	  INTRODUCTION	  TO	  3D-­‐TUMOROID	  CANCER	  MODEL	  	  
In	   vitro	   studies	   form	   a	   fundamental	   part	   of	   investigations	   into	   cancer	   biology	  and	   therapeutics.	   2-­‐D	   cell	   models	   have	   many	   benefits,	   including	   cost	  effectiveness,	   reproducibility,	  various	  options	   for	  assaying	   treatment	  response,	  reducing	  the	  demand	  for	  in	  vivo	  studies	  and	  general	  efficiency	  of	  time.	  However,	  the	  need	   for	   in	   vivo	   studies	   and	   the	   role	  of	   in	   vitro	   investigations	  primarily	   as	  pilot	   pre-­‐clinical	   data	   indicates	   that	   limitations	   do	   exist,	   particularly	   those	  related	   to	  mimicking	   the	   chaotic,	   heterogeneous	   and	  dynamic	   tumour	   stromal	  environment,	  and	  the	  impact	  of	  host-­‐related	  factors	  on	  the	  progression	  phase	  of	  carcinogenesis(49).	  	  	  	  Recent	   work	   by	   Nyga	   et	   al.	   (2013)(50)	   demonstrated	   how	   partial	   plastic	  compression	  could	  be	  used	   to	  develop	  a	  3-­‐D	  colorectal	   cancer	  model	   that	  also	  comprised	   stromal	   cells	   (fibroblast	   +/-­‐	   endothelial).	   The	   important	   findings	  from	  the	  group	  include:	  reduced	  rate	  of	  cell	  growth	  compared	  to	  2-­‐D	  culture,	  the	  formation	   of	   spheroids	   preferentially	   in	   the	   periphery	   of	   the	   cancer	  compartment	   within	   the	   construct	   away	   from	   the	   hypoxic	   core	   and	   the	  production	   of	   VEGF	   at	   the	   invasive	   edge.	   In	   this	   way	   the	   Nyga	   model	   does	  appear	   to	   be	   a	   far	   better	   mimic	   of	   in	   vivo	   conditions	   compared	   to	   the	   much	  tested	  2-­‐D	  cell	  cultures.	  
1.10	  INTRODUCTION	  TO	  BIOLUMINESCENT	  PDT	  The	  ability	  of	  certain	  biological	  systems	  to	  emit	  light	  from	  an	  organic	  source	  is	  of	  much	   interest	   to	   biomedical	   research(51).	   Bioluminescence	   is	   naturally	  occurring	  process	  whereby	  visible	  light	  is	  emitted	  as	  a	  by-­‐product	  of	  a	  chemical	  reaction	   taking	   place	   within	   living	   organisms(51).	   This	   natural	   phenomenon	  happens	   in	   various	   types	   of	   organisms	   including	   bacteria,	   marine	   organisms	  (including	  plants)	  and	  insects(52-­‐54).	  Photinus	  pyralis	  (American	  firefly)	  is	  one	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of	   the	   best-­‐studied	   organisms	   found	   across	   the	   different	   species	   of	  bioluminescent	  insects(51,	  55).	  Most	  bioluminescent	  systems	  involve	  the	  energy	  dependent	   oxidation	   of	   the	   heterocyclic	   carboxylic	   acid,	   Luciferin	   (LH2)	   or	  Luciferin-­‐like	  substrate.	  The	  best	  studied	  is	  the	  firefly	  Luciferin-­‐Luciferase	  (Luc)	  system(51)	  which	  occurs	  as	  follows:	  	  
Stage	   1:	   Luc	   mediated	   conversion	   of	   firefly	   Luciferin	   (D-­‐Luciferin)	   to	   a	  
luciferyl	  adenylate	  (reaction	  requires	  ATP	  and	  Mg2+	  as	  co-­‐factor)	  Luc	  +	  LH2	  +	  ATP	  (Mg2+)	  ⇌	  Luc⋅LH2-­‐AMP	  +	  PPi	   	  
Stage	   2:	   Oxidation	   of	   reactive	   luciferyl	   adenylate	   at	   active	   site	   of	  
Luciferase,	  resulting	  in	  production	  of	  an	  excited	  by-­‐product	  (oxyluciferin)	  Luc⋅LH2-­‐AMP	  +	  O2	  →	  Luc⋅AMP⋅Oxyluciferin˙	  +	  CO2	  
Stage	   3:	   Return	   of	   excited	   oxyluciferin	   to	   ground	   state	   associated	   with	  
emission	  of	  a	  photon	  of	  visible	  light	  Luc⋅AMP⋅Oxyluciferin˙	  →	  Luc	  +	  Oxyluciferin	  +	  AMP	  +	  hv	  (≈600	  nm)	  Equations	  adapted	  from	  Branchini	  et	  al.(55)	  	  The	  versatility	  and	  emission	  profiles	  of	   the	  different	   luciferases	  make	   them	  an	  intriguing	  and	  exciting	  prospect	  for	  PDT	  and	  potentially	  PCI.	  The	  benefits	  would	  include	  a	  greater	  level	  of	  accessibility	  to	  deep	  lying	  tumours	  and/or	  metastases	  allied	   to	   a	   suitable	   level	   of	   tissue	   penetration	   giving	   the	   red-­‐shifted	   emission	  peaks	  of	  Fluc.	  A	  benefit	  may	  also	  be	  seen	  in	  irregularly	  shaped	  tumours	  that	  are	  often	  difficult	  to	  illuminate	  in	  a	  uniform	  manner.	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1.11	  	  SUMMARY	  OF	  OBJECTIVES:	  
Chapter	   3	   –	   The	   Role	   of	   Reduction	   and	   Oxidation	   in	   Photochemical	  
Internalisation.	  The	  studies	  performed	   in	   this	  chapter	   investigated	   the	  role	  of	   the	   intracellular	  REDOX	   environment	   in	   PCI-­‐enhanced	   delivery	   of	   both	   saporin	   and	  mitoxantrone.	  Furthermore,	  it	  reports	  on	  the	  factors	  that	  influenced	  the	  balance	  between	  PDT	  and	  PCI	  induced	  cytotoxicity.	  These	  experiments	  were	  carried	  out	  in	  4T1-­‐luc2	  murine	  breast	  adenocarcinoma	  cells.	  	  	  
Chapter	  4	  –	  Photochemical	  Internalisation	  and	  Small	  Molecule	  Carriers.	  This	   chapter	  aimed	   to	   investigate	   the	  effect	   that	  SMoCs	  had	  on	   the	  delivery	  of	  fluorescently	   labeled	   siRNA	   into	   4T1-­‐luc2	   and	   MCF7	   (human	   breast	   cancer	  cells).	   It	   went	   on	   to	   assess	   the	   impact	   of	   PCI	   on	   SMoC-­‐enhanced	   deliver	   of	  fluorescently	  labeled	  siRNA.	  	  
	  
Chapter	  5	  –	  Photochemical	  Internalisation	  in	  a	  £D	  Tumour	  Model.	  In	  this	  chapter	  the	  novel	  compressed	  collagen	  artificial	  cancer	  mass	  model	  was	  used	  to	  assess	  the	  potency	  of	  PCI	  in	  a	  3D	  structure.	  The	  aims	  of	  the	  studies	  were	  to	  first	  assess	  if	  4T1	  cells	  could	  be	  grown	  into	  3D	  tumoroids	  and	  subsequently	  determine	  if	  PCI	  could	  be	  used	  to	  enhance	  saporin	  cytotoxicity	  in	  a	  3D	  model.	  	  	  
	  
Chapter	  6	  –	  Bioluminescent	  Photodynamic	  Therapy.	  In	  this	  chapter	  Gaussia	  (MCF7-­‐GLuc)	  and	  firefly	  (4T1-­‐luc2)	  luciferase	  expressing	  cancer	  cells	  were	  used	  to	  investigate	  if	  bioluminescence	  could	  be	  used	  to	  trigger	  PDT	   induced	   cytotoxicity.	   Two	   photosensitisers	   were	   assessed:	  tetrabromorhodamine-­‐123	  and	  hypericin.	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CELL	  LINES	  
2.1	  4T1-­‐luc2	  cell	  line	  The	  4T1-­‐luc2	  (initial	  passage	  number	  =	  7,	  all	  experiments	  carried	  out	  within	  20	  passages)	   murine	   mammary	   adenocarcinoma	   cell	   line	   (Caliper	   Life	   Sciences,	  Hopkinton,	   MA,	   USA)	   expresses	   a	   stably	   transfected	   firefly	   luciferase	   gene	  (Luc2).	  This	  was	  the	  main	  cell	  line	  used	  throughout	  the	  PhD	  study	  to	  investigate	  Photodynamic	   Therapy	   (PDT),	   Photochemical	   Internalisation	   (PCI),	  Bioluminescence-­‐mediated	   PDT	   and	   the	   work	   on	   Small	   Molecule	   Carries	  (SMoCs).	  The	  parental	  cell	  line	  is	  the	  ATCC	  (CRL	  –	  2539™)	  cell	  line.	  Gene	  transfer	  was	  performed	  using	  a	  pGL4	  luc2	  Lentivirus.	  In	  vitro	  bioluminescence	  produces	  approximately	   6500	   photons/sec/cell	   depending	   on	   imaging	   and	   culturing	  conditions.	   Thus	   this	   enables	   in	   vivo	   bioluminescent	   imaging	   for	   growing	  tumours	  and	   is	   therefore	  suitable	   for	  extrapolating	  this	   investigation	  to	   in	  vivo	  preclinical	  model	  (Nu/nu)	  mice	  in	  the	  future(56,	  57).	  




Figure	  2.1–	  4T1	  in	  vivo	  bioluminescence	  (subcutaneous	  implantation	  model).	  	  4T1-­‐luc2	  cells	  (five)	  were	  subcutaneously	  injected	  into	  dorsal	  aspect	  near	  the	  thigh	  in	  female	   nu/nu	  mouse.	   Imaging	  was	   undertaken	   10	  minutes	   after	   intraperitoneal	   (i.p.)	  injection	  of	  Luciferin	  (150	  mg/kg).	  Detection	  of	  the	  bioluminescent	  signal	  (measured	  by	  IVIS	   spectrum)	   significantly	   preceded	   caliper	   measurement.	   (Adapted	   from	   Caliper	  Lifesciences,	  UK)(58).	  
2.2	  MCF7	  cell	  line	  The	   MCF7	   (initial	   passage	   number	   =	   26,	   all	   experiments	   carried	   out	   with	   12	  passages),	   human	   breast	   adenocarcinoma	   cell	   line	   (European	   Collection	   of	  Animal	   Cell	   Cultures,	   Porton	   Down,	   UK),	   was	   previously	   bought	   and	   was	  available	  in	  the	  laboratory	  at	  UCL.	  	  
2.3	  MCF7	  Firefly	  and	  Gaussia	  Luciferase	  The	  native	  MCF7	  cells	  were	  transduced	  to	  produce	  two	  luciferase	  expressing	  cell	  lines:	  MCF7-­‐FLuc	  and	  MCF7-­‐GLuc.	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2.4	  CELL	  CULTURE	  PREPARATION	  AND	  REAGENTS	  The	   4T1	   cells	   were	   routinely	   cultured	   in	   Roswell	   Park	   Memorial	   Institute	  medium	   (RPMI	   1640,	   Sigma-­‐Aldrich®,	   Poole	   (Dorset),	   UK)	   supplemented	  with	  10%	  (v/v)	   fetal	  bovine	  serum	  (FBS,	  Gibco®	  Life	  Technologies,	  Paisley,	  UK)	   in	  a	  humidified	   atmosphere	   of	   5%	   CO2/air,	   37oC.	   MCF7	   cells	   were	   grown	   in	  Dulbecco’s	  Modified	   Eagle’s	  Medium/Nutrient	   F-­‐12	   Ham	   (DMEM	   F-­‐12,	   Sigma-­‐Aldrich)	  .	  	  	  Cells	  were	   split	   via	   standard	   technique.	   Confluent	   cells	  were	  washed	   twice	   in	  phosphate	  buffered	  saline	  (1X	  without	  Ca2+	  or	  Mg2+),	  prior	  to	  trypsinisation	  (3	  minutes	   –	   4T1,	   2	   minutes	   –	   MCF7)	   (1.0	   mg	  ml−1	   in	   0.2%	   phosphate-­‐buffered	  saline	   (PBS)/EDTA),	   centrifuged	   (×2,	   400g,	   5	  min).	   Once	   the	   supernatant	  was	  discarded,	   cells	   were	   re-­‐suspended	   in	  media	   and	   used	   for	   routine	   passage	   or	  further	   experimental	   work.	   For	   plating	   (experimental)	   into	   96-­‐well	   plates	  (Nunc,	  Roskilde,	  Denmark)	   (100	  μL	  well−1)	   cells	  were	   re-­‐suspended	   at	   10,000	  cells/100	  μL.	  
2.5	  CHEMICALS	  AND	  DRUGS	  	  All	  chemicals	  were	  purchased	  from	  Sigma-­‐Aldrich,	  unless	  otherwise	  indicated	  in	  the	  text.	  
2.6	  Photosensitisers	  	  TPPS2a	   (disulfonated	   meso-­‐tetraphenylporphyrin,	   PCI	   Biotech,	   Oslo,	   Norway)	  dissolved	   in	  dimethyl	   sulfoxide	   (DMSO)	   to	  a	   stock	  concentration	  of	  350	  µg/ml	  and	  subsequently	  divided	  in	  to	  aliquots	  and	  stored	  (as	  solution)	  at	  −40°C,	  	  in	  the	  dark,	  until	  use.	  Serial	  dilutions	  were	  subsequently	  dissolved	  into	  PBS	  and	  appropriate	  media.	  The	   final	  dissolved	  concentration	  of	  DMSO	  about	  <1%	  and	  was	  well	  below	  cytotoxic	  levels.	  	  Hypericin	   (HYP)	   was	   prepared	   in	   DMSO	   and	   was	   diluted	   in	   PBS	   to	   a	   stock	  solution	   of	   1.0	   mM	   in	   aliquots	   and	   stored	   at	   -­‐20°C.	   Serial	   dilutions	   were	  subsequently	  dissolved	  into	  PBS	  and	  appropriate	  media.	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Tetrabromorhodamine-­‐123	   (TBR,	   Biotium®,	   Cambridge	   Bioscience®,	  Cambridge,	  UK)	  was	  dissolved	  in	  DMSO	  to	  a	  stock	  solution	  of	  100	  μM	  and	  stored	  in	   the	   dark	   at	   4°C.	   Serial	   dilutions	  were	   subsequently	   dissolved	   into	   PBS	   and	  appropriate	  media.	  
2.7	  Cytotoxins	  Saporin	   (SAP,	   lyophilized	   protein),	   a	   type	   1	   Ribosome	   inactivating	   protein	  (cytotoxin)	   was	   initially	   dissolved	   in	   sterile	   water	   and	   then	   PBS	   to	   a	   stock	  solution	  of	  1	  μM	  and	  stored	  at	  4°C.	  Serial	  dilutions	  were	  made	  up	  in	  appropriate	  media.	  	  The	   anthracenedione	   Mitoxantrone	   (MTX)	   was	   dissolved	   in	   DMSO	   to	   a	   stock	  solution	  of	  250	  μg/ml	  and	  stored	  at	  4⁰C.	  
2.8	  Reduction-­‐Oxidation	  reagents	  Powdered	   L-­‐histidine	   (LH))	   was	   dissolved	   in	   heated	   (37.5°C)	   PBS	   to	   a	   stock	  solution	  of	  50	  mM.	  	  Buthionine	   Sulfoximine	   (BSO)	   a	   glutathione-­‐depleting	   agent	   was	   dissolved	   in	  PBS	  to	  a	  stock	  concentration	  of	  100	  μg/ml	  and	  subsequently	  stored	  at	  4⁰C.	  	  Bovine	   superoxide	   dismutase	   (SOD),	   a	   reducing	   enzyme	   that	   quenches	  intracellular	   superoxide	   free	   radical	   load	   (fig.	   2.2).	   SOD	   was	   dissolved	   sterile	  water	  and	  subsequently	  PBS	  to	  a	  stock	  solution	  of	  5	  KU	  in	  aliquots	  and	  stored	  at	  -­‐20°C.	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Figure	  2.2	  –	   Influence	  of	  superoxide	  dismutase	   (SOD)	  on	  the	   intracellular	  REDOX	  
environment.	  	  SOD	   plays	   an	   important	   role	   in	   maintaining	   superoxide	   and,	   in	   conjunction	   with	  catalase,	   hydroxyl	   radical	   homeostasis.	   Therefore,	   it	   may	   play	   an	   important	   role	   in	  quenching	   the	   excess	   of	   reactive	   oxygen	   species	   produced	   following	   activation	   of	   a	  photosensitiser.	  (Taken	  from	  Sigma	  Aldrich®	  website)(59)	  	  
2.9	  Luciferases	  Coelenterazine	   (Coele.,	   Life	   Technologies®	   ,	   Paisley,	   UK)	   is	   a	   substrate	   for	  Gaussia	   Luciferase,	   which	   was	   expressed	   within	   MCF7-­‐GLuc	   cells.	   Due	   to	   its	  poor	  solubility	  coelenterazine	  was	  dissolved	   in	  methanol	  to	  a	  stock	  solution	  of	  100	   µg/ml.	   Serial	   dilutions	   were	   made	   up	   in	   PBS.	   Due	   to	   its	   poor	   oxidative	  stability	  and	  lack	  of	  equipment	  to	  create	  an	  oxygen	  free	  environment,	  Coele.	  was	  not	  kept	  frozen.	  	  This	  along	  with	  the	  issues	  encountered	  with	  its	  residual	  toxicity	  at	   higher	   doses	   resulted	   in	   the	   MCF7-­‐GLuc-­‐Coele.	   model	   for	   bioluminescence	  being	  abandoned	  in	  favour	  of	  the	  4T1-­‐luc2-­‐Luciferin	  model.	  D-­‐Luciferin	  (D-­‐Luc,	  Life	  Technologies)	  is	  a	  substrate	  for	  firefly	  luciferase,	  which	  was	  expressed	   in	  both	  the	  MCF7-­‐FLuc	  and	  4T1-­‐luc2	  cell	   lines.	  The	  sodium	  salt	  preparation	  of	  D-­‐Luc	  was	   readily	  dissolvable	   in	  PBS	   into	  aliquots	   (100	  µg/ml)	  and	  stored	  at	  -­‐20°C.	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2.10	  Alexa-­‐488	  labeled	  saporin	  
PROTEIN	  BUFFER	  EXCHANGE:	  5	  mg	  of	  Saporin	  lyophilized	  protein	  (Molecular	  Weight	  :	  30000)	  was	  made	  up	  in	  1.5	  ml	  de-­‐ionised	  water	  (dH20)	  to	  a	  concentration	  of	  3.33	  mg/ml,	  which	  is	  equal	  to	  111	  µM.	  Carbonate	  buffer;	  (9	  ml	  0.1	  M	  	  NaHCO3	  +	  1	  ml	  0.1	  M	  Na2CO3)	  was	  made	  up	  and	  pH	  buffered	  to	  make	  a	  final	  solution	  (pH	  =	  9.24).	  This	  was	  subsequently	  sterile	  filtered	  through	  a	  0.45	  µm	  syringe	  filter.	  	  A	  PD10	  column	  (GE	  Healthcare,	  Little	  Chalfont	  (Bucks),	  UK)	  was	  equilibrated	  3	  times	  with	  carbonate	  buffer	  (pH	  9.24)	  using	  a	  spin	  protocol	  (1000g	  /	  2	  min)	  to	  elute.	  Sample	  was	  then	  transferred	  to	  a	  clean	  falcon	  tube	  with	  1.5	  ml	  protein	  solution	  added	  to	  the	  top,	  followed	  by	  adding	  1ml	  stacking	  buffer	  (carbonate,	  pH	  9.24)	  before	  further	  spinning	  to	  elute	  protein	  in	  new	  buffer.	  	  2	  ml	  was	  removed	  out	  of	  the	  column.	  It	  was	  assumed	  no	  loss	  of	  protein	  therefore	  protein	  concentration	  2.5	  mg/ml	  or	  83.3	  μM	  in	  carbonate	  (pH	  9.24).	  	  
CONJUGATION	  REACTION:	  1	  mg	  of	  Alexa	  Fluor	  488	  carboxylic	  acid,	  succinimidyl	  ester	  (Molecular	  Weight:	  643.41,	  Life	  Technologies),	  was	  dissolved	  in	  233	  µL	  DMSO	  to	  a	  concentration	  of	  4.29	  mg/ml;	  this	  equals	  6.668	  mM.	  This	  solution	  was	  vortexed	  to	  mix	  and	  222	  µL	  was	  immediately	  added	  to	  the	  2	  ml	  protein	  solution	  above.	  This	  new	  mixture	  was	  vortexed	  again	  to	  mix,	  covered	  in	  foil	  and	  placed	  on	  overhead	  rotation	  to	  mix	  at	  12	  rpm	  for	  1	  hour	  at	  room	  temperature.	  	  	  Final	  volume	  =	  2222	  µL	  Final	  Saporin	  =	  	  75	  µM	  Final	  Alexa	  Dye	  =	  666.2	  µM	  Molar	  dye	  to	  protein	  ratio	  =	  9	  to	  1	  	  Final	  DMSO	  =	  10%	  	  
CLEAN	  UP/BUFFER	  EXCHANGE:	  A	  PD10	  column	  (GE	  Healthcare)	  was	  equilibrated	  3	  times	  with	  PBS	  using	  a	  spin	  protocol	   (1000g	  /	  2	  min)	   to	   elute.	  This	  was	   transferred	   to	  a	   clean	   falcon	  with	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2.222	   ml	   of	   conjugate	   solution	   added	   to	   the	   top.	   Subsequently,	   278	   µL	   of	  stacking	  buffer	  (PBS)	  was	  added	  and	  the	  mixture	  spun	  to	  elute	   the	  conjugated	  protein	   in	  new	  buffer.	  This	  was	  then	  sterile	   filtered	  through	  a	  0.45	  µm	  syringe	  filter.	  2.5	  ml	  of	  filtered	  solution	  was	  recovered	  out	  of	  column.	  Again	  assuming	  no	  loss,	  the	  protein	  was	  now	  at	  2	  mg/ml	  or	  67	  µM	  in	  PBS.	  This	  was	  then	  stored	  in	  the	  dark	  at	  4°C.	  
QUANTIFICATION	  	  Quantification	  was	  calculated	  using	  the	  following	  equations:	  Protein	  Concentration	  (M)	  =	  	  [A280	  –	  (A495	  x	  0.11)]	  x	  dilution	  factor	  
	   	   	   	   	   	   	   23380	  where	  23380	  cm-­‐1	  M-­‐1	  is	  the	  molar	  extinction	  coefficient	  of	  saporin	  and	  0.11	  is	  a	  correction	  factor	  to	  account	  for	  absorption	  of	  the	  dye	  at	  280	  nm.	  	  Moles	  dye	  per	  mole	  protein	  =	  	  	  	  	  	  	  	  	  	  	  	  A495	  x	  dilution	  factor	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  .	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   	   	  	  	  	  	  	  	  	  	  71000	  x	  protein	  concentration	  (M)	  where	  71000	  cm-­‐1	  M-­‐1	   is	   the	  approximate	  molar	   extinction	   coefficient	  of	  Alexa	  Fluor®488	  at	  495	  nm.	  Absorbance	  =	  Abs	  MW	  saporin	  =	  28501,	  Abs	  max	  ε280	  =	  23380	  cm-­‐1m-­‐1	  MW	  dye	  =	  643.41,	  Abs	  max	  ε495	  =	  71000	  cm-­‐1m-­‐1.	  	  Correction	  factor	  for	  dye	  à	  0.11	  =	  A280/A495	  (fig.	  2.3)	  	  
	  
Figure	  2.3	  –	  Absorption	  spectroscopy	  for	  SAP	  –	  Alexa-­‐488	  conjugate.	  	  Two	  samples:	  (1)	  Red	  line	  -­‐	  diluted	  1	  in	  5	  in	  PBS,	  (2)	  Blue	  line	  -­‐	  diluted	  1	  in	  10	  in	  PBS.	  Data	  was	  normalised	  to	  900	  nm.	  For	  the	  1	  in	  5	  dilution	  the	  ABS	  =	  1	  therefore	  cannot	  use	  reliably.	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A	  
1	  in	  10	   Wavelength	  (nm)	   Absorption	  (A	  BS)	  
Dye	   495	   0.58	  
Protein	   280	   0.18	  
	  
B	  
	   Molecular	  
weight	  
Extinction	  Coefficient	  	  
@	  280	  nm	  (ɛ280)	  
Extinction	  Coefficient	  	  
@	  495	  nm	  (ɛ495)	  
Dye	   643.41	   7810	   71000	  
Protein	   28501	   23380	   -­‐	  
	  
C	  
	   Molar	   µM	   µg/ml	  
Dye	   8.12	  x	  10-­‐6	   81.76	   0.052	  
Protein	   4.94	  x	  10-­‐6	   49.428	   1.409	  	  
Table	  1	  -­‐	  Calculation	  of	  conjugation	  ratio	  and	  SAP	  stock	  concentration.	  	  	  
A	  =	  ɛ	  x	  C	  where	  A	  =	  absorption,	  C	  =	  molar	  concentration,	  ɛ	  =	  extinction	  coefficient.	  M	  =	  
B/R	  where	  M	  =	  molar	  concentration,	  B	  =	  mg/ml,	  R	  =	  molecular	  weight	  	  Based	  on	  Table	  1	  (above)	  the	  following	  calculations	  can	  be	  made:	  
Molar	  Dye	  (A495)	  =	  8.12	  x	  10-­‐6	  At	  this	  M	  the	  abs	  for	  the	  dye	  @	  280	  =	  0.06	  Based	  on	  A280	  for	  dye,	  the	  A280	  for	  protein	  =	  0.12	  Therefore	  Molar	  Protein	  (A280)	  =	  4.94	  x	  10-­‐6	  This	  translates	  into	  a	  protein	  concentration	  (SAP)	  of	  49	  µM	  with	  a	  dye-­‐loading	  ratio	  of	  2	  per	  molecule	  of	  SAP.	  
2.11	  SMoCs	  The	  SMoCs	  used	  in	  this	  thesis	  were	  kindly	  synthesised	  and	  donated	  by	  Professor	  David	  Selwood,	  Wolfson	  Institute,	  UCL.	  
2.12	  SMoC	  –	  siRNA-­‐Alexa-­‐555	  conjugation	  In	   order	   to	   monitor	   the	   facilitative	   SMoC	   effect	   on	   the	   uptake	   of	   siRNA	   a	  fluorescently	   labelled	  siRNA	  oligomer	  was	  used.	  Alexa	  Fluor®	  Red	  Fluorescent	  oligonucleotide	  (Invitrogen,	  LifeTechnologies,	  Poole	  (Dorset),	  UK)	  supplied	  as	  a	  20	  μM	  stock	  of	  Alexa	  Fluor®	  555-­‐labeled,	  double	  stranded	  RNA	  oligomer	  in	  100	  mM	   KOAc,	   30	  mM	  HEPES-­‐KOH,	   pH	   7.4,	   and	   2	  mM	  MgOAc	   (annealing	   buffer).	  Confocal	   microscopy	   was	   used	   to	   determine	   the	   intracellular	   localisation.	  Lipofectamine®	   RNAiMAX	   (Invitrogen)	   was	   chosen	   as	   a	   positive	   control	   for	  ‘gold	  standard’	  siRNA	  transfection.	  The	  oligonucleotide	  was	  diluted	  in	  PBS	  to	  a	  final	   concentration	   of	   1	   μM	   either	   alone	   or	   in	   combination	   with	   10	   μM	   4G-­‐
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BfSMoC-­‐	   COOH,	   2.	   The	   oligonucleotide/4G-­‐BfSMoC-­‐COOH,	   2	   was	   given	   15	  minutes	   to	   complex	   at	   room	   temperature.	   Final	   dilutions	   were	   made	   in	   the	  appropriate	  cell	  medium	  (4T1	  –	  RPMI,	  MCF7	  –	  DMEM	  F-­‐12).	  Both	  cell	  lines	  were	  treated	  with	  media	  (alone),	  oligonucleotide	  (alone),	  4G-­‐BfSMoC-­‐COOH,	  2	  (alone)	  or	   oligonucleotide/4G-­‐BfSMoC-­‐COOH,	   2	   for	   24	   hours	   at	   37°C.	   Lipofectamine	  controls	   were	   transfected	   according	   to	   manufacturers’	   instructions	   to	   a	   final	  concentration	   of	   3.75	   μL/mL	   +	   oligonucleotide.	   Cells	  were	  washed	   twice	  with	  PBS	  and	  treated	  with	  phenol-­‐red-­‐free	  media	  (Sigma-­‐Aldrich®)	  prior	  to	  confocal	  imaging.	  	  
2.13	  3-­‐	  [4,	  5-­‐dimethylthiazolyl]-­‐2,	  5-­‐diphenyltetrazolium	  bromide	  (MTT)	  
Assay	  The	  primary	  cell	  viability	  assay	  utilised	  for	  the	  in	  vitro	  studies	  in	  this	  thesis	  was	  the	   3-­‐	   [4,5-­‐dimethylthiazolyl]-­‐2,5-­‐diphenyltetrazolium	   bromide	   (MTT,	   Sigma-­‐Aldrich®)	  assay.	  Reduction	  of	  the	  hydrophilic	  tetrazonium	  salt	  by	  mitochondrial	  dehydrogenases	   results	   in	   purple	   insoluble	   formazan	   derivative.	   Therefore,	  metabolic	   activity	   was	   taken	   as	   a	   measure	   of	   viability.	   At	   experimental	   end	  points,	   medium	   was	   aspirated	   and	   washed	   (PBS),	   followed	   by	   a	   2	   hour	  incubation	   with	   100	   μl	   MTT	   (1	   μg/ml	   in	   RPMI)	   at	   37°C,	   5%	   CO2.	   MTT	   was	  replaced	  with	  Dimethyl	   Sulfoxide	   (DMSO,	   100	  μL/well)	   to	   solubilise	   formazan	  crystals.	   	   The	   absorbance	   of	   the	   formazan	   derivative	   was	   quantified	   using	   a	  micro	   plate	   reader	   (ELx800	   Biotek	   4,	   Bedfordshire,	   UK).	   This	   protocol	   is	  well	  described	  in	  the	  literature(25,	  37).	  
2.14	  AlamarBlue®	  AlamarBlue®	   was	   used	   as	   an	   alternative	   to	   MTT	   for	   the	   3D-­‐tumour	   model,	  mainly	   due	   to	   the	   benefit	   of	   it	   being	   a	   non-­‐toxic	  metabolic	   assay.	   As	  with	   the	  MTT	  assay,	   it	   is	   commonly	  used	   to	  assess	   cell	   viability.	  The	  assay	  comprises	  a	  fluorometric/colorimetric	   growth	   indicator,	   which	   is	   proportional	   to	   the	  metabolic	  activity	  of	  the	  cells.	  It	  specifically	  incorporates	  an	  oxidation-­‐reduction	  (REDOX)	   indicator,	   which	   both	   fluoresces	   and	   undergoes	   a	   shift	   in	   colour	   in	  response	  to	  reduction	  of	  the	  growth	  medium	  resulting	  from	  cell	  growth(60).	  	  AlamarBlue®	  was	  added	  to	  cell	  seeded	  collagen	  gels	  and	  was	  performed	  on	  day	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7	   by	   adding	   2	  ml	   of	   1:10	   AlamarBlue®	   to	   the	   existing	  media	   surrounding	   the	  collagen	  gels.	  The	  samples	  were	  then	   incubated	  for	  4h	  before	  transferring	  100	  μL	   (x6)	   samples	   of	   the	   media	   into	   a	   clear	   flat-­‐bottom	   96-­‐well	   plate.	  Subsequently,	  fluorescence	  was	  scanned	  for	  each	  treatment	  group	  (Ex	  560	  nm/	  Em	  590	  nm).	  
2.15	  LUCIFERASE	  TRANSDUCTION	  Transduction	   of	   human	   MCF7	   cells	   with	   firefly	   and	   Gaussia	   luciferase	   was	  required	   in	   order	   to	   perform	   prospective	   bioluminescence	   studies.	   The	  materials	  required	  for	  gene	  transduction	  (lentiviral	  vector,	  luciferase	  genes	  and	  polybrene)	  were	  kindly	  supplied	  by	  Dr	  Martin	  Pulé	  (Cancer	  Institute,	  UCL)	  with	  experimental	  guidance	  provided	  by	  Dr	  Amit	  Jathoul	  (Cancer	  Institute,	  UCL).	  	  Procedure	  
24	  hours	  prior	  to	  transduction:	  MCF7	  cells	  were	  split	  into	  a	  6-­‐well	  tissue	  culture	  plate	  at	  3.0x105	  per	  well	  in	  DMEM	  F-­‐12	  supplemented	  10%	  FBS.	  	  The	  cells	  were	  then	  incubated	  at	  37°C	  for	  24h	  to	  enable	  growth	  to	  a	  desired	  confluence	  of	  40-­‐60%,	  which	  is	  necessary	  for	  optimal	  transduction.	  	  
Transduction:	  Cells	  were	   checked	  under	   a	   light	  microscope	   in	  order	   to	   assess	  health	   and	  confirm	  that	  they	  had	  reached	  the	  right	  confluence.	  The	  media	  was	  aspirated	  and	  replaced	  with	  1.5	  ml	  of	  new	  media	  in	  each	  well.	  	  150	  µL	  of	  viral	  supernatant	  per	  well	  for	  1x	  concentration	  was	  added	  to	  each	  appropriate	  well.	  In	  addition	  to	  this	  a	  linker	  molecule	  (polybrene)	  was	  added	  directly	  to	  media	  to	  achieve	  a	  final	  concentration	  of	  8	  μg/ml.	  The	  plates	  were	  gently	   rocked	   on	   a	   plate	   shaker	   to	   facilitate	   the	   even	   distribution	   of	   both	  virus	   and	   linkers.	   Cells	   were	   then	   incubated	   at	   37oC	   for	   24h.	   Media	  containing	  viral	  supernatant	  and	  polybrene	  was	  aspirated	  and	  replaced	  with	  appropriate	  media.	  The	  cells	  were	  then	  re-­‐incubated	  for	  a	  further	  72h	  prior	  to	   assessment	   of	   trans-­‐gene	   expression	   using	   flow	   cytometry.	   The	   entire	  process	  can	  be	  repeated	  by	  adding	  viral	  supernatant	  and	  polybrene	   if	  gene	  expression	  is	  found	  to	  be	  unsatisfactory.	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NB.	  This	  process	  took	  place	  in	  antibiotic	  naïve	  cells	  as	  advised	  by	  Dr	  Jathoul.	  Trans-­‐gene	  expression	  was	  confirmed	  using	  flow	  cytometry.	  Once	  performed	  cells	  were	  subsequently	  sorted	  using	  fluorescence-­‐activated	  cell	  sorting	  (FACS)	  to	  maximize	  the	  density	  of	  highly	  expressing	  cells	  (see	  chapter	  6).	  Subsequently	  flow	  cytometry	  was	  repeated	  to	  confirm	  the	  final	  level	  of	  trans-­‐gene	  expression.	  
2.16	  PDT/PCI	  EXPERIMENTS	  The	   PDT	   and	   PCI	   experiments	   followed	   a	   standard	   format	   comprising	   the	  following:	  1. Cells	  were	   trypsinised	   as	  described	   above	  and	   following	   centrifugation,	  they	  were	  counted	  using	  a	  haemocytometer.	  Cells	  were	  then	  diluted	  and	  plated	  into	  96-­‐well	  plates	  (Thermo	  Scientific®	  Nunc®	  clear,	  flat	  bottom	  96-­‐well	  plates,	  UK)	   at	   a	   cell	   number	   of	   12	   x	   104	   ml-­‐1.	   Each	   treatment	   group	   comprised	   a	  minimum	  of	  16	  x	  100	  µL	  wells.	  There	  was	  a	  minimum	  of	   five	  repeats	   for	  each	  PDT/PCI	  experiment.	  	  2. Following	   24h	   incubation	   at	   37°C	   the	   various	   drug	   combinations	  (described	   in	   the	   results	   of	   the	   PCI	   chapter)	   were	   added.	   For	   the	   light-­‐after	  protocol,	  each	  treatment	  combination	  was	  added	  at	   this	   time	  (fig.	  2.6).	  For	  the	  light-­‐before	   protocol,	   only	   photosensitiser	   and	   REDOX	   drugs	   (BSO/LH/SOD)	  were	  added	  (fig.	  2.7).	  The	  entire	  process	  took	  place	  under	  dark	  conditions	  in	  the	  whole	   laboratory	   area.	   Plates	  were	   then	  wrapped	   in	   foil	   and	   re-­‐incubated	   for	  24h	  at	  37°C.	  	  3. 24h	   later	   the	   cells	   were	   washed	   twice	   in	   PBS.	   Subsequently,	   media	   or	  appropriate	  doses	  of	  the	  REDOX	  drugs	  were	  added	  to	  the	  appropriate	  treatment	  groups	   (for	   both	   light-­‐after	   and	   light-­‐before	   treatment	   regimens).	   In	   this	  way,	  excess	   photosensitiser	   and	   cytotoxin	   (SAP/MTX)	   were	   removed	   from	   the	  extracellular	  environment.	  Cells	  were	  then	  re-­‐incubated	  at	  37°C	  for	  a	  further	  4h	  or	   immediately	   illuminated.	   The	   plates	   were	   then	   illuminated	   for	   the	  appropriate	   time	   (seconds)	   using	   a	   blue	   lamp,	   LumiSource®	   (PCI	   Biotech,	  Norway),	   which	   emits	   light	   uniformly	   from	   four	   fluorescence	   tubes	   (spectral	  region	  375-­‐450	  nm)	  with	  a	  fluence	  rate	  of	  7	  mW	  cm-­‐2	  (fig.	  2.4).	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Figure	  2.4	  –	  Plate	  illuminator.	  	  (A)	  LumiSource®	  OFF,	  (B)	  LumiSource®	  ON.	  Comprises	  a	  bank	  of	  4	  fluorescent	  tubes.	  In	  order	  to	  maximise	  illumination	  a	  light	  impermeable	  box	  is	  placed	  over	  the	  plate	  during	  illumination.	  	  	  4. Cells	  were	  subsequently	  re-­‐incubated	  at	  37°C	  for	  24h/72h	  (light-­‐after)	  or	  media	  changed	  with	  the	  addition	  of	  cytotoxin	  +/-­‐	  the	  appropriate	  REDOX	  drugs	  (either	  in	  combination	  or	  alone).	  Again,	  these	  were	  re-­‐incubated	  for	  24h/72h.	  5. Cells	  were	  subsequently	  washed	  twice	  in	  PBS	  and	  treated	  with	  MTT	  (100	  µL,	  1mg/ml,	  made	  up	  in	  media)	  and	  incubated	  for	  2h.	  At	  this	  point,	  the	  MTT	  was	  removed	   and	   the	   remaining	   crystals	  were	  dissolved	   in	  DMSO	  and	  placed	  on	   a	  plate	  shaker	  for	  5	  minutes	  prior	  to	  reading	  absorbance	  on	  the	  plate	  reader	  (fig.	  2.5).	  	  
	  
Figure	  2.5	  –	  Plate	  reader.	  	  The	   absorbance	   of	   the	   formazan	   derivative	   (MTT)	  was	   quantified	   using	   a	  microplate	  reader	  (ELx800	  Biotek	  4).	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  A	  	  
	  B	  
Figure	  2.6	  –	  Light	  ’after’	  cytotoxin	  treatment	  regimen	  timelines.	  	  For	   this	   regimen,	   cells	   were	   treated	   with	   photosensitiser	   and	   cytotoxin	   +/-­‐	   REDOX	  agent	  prior	  to	  illumination.	  Cells	  were	  exposed	  to	  MTT	  (cell	  viability	  assay)	  24h	  (A)	  or	  72h	  (B)	  following	  illumination.	  For	  the	  ‘immediate’	  illumination	  group	  there	  was	  no	  4h	  re-­‐incubation	  following	  drug	  wash	  off	  at	  48h.	  (MTT	  plate	  image	  from	  Wikipedia).	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  A	  	  
	  B	  
Figure	  2.7–	  Light	  ’before’	  cytotoxin	  treatment	  regimen	  timelines.	  	  For	   this	   regimen,	   cells	   were	   treated	   with	   photosensitiser	   +/-­‐	   REDOX	   agent	   prior	   to	  illumination	  with	   cytotoxin	   added	  after	   exposure	   to	   light.	   Cells	  were	   exposed	   to	  MTT	  (cell	   viability	   assay)	   24h	   (A)	   or	   72h	   (B)	   following	   illumination.	   For	   the	   ‘immediate’	  illumination	  group	  there	  was	  no	  4h	  re-­‐incubation	  following	  drug	  wash	  off	  at	  48h.	  (MTT	  plate	  image	  from	  Wikipedia).	  
2.17	  BIOLUMINESCENT	  PDT	  The	   bioluminescent	   PDT	   experimental	   protocol	   was	   based	   upon	   the	   standard	  PDT/PCI	   protocol	  with	   a	   few	   alterations.	   Firstly,	   there	   is	   the	   consideration	   of	  adding	   D-­‐luciferin	   or	   coelenterazine	   for	   light	   production,	   in	   particular	   the	  amount	  of	  time	  required.	  This	  was	  determined	  by	  performing	  emission	  kinetics	  work	   for	   the	   MCF7-­‐GLuc	   species	   whereby,	   the	   intensity	   and	   duration	   of	   the	  bioluminescent	   signal	   was	  measured	   over	   time.	   This	   was	   achieved	   by	   adding	  coelenterazine	  (25µg/ml)	  to	  cells	  that	  had	  been	  growing	  for	  24h	  (seeded	  at	  15	  x	  104)	   in	   black	   96-­‐well	   plates	   (Thermo	   Scientific®	   Nunc®	   UK)	   and	   reading	   the	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bioluminescence	  initially	  for	  spectral	  analysis	  before	  a	  kinetic	  measurement	  was	  taken	   for	   emission	   between	   460	   nm-­‐490	   nm	   (Varioskan	   Flash,	   Thermo	  Scientific,	  Loughborough,	  UK).	  Subsequently,	  a	  treatment	  time	  of	  2	  x	  15	  minutes	  (900	  s)	  was	  decided	  upon.	  Furthermore,	  following	  the	  acquisition	  of	  initial	  data	  it	  was	  determined	  that	  the	  extracellular	  secretion	  of	  GLuc	  might	  necessitate	  the	  presence	  of	  photosensitiser	  in	  the	  media	  (phenol	  free	  RPMI-­‐1640	  or	  phenol	  free	  DMEM	   F-­‐12)	   both	   without	   FBS	   (as	   this	   can	   bind	   the	   luciferin)	   at	   the	   time	   of	  bioluminescence.	  This	  was	  done	  to	  enhance	  the	  BRET	  effect(61-­‐63)	  as	  described	  in	  chapter	  6.	  	  1. Cells	  were	   trypsinised	   as	   described	   above	   and	   following	   centrifugation,	  they	  were	  counted	  using	  a	  haemocytometer.	  Cells	  were	  then	  diluted	  and	  plated	  into	   96-­‐well	   plates	   (Thermo	   Scientific®	   Nunc®	   white	   (bioluminescence	  enhanced),	  flat	  bottom	  96-­‐well	  plates,	  UK)	  at	  a	  cell	  number	  of	  8	  x	  104	  ml-­‐1.	  Each	  treatment	   group	   comprised	   a	   minimum	   of	   16	   x	   100	   µL	   wells.	   There	   was	   a	  minimum	  of	  three	  repeats	  for	  each	  bioluminescent	  PDT	  experiment.	  	  2. Following	   48h	   incubation	   at	   37°C	   the	   various	   drug	   combinations	  described	  later	  (chapter	  6)	  were	  added.	  Each	  treatment	  combination	  was	  added	  at	  this	  time	  +/-­‐	  SOD.	  The	  entire	  process	  took	  place	  under	  dark	  conditions	  in	  the	  lab.	  Plates	  were	  then	  wrapped	  in	  foil	  and	  re-­‐incubated	  for	  4h	  (hypericin)	  or	  1.5h	  (TBR)	  at	  37°C.	  	  3. Cells	  were	  then	  washed	  twice	  in	  PBS.	  Subsequently,	  phenol	  free	  media	  or	  appropriate	   doses	   of	   the	   photosensitiser	   +	   luciferin	   (D-­‐luciferin	   or	  coelenterazine)	  +/-­‐	  SOD	  were	  added	  to	  the	  appropriate	  treatment	  groups	  for	  15	  minutes.	   The	   media	   was	   then	   removed	   and	   the	   same	   process	   repeated	   for	   a	  further	  15	  minutes.	  The	  media	  was	  removed	  again	  and	  replaced	  with	  media	  +/-­‐	  SOD.	  	  	  4. Following	   a	   2h	   incubation	   period,	   cell	   viability	   was	   assessed	   using	   the	  MTT	  protocol	  described	  above.	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2.18	  CONFOCAL	  MICROSCOPY	  
Cell	  preparation:	  	  4T1	  (murine)	  breast	  cancer	  cells	  (1	  x	  104)	  were	  seeded	  on	  35	  mm	  diameter	  glass-­‐bottomed,	  polylysine	  coated	  Fluorodishes™	  WPI,	  UK).	  	  They	  were	   incubated	   for	   48	   to	   encourage	   adherence	   and	  optimal	   sub-­‐confluent	   cell	  spreading	  for	  imaging.	  Pilot	  studies	  were	  performed	  to	  optimize	  cell	  seeding	  and	  incubation	   length	   pre-­‐treatment.	  	  	   4T1	   cells	   were	   incubated	   with	   fully	  supplemented	   fresh	   RPMI-­‐1640	   Medium.	   At	   48h-­‐post	   seeding,	   the	   cells	   were	  treated	  with	  drug	   (SAP-­‐488	  or	  MTX)	   for	  24h	  at	  37°C.	  Cells	  were	   subsequently	  washed	  with	  PBS	  and	  bathed	  in	  appropriate	  phenol-­‐free	  media	  for	  a	  further	  4h.	  At	  which	  point	  cells	  were	  either:	  i)	  illuminated	  for	  90	  s	  (using	  the	  LumiSource®	  illuminator)	  with	   confocal	   images	   taken	  after	   a	   final	  4	  h	   incubation	  period;	   ii)	  Confocal	   images	  were	   taken	   initially	   followed	  by	  on-­‐stage	  exposure	   to	   the	  405	  nm	  confocal	   laser	  for	  15s	  before	  further	  images	  were	  taken	  at	  two	  time	  points	  (immediately	  and	  240	  s	  after	  405	  nm	  laser).	  Short	  exposures	  were	  employed	  in	  order	  to	  protect	  the	  integrity	  of	  the	  cell	  and	  so	  as	  not	  to	  perturb	  the	  fluorescence	  distribution.	   Appropriate	   controls	   were	   used	   throughout.	   Different	  combinations	  of	  excitation/detection	  wavelengths	  were	  used	  for	  Alexa	  –	  488	  (Ex	  488	  nm,	  Em	  520	  nm)	  and	  MTX	  (Ex	  635	  nm,	  Em	  647	  nm)	  compared	  to	  TPPS2a	  in	  order	  avoid	  crosstalk	  (controls	  were	  checked)	  and	  limit	  the	  excitation	  of	  TPPS2a	  	  (405	  nm).	  
	  
Saporin	   –	   Alexa	   488	   complex:	   This	   was	   prepared	   according	   to	   manufacturers’	  specification	  as	  described	  above.	  Final	  dose	  used	  for	  imaging	  was	  40	  nM	  (SAP-­‐488).	  	  Lysotracker®	  Green	  (LYG:	  Invitrogen,	  UK)	  experiment:	  Following	  24h	  incubation	  with	   MTX,	   cells	   were	   washed	   and	   treated	   with	   LYG	   50	   nM	   (used	   to	   image	  endolysosomal	  compartments)	  for	  30	  min	  prior	  to	  confocal	  imaging	  (Ex	  488	  nm,	  Em	  520	  nm).	  	  	  	  Monochlorobimane	  (mBCl,	  Life	  Technologies):	  this	  is	  a	  thiol	  probe	  that	  remains	  non-­‐fluorescent	  until	  conjugated.	   It	  can	  react	  with	   low	  molecular	  weight	   thiols	  
	   50	  
including	   glutathione(64-­‐66)	   and	   mercaptopurine.	   This	   probe	   was	   used	   to	  determine	   intracellular	   glutathione	   expression	   with	   or	   without	   BSO.	   The	  absorption/emission	  maximum	  for	  the	  glutathione-­‐monochlorobimane	  	  conjugate	   is	  ∼394/490	  nm.	  Cells	  were	  treated	  with	  40	  µM	  mBCl	   in	  RPMI-­‐1640	  for	   20	   minutes	   prior	   to	   confocal	   microscopy	   as	   per	   previously	   reported	  protocol(66).	  	  	  
	  
Confocal	  microscope:	  Cells	  were	  observed	  using	  an	   inverted	  Olympus	  Fluoview	  1000	  confocal	  laser-­‐scanning	  microscope	  to	  determine	  intracellular	  localisation	  of	   MTX,	   LYG,	   mBCl	   or	   SAP-­‐488.	  	   Fluorescence	   confocal	   images	   were	   obtained	  using	   a	   60	   x	   1.35	   NA	   oil	   immersion	   or	   a	   20	   x	   0.75	   NA	   objective	   (Olympus).	  Fluoview	  FV1000	  (Olympus)	  and	  Image	  J	  software	  were	  used	  to	  analyse	  images.	  A	   minimum	   of	   five	   samples,	   of	   equal	   area,	   was	   taken	   in	   order	   to	   perform	  quantitative	   analysis	   of	   mean	   fluorescence.	   Each	   experiment	   was	   repeated	  twice.	  	  	  
2.19	  Lipid	  peroxidation	  confocal	  studies	  In	  order	  to	  assess	  the	  impact	  of	  ROS	  production	  on	  lipid	  peroxidation	  the	  Image-­‐iT®	   Peroxidation	   Kit	   (Life	   Technologies,	   Molecular	   Probes®,	   UK).	   Oxidation	   of	  the	   fluorophore,	  within	   live	   cells,	   results	   in	  a	   shift	   in	   fluorescence	   from	  red	   to	  green(67),	   which	   enables	   ratiometric	   analysis(68)	   of	   lipid	   peroxidation	   as	   a	  result	  of	  photosensitiser	  mediated	  ROS	  production.	  	  Cells	  were	   prepared	   as	   described	   above	   in	   polylysine-­‐coated	   fluorodishes	   and	  treated	   with	   chosen	   doses	   and	   combinations	   of	   TPPS2a,	   SAP	   and	   BSO.	  Appropriate	   controls	   were	   used	   throughout.	   However,	   the	   Cumene	  hydroperoxide	   positive	   control	   proved	   too	   toxic	   for	   the	   cells	   at	   the	   doses	  recommended	  by	  the	  manufacturer.	  	  	  The	   lipid	  probe	  was	  prepared	  as	  per	   the	  manufacturers	  guidelines.	  The	  probe,	  which	   is	   pre-­‐dissolved	   in	   DMSO	   to	   10	   mM,	   was	   diluted	   in	   media	   to	   a	   final	  concentration	  of	  10	  µM.	  This	  was	  added	  to	  cells	   that	  had	  already	  been	   treated	  for	   24h	   with	   appropriate	   agents	   and	   illuminated	   using	   the	   LumiSource®	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illuminator.	  These	  cells	  were	  incubated	  for	  30	  minutes	  at	  37°C	  and	  subsequently	  washed	  in	  PBS	  three	  times.	  Following	  washing,	  phenol-­‐free	  media	  was	  added	  to	  the	  cells	  prior	  to	  confocal	  imaging.	  	  	  The	  confocal	  settings	  used:	  	  
- Reduced	  form	  of	  probe.	  Recommended	  excitation	  and	  emission	  maxima	  are	  581/591	  nm.	  Settings	  used	  559/579-­‐615	  nm.	  
- Oxidised	  form	  of	  probe,	  488/510	  nm.	  Settings	  used	  488/490-­‐525	  nm.	  	  	  Appropriate	   controls	   were	   utilized	   including	   dark	   controls.	   Triplicate	   repeats	  were	  performed	  and	  quantitative	  analysis	  was	  performed	  as	  described	  above	  in	  order	  to	  provide	  ratiometric	  comparison	  between	  reduced	  and	  oxidized	  lipid.	  
2.20	  SMoC	  confocal	  studies	  Cells	   were	   prepared	   for	   confocal	   as	   described	   above	   and	   treated	   with	  appropriate	   SMoC,	   siRNA-­‐Alexa-­‐555,	   lipofectamine	   concentrations	   and	  combinations	   as	   described	   above.	   Original	   image	   files	   were	   analysed	   using	  Image	  J	  software.	  Image	  J	  software	  was	  again	  used	  to	  analyse	  the	  uptake	  of	  the	  labelled	   siRNA	   +/-­‐	   4G-­‐BfSMoC-­‐COOH,	   2	   in	   order	   to	   quantify	   the	   mean	  intracellular	   signal	   intensity	   in	   comparison	   to	   the	   background	   level	   of	  fluorescence(69).	  Appropriate	  controls	  were	  used	  throughout.	  
2.21	  3D	  ARTIFICIAL	  CANCER	  MASS	  SYNTHESIS	  AND	  PCI	  STUDIES	  The	   3D	   artificial	   cancer	   masses	   (ACMs)	   were	   based	   on	   a	   type	   I	   collagen	  hydrogel,	  in	  to	  which	  4T1	  cancer	  cells	  were	  embedded	  and	  the	  complex	  placed	  under	   plastic	   compression	   with	   the	   aim	   of	   increasing	   both	   cell	   and	   matrix	  density.	  	  The	  methodology	  follows	  the	  model	  reported	  by	  Nyga	  et	  al.	  (2013)(50).	  	  	  The	   first	   step	   was	   the	   preparation	   of	   the	   collagen	   hydrogel	   and	   4T1	   cell	  complex/artificial	  cancer	  mass	  (ACM).	  For	  this,	  rat-­‐tail	  type	  I	  collagen,	  2.04	  mg	  ml-­‐1	   in	   0.6%	   acetic	   acid	   (Fist	   Link	  UK)	  was	   complexed	  with	   10x	   concentrated	  minimum	   essential	   Eagle’s	   medium	   (0.4ml)	   (MEM,	   Life	   Technologies,	   Paisley,	  UK).	  In	  order	  to	  neutralise	  the	  acidic	  solution,	  initially	  5	  M	  NaOH	  was	  added	  as	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individual	  drops.	  As	  the	  colour	  of	   the	  mixture	  changed	  to	  pink,	  1	  M	  NaOH	  was	  used	   until	   the	   correct	   colour	   was	   achieved	   (fig.	   2.8),	   indicating	   ~pH	   7.3	   (the	  mixture	  was	  agitated	  throughout	  to	  facilitate	  mixing).	  Following	  this	  the	  mixture	  was	  put	  on	  ice	  to	  enable	  the	  dispersion	  of	  air	  bubbles	  present	  due	  to	  the	  mixing	  process.	  If	  the	  mixture	  was	  not	  rapidly	  cooled	  it	  would	  have	  set,	  rendering	  it	  not	  suitable	  for	  cell	  implantation.	  	  
	  
Figure	  2.8	  –	  Neutralisation	  of	  rat-­‐tail	  collagen	  and	  acetic	  acid	  using	  NaOH.	  	  (A)	  Type	   I	  collagen	  (2.4	  mg	  ml-­‐1)	  with	  0.6%	  acetic	  acid	  prior	   to	  addition	  of	  NaOH,	  (B)	  neutralised	   type	   I	   collagen/acetic	   acid	   following	   addition	   of	   NaOH.	   The	   bright	   pink	  colour	  indicates	  ~pH	  7.3.	  	  During	  this	  time	  a	  mould	  was	  set	  up	  with	  a	  165	  µm	  steel	  mesh	  and	  a	  nylon	  mesh	  on	  absorbent	  paper	  at	  the	  bottom.	  A	  0.4ml	  (for	  a	  4ml	  collagen	  gel)	  suspension	  of	  4T1	  cancer	  cells	  (6.4	  million)	  was	  added	  to	  the	  collagen	  and	  gently	  mixed	  using	  a	   Pasteur	   pipette.	   The	   volume	   ratios	   of	   collagen:MEM:cell	   suspension	   were	  8:1:1(50).	   This	   mixture	   (4	   ml)	   was	   then	   poured	   into	   the	   rectangular	   mould	  resting	   on	   a	   glass	   slide,	   which	   is	   in	   turn	   on	   top	   of	   filter	   paper.	   Mixture	   was	  allowed	  to	  set	  for	  30	  minutes	  at	  room	  temperature.	  The	  steel	  mesh	  was	  placed	  on	  top	  of	  the	  filter	  paper,	  with	  the	  nylon	  mesh	  placed	  above	  the	  steel	  mesh.	  The	  3	  were	   then	  placed	  over	   the	  opening	  of	   the	  mould	  and	   the	  mould	   inverted.	  At	  which	   point	   the	  mould	   was	   placed	   under	   compression	   for	   30	   s	   using	   a	   175g	  weight.	   The	   mould	   was	   then	   inverted,	   the	   mesh	   removed	   and	   placed	   on	   the	  other	  side	  and	  the	  process	  repeated	  for	  a	  further	  30	  s	  of	  compression.	  The	  whole	  process,	   undertaken	   under	   sterile	   conditions,	   enabled	   liquid	   expulsion	   and	  defined	  compression	  of	  the	  cell-­‐populated	  gel	  (ACM).	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The	  compressed	  ACM	  was	  cut	  in	  to	  4	  equal	  pieces	  using	  a	  sterile	  surgical	  blade.	  These	   were	   transferred	   to	   individual	   wells	   within	   a	   12-­‐well	   plate.	   The	   AMCs	  were	  then	  anchored	  on	  to	  an	  acellular	  collagen	  scaffold	  (hydrogel),	  using	  10	  ml	  of	  uncompressed	  collagen	  gel	  (collagen:MEM	  ratio	  9:1)	  (fig.	  2.9).	  	  The	  resultant	  3D	   cultures	   comprising	   a	   central	   dense	  ACM	   surrounded	  by	   acellular	   collagen	  (to	  mimic	  cancer	  stroma)	  have	  been	  termed:	  tumoroids.	  Plates	  were	  incubated	  	  for	  30	  minutes	   at	   37°C.	  Media	  was	   then	   added	   (DMEM	  F-­‐12	  +	  10%	   (v/v)	  FBS	  and	  10%	  penicillin/streptomycin)	  and	  the	  cells	  incubated	  for	  24h.	  At	  this	  point	  the	  media	  was	   changed	   to	   (RPMI	  +	  10%	  (v/v)	  FBS)	   and	   the	  ACM	  grown	   for	   a	  further	  6	  days	  prior	  to	  experimentation.	  Media	  was	  changed	  every	  48h.	  	  At	  day	  7	   tumoroid	   growth	  was	   assessed	  using	   a	   light	  microscope.	  Drugs	  were	  subsequently	  added	  to	  the	  tumoroids:	  Control	  (media,	  RPMI-­‐1640),	  PDT	  (TPPS2a	  0.8	  µg/ml),	  Cytotoxin	  (SAP	  60	  nM)	  and	  PCI	  (TPPS2a	  +	  SAP).	  All	  of	  this	  performed	  under	  standard	  ‘dark’	  conditions.	  These	  were	  subsequently	  wrapped	  in	  foil	  and	  incubated	   for	  24	  hours.	  Media	  was	   then	  carefully	  aspirated	  and	   the	   tumoroids	  washed	   three	   times	  with	   PBS.	  Media	  was	   then	   added	   and	   the	   ACMs	  were	   re-­‐incubated	  for	  4h	  at	  37°C.	  	  	  The	   tumoroids	  were	   then	   illuminated	  using	   the	  LumiSource®	   illuminator	   for	  3	  minutes,	   before	   being	   transferred	   back	   to	   the	   incubator.	   The	   tumoroids	  were	  then	  left	  to	  recover	  for	  7	  days	  (media	  changed	  every	  48h).	  The	  7-­‐day	  delay	  was	  chosen	   based	   on	   advice	   given	   by	   colleagues	   at	   the	   Royal	   Free	   Hospital,	  Department	   of	   Surgery,	   who	   have	   a	   great	   level	   of	   experience	   in	   3D-­‐tumour	  models.	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Figure	  2.9	  –	   Illustration	  of	   stepwise	  synthesis	  of	  4T1	  cell	  Artificial	  Cancer	  Mass.	  Following	   synthesis	   the	   ACM	   was	   grown	   for	   7	   days,	   and	   tumoroid	   growth	   assessed	  under	  light	  microscope	  prior	  to	  addition	  of	  drugs.	  	  	  The	   timings	   used	   for	   in	   vitro	   experiments	   (24h	   or	   72h)	  would	   not	   have	   been	  sufficient	   to	   detect	   a	   significant	   cytotoxic	   effect.	   AlamarBlue®	   toxicity	   assay,	  subsequently	  performed	  prior	  to	  fixation	  in	  formalin.	  	  
2.22	  STATISTICS	  Results	   generated	   from	   the	   work	   undertaken	   for	   this	   thesis	   were	   generally	  parametric,	   as	   befitting	   data	   derived	   from	   experimental	   repeat	   laboratory	  protocols.	   	   All	   statistical	   analysis	   was	   undertaken	   using	   Microsoft	   Excel	   and	  subsequently	  GraphPad	  PRISM.	  	  Gaussian	  distribution	  was	  confirmed	  and	  analysis	  was	  undertaken	  by	  one-­‐way	  ANOVA	  followed	  by	  post	  hoc	  analysis	   (Tukey’s),	  non-­‐parametric	   investigations	  were	  undertaken	  for	  data	  sets	  with	  small	  repeats	  per	  group	  <4).	  Repeats	   for	   most	   experiments	   were	   n=6	   per	   group,	   with	   a	   minimum	   of	   n=4.	  Routinely,	   each	   of	   these	   numbers	   were	   averages	   of	   multiple	   readings.	   For	  example,	   multiwell	   data	   were	   averaged	   as	   appropriate	   (for	   example	   8	   well	  readings	  =	  one	  average	  number,	  then	  used	  for	  statistical	  analysis).	  In	  addition	  all	  multiwall	  data	  was	  normalised	  (using	  GraphPad	  PRISM)	  to	  enable	  comparison.	  In	   other	   experiments	   (for	   example	   tumoroids/confocal),	   numbers	   were	  averages	  of	  duplicates.	  Significance	  was	  taken	  at	  p<0.05.	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SCIENTIFIC	  BACKGROUND	  	  Reduction-­‐oxidation	   (REDOX)	  homeostasis	   is	  vitally	   important	   for	   the	   survival	  of	   mammalian	   cells.	   Physiological	   REDOX	   homeostasis	   is	   maintained	   by	  appropriately	  balancing	  the	  levels	  of	  pro-­‐oxidants	  and	  antioxidants	  within	  a	  cell.	  The	  majority	  of	  reactive	  oxygen	  species	  (ROS)	  are	  produced	  by	  mitochondria	  in	  the	   electron-­‐chain	   during	   aerobic	   respiration(70).	   Other	   sources	   of	   ROS	  production	   include	   the	   hepatic	   cytochrome	   P450	   (CYP450)	   system,	   which	   is	  involved	  in	  the	  metabolism	  of	  toxic	  and	  non-­‐toxic	  compounds;	  and	  the	  xanthine	  oxidase	   pathway	   during	   the	   formation	   of	   H2O2(71).	   The	   roles	   of	   ROS,	   at	   sub-­‐micromolar	   levels,	   as	   secondary	   messengers	   for	   triggering	   cell	   proliferation,	  gene	  expression	  and	  apoptosis	  have	  also	  been	  described.	   	  Pi	  et	  al.	   (2007)	  (72)	  reported	  that	  H2O2	  generated	  from	  glucose	  metabolism	  has	  an	  important	  role	  in	  triggering	  insulin	  secretion	  from	  𝛽-­‐cells	  of	  the	  pancreas.	  However,	  excessive	  or	  persistently	  elevated	   levels	  of	  H2O2	  have	  been	  shown	  to	  disrupt	  mitochondrial	  activity(73)	   and	   alter	   macromolecules	   subsequently	   contributing	   to	   the	  pathogenesis	  of	  diabetes	  mellitus	  (74).	  ROS	  are	  also	  implicated	  in	  carcinogenesis	  and	  the	  development	  of	  the	  multidrug	  resistant	  (MDR)	  phenotype.	  For	  example	  ROS	   have	   been	   shown	   to	   modulate	   the	   structure(71),	   activity(75)	   and	   gene	  expression	   (via	   the	   activation	   of	   hypoxia-­‐inducible	   factor)(76,	   77)	   of	   cellular	  efflux	   pumps	   up-­‐regulated	   in	   the	   MDR	   phenotype.	   Overexpression	   and/or	  increased	   activity	   of	   such	   pumps	   is	   an	   important	   feature	   in	  MDR.	   In	   order	   to	  manage	  higher	  levels	  of	  endogenous	  ROS,	  antioxidants	  are	  produced	  by	  a	  variety	  of	   enzymes	   including	   catalase,	   superoxide	   dismutase	   (SOD)	   glutathione	  peroxidase	   and	   glutathione	   S-­‐tranferase(71,	   78).	   If	   the	   balance	   is	  weighted	   in	  favour	   of	   oxidation	   it	   may	   result	   in	   intolerable	   and	   potentially	   mutagenic	  oxidative	   stresses.	   For	   example,	   Sies	   and	   Cadenas	   (1985)(79),	   described	   the	  potential	   detrimental	   effects	   of	   oxidative	   stresses	   on	   nucleic	   acids,	   lipids	   and	  structural	   carbohydrates.	   One	   of	   the	   well-­‐described	   mechanisms	   for	   cellular	  protection	   against	   ROS	   damage	   is	   under	   the	   regulation	   of	   Nuclear	   Factor	  (erythroid-­‐derived	   2)-­‐like	   2	   also	   known	   as	   NFE2L2	   or	   Nrf2	   (80,	   81).	   Under	  normal	   REDOX	   conditions,	   Nrf2,	   is	   kept	   inactive	   following	   binding	   to	   Keap1	  (Nrf2-­‐Keap1),	   which	   prevents	   it	   acting	   as	   a	   transcription	   factor	   for	   the	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antioxidant	   response	   element	   (ARE)	   associated	   genes	   that	   encode	   a	   range	   of	  antioxidants.	   However	   following	   oxidative	   attack	   Nfr2-­‐Keap1	   is	   cleaved,	  subsequently	  liberating	  Nfr2	  to	  transcribe	  ARE	  associated	  genes	  to	  enhance	  the	  reducing	  power	  of	  the	  cell.	  	  	  	  Lipid	   peroxidation	   is	   a	   very	   important	   consequence	   of	   ROS	   interactions	   with	  polyunsaturated	  fatty	  acids	  (PUFAs).	  PUFAs	  play	  a	  variety	  of	  important	  roles	  in	  cell	  signalling,	  membrane	  structure	  and	  function,	  regulation	  of	  gene	  expression	  notwithstanding	  energy	  provision(82).	  	  Linoleic	  acid	  (C18:2n-­‐6)	  and	  α-­‐linolenic	  acid	   are	   the	   two	   essential	   fatty	   acids	   that	   animals	   are	   entirely	   dependent	   on	  from	  plant	  sources.	  PUFAs	  are	  known	  to	  exhibit	  a	  particularly	  high	  sensitivity	  to	  oxidative	   stresses	   when	   compared	   to	   other	   cellular	   macromolecules.	   Of	   the	  PUFAs,	  phospholipids	  are	  particularly	  susceptible	  to	  oxidative	  damage	  not	  least	  owing	   to	   their	   proximity	   to	   enzymatic	   and	   non-­‐enzymatic	   systems	   that	   can	  generate	   pro-­‐oxidative-­‐free	   radical	   species(83).	   Wagner	   et	   al	   (1994)(84)	  reported	   that	   the	   sensitivity	   of	   PUFAs	   to	   oxidative	   damage	   increases	  with	   the	  number	  of	  double	  bonds	  per	  fatty	  acid	  molecules,	  thus	  the	  more	  unsaturated	  a	  fatty	  acid	  the	  greater	  the	  reducing	  power	  it	  possesses.	  	  Of	  particular	  importance	  when	  considering	  the	  effect	  of	  photosensitiser	  mediated	  ROS	  generation	  in	  the	  membranes	  of	   organelles	   is	   the	   fact	   that	  30-­‐80%	  of	   the	  mass	  of	   the	  biological	  cell	  membrane	  is	  made	  up	  of	  lipids(82).	  	  The	  peroxidation	  of	  lipids,	  as	  described	  by	  Catala	  (2006)(83)	  is	  a	  3	  step	  process	  involving:	  	  	  i) Initiation	   –	   this	   includes	   the	   abstraction	   of	   a	   hydrogen	   atom	   from	   a	  methylene	   group	   in	   PUFA,	   mainly	   phospholipids.	   This	   can	   be	   triggered	   by	  reaction	  with	  among	  others	  peroxyl	  (ROO•),	  hydroxyl	  (OH•)	  and	  alkoxyl	  (RO•)	  radicals	   but	   not	   H2O2	   or	   superoxide	   (O2-­‐•)(85).	   The	   process	   involves	   the	  reaction	  between	  a	  free	  radical	  e.g.	  OH•	  with	  PUFAs	  resulting	  in	  the	  formation	  of	  a	   lipid	  radical,	  which	  subsequently	  reacts	  with	  O2	  forming	  lipid	  peroxyl	  radical	  (LOO•).	   Following	   this	   the	   lipid	   peroxyl	   can	   abstract	   hydrogen	   from	   -­‐CH2-­‐	  forming	  a	  lipid	  hydroperoxide	  (LOOH)	  and	  a	  second	  lipid	  radical(83).	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ii) Propagation	  –	  a	  chain	  reaction	  is	  set	  up	  as	  LOOH	  can	  undergo	  reductive	  cleavage	  by	  reduced	  transition	  metals	  such	  as	  Fe2+	  forming	  LO•	  (alkoxyl	  	  radical)(82).	  Both	  LOO•	  and	  LO•	  can	  oxidise	  other	  unsaturated	   fatty	  acids	   in	  a	  process	  that	  is	  governed	  by	  the	  reactivity	  of	  free	  radicals	  thus,	  for	  example,	  the	  LOO•	  radical	  is	  more	  reactive	  than	  PUFA•	  thus	  will	  propagate	  the	  reaction	  (86).	  It	   is	   important	   to	  note	  at	   this	  point	   that	   there	  are	  different	  chemical	   reactions	  involved	  in	  forming	  LOOH,	  which	  occur	  with	  the	  different	  ROS,	  for	  example,	  with	  singlet	  oxygen	  there	  is	  the	  ‘ene’	  reaction	  with	  unsaturated	  double	  bonds.	  	  iii) 	  Termination	   –	   this	   process	   is	   facilitated	   by	   the	   presence	   of	   transition	  metals	   and	   ascorbic	   acid	   (vitamin	   C).	   LOOH	   decomposes	   to	   yield	   a	   range	   of	  products	   including	   reactive	   aldehydes	   such	   as	   4-­‐hydroxynonenal,	   4-­‐hydroxyhexenal,	  and	  malonaldehyde.	  	  	  
	  
Figure	  3.1	  –	  Chemical	  steps	  for	  Lipid	  Peroxidation.	  	  Diagrammatic	   representation	   of	   process	   for	   lipid	   peroxidation	   including	  docosahexaenoicacid	  (22:6n-­‐3),	  R1=fatty	  acid,	  R2=fragmentation	  products	  of	  fatty	  acid	  oxidation.	  Catala	  2009(82)	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iv) Of	   the	   reactive	   aldehydes,	   4-­‐hydroxy-­‐2-­‐nonenal	   (HNE)	   is	   the	   main	  aldehyde	   formed	   from	   n-­‐6	   fatty	   acids	   including	   linoleic	   and	   arachadonic	  acid(83)	   and	   these	   have	   been	   shown	   to	   increase	  within	  membranes	   following	  oxidative	  insults(87).	  Whilst	  4-­‐hydroxy-­‐2-­‐hexenal	  (HHE)	  is	  formed	  following	  the	  decomposition	   of	   n-­‐3	   (e.g.	   α-­‐linolenic	   and	   docosahexaenoic	   acid)	   lipid	  hydroperoxides.	   These	   aldehydes	   play	   an	   important	   role	   in	   prolonging	   the	  effects	  of	  oxidative	  attack	  as	  they	  can	  persist	  for	  longer	  than	  free	  radicals	  owing	  to	  their	  relative	  stability.	  Further	  more	  they	  can	  diffuse	  within	  or	  even	  out	  of	  a	  cell	   and	   covalently	   react	   with	   distant	   targets	   including	   proteins,	   DNA	   and	  phospholipids(83).	   Sub-­‐lethal	   doses	   of	   the	   HNE	   and	   HHE	   have	   also	   been	  implicated	   in	   both	   physiological	   and	   pathophysiological	   processes	  where	   they	  can	   function	   as	   second	   messengers	   to	   regulate	   among	   other	   functions	   cell	  division(88),	  differentiation(89),	  and	  apoptosis(90).	  This	   indicates	   that	   the	  by-­‐products	  of	  lipid	  peroxidation	  can	  have	  a	  significant	  effect	  of	  cell	  function	  even	  if	  the	  oxidative	  insult	  that	  initiated	  their	  formation	  is	  primarily	  non-­‐lethal.	  	  	  Given	   the	   preference	   in	   PCI	   to	   utilise	   amphiphilic	   photosensitisers	   that	  preferentially	   reside	   within	   the	   phospholipid	   bilayer(26)	   it	   is	   important	   to	  consider	   the	   potential	   effects	   of	  ROS	   generation	  within	   this	   lipid	   environment	  and	  potential	  generation	  of	  lipid	  hydroperoxides	  +/-­‐	  reactive	  aldehydes.	  	  
3.1	  Disulfonated	  meso-­‐tetraphenylporphyrin	  (TPPS2a)	  The	  photosensitiser	  of	  choice	  in	  this	  study	  was	  TPPS2a,	  owing	  to	  its	  amphiphilic	  properties	   making	   it	   an	   ideal	   photosensitiser	   for	   PCI(26).	   In	   addition	   to	   its	  ability	  to	  act	  as	  a	  photosensitiser	  for	  PDT,	  the	  suitability	  of	  TPPS2a	  for	  PCI	  is	  well	  described	  in	  the	  literature	  for	  both	  in	  vitro	  and	  in	  vivo	  studies(24,	  43,	  91).	  TPPS2a	  has	   a	   very	   similar	   structure	   to	   the	   chlorin-­‐based	   photosensitiser,	   Amphinex®	  (fig.	   3.2),	   which	   is	   currently	   undergoing	   clinical	   trials	   for	   PCI	   of	   bleomycin	   in	  head	  and	  neck	  cancer	  and	  cholangiocarcinomas.	  	  The	  ‘targeting’	  of	  TPPS2a	  to	  the	  endo-­‐lysosomal	   membranes	   is	   a	   product	   of	   its	   amphiphilic	   structure	   with	  sulfonation	   on	   adjacent	   phenyl	   rings	   and	   the	   methodology	   employed	   in	   this	  study	  (e.g.	  4	  hour	  wash	  out	  period).	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Figure	   3.2	   –	   Molecular	   weight	   and	   structure	   of	   three	   disulfonated	   amphiphilic	  
photosensitisers.	  	  	  Sulfonation	  of	   the	  photosensitisers	   confers	  amphiphilic	  properties.	  TPPS2a	   and	  TPCS2a	  (Amphinex®)	   share	   almost	   identical	   structures.	   Amphinex	   has	   been	   specifically	  synthesised	  for	  use	  in	  humans,	  therefore	  using	  TPPS2a	  (activated	  by	  blue-­‐light)	  does	  not	  negate	  the	  relevance	  of	  this	  thesis	  to	  potential	  clinical	  application.	  
3.2	  Saporin	  and	  the	  Ribosome	  Inactivating	  Proteins	  The	  chosen	  cytotoxins	  are	  both	  good	  candidates	  for	  studying	  enhanced	  delivery.	  Saporin	   (SAP)	   is	   a	   30kD	   plant	   ribosome	   inactivating	   protein	   (RIP,	   type	   I)	  isolated	   from	   the	   soapwort	  Saporinaria	   officinalis(92).	   Being	   a	   type	   I	   RIP,	   SAP	  comprises	  a	  single,	  enzymatically	  active	  A-­‐chain,	  whereas	  the	  type	  II	  RIPs	  such	  as	  Ricin	  comprise	   the	  A-­‐chain,	   linked	   to	  a	   lectin	  B-­‐chain	  via	  a	  disulfide	  bridge.	  The	   B-­‐chain	   enables	   Type	   II	   RIPs	   to	   bind	   to	   carbohydrate-­‐based	   cell	   surface	  receptors,	  which	   facilitates	   their	  entry	   in	   to	   the	  cell.	  Consequently,	   the	  Type	   II	  agents	  demonstrate	  enhanced	  selectivity	  and	  uptake(93).	  These	  toxic	  inhibitors	  of	   translation	   irreversibly	   disrupt	   ribosomal	   RNA	   ribosomal	   subunit(94).	  Adenine	  residues	  in	  large	  rRNAs	  are	  the	  in	  vitro	  targets	  for	  SAP,	  which	  catalyzes	  depurination	  reactions	   resulting	   in	   loss	  of	   function(95).	  Endo	  et	  al.	   (1987)(94,	  96)	   demonstrated	   that	   the	   principal	   enzymatic	   activity	   of	   RIPs	   is	   an	   N-­‐glycosidation	   to	   remove	  A4324	   in	   the	  28S	   rRNA	   in	   the	  60	   s	   subunit	  of	   the	   rat	  ribosome(97).	   This	   adenine	   is	   part	   of	   a	   tetranucleotide	  G(A4324)GA	   sequence	  within	   a	   highly	   conserved	   (among	   eukaryotic	   rRNA)	   region	   of	   large	   rRNAs	  known	  as	  the	  α-­‐sarcin	  loop.	  Once	  the	  target	  adenine	  is	  irreversibly	  modified	  this	  consequently	  impairs	  ribosome	  interaction	  with	  elongation	  factor	  (EF)	  –	  2,	  thus	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blocking	  translation(98,	  99).	  This	  is	  mediated	  by	  the	  inhibition	  of	  EF-­‐1	  and	  EF-­‐2-­‐dependent	  GTPases.	  	  	  	  As	  described	  above,	  unlike	  the	  type	  II	  RIPs,	  SAP	  and	  other	  type	  I	  agents	  such	  as	  pokeweed	   antiviral	   protein	   (PAP),	   only	   possess	   a	   single	   A-­‐chain(100),	   which	  significantly	   impairs	   the	   cytosolic	   uptake,	   retention	   and	   delivery	   to	   site	   of	  action.	   This	   effect	   has	   been	   shown	   in	   animal	  models	   and	   human	   trials	  where	  there	  has	  been	  a	  significant	  difference	  in	  the	  toxic	  effects	  associated	  with	  the	  use	  of	  type	  I	  versus	  type	  II	  RIPs.	  For	  example,	  Ricin	  (type	  II	  RIP)	  found	  in	  the	  seeds	  of	  Ricinus	  communis	  L.	  (from	  castor	  beans)	  is	  potently	  toxic	  to	  both	  humans	  and	  animals(93).	   The	   toxic	   side	   effects	   associated	   with	   castor	   beans	   include	  gastrointestinal	   upset	   (nausea,	   haematochezia,	   necrotic	   hepatitis),	   central	  nervous	   system	   disruption	   (depressed	   Glasgow	   Coma	   Score,	   seizures)	   and	  nephrotoxicity	   (glomerulonephritis)(101).	   In	   rats,	   high	   doses	   of	   type	   II	   RIPs	  have	   been	   shown	   to	   result	   in	   death	   within	   6-­‐10	   hours.	   At	   such	   doses	   death	  preceded	  the	  detection	  of	  lethal	  lesions	  in	  parenchymal	  organs(93).	  Type	  I	  RIPs	  in	   comparison	   have	   been	   shown	   to	   exhibit	   limited,	   if	   any,	   fatal	   effects	   at	  therapeutic	  doses.	  For	  example,	  trichosanthin	  given	  as	  an	  antiretroviral	  agent	  in	  patients	   with	   Acquired	   Immune	   Deficiency	   Syndrome	   (AIDS)	   resulted	   in	   the	  development	   of	   prodromal	   symptoms	   including	   fevers,	   flu-­‐like	   symptoms,	  rashes	  and	  join	  pain(93,	  102).	  	  	  	  Given	  that	  both	  types	  of	  RIPs	  have	  been	  shown	  to	  have	  similar	  levels	  of	  activity	  in	   cell-­‐free	   systems(103).	   This	   coupled	   with	   the	   reported	   observations	   that	  modifications	  to	  type	  I	  RIPs,	  including	  conjugations	  to	  form	  immunotoxins,	  have	  been	   shown	   to	   enhance	   their	   toxicity	   e.g.	   SAP	   for	   Hodgkin’s	   disease(104).	  Battelli	   et	   al.	   (1990)(105)	   demonstrated	   that	   IgG-­‐conjugation	   or	  homopolymerisation	  reduced	  the	  Activity-­‐toxicity	  index	  (10-­‐3	  x	  units	  x	  LD50)	  for	  SAP	  by	  a	  factor	  of	  277	  and	  48	  respectively.	  Gelonin,	  another	  type	  I	  RIP,	  also	  had	  a	   significant	   reduction	   in	   Activity-­‐toxicity	   index	   by	   a	   factor	   of	   165	   (IgG-­‐conjugate)	  and	  174	  (homopolymer).	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Although	   the	   lack	  of	   the	   lectin	  B-­‐chain	  clearly	   limits	   the	  rate	  of	   internalisation	  for	  SAP	  and	  other	   type	   I	  RIPs(97),	   it	  would	  be	   incorrect	   to	  suggest	   there	   is	  no	  uptake	  and	  this	  is	  supported	  by	  the	  observations	  of	  many	  groups	  working	  with	  such	  agents.	  Although	  SAP	  based	  immunotoxins	  have	  seen	  promising	  results	  in	  experimental	  models	   there	   is	  a	  body	  of	  evidence	   to	  suggest	   that	  enhanced	  cell	  membrane	  binding	  is	  not	  the	  only	  factor	  that	  determines	  overall	  efficacy.	  Many	  mechanisms	  for	  internalisation	  have	  been	  described	  for	  type	  I	  RIPs	  including:	  	  
• Passive	  uptake	  such	  as	  fluid	  phase	  pinocytosis(106)	  
• Receptor-­‐mediated	   via	   α2-­‐macroglobulin/low-­‐density	   lipoprotein	  receptor-­‐related	  protein	   (LRP)(107),	   however	   this	   school	   of	   thought	   has	   been	  challenged	   by	   observations	   indicating	   that	   LRP-­‐positive	   or	   –negative	   cells	  showed	  comparable	  sensitivity	  to	  SAP.	  This	  indicates	  that	  receptor-­‐independent	  endocytosis	  may	  play	  an	  important	  role	  (108).	  This	  view	  is	  supported	  by	  work	  performed	  by	  Bolognesi	  et	  al.	   (2012)(109)	  using	  confocal	  microscopy,	  utilising	  indirect	   immunofluorescence	   analysis	   and	   transmission	   electron	   microscopy	  utilising	  direct	  assay	  with	  gold	  conjugated	  SAP-­‐S6	  and	  indirect	  immunoelectron	  microscopy	  assay.	  They	  reported	  that	  SAP-­‐S6	  was	  taken	  up	  mainly	  by	  receptor-­‐independent	  endocytosis	  in	  HeLa	  cells.	  Furthermore,	  they	  found	  that	  just	  fewer	  than	  1	  in	  3	  endocytosed	  SAP	  molecules	  ended	  up	  in	  endosomes	  compared	  to	  1	  in	  10	  ending	  up	   in	   the	  Golgi-­‐apparatus.	   	  Studies	  on	   intracellular	   trafficking	   found	  progressive	  accumulation	  in	  perinuclear	  vesicular	  structures(109).	  	  However,	  it	  is	   important	  to	  stress	  that	  any	  such	  receptor-­‐mediated	  uptake	  mechanisms	  for	  SAP	  and	  other	  type	  I	  RIPs	  are	  likely	  to	  be	  significantly	  inferior	  to	  those	  utilized	  by	  type	  II	  RIPs	  such	  as	  ricin.	  	  SAP	   induced	   cell	   kill	   is	   likely	   to	   involve	   a	   combination	   of	   both	   apoptosis	   and	  necrosis.	   This	   reflects	   the	   cell	   type-­‐dependent	   and	  multi-­‐direction	   pathway	   of	  SAP	   trafficking	   once	   endocytosed.	   The	   effects	   of	   inhibiting	   protein	   synthesis	  within	   a	   cell	   will	   lead	   to	   variable	   consequences	   and	   modes	   of	   cytotoxicity	   in	  different	  cell	   lines.	  Furthermore,	   there	   is	  an	  emergence	  of	  evidence	   to	  support	  SAP	   induced	   DNA	   damage,	   either	   secondary	   to	   N-­‐glycosylase	   activity	   or	  oxidative-­‐stress	  induction(110).	  The	  latter	  mechanism	  is	  of	  particular	  interest	  in	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this	  study	  given	  the	  oxidative	  stress	  the	  cell	  is	  put	  under	  following	  the	  activation	  of	  a	  photosensitiser.	  Polito	  et	  al.	  (2013)(97)	  concluded	  that	  “apoptosis	  seems	  to	  be	  the	  main	  detectable	  effect	  in	  several	  different	  cell	  lines.”	  	  	  Important	   chemico-­‐physical	   properties	   of	   SAP	   include	   its	   resistance	   to	   high	  temperature,	   denaturation	   by	   urea	   or	   guanidine	   and	   attack	   by	   proteolytic	  enzymes(111).	   This	   may	   be	   of	   benefit	   in	   the	   potentially	   harsh	  microenvironment	  of	  photosensitised	  endosomes.	  The	  characteristics	  of	  SAP,	  as	  described	  above	  make	  it	  an	  ideal	  candidate	  for	  PCI:	  
• Relatively	  large	  protein	  (30kDa)	  requiring	  endocytic	  uptake.	  	  
• Poor	   endocytic	   uptake	   and	   delivery	   to	   intracellular	   site	   of	   action,	   thus	  potentially	  limiting	  systemic	  side	  effects.	  
• Highly	  potent	  cytotoxic	  activity	  exerted	  by	  A-­‐chain	  upon	  reaching	  target.	  
• No	  phototoxic	  activity.	  
• Chemico-­‐physical	  robustness.	  
3.3	  Mitoxantrone	  Mitoxantrone	  is	  an	  anthacenedione	  cytotoxin.	  Its	  principle	  mechanism	  of	  action	  is	   to	   inhibit	   topoisomerase	   II.	   The	   resultant	   intercalation	   between	   DNA	   bases	  impairs	  DNA	  synthesis	  and	  repair	  in	  both	  healthy	  and	  malignant	  cells.	  It	  is	  used	  for	   the	   treatment	   of	   malignancies	   including	   hormone-­‐independent	   prostate	  cancer,	   metastatic	   breast	   cancer	   and	   haematological	   malignancies	   (non-­‐Hodgkin’s	   lymphoma	   and	   acute	  myeloid	   leukaemia).	   It	   also	   has	   a	   therapeutic	  role	  to	  reduce	  the	  rate	  of	  disease	  progression	  in	  secondary	  progressive	  multiple	  sclerosis.	   The	   selectivity	   of	  MTX	   is	   based	  on	   the	   accessibility	   of	  DNA	   thus	   fast	  dividing	  cells,	  which	  have	  more	  exposed	  DNA	  e.g.	  colorectal	  cells	  in	  the	  crypt	  of	  Lieberkuhn	   and	   leukocytes	   can	   often	   be	   innocent	   bystanders	   sensitive	   to	   the	  cytotoxic	  effects	  of	  MTX.	  The	  side	  effect	  profile	  varies	  in	  severity	  and	  is	  linked	  to	  total	   cumulative	   dose.	   Specific	   side	   effects	   include:	   gastrointestinal	   upset	  (nausea	   and	   vomiting),	   alopecia	   and	   immunosuppression.	   A	  major	   problem	   is	  the	   development	   of	   irreversible	   cardiomyopathy.	   Cardiomyopathy	   and	  myelosuppresssion	  represent	  two	  dose-­‐limiting	  side	  effects(112,	  113).	  MTX	  and	  similar	   drugs	   such	   as	   Adriamycin	   are	   retained	   within	   cytoplasmic	   vesicular	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structures	  such	  as	  lysosomes(25,	  114).	  Mitoxantrone	  has	  a	  weak-­‐base	  structure,	  thus	   like	   other	   basic	   anticancer	   agents	   (e.g.	   doxorubicin)	   MTX	   appears	   to	  accumulate	   in	   acidic	   endosomes(115)	   and	   lysosomes	   owing	   to	   protonation	   of	  the	  amino	  groups,	  a	  process	  known	  as	  ion-­‐trapping,	  which	  reduces	  their	  overall	  cytotoxicity	  (fig.	  3.3).	  	  
	  
Figure	  3.3	  –	  Molecular	  structure	  of	  Mitoxantrone.	  	  Furthermore,	  cells	  expressing	  resistant	  phenotypes,	  such	  as	  multidrug	  resistant	  MCF-­‐7	   (breast	   cancer)	   cell	   line	   have	   been	   shown	   to	   exclude	   MTX	   from	   the	  nuclear	   compartment	   where	   its	   DNA	   targets	   reside(25)	   a	   finding	   that	   is	  supports	   observations	   by	   Smith	   et	   al.	   (1992)(116)	   using	   EMT6/AR1.0	   and	  EMT6/CR1.0	  p-­‐glycoprotein	  expressing	  murine	  breast	  cancer	  cell	  lines.	  The	  characteristics	  of	  MTX	  including	  its	  potency,	  known	  resistant	  mechanisms,	  cytoplasmic	   vesicular-­‐sequestration	   and	   previous	   observations	   as	   a	   suitable	  agent	   for	   PCI	   in	   resistant	   breast	   (MCF-­‐7/R)	   and	   bladder	   (MGHU1/R)	   cell	  lines(25)	  has	  led	  to	  its	  nomination	  as	  a	  cytotoxin	  for	  PCI	  studies	  in	  this	  chapter.	  
AIMS	  The	  studies	  performed	  in	  this	  chapter	  aim	  to	  take	  a	  closer	  look	  at	  the	  role	  of	  ROS	  in	  disulfonated	  meso-­‐tetraphenylporphyrin	  (TPPS2a)-­‐mediated	  PCI	  of	  the	  type	  I	  ribosome	   inactivating	   protein	   SAP	   (SAP)	   and	   the	   topoisomerase	   II	   inhibitor	  Mitoxantrone	   (MTX).	   In	   particular	   to	   assess	   how	   manipulating	   the	   reducing	  capacity	   of	   the	   intracellular	   environment	   may	   affect	   the	   efficiency	   of	   PCI.	  Buthionine	   Sulfoximine	   (BSO)	   is	   a	   synthetic	   amino	   acid	   (fig.	   3.4)	   that	  irreversibly	   inhibits	   gamma-­‐glutamylcysteine	   synthetase,	   the	   enzyme	   required	  
	   65	  
in	   the	   first	   step	   of	   glutathione	   synthesis	   (117).	   In	   doing	   so	   BSO	   attenuates	  intracellular	   levels	   of	   the	   powerful	   reducing	   agent	   glutathione	   (GSH),	   thereby	  increasing	  susceptibility	   to	  oxidative	  damage.	  BSO	  has	  been	  shown	  to	  partially	  reverse	   drug-­‐resistance	   in	   MRP1	   –	   overproducing	   cells	   associated	   with	  decreased	   levels	   of	   GSH	   and	   increased	   intracellular	   accumulation	   of	  daunorubicin(75).	  	  
	  
Figure	  3.4	  –	  Molecular	  structure	  of	  Buthionine	  Sulfoximine.	  	  L-­‐histidine	   (LH)	   is	   a	   naturally	   occurring	   amino	   acid	   that	   has	   been	   shown	   to	  interfere	   with	   REDOX	   reactions	   by	   scavenging	   hydroxyl	   and	   1O2	   (118)	   free	  radicals.	   Pharmacological	   doses	   of	   histidine	   have	   also	   been	   shown	   to	   have	   an	  anti-­‐inflammatory	  effect	  in	  animal	  models(119).	  	  	  The	  ultimate	  aim	  of	  this	  chapter	  is	  to	  unpick	  the	  different	  factors	  that	  not	  only	  govern	  PCI	  but	  also	  influence	  the	  balance	  between	  PDT	  and	  PCI,	  specifically:	  
• Photosensitiser	  dose	  
• Cellular	  location	  of	  photosensitiser	  at	  time	  of	  ROS	  generation	  
• Chemotoxin	  dose	  
• Light	  dose	  
• Time	  following	  PS	  activation	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RESULTS	  
3.4	  PCI	  	  The	   ‘light-­‐after	   chemotherapy’	   regimen	   can	   also	   be	   described	   as	   the	   standard	  PCI	   protocol.	   In	   this	   guise	   the	   photosensitiser	   and	   cytotoxin	   are	   co-­‐incubated	  prior	   to	   activation	   of	   the	   photosensitiser	   using	   light,	   hence	   ‘light-­‐after’.	   At	   the	  intracellular	   level	   this	   theoretically	  enables	   the	  co-­‐localisation	  of	   the	  cytotoxin	  (luminal)	   and	   photosensitiser	   (phospholipid	   membrane)	   within	   organelles	  including	  endosomes.	  	  	  Figure	  3.5	  depicts	   the	  results	  of	   ‘standard’	  PCI	   in	   the	  4T1	  cells,	   specifically	   the	  effects	   of	   combining	   TPPS2a	   (TP)	   with	   SAP	   (SAP)	   or	  Mitoxantrone	   (MTX)	   for	  24hs	   prior	   to	   illumination.	   The	   4h	   delay	   between	  washing	   off	   the	   drugs	  with	  phosphate	   buffered	   saline	   (PBS)	   and	   illumination	   represents	   the	   ‘chasing’	  period	  (120).	  This	  effect	  will	  be	  further	  described	  in	  this	  chapter.	  The	  cells	  were	  illuminated	  for	  2	  minutes.	  Following	  a	  24h-­‐resting	  period	  the	  cells	  were	  assayed	  using	  the	  3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	  (MTT)	  assay.	  	  	  Following	   120	   s	   illumination,	   0.6	   µg/ml	   TPPS2a	   (TP)	   killed	   23%	   of	   4T1	   cells	  compared	  to	  control	  (p<0.01,	  Fig	  3.5a),	  which	  is	  the	  photodynamic	  therapy	  (PDT	  effect).	  	  The	  cytotoxic	  effect	  of	  SAP	  15	  nM	  alone	  (chemotherapy)	  was	  4%.	  Upon	  combination	  of	  TP	  +	  SAP	  (PCI)	  there	  was	  57%	  increased	  cytotoxicity	  compared	  to	  control	  (p<0.01).	  This	  corresponds	  to	  a	  34%	  and	  53%	  increase	  in	  cytotoxicity	  compared	  to	  PDT	  or	  chemotherapy	  alone,	  respectively	  (p<0.01).	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Figure	  3.5	  –	  TPPS2a-­‐mediated	  Photochemical	  Internalisation	  (higher	  dose).	  	  4T1	  breast	  cancer	  cells	  treated	  with	  TPPS2a	  o.6	  µg	  ml-­‐1	  alone	  (PDT)	  or	  plus:	  (a)	  SAP	  15	  nM,	   (b)	   MTX	   0.4	   µg	   ml-­‐1	   (PCI).	   Cells	   exposed	   to	   120	   s	   of	   light	   using	   LumiSource®	  illuminator	  4h	  after	  drugs	  washed	  off.	  SAP-­‐PCI	  killed	  34%	  and	  53%	  more	  cells	  than	  PDT	  or	   cytotoxin	   (SAP)	   alone	   (p<0.01).	   Cell	   viability	  measured	  using	  MTT	  assay	  24h	   after	  illumination	  (absorbance	  read	  at	  490	  nm).	  Cytotoxin/PCI	  refers	  to	  SAP	  (a)	  and	  MTX	  (B).	  	  Fig	  3.5b	  shows	  results	  obtained	   from	  the	  same	  protocol	  as	  3.5a,	  except	   in	   this	  instance,	   using	   the	   same	   fundamental	   protocol;	   SAP	   was	   exchanged	   for	   the	  topoisomerase	  inhibitor	  MTX	  (Fig	  3.5b).	  The	  PDT	  effect	  was	  the	  same,	  however,	  MTX	  alone	  triggered	  53%	  increased	  cytotoxicity	  compared	  to	  control	  (p<0.01).	  The	  combination	  of	  TP	  +	  MTX	  yielded	  54%	  increased	  cytotoxicity	  compared	  to	  control	  (p<0.01).	  Thus	  the	  PCI	  group	  in	  3.5b	  had	  a	  31%	  increase	  in	  cytotoxicity	  compared	  to	  PDT	  alone	  (p<0.01)	  but	  there	  was	  no	  significant	  increase	  compared	  to	  MTX	  alone.	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Combining	   TP	   +	   SAP	   in	   the	   presence	   of	   light	   appeared	   to	   increase	   the	  cytotoxicity	   of	   either	   agent	   on	   its	   own	   (fig.	   3.5a).	   However,	   this	   effect	   is	   not	  mirrored	   with	   MTX	   (fig	   3.5b)	   where	   under	   the	   conditions	   of	   this	   study,	   for	  example,	   TP	  dose,	   illumination	   time	   and	  MTX	  dose,	   combining	   the	   two	   agents	  (TP+MTX)	  had	  no	  effect	  beyond	  the	  inherent	  cytotoxicity	  of	  MTX	  alone.	  	  In	   order	   to	   optimise	   any	   PCI	   effect	   the	   next	   step	  was	   to	   dissect	   the	   different	  variables	   that	   potentially	   play	   a	   role	   in	   determining	   the	   rate,	   total	   level	   and	  localisation	   of	   ROS	   generation	   following	   the	   activation	   of	   the	   photosensitiser	  (TP).	  	  	  
3.5	  Variable	  1:	  Photosensitiser	  Dose	  Two	  different	  doses	  of	  TP	  were	  tested	  within	  a	  “light	  after”	  protocol.	  Figure	  3.6a	  illustrates	   that	   0.3	   µg/ml	   of	   TPPS2a	   caused	   less	   than	   10%,	   albeit	   significant,	  cytotoxicity	   when	   4T1	   cells	   were	   illuminated	   for	   2	   minutes	   (PDT).	   The	  combination	  of	  TP	  +	  SAP	  (15	  nM)	  resulted	  in	  49%	  cell	  kill,	  which	  translate	  into	  41%	  and	  44%	  increased	  cytotoxicity	  compared	  to	  PDT	  or	  chemotherapy	  alone,	  respectively	  (P<0.01).	  MTX	  (fig	  3.6b)	  yielded	  a	  similar	  trend	  to	  that	  seen	  in	  cells	  treated	  with	  0.6	  µM	  of	  TP	  (fig	  3.5b).	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Figure	  3.6	  –	  TPPS2a-­‐mediated	  Photochemical	  Internalisation	  (lower	  dose).	  	  4T1	  breast	  cancer	  cells	  treated	  with	  TPPS2a	  0.3µg	  ml-­‐1	  alone	  (PDT)	  or	  plus:	  (a)	  SAP	  15	  nM,	   (b)	   MTX	   0.4	   µg	   ml-­‐1	   (PCI).	   Cells	   exposed	   to	   120	   s	   of	   light	   using	   LumiSource®	  illuminator	  4h	  after	  drugs	  washed	  off.	  SAP-­‐PCI	  killed	  41%	  and	  44%	  more	  cells	  than	  PDT	  or	   cytotoxin	   (SAP)	   alone	   (p<0.01).	   Cell	   viability	  measured	  using	  MTT	  assay	  24h	   after	  illumination	  (absorbance	  read	  at	  490	  nm).	  Cytotoxin/PCI	  refers	  to	  SAP	  (a)	  and	  MTX	  (B).	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Figure	   3.7	   –	   TPPS2a-­‐mediated	   Photochemical	   Internalisation	   (lower	   dose	   versus	  
higher	  dose).	  	  4T1	  breast	  cancer	  cells	  treated	  with	  TPPS2a	  0.3µg	  ml-­‐1	  (white	  histogram)	  or	  o.6	  µg	  ml-­‐1	  (black	  histogram)	  alone	  (PDT)	  or	  plus:	  SAP	  15	  nM	  (SAP-­‐PCI)	  or	  MTX	  0.4	  µg	  ml-­‐1	  (MTX-­‐PCI).	   Cells	   exposed	   to	   120	   s	   of	   light	   using	   LumiSource®	   illuminator	   4h	   after	   drugs	  washed	   off.	   For	   SAP-­‐PCI	   there	  was	   a	   12%	   (p<0.0001)	   and	   8%	   (p<0.001)	   increase	   in	  PDT	  and	  PCI	  for	  TPPS2a	  o.6	  µg	  ml-­‐1	  compared	  to	  o.3µg	  ml-­‐1.	  Cell	  viability	  measured	  using	  MTT	  assay	  24h	  after	  illumination	  (absorbance	  read	  at	  490	  nm).	  
3.6	  Variable	  2:	  Light	  Dose	  Given	  the	  observed	  effects	  of	  doubling	  the	  photosensitiser	  dose	  on	  PDT/PCI,	  one	  possible	   theory	   is	   that	   the	   potential	  maximum	  ROS	   load	   generated	  within	   the	  cell,	   post-­‐illumination,	   plays	   a	   pivotal	   role	   in	   the	   efficacy	   of	   either	   technique.	  However,	   although	   the	   photosensitiser	   is	   the	   substrate	   for	   ROS	   generation,	  oxygen	   and	   light	   are	   vital	   ingredients	   for	   successful	   initiation	   and	   subsequent	  propagation	  of	  ROS	  generation.	   In	  order	   to	   further	  assess	   the	  effect	  of	  varying	  light	   dose	   (duration	   of	   illumination)	   on	   PDT,	   PCI	   and	   the	   PDT:PCI	   ratio,	  illumination	  time	  studies	  were	  performed.	  	  	  	  	  The	  effect	  of	   increasing	   illumination	   time,	   from	  60	   -­‐	  300	  seconds,	  on	  PDT	  and	  PCI	  of	  SAP	  30	  nM	  was	  investigated	  (fig	  3.8).	  TP	  (0.6	  µg/ml)	  without	  illumination	  (‘dark’	   PDT)	   resulted	   in	   no	   significant	   cell	   kill.	   TP	   (0.6	   µg/ml)+	   SAP	   (30	   nM)	  without	   illumination	   (‘dark’	   PCI)	   resulted	   in	   12%	   cytotoxicity	   compared	   to	  control	   (p<0.01).	   However,	   this	   represented	   no	   significant	   difference	   when	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compared	  to	  the	  residual	  toxicity	  of	  SAP	  (30	  nM).	  For	  the	  standard	  PCI	  protocol,	  comprising	  a	  4h	  incubation	  period	  prior	  to	  illumination	  the	  cytotoxicity	  for	  PDT	  ranged	  from	  12%	  at	  60	  seconds	  (p<0.01)	  to	  a	  maximum	  of	  43%	  at	  240	  seconds	  (p<0.01).	  Between	  60	  –	  300	  s,	  the	  only	  significant	  differences	  in	  PDT	  cytotoxicity	  (versus	  60	  s)	  occurred	  above	  180	  s.	  	  	  	  	  	  	  
	  
Figure	   3.8	   –	   Effect	   of	   increasing	   light	   dose	   on	   TPPS2a-­‐mediated	   Photochemical	  
Internalisation	  of	  Saporin.	  	  4T1	  breast	  cancer	  cells	  treated	  with	  TPPS2a	  0.6	  µg	  ml-­‐1	  alone	  (PDT,	  white	  histogram)	  or	  0.6	  µg	  ml-­‐1	  +	  SAP	  30	  nM	  (PCI,	  red	  histogram).	  Cells	  exposed	  to	  increasing	  durations	  of	  light	  from	  no	  light	  (dark)	  to	  300	  s	  of	  light	  using	  LumiSource®	  illuminator	  4h	  after	  drugs	  washed	  off.	  A	  light-­‐dose	  dependent	  increase	  in	  cytotoxicity	  was	  observed	  for	  both	  PDT	  and	  PCI	  achieving	  43%	  and	  83%	  cell	  kill,	  respectively	  at	  300	  s	  illumination.	  Cell	  viability	  measured	  using	  MTT	  assay	  24h	  after	  illumination	  (absorbance	  read	  at	  490	  nm).	  	  The	  cytotoxicity	  of	  PCI–SAP-­‐30	  demonstrated	  a	  light-­‐dose	  dependent	  increase	  in	  cytotoxicity	   of	   83%	   (p<0.01)	   from	   no	   illumination	   (‘dark’)	   though	   to	   300	   s	  illumination.	  One	  trend	  that	  was	  observed	  is	  that	  as	  the	  light-­‐dose	  increased,	  the	  differential	   between	   PDT	   and	   PCI	   also	   rose;	   for	   example,	   at	   60	   seconds	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illumination	   there	  was	   a	   12%	   (p<0.01)	   increase	   in	   cytotoxicity,	  which	   rose	   to	  46%	  (p<0.01)	  at	  300	  s	  illumination.	  	  	  	  
	  
Figure	   3.9	   –	   Effect	   of	   increasing	   light	   dose	   on	   TPPS2a-­‐mediated	   Photochemical	  
Internalisation	  of	  Mitoxantrone.	  	  4T1	  breast	  cancer	  cells	  treated	  with	  TPPS2a	  0.6	  µg	  ml-­‐1	  alone	  (PDT,	  white	  histogram)	  or	  0.6	   µg	   ml-­‐1	   +	   MTX	   1.5	   µg	   ml-­‐1	   (PCI,	   purple	   histogram).	   Cells	   exposed	   to	   increasing	  durations	  of	   light	  from	  no	  light	  (dark)	  to	  300	  s	  of	   light	  using	  LumiSource®	  illuminator	  4h	  after	  drugs	  washed	  off.	  A	  light-­‐dose	  dependent	  increase	  in	  cytotoxicity	  was	  observed	  for	   both	   PDT	   and	   PCI	   achieving	   43%	   and	   76%	   cell	   kill,	   respectively	   at	   300	   s	  illumination.	   Cell	   viability	   measured	   using	   MTT	   assay	   24h	   after	   illumination	  (absorbance	  read	  at	  490	  nm).	  
	  The	   effect	   of	   increasing	   illumination	   time,	   from	   60	   –	   300	   seconds,	   was	   also	  investigated	  on	  PDT	  and	  PCI	  of	  MTX	  1.5	  µg/ml	  (fig.	  3.9).	  The	  PDT	  results	  mirror	  those	  seen	  in	  figure	  3.8.	  The	  ‘dark’	  control	  for	  PCI	  –	  MTX	  demonstrated	  51%	  cell	  kill	   (p<0.01).	   However,	   this	   observation	   was	   confounded	   by	   the	   background	  cytotoxicity	  that	  was	  exerted	  by	  MTX	  1.5	  µg/ml	  alone,	  which	  was	  47%	  (data	  not	  shown,	   p<0.01).	   Thus,	   there	   was	   no	   significant	   difference	   observed	   between	  MTX	  alone	  and	  PCI	  –	  MTX	  ‘dark’	  control.	  With	  this	  in	  mind	  it	  was	  interesting	  to	  observe	   that	   it	   was	   only	   after	   240	   s	   that	   PCI-­‐MTX	   produced	   increased	  cytotoxicity	   compared	   to	  MTX	  alone	  or	   ‘dark’	   control,	   though	   the	  9%	   increase	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was	   not	   statistically	   significant.	   After	   300	   s	   illumination,	   PCI-­‐MTX	   increased	  cytotoxicity	  by	  25%	  (p<0.01)	  and	  29%	  (p<0.01)	  compared	  to	  ‘dark’	  control	  and	  MTX	  alone,	  respectively.	  	  
3.7	  Variable	  3:	  Photosensitiser	  localisation	  To	   investigate	   this	  variable	   the	  studies	   in	   this	  section	   take	  a	  closer	   look	  at	   the	  impact	  of	  the	  ‘chasing’	  period	  prior	  to	  illumination(120).	  This	  chasing	  period	  of	  4h	   enables	   the	   	   ‘leak’	   of	   the	   photosensitiser	   from	   the	   cell	   membrane	   with	  accumulation	  in	  endo-­‐lysosomal	  membranes.	  	  The	  relative	  effect	  of	  the	  4h	  ‘chasing’	  period	  on	  TP-­‐based	  PDT	  in	  4T1	  cells	  with	  increasing	  duration	  of	  illumination	  from	  60	  s-­‐300	  s	  is	  illustrated	  in	  figure	  3.10a.	  The	  general	   trend	  is	  consistent	  with	   ‘light’	  dose-­‐dependent	  toxicity	   in	  both	  the	  ‘immediate’	   and	   ‘4h’	   illumination	   groups.	   However,	   as	   illumination	   time	  increased,	   cells	   that	  were	   exposed	   to	   light	   immediately	   after	  wash-­‐off	   of	   drug	  exhibited	   significantly	   greater	   sensitivity	   to	   PDT	   compared	   to	   those	   cells	   that	  were	   incubated	   for	   4h	   prior	   to	   illumination.	   Consequently,	   resulting	   in	  progressive	   divergence	   of	   cell	   survival	   between	   the	   two	   groups.	   Following	   60	  seconds	   of	   illumination	   1	   in	   4	   cells	   in	   the	   immediate	   group	   were	   killed	  compared	  to	  1	  in	  6	  cells	  in	  the	  4h	  group.	  This	  represents	  a	  9%	  reduction	  in	  PDT-­‐induced	  cytotoxicity	  if	  the	  cells	  were	  incubated	  for	  4	  hours	  prior	  to	  illumination	  (p<0.01).	   	   After	   150	   seconds	   of	   illumination	   more	   than	   75%	   of	   cells	   in	   the	  immediate	  group	  were	  killed	  compared	  to	  just	  below	  25%	  cells	  in	  4h	  group.	  This	  corresponded	  to	  a	  55%	  increase	  in	  cytotoxicity	  (immediate	  vs.	  4h,	  p<0.01).	  300	  seconds	   of	   illumination	   resulted	   in	   over	   95%	   cytotoxicity	   in	   the	   immediate	  group	  compared	  to	  45%	  in	  the	  4h	  group.	  This	  indicated	  that	  by	  illuminating	  cells	  immediately	  we	  were	   able	   to	   achieve	  PDT-­‐related	   cytotoxicity	   at	   150	   seconds	  illumination,	   which	   was	   22%	   greater	   than	   that	   achieved	   after	   300	   seconds	  illumination	   in	   cells	   that	   had	   been	   re-­‐incubated	   for	   4h	   prior	   to	   illumination	  (p<0.01).	  This	  is	  consistent	  with	  a	  hypothesis	  that	  PDT	  is	  more	  effective	  in	  this	  model	  when	  the	  photosensitizer	  is	  within	  the	  plasma	  membrane.	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The	  effect	  of	  the	  4h	  incubation	  time	  between	  drug	  wash-­‐off	  and	  illumination	  on	  PCI-­‐SAP	   is	   graphically	   expressed	   in	   figure	   3.10b.	   As	   seen	   in	   figure	   3.10b	   the	  general	   trend	   was	   consistent	   with	   ‘light’	   dose-­‐dependent	   toxicity	   in	   both	  treatment	   groups.	   Furthermore,	   between	   60	   –	   300	   s,	   cells	   in	   the	   immediate	  illumination	  group	  exhibited	  increased	  cytotoxicity	  compared	  to	  cells	  in	  the	  4h	  group.	  	  However,	  unlike	  PDT,	  the	  average	  difference	  between	  the	  immediate	  and	  4h	   group	  was	   reduced.	   For	   example,	   after	   60	   s	   illumination	   over	   5	   in	   every	  8	  cells	  in	  the	  immediate	  group	  were	  killed	  compared	  to	  over	  2	  in	  every	  8	  cells	  in	  the	   4h	   group,	   representing	   a	   39%	   increase	   in	   cytotoxicity	   (p<0.01).	   This	  differential	   remained	   relatively	   consistent	   at	  150	   seconds	  where	   the	  observed	  increase	  in	  cytotoxicity	  was	  41%	  (immediate	  vs.	  4h).	  After	  300	  s,	  this	  differential	  between	   the	   ‘immediate’	   and	   ‘4h’	   groups	   had	   reduced	   to	   11%	  with	   over	   9	   in	  every	  10	  cells	   in	  the	   ‘immediate’	  group	  and	  over	  8	   in	  every	  10	  cells	   in	  the	   ‘4h’	  group	  dying	  (p<0.01).	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Figure	  3.10	  –	  Impact	  that	  timing	  of	  illumination	  following	  removal	  of	  TPPS2a	  has	  on	  
Photochemical	  Internalisation	  of	  Saporin.	  	  4T1	  breast	  cancer	  cells	  treated	  with	  TPPS2a	  0.6	  µg	  ml-­‐1	  alone	  (PDT)	  or	  0.6	  µg	  ml-­‐1	  +	  SAP	  30	   nM	   (PCI,).	   (a)	   PDT	   treatment	   group	   –	   cells	   illuminated	   either	   immediately	   (black	  line)	  or	  4h	  (red	   line)	  after	  wash	  off	  of	  TP;	   (b)	  PCI	   treatment	  group	  –	  cells	   illuminated	  either	  immediately	  (black	  line)	  or	  4h	  (red	  line)	  after	  drugs	  washed	  off;	  (c)	  PDT	  (white	  histogram)	  versus	  PCI	  (grey	  histogram)	  –	  for	  cells	  illuminated	  immediately	  after	  drugs	  washed	   off;	   (d)	   PDT	   (white	   histogram)	   versus	   PCI	   (red	   histogram)	   –	   for	   cells	  illuminated	  4h	  after	  drugs	  washed	  off	  Cells	  illuminated	  for	  increasing	  durations	  of	  time	  up	   to	   300	   s	   using	   LumiSource®	   illuminator.	   Cell	   viability	  measured	   using	  MTT	   assay	  24h	  after	  illumination	  (absorbance	  read	  at	  490	  nm).	  
	  Figures	   3.10c	   and	   3.10d	   illustrate	   the	   difference	   between	  PDT	   and	  PCI	  within	  the	  immediate	  and	  4h	  groups,	  respectively.	  The	  most	  striking	  observation	  is	  that	  for	   illumination	   times	   ≥	   180	   seconds	   there	   was	   no	   significant	   difference	   in	  cytotoxicity	  between	  PDT	  vs.	  PCI	  (fig.	  3.10c).	  The	  largest	  differential	  was	  at	  60	  s	  illumination	   where	   PCI	   induced	   cytotoxicity	   was	   2.7	   times	   greater	   than	   PDT	  with	  a	  42%	  increase	  in	  cell	  kill	  (p<0.01).	  The	  differential	  reduced	  to	  12%	  at	  150	  s	   (p<0.01)	   and	   subsequently	   <1%	   at	   180	   s	   illumination.	   This	   indicated	   that	  when	  illumination	  time	  was	  ≥	  180	  s	  there	  is	  no	  difference	  between	  PDT	  versus	  PCI	  induced	  cell	  kill.	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Figure	  3.10d	  shows	   that	  unlike	   the	   ‘immediate’	   illumination	  group	   (fig.	  3.10c),	  cells	   that	   were	   exposed	   to	   light	   after	   a	   4h	   incubation	   period	   consistently	  exhibited	   significantly	   increased	   cytotoxicity	   for	   PCI	   versus	   PDT.	   After	   60	   s,	  illumination	  the	  cytotoxic	  effect	  in	  the	  PCI	  group	  was	  1.8	  times	  greater	  than	  the	  PDT	  group	  with	  12%	  increased	  cytotoxicity	  (p<0.01).	  After	  150	  s	  of	  illumination	  this	  ratio	   increased,	  such	  that	  the	  PCI	  group	  experienced	  2.2	  times	  greater	  cell	  kill	   than	   the	   PDT	   group	   with	   27%	   increased	   cell	   kill	   (p<0.01).	   	   The	   greatest	  differential	   was	   observed	   after	   240	   s	   illumination	   when	   43%	   increased	  cytotoxicity	  was	   observed	   in	   the	   PCI	   group	   compared	   to	   the	   PDT	   group.	   This	  represents	  1.9	  times	  increased	  cell	  kill	  (p<0.01).	  	  	  	  	  The	   effect	   of	   immediate	   versus	   4h-­‐delayed	   illumination	   on	   the	   PCI	   of	   MTX	   is	  shown	   in	   figure	   3.11.	   A	   similar	   trend	   to	   that	   seen	   with	   SAP	   is	   seen	   for	   the	  ‘immediate’	  group	  (fig.	  3.11a)	  whereby	   there	   is	  an	   initial	   light-­‐dose	  dependent	  increase	  in	  cytotoxicity,	  prior	  to	  a	  flat	  nadir.	  At	  60	  s	  cells	  treated	  with	  TP	  +	  MTX	  experienced	  37%	  increased	  cell	  kill	  compared	  to	  TP-­‐alone	  (p<0.01),	  though	  the	  magnitude	  of	  this	  result	  is	  attenuated	  by	  the	  fact	  that	  after	  60	  s	  illumination	  PCI-­‐MTX	   enhanced	   the	   cytotoxicity	   of	   MTX-­‐alone	   by	   15%	   (p<0.01).	   After	   120	   s	  illumination	   the	   impact	   of	   the	   photosensitiser	   both	   for	   PDT	   (alone)	   and	   PCI	  (+MTX)	   led	   to	   27%	   and	   38%	   increase	   in	   cytotoxicity,	   respectively	   (p<0.01).	  However,	  this	  represents	  a	  28%	  decrease	  in	  the	  difference	  between	  PCI	  versus	  PDT	  cytotoxicity.	   In	   fact	   for	   illumination	  times	  >120	  s	  there	  appeared	  to	  be	  no	  significant	  increase	  in	  cytotoxicity	  (PCI	  versus	  PDT).	  	  	  No	   significant	   increase	   in	   cytotoxicity	   was	   seen,	   in	   cells	   that	   underwent	   a	   4h	  incubation	  period	  prior	   to	   illumination,	   until	   cells	  were	   exposed	   to	  ≥	  240	   s	   of	  light.	   The	   maximum	   cell	   kill	   achieved	   after	   300	   s	   of	   illumination	   was	   76%,	  corresponding	  to	  a	  29%	  increase	  compared	  to	  MTX-­‐alone	  and	  32%	  compared	  to	  PDT	  (p<0.01).	  	  Figure	  3.11c	  illustrates	  the	  differential	  effects	  observed	  between	  PCI	  when	  cells	  were	  illuminated	  either	  immediately	  after	  24h	  incubation	  or	  following	  4h	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incubation	   in	   drug-­‐free	  media.	   It	  was	   observed	   is	   that	   immediate	   illumination	  resulted	   in	   increased	   cell	   kill	   across	   all	   light-­‐doses	   investigated.	   	   The	   greatest	  difference	  was	  observed	   following	  120	  s	  of	   light	   (45%,	  p<0.01),	  however	  after	  300	  s	  of	  illumination	  this	  reduced	  to	  18%	  (p<0.01).	  	  
	  
Figure	  3.11	  –	  Impact	  that	  timing	  of	  illumination	  following	  removal	  of	  TPPS2a	  has	  on	  
Photochemical	  Internalisation	  of	  Mitoxantrone.	  	  4T1	  breast	  cancer	  cells	  treated	  with	  TPPS2a	  0.6	  µg	  ml-­‐1	  alone	  (PDT)	  or	  0.6	  µg	  ml-­‐1	  +	  MTX	  1.5	   µg	  ml-­‐1	   	   (PCI,).	   (a)	   PDT	   (white	   histogram)	   versus	   PCI	   (grey	   histogram)	   –	   for	   cells	  illuminated	  immediately	  after	  drugs	  washed	  off;	  (b)	  PDT	  (white	  histogram)	  versus	  PCI	  (purple	  histogram)	  –	  for	  cells	  illuminated	  4h	  after	  drugs	  washed	  off;	  (c)	  PCI	  treatment	  group	  –	  cells	  illuminated	  either	  immediately	  (black	  line)	  or	  4h	  (purple	  line)	  after	  drugs	  washed	   off.	   Cells	   illuminated	   for	   increasing	   durations	   of	   time	   up	   to	   300	   s	   using	  LumiSource®	   illuminator.	   Cell	   viability	   measured	   using	   MTT	   assay	   24h	   after	  illumination	  (absorbance	  read	  at	  490	  nm).	  
3.8	  Variable	  4:	  Intracellular	  REDOX	  Environment	  This	   section	   focuses	   on	   the	   effect	   alterations	   in	   the	   intracellular	   REDOX	  environment	  have	  on	  both	  PDT	  and	  PCI.	  Given	  the	  accepted	  important	  role	  that	  ROS	  play	  in	  photosensitiser-­‐mediated	  cell	  damage	  this	  section	  investigates	  what	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effect,	  if	  any,	  altering	  the	  intracellular	  REDOX	  environment	  has	  on	  both	  PDT	  and	  PCI.	  	  
	  
Figure	  3.12	  –	  Impact	  of	  Buthionine	  Sulfoximine	  on	  TPPS2a-­‐mediated	  Photodynamic	  
Therapy.	  	  4T1	   breast	   cancer	   cells	   treated	   with	   TPPS2a	   0.6	   µg	   ml-­‐1	   alone.	   (a)	   Cells	   illuminated	  immediately	  after	  TP	  washed	  off	  with	  (blue	  line)	  or	  without	  (black	  line)	  BSO	  1.0	  µg	  ml-­‐1;	  (b)	  Cells	  illuminated	  4h	  after	  TP	  washed	  off	  with	  (orange	  broken	  line)	  or	  without	  (black	  broken	  line)	  BSO	  1.0	  µg	  ml-­‐1.	  Cells	  illuminated	  for	  increasing	  durations	  of	  time	  up	  to	  300	  s	   using	   LumiSource®	   illuminator.	   Cell	   viability	   measured	   using	   MTT	   assay	   24h	   after	  illumination	  (absorbance	  read	  at	  490	  nm).	  	  Figure	  3.12	  illustrates	  the	  effect	  that	  treating	  cells	  with	  the	  glutathione	  synthase	  inhibitor,	   buthionine	   sulfoximine	   (BSO),	   has	   on	   PDT	   either	   when	   cells	   were	  illuminated	   immediately	   (3.11a)	   or	   4h	   (3.11b)	   after	   washing	   off	   the	  photosensitiser.	  BSO	  alone	  killed	  6%	  of	  cells	  (p<0.01).	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under	   ‘dark’	   conditions	   the	   combination	   of	   TP	   (0.6	   µg/ml)	   +	   BSO	   (1.0	   µM)	  caused	  no	  significant	  change	  in	  cytotoxicity	  compared	  to	  ‘dark’	  PDT	  alone.	  	  Figure	   3.12a	   (immediate)	   shows	   that	   above	   60	   s	   illumination	   at	   which	   point	  there	   was	   a	   15%	   increase	   in	   cytotoxicity	   (p<0.01),	   there	   was	   no	   difference	  between	  PDT	  and	  PDT	  +	  BSO.	  	  Figure	  3.12b	  (4h	  delay)	  shows	  that	  for	  illumination	  durations	  ≤	  120	  s,	  there	  was	  no	  significant	  difference	  in	  cytotoxicity	  between	  PDT	  versus	  PDT	  +	  BSO.	  Those	  cells	   exposed	   to	   ≥150	   s	   illumination	   experienced	   a	   non-­‐linear	   increase	   in	  cytotoxicity	  compared	   to	  PDT	  alone.	  For	  example,	  after	  150	  s	   illumination,	   the	  addition	  of	  BSO	  resulted	  in	  a	  19%	  increase	  in	  cell	  killing	  (p<0.01),	  representing	  a	  cytotoxicity	  ratio	  of	  1	  in	  4.3	  for	  PDT	  and	  1	  in	  2.4	  for	  PDT	  +	  BSO.	  After	  180	  s	  the	  addition	  of	  BSO	  enhanced	   the	  PDT	  effect	   by	  55%	   (p<0.01),	   this	   represented	   a	  cytotoxicity	   ratio	  of	  1	   in	  3.8	   for	  PDT	  and	  1	   in	  1.2	   for	  PDT	  +	  BSO.	  The	  greatest	  difference	  was	  seen	  after	  240	  s	  illumination	  when	  the	  differential	  was	  increased	  to	  61%	  (p<0.01).	  This	  may	  indicate	  that	  GSH	  prevents	  or	  reduces	  delayed	  PDT	  cytotoxicity.	  	  Figure	  3.13a	  shows	  the	  difference	  in	  cytotoxicity	  profiles	  between	  PDT	  +	  BSO	  for	  cells	   in	   the	   immediate	   versus	  4h	   groups.	   Comparison	  with	   fig.	   3.10a	   indicated	  that	  BSO	  had	  a	  significant	  effect	  on	  PDT	  when	  a	  4h	  delay	  was	  utilised	  prior	   to	  illumination.	  Figure	  3.13b	  further	  reinforces	  the	  enhancing	  effect	  of	  BSO	  on	  ‘4h	  delayed’	  PDT	  compared	  to	  ‘immediate’	  PDT.	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Figure	  3.13	  –	  Impact	  of	  Buthionine	  Sulfoximine	  on	  TPPS2a-­‐mediated	  Photodynamic	  
Therapy	  (Immediate	  versus	  4h	  protocol).	  	  4T1	   breast	   cancer	   cells	   treated	   with	   TPPS2a	   0.6	   µg	   ml-­‐1	   +	   BSO	   1.0	   µg	   ml-­‐1.	   (a)	   Cells	  illuminated	  immediately	  (blue	  line)	  or	  4h	  (orange	  broken	  line)	  after	  TP	  washed	  off;	  (b)	  difference	  in	  mean	  cytotoxicity	  for	  immediate	  versus	  4h-­‐delayed	  illumination,	  grey	  area	  represents	   PDT	   +	   BSO,	   yellow	   area	   represents	   PDT.	   Cells	   illuminated	   for	   increasing	  durations	   of	   time	  up	   to	   300	   s	   using	   LumiSource®	   illuminator.	   Cell	   viability	  measured	  using	  MTT	  assay	  24h	  after	  illumination	  (absorbance	  read	  at	  490	  nm).	  
	  Although	  up	   to	  90	  s	   illumination	   the	  difference	  between	  the	  mean	  cytotoxicity	  (Immediate	  minus	  4h)	  is	  greater	  for	  PDT	  +	  BSO,	  at	  all	  time	  points	  beyond	  90	  s	  the	   difference	   in	   means	   is	   significantly	   less	   for	   PDT	   +	   BSO	   compared	   to	   PDT	  alone.	  For	  example,	  at	  120	  s	  the	  difference	  in	  mean	  cell	  viability	  is	  57%	  and	  39%	  for	  PDT	  and	  PDT	  +	  BSO	  respectively.	  After	  180	  s	   illumination	  this	   increases	   to	  68%	   for	  PDT	  and	  12%	   for	  PDT	  +	  BSO.	  The	   shape	  of	   the	  marginally	  negatively	  skewed	  PDT	  +	  BSO	  graph	  (fig.	  3.13b)	  indicates	  that	  at	  higher	  illumination	  times	  BSO	  has	  a	  greater	  effect	  on	  ‘4h	  delay’	  PDT	  compared	  to	  ‘immediate’	  illumination.	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Figure	  3.14	  –	  Impact	  of	  Buthionine	  Sulfoximine	  on	  TPPS2a-­‐mediated	  Photochemical	  
Internalisation	  of	  Saporin.	  	  4T1	   breast	   cancer	   cells	   treated	  with	   TPPS2a	   0.6	   µg	  ml-­‐1	   +	   SAP	   30	   nM	   (PCI).	   (a)	   Cells	  illuminated	  immediately	  after	  drugs	  washed	  off	  with	  (blue	  line)	  or	  without	  (black	  line)	  BSO	  1.0	   µg	  ml-­‐1;	   (b)	   Cells	   illuminated	  4h	   after	   drugs	  washed	  off	  with	   (orange	  broken	  line)	   or	   without	   (black	   broken	   line)	   BSO	   1.0	   µg	  ml-­‐1.	   Cells	   illuminated	   for	   increasing	  durations	   of	   time	  up	   to	   300	   s	   using	   LumiSource®	   illuminator.	   Cell	   viability	  measured	  using	  MTT	  assay	  24h	  after	  illumination	  (absorbance	  read	  at	  490	  nm).	  
	  The	   effect	   of	   BSO,	   for	   both	   ‘immediate’	   (fig.	   3.14a)	   and	   ‘4h	   delay’	   (fig	   3.14b)	  regimens,	  on	  PCI	  is	  shown	  in	  figure	  3.14.	  PCI	  +	  BSO	  in	  the	  absence	  of	  light	  (‘dark’	  control)	   resulted	   in	  24%	  cytotoxicity,	  which	  corresponded	   to	  a	  12%	  increased	  compared	  to	  ‘dark’	  PCI	  alone.	  	  	  For	  the	  ‘immediate’	  illumination	  group	  BSO	  enhanced	  PCI-­‐mediated	  cytotoxicity	  by	  11%	  (p<0.01)	  after	  60	  s	  illumination	  and	  15%	  (p<0.05)	  after	  90	  s.	  However,	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these	   findings	   need	   to	   be	   taken	   in	   the	   context	   of	   the	   12%	   ‘dark’	   toxicity	   seen	  with	   the	   addition	   of	  BSO	   to	   PCI.	   For	   illumination	   times	   longer	   that	   90	   s	   there	  was	  no	  significant	  increase	  in	  cytotoxicity	  associated	  with	  BSO	  treatment.	  	  The	  effect	  of	  BSO	  on	  ‘4h	  delay’	  PCI	  is	  seen	  in	  figure	  3.14b.	  After	  60	  s	  illumination	  there	   was	   a	   22%	   increase	   in	   cytotoxicity	   associated	   with	   application	   of	   BSO	  (p<0.01).	   This	   increase	   was	  maintained	   after	   150	   seconds	   illumination	   (21%,	  p<0.01).	  The	  peak	  increase	  in	  cytotoxicity	  of	  25%	  occurred	  after	  180	  s	  exposure	  to	  light	  (p<0.01).	  	  	  Figure	  3.15a	  shows	  the	  difference	  in	  cytotoxicity	  profiles	  between	  PCI	  +	  BSO	  for	  cells	   in	   the	   immediate	   versus	   4h	   groups.	   This	   graph	   illustrates	   that	   for	  illumination	  times	  <180	  s,	  there	  was	  a	  significant	  increase	  in	  cytotoxicity	  in	  the	  ‘immediate’	   group	   compared	   to	   the	   ‘4h’	   group	  with	   a	  maximum	   difference	   of	  32%	  seen	  when	  cells	  were	  illuminated	  for	  120	  seconds	  (p<0.01).	  Between	  180	  s	  –	  300	  s	   illumination	   there	  was	  no	  difference	   in	   cytotoxicity	  observed	  between	  the	  two	  groups	  with	  over	  9.3	  in	  every	  10	  cells	  being	  killed	  (p<0.01).	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Figure	  3.15	  –	  Impact	  of	  Buthionine	  Sulfoximine	  on	  TPPS2a-­‐mediated	  Photochemical	  
Internalisation	  of	  Saporin	  (Immediate	  versus	  4h	  protocol).	  	  4T1	  breast	  cancer	  cells	  treated	  with	  TPPS2a	  0.6	  µg	  ml-­‐1	  +	  SAP	  30	  nM	  +	  BSO	  1.0	  µg	  ml-­‐1	  (enhanced	   PCI).	   (a)	   Cells	   illuminated	   immediately	   (blue	   histogram)	   or	   4h	   (orange	  histogram)	   after	   drugs	   were	   washed	   off;	   (b)	   difference	   in	   mean	   cytotoxicity	   for	  immediate	  versus	  4h-­‐delayed	  illumination,	  grey	  area	  represents	  PCI	  +	  BSO,	  orange	  area	  represents	   PCI.	   Cells	   illuminated	   for	   increasing	   durations	   of	   time	   up	   to	   300	   s	   using	  LumiSource®	   illuminator.	   Cell	   viability	   measured	   using	   MTT	   assay	   24h	   after	  illumination	  (absorbance	  read	  at	  490	  nm).	  
	  Comparison	  of	  the	  %	  viability	  after	  180	  s	  illumination	  in	  the	  ‘4h’	  group	  with	  the	  that	  in	  fig.	  3.10b	  shows	  a	  24%	  increase	  in	  cytotoxicity	  for	  PCI	  +	  BSO	  compared	  to	  PCI	   alone.	   Figure	   3.15b	   shows	   that	   in	   the	   presence	   of	   BSO	   there	   was	   no	  significant	  difference	   in	  the	  mean	  survival	  of	  cells	   treated	  with	  TP	  0.6	  µg/ml	  +	  SAP	  30	  nM	  (PCI)	  and	  exposed	  to	  ≥180	  illumination	  between	  the	  ‘immediate’	  and	  ‘4h’	   groups.	   For	   example,	   PCI	   alone	   on	   cells	   exposed	   to	   180	   s	   illumination	  
	   84	  
resulted	   in	   24%	   increased	   killing	   in	   the	   ‘immediate’	   group	   compared	   to	   ‘4h’	  however;	  this	  difference	  was	  completely	  eradicated	  upon	  addition	  of	  BSO.	  	  	  	  Figure	  3.16	  illustrates	  the	  effect	  of	  BSO	  on	  PCI	  of	  MTX	  1.5	  µg/ml.	  In	  figure	  3.16a	  no	  significant	  increase	  in	  cytotoxicity	  was	  observed	  upon	  addition	  of	  BSO,	  across	  all	   the	   light	   durations,	   in	   the	   immediate	   illumination	   group.	   The	   maximum	  increase	  was	  8.4%	  at	  90	   s	   illumination	   (p>0.05).	   	   Figure	  3.16b	   shows	   that	   for	  illumination	  durations	  <180	  s	  there	  was	  no	  significant	  increase	  in	  cytotoxicity	  in	  the	  ‘4h’	  group.	  However	  after	  180	  s	  and	  240	  s	  of	  light	  treatment	  there	  was	  30%	  and	   24%	   increased	   cell	   killing,	   respectively	   (p<0.01).	   The	   maximum	   cell	   kill	  achieved	  was	   90%,	   achieved	   after	   300	   seconds	   of	   light	   exposure,	   though	   it	   is	  important	   to	   consider	   that	  MTX	  alone	  has	  about	  47%	  cytotoxicity	  and	  TP	   (0.6	  µg/ml)	  +	  MTX	  ‘dark	  control’	  has	  53%	  cytotoxicity	  +/-­‐	  BSO.	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Figure	  3.16	  –	  Impact	  of	  Buthionine	  Sulfoximine	  on	  TPPS2a-­‐mediated	  Photochemical	  
Internalisation	  of	  Mitoxantrone.	  	  4T1	  breast	  cancer	  cells	  treated	  with	  TPPS2a	  0.6	  µg	  ml-­‐1	  +	  MTX	  1.5	  µg	  ml-­‐1	  	  (PCI).	  (a)	  Cells	  illuminated	  immediately	  after	  drugs	  washed	  off	  with	  (blue	  line)	  or	  without	  (black	  line)	  BSO	  1.0	   µg	  ml-­‐1;	   (b)	   cells	   illuminated	   4h	   after	   drugs	  washed	   off	  with	   (orange	   broken	  line)	  or	  without	  (black	  broken	   line)	  BSO	  1.0	  µg	  ml-­‐1;	   (c)	  cells	   illuminated	   immediately	  after	  TP	  (PDT,	  black	  line)	  or	  drugs	  (PCI,	  blue	  line)	  were	  washed	  off;	  (d)	  cells	  illuminated	  4h	  after	  TP	  (PDT,	  black	  line)	  or	  drugs	  (PCI,	  blue	  line)	  were	  washed	  off.	  Cells	  illuminated	  for	   increasing	   durations	   of	   time	   up	   to	   300	   s	   using	   LumiSource®	   illuminator.	   Cell	  viability	   measured	   using	   MTT	   assay	   24h	   after	   illumination	   (absorbance	   read	   at	   490	  nm).	  
	  Figure	  3.16c	  compares	  the	  effect	  of	  BSO	  on	  PDT	  and	  MTX-­‐PCI	  in	  the	  ‘immediate’	  group.	  The	  graph	  illustrates	  a	  converging	  cytotoxicity	  profile	  between	  PDT+BSO	  and	  PCI+BSO.	  The	  former	  has	  significantly	  reduced	  ‘dark’	  cytotoxicity	  compared	  to	  the	  latter	  (55%,	  p<0.01).	  This	  is	  almost	  entirely	  due	  to	  the	  cytotoxic	  effect	  of	  MTX.	   After	   90	   s	   illumination	   this	   difference	   reduces	   to	   29%	   (p<0.01).	   At	   this	  time	  point	  there	  is	  a	  46%	  increase	  in	  PDT+BSO	  cytotoxicity	  compared	  to	  ‘dark’	  control.	   At	   the	   same	   time	   point	   the	   increase	   in	   PCI+BSO	   cytotoxicity	   is	   18%,	  representing	  a	  2.6-­‐fold	  differential	   in	   improved	  PDT+BSO	  cytotoxicity	  between	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0-­‐90	   s	   illumination	   and	   PCI+BSO.	   Illumination	   times	   >180	   s	   were	   associated	  with	  >93%	  cytotoxicity	  with	  no	  difference	  between	  the	  two	  groups.	  	  	  A	  very	  similar	  pattern	  of	  convergence	  between	  PDT+BSO	  and	  PCI+BSO	  induced	  cytotoxicity	   is	   seen	   in	   the	   ‘4h’	   group	   (fig.	   3.16d).	  After	  90	   s	   illumination	   there	  was	   39%	   increased	   cytotoxicity	   observed	   in	   the	   PCI+BSO	   group	   compared	   to	  PDT+BSO.	   However,	   this	   represents	   a	   19%	   increase	   in	   PDT+BSO	   cytotoxicity	  compared	  to	  ‘dark’	  control.	  In	  the	  PCI+BSO	  group	  a	  1%	  increase	  in	  cytotoxicity	  in	  cytotoxicity	  was	  seen	  over	  the	  same	  illumination	  time	  period.	  Much	   like	  the	  ‘immediate’	   group,	   there	   was	   no	   significant	   difference	   in	   cytotoxicity	   for	  illumination	  durations	  >180	  seconds.	  However	  the	  ultimate	  level	  of	  cytotoxicity	  achieved	  was	  92%	  compared	  to	  control.	  	  
3.9	  Variable	  5:	  Illumination	  ‘before’	  versus	  ‘after’	  cytotoxin	  treatment	  In	   this	   section	   the	   investigation	   focuses	   on	   the	   effect	   of	   altering	   the	   timing	   of	  light	   treatment,	   either	   ‘before’	   or	   ‘after’	   treatment	   with	   the	   cytotoxin.	   The	  former	   regimen	   involved	  exposing	   cells	   treated	  with	   a	  photosensitiser	   to	   light	  prior	   to	   cytotoxin	   treatment.	   The	   latter	   was	   the	   ‘standard’	   PCI	   protocol	   with	  light	  treatment	  following	  24h	  co-­‐incubation	  of	  photosensitiser	  and	  cytotoxin.	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Figure	   3.17	   –	   Comparison	   of	   the	   light	   ‘after’	   versus	   light	   ‘before’	   Saporin	  
Photochemical	  Internalisation	  protocols.	  4T1	  breast	  cancer	  cells	  treated	  with	  different	  combinations	  of	  TPPS2a	  0.3	  µg	  ml-­‐1,	  	  SAP	  15	  nM	  and	  BSO	  1.0	   µg	  ml-­‐1.	   Saporin	  was	   added	   to	   appropriate	   treatment	   groups	  either	   preceding	   (light	   ‘after’)	   or	   following	   (light	   ‘before’)	   illumination.	   Exposure	   to	  light	   took	   place	   4h	   after	   drugs	   were	   washed	   off.	   Cells	   illuminated	   for	   120	   s	   using	  LumiSource®	   illuminator.	  BSO	   increased	  PCI	  cytotoxicity	  by	  25%	  (p<0.01)	   in	   the	   light	  ‘before’	   group	   (blue	   histogram).	   Cell	   viability	   measured	   using	   MTT	   assay	   24h	   after	  illumination	  (absorbance	  read	  at	  490	  nm).	  
	  The	   two	  PCI	  protocols	   (light	   ‘after	   versus	   light	   ‘before’)	  were	   compared	  when	  using	  TP	  0.3	  µg/ml	  and	  SAP	  15	  nM	  (fig.	  3.17).	  The	  combination	  of	  TP,	  SAP	  and	  120	   s	   illumination	   (PCI)	   in	   the	   light	   ‘after’	   cytotoxin	  protocol	   resulted	   in	  41%	  and	  47%	  increased	  cell	  kill	   compared	  to	  either	  PDT	  or	  SAP	  alone,	  respectively	  (p<0.01).	   In	   comparison	   there	  was	  no	   significant	  kill	   effect	   seen	   for	  PCI	   in	   the	  light	   ‘before’	  group.	  Addition	  of	  BSO	  to	   the	  PCI	  group	   led	  to	  a	  10%	  increase	   in	  cytotoxicity	  in	  the	  light	  ‘after’	  group	  (p<0.01),	  whereas	  in	  the	  light	  ‘before’	  group	  a	   25%	   increase	   was	   observed	   (p<0.01).	   	   Furthermore,	   subsequent	   to	   the	  addition	  of	  BSO,	  the	  cytotoxic	  differential	  between	  the	  light	  ‘after’	  versus	  ‘before’	  groups	  narrowed	  from	  46%	  (p<0.01)	  to	  34%	  (p<0.01).	  Buthionine	  sulfoximine	  also	  enhanced	  the	  efficacy	  of	  photosensitiser	  alone	  (PDT)	  by	  20%	  (p<0.01).	  The	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greatest	  magnitude	  of	  cell	  kill	  was	  seen	  in	  cells	  treated	  with	  PCI+BSO	  in	  the	  light	  ‘after’	  group,	  with	  69%	  cytotoxicity	  achieved.	  	  	  Figure	   3.18	   illustrates	   the	   comparison	   between	   the	   light	   ‘before’	   versus	   light	  ‘after’	   protocols	   for	   both	   SAP	   15	   nM-­‐PCI	   (fig.	   3.18a)	   and	  MTX	   0.4	   µg/ml	   (fig.	  3.18b).	   In	   these	   experiments	   the	   TPPS2a	   dose	   was	   doubled	   to	   0.6	   µg/ml.	   An	  interesting	  point	   to	  note	   is	   the	  effect	  of	   increasing	  the	  photosensitiser	  dose	  on	  the	   light	   ‘before’	   regimen.	   Specifically,	   comparison	   of	   the	   PCI	   group	   in	   figure	  3.18a	  with	  that	  from	  figure	  3.17	  shows	  that	  the	  PCI	  effect	  in	  the	   ‘before’	  group	  increases	   by	   47%	   (p<0.01).	   	   There	   was	   only	   a	   marginal	   increase	   in	   PCI	  cytotoxicity	  for	  the	  light	  ‘after’	  group	  after	  the	  photosensitiser	  was	  doubled.	  	  	  The	   differential	   cytotoxicity	   between	   the	   two	   groups	   reduced	   from	   20%	  (p<0.01)	  with	  0.3	  µg/ml	  TP	  to	  8%	  (p<0.05)	  with	  0.6	  µg/ml	  TP.	  Addition	  of	  BSO	  to	  the	  PCI	   treatment	  group	  resulted	   in	  a	  12%	  (p<0.01)	   increase	   in	  cytotoxicity	  compared	  to	  PCI	  alone.	  This	  is	  comparable	  to	  the	  increase	  seen	  using	  SAP	  30	  nM	  (17%,	  P<0.05,	   fig.	  3.14b).	   	  No	  significant	  difference	  was	  observed	  between	  PCI	  versus	  PCI	  +	  BSO	  in	  the	  light	  ‘before’	  group	  (fig.	  3.18a).	  	  	  Figure	  3.18b	  shows	  a	  similar	  pattern	  to	  that	  seen	  in	  figure	  3.18a.	  Specifically	  the	  light	   ‘after’	  protocol	  achieved	   the	  highest	  overall	   level	  of	   cell	  kill,	   compared	   to	  control,	  for	  both	  PCI	  (54%,	  p<0.01)	  and	  PCI	  +	  BSO	  (71%,	  P<0.01).	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Figure	   3.18	   –	   Comparison	   of	   the	   light	   ‘after’	   versus	   light	   ‘before’	   Saporin	   or	  
Mitoxantrone	  Photochemical	  Internalisation	  protocols.	  	  4T1	  breast	   cancer	   cells	   treated	  with	   different	   combinations	   of	   (a)	   TPPS2a	   0.6	   µg	  ml-­‐1,	  SAP	  15	  nM	  and	  BSO	  1.0	  µg	  ml-­‐1;	  (b)	  TPPS2a	  0.6	  µg	  ml-­‐1,	  MTX	  0.4	  µg	  ml-­‐1	  and	  	  BSO	  1.0	   µg	  ml-­‐1.	   SAP	   (a)	   or	  MTX	   (b)	  was	   added	   to	   the	   appropriate	   treatment	   groups	  either	   preceding	   (light	   ‘after’)	   or	   following	   (light	   ‘before’)	   illumination.	   Exposure	   to	  light	   took	   place	   4h	   after	   drugs	   were	   washed	   off.	   Cells	   illuminated	   for	   120	   s	   using	  LumiSource®	   illuminator.	   Cell	   viability	   measured	   using	   MTT	   assay	   24h	   after	  illumination	  (absorbance	  read	  at	  490	  nm).	  
	  However,	   an	   interesting	   observation	   can	   be	  made	   on	   closer	   inspection	   of	   the	  results.	   In	   the	   light	   ‘after’	   protocol	  where	  MTX	   is	   added	   to	   the	   cells	   24	   hours	  after	   initial	   seeding,	   53%	   cytotoxicity	   is	   observed.	   Indicating	   there	   is	   no	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significant	  increase	  with	  PCI	  (1%).	  However,	  the	  light	  ‘before’	  protocol	  involves	  treating	   the	   cells	   with	  MTX	   48	   hours	   after	   cell	   seeding.	   This	   resulted	   in	   18%	  cytotoxicity,	  a	  full	  35%	  less	  than	  in	  the	  light	  ‘after’	  group.	  Consequently,	  despite	  achieving	  13%	  (p<0.01)	  less	  ultimate	  cell	  kill	  than	  PCI	  in	  the	  light	  ‘after’	  group,	  the	   light	   ‘before’	   PCI-­‐MTX	   regimen	   resulted	   in	   a	   23%	   (p<0.01)	   increase	   in	  cytotoxicity	  compared	  to	  MTX	  alone.	  	  Addition	  of	  BSO	  enhanced	  PCI	  in	  the	  light	  ‘after’	  group	  by	  17%	  (p<0.01),	  though	  there	   was	   no	   significant	   difference	   observed	   in	   the	   light	   ‘before’	   group.	   The	  addition	  of	  BSO	  to	  PDT	  resulted	  in	  17%	  (p<0.01)	  increased	  cytotoxicity.	  	  	  	  In	   order	   to	   better	   simulate	   the	   clinical	   picture	   with	   regard	   to	   cancer	  therapeutics,	  where	  multiple	   therapeutics	  are	  often	  used	   in	  a	   single	   treatment	  regimen,	  SAP	  and	  MTX	  were	  given	  in	  combination	  to	  assess	  whether	  or	  not	  PCI	  would	  enhance	  the	  delivery	  of	  a	  combined	  therapy.	  	  	  	  The	  relative	  toxicity	  associated	  with	  combining	  SAP	  +	  MTX	  for	  PCI	  (120	  seconds	  illumination)	  was	  compared	  with	  single	  agent	  PCI	  +/-­‐	  BSO	  in	  this	  investigation	  (fig.	  3.19).	  In	  the	  light	  ‘after’	  group,	  Combination	  (SAP	  +	  MTX)-­‐PCI	  (Combo-­‐PCI)	  resulted	  in	  14%	  (p<0.01)	  and	  17%	  (p<0.01)	  increased	  cell	  kill	  compared	  to	  SAP-­‐PCI	   and	   MTX-­‐PCI	   respectively.	   In	   the	   light	   ‘before’	   group,	   Combo-­‐PCI	   did	   not	  significantly	   increase	   cytotoxicity	   compared	   to	   SAP-­‐PCI,	   though	   MTX-­‐PCI	   was	  enhanced	  by	  15%	  (p<0.01).	   Interestingly	   in	   the	  SAP	  +	  MTX	  (S/M,	  without	  TP)	  control	  (data	  not	  shown),	  there	  was	  a	  significant	  difference	  in	  cytotoxicity	  with	  the	   light	   ‘after’	   (LA)	   regimen	   eliciting	   52%	   (p<0.01)	   cytotoxicity	   compared	   to	  22%	   (p<0.01)	   in	   the	   light	   ‘before’	   (LB)	   group.	   Therefore,	   for	   Combo-­‐PCI	   (LA)	  there	  was	   no	   significant	   increase	   in	   cell	   kill	   compared	   to	   S/M	   (LA).	   However,	  Combo-­‐PCI	  (LB)	  increased	  cytotoxicity	  by	  34%	  (p<0.01)	  compared	  to	  S/M	  (LB).	  Overall,	  Combo-­‐PCI	  was	  more	  effective	  (for	  total	  cell	  kill)	  with	  the	  LA	  protocol,	  which	  produced	  15%	  increased	  cell	  kill	  compared	  to	  the	  LB	  protocol.	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Figure	   3.19	   –	   Comparison	   of	   the	   light	   ‘after’	   versus	   light	   ‘before’	   Combination	  
Photochemical	  Internalisation	  protocols.	  	  4T1	  breast	  cancer	  cells	  treated	  with	  different	  combinations	  of	  TPPS2a	  0.3	  µg	  ml-­‐1,	  	  SAP	  15	  nM,	  MTX	  0.4	  µg	  ml-­‐1	  and	  BSO	  1.0	  µg	  ml-­‐1.	  Saporin	  and	  or	  MTX	  was	  added	  to	  the	  appropriate	  treatment	  groups	  either	  preceding	  (light	  ‘after’)	  or	  following	  (light	  ‘before’)	  illumination.	   Exposure	   to	   light	   took	   place	   4h	   after	   drugs	   were	   washed	   off.	   Cells	  illuminated	  for	  120	  s	  using	  the	  LumiSource®	  illuminator.	  (*)	  BSO	  increased	  combo-­‐PCI	  cytotoxicity	  by	  18%	  (p<0.01)	  in	  the	  light	   ‘before’	  group	  (blue	  histogram).	  Cell	  viability	  measured	  using	  MTT	  assay	  24h	  after	  illumination	  (absorbance	  read	  at	  490	  nm).	  
	  Addition	   of	   BSO	   to	   Combo-­‐PCI	   (LA)	   resulted	   in	   18%	   (p<0.01)	   increased	  cytotoxicity	  reaching	  a	  maximum	  of	  89%	  cell	  kill	  compared	  to	  control.	  This	  also	  represents	  a	  19%	  and	  18%	   increase	  compared	   to	  BSO	  enhanced	  SAP-­‐PCI	   (LA)	  and	  MTX-­‐PCI	  (LA)	  respectively	  (p<0.01).	  The	  BSO	  +	  SAP	  +	  MTX	  (B/S/M,	  without	  TP)	  control	   (LA)	  produced	  55%	  (p<0.01)	  cytotoxicity	  compared	   to	  control	   (no	  treatment).	  Thus	  BSO	  enhanced	  Combo-­‐PCI	   (LA)	  produced	  34%	   increased	   cell	  kill	  compared	  B/S/M	  (LA)	  (p<0.01).	  	  Addition	  of	  BSO	  to	  Combo-­‐PCI	  (LB)	  had	  no	  effect	   on	   cytotoxicity.	   However,	   there	  was	   a	   12%	   (p<0.01)	   and	   18%	   (p<0.01)	  increase	   compared	   to	   BSO	   enhanced	   SAP-­‐PCI	   (LB)	   and	   MTX-­‐PCI	   (LB)	  respectively.	   B/S/M	   (LB)	   caused	   23%	   cell	   kill	   compared	   to	   control	   (no	  treatment).	  Therefore,	  Combo-­‐PCI	  +	  BSO	  (LB)	  killed	  32%	  more	  cells	  than	  B/S/M	  (LB)	  (p<0.01).	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It	  is	  important	  to	  note	  that	  there	  was	  <3%	  increase	  in	  cytotoxicity	  upon	  addition	  of	  BSO	  to	  S/M	  for	  both	  LA	  and	  LB	  protocols.	  	  
3.10	  Variable	  6:	  Time	  between	  photosensitiser	  activation	  and	  survival	  assay	  In	  this	  study	  the	  effect	  of	  prolonging	  the	  time	  to	  MTT-­‐assay	  from	  24	  hours	  post-­‐light	  to	  72	  hours	  post-­‐light	  was	  investigated.	  	  	  Figure	  3.20	   shows	   four	   graphical	   comparisons	   in	   cell	   viability	   at	   24h	   and	  72h	  post-­‐light	  for	  both	  LB	  (blue)	  and	  LA	  (red)	  PCI	  protocols.	  	  Figure	  3.20a	  represents	  the	   light	   ‘after’	   protocol	   for	   SAP-­‐PCI.	   In	   the	   PDT	   alone	   group,	   a	   6%	   (p<0.01)	  increase	  in	  cell	  kill	  was	  observed	  at	  72h	  compared	  to	  24h.	  For	  SAP	  15	  nM	  alone	  the	   increase	   was	   13%	   (p<0.01)	   at	   72h,	   therefore,	   18%	   (p<0.01)	   cytotoxicity	  compared	   to	   control.	  There	  was	  no	   significant	   increase	   in	   cytotoxicity	   for	  BSO	  between	  24h	  and	  72h;	  therefore,	  it	  remained	  <10%	  compared	  to	  control.	  At	  72h,	  the	   cytotoxicity	   of	   SAP-­‐PCI	   increased	   by	   28%	   (p<0.01)	   compared	   to	   24h	   to	  achieve	  a	  total	  of	  85%	  (p<0.01)	  compared	  to	  control.	  This	  represented	  a	  2.4-­‐fold	  and	  3.7-­‐fold	  increase	  in	  cytotoxicity	  compared	  to	  PDT	  alone	  (72h)	  or	  SAP	  alone	  (72h)	   respectively	   (p<0.01).	   In	  contrast,	   at	  24h	   there	  was	  a	  2-­‐fold	  and	  13-­‐fold	  increase	  in	  cytotoxicity	  compared	  to	  PDT	  alone	  or	  SAP	  alone	  respectively.	  In	  the	  PDT-­‐BSO	   group	   a	   13%	   (p<0.01)	   increase	   in	   cell	   kill	   was	   observed	   at	   72h	  compared	  to	  24h,	  corresponding	  to	  a	  maximal	  30%	  (p<0.01)	  cell	  kill	  compared	  to	  control.	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Figure	  3.20	  –	   Investigation	   into	   the	   impact	  on	   cytotoxicity	  of	  waiting	  72h	  versus	  
24h	   post-­‐illumination	   for	   Buthionine	   Sulfoximine	   enhanced	   Photochemical	  
Internalisation	  of	  Saporin	  or	  Mitoxantrone.	  	  4T1	  breast	  cancer	  cells	  treated	  with	  different	  combinations	  of	  TPPS2a	  0.6	  µg	  ml-­‐1,	  	  SAP	  15	  nM,	  MTX	  0.4	  µg	  ml-­‐1	  and	  BSO	  1.0	  µg	  ml-­‐1.	  (a)	  Cells	  were	  treated	  with	  TP	  or	  SAP	  or	  BSO	  alone	  or	  in	  combination	  and	  illuminated	  for	  120	  s	  at	  a	  time	  point	  4h	  after	  drugs	  were	   washed	   off,	   MTT	   performed	   24h	   (white	   histogram)	   or	   72h	   (red	   striped)	   after	  illumination;	  (b)	  cells	  were	  treated	  with	  TP	  and/or	  BSO	  and	  illuminated	  for	  120	  s	  at	  a	  time	  point	   4h	   after	   drugs	  were	  washed	  off,	   SAP	   and/or	  BSO	   added	   after	   illumination	  (light	   ‘before’),	   MTT	   performed	   24h	   (white	   histogram)	   or	   72h	   (red	   solid)	   after	  illumination;	  (c)	  same	  protocol	  as	  (a)	  except	  SAP	  replaced	  with	  MTX,	  MTT	  performed	  24h	  (white	  histogram)	  or	  72h	  (purple	  striped)	  after	  illumination;	  (d)	  same	  protocol	  as	  (c)	   (light	   ‘before)	   except	   SAP	   replaced	   with	   MTX,	   MTT	   performed	   24h	   (white	  histogram)	  or	  72h	  (purple	  solid)	  after	  illumination.	  (*)	  addition	  of	  BSO,	  enhanced	  SAP-­‐PCI	  cytotoxicity	  by	  11%	  at	  72h	  (p<0.01)	  resulting	  in	  >95%	  cell	  kill,	  (**)	  addition	  of	  BSO,	  enhanced	  MTX-­‐PCI	  cytotoxicity	  by	  23%	  at	  72h	  (p<0.01).	  Cell	  viability	  measured	  using	  MTT	  assay	  (absorbance	  read	  at	  490	  nm).	  	  	  The	   PCI	   +	   BSO	   group	   experienced	   the	   highest	   level	   of	   cell	   kill	   at	   72h.	   A	   26%	  (p<0.01)	   increase	   in	   cytotoxicity	   was	   observed	   compared	   to	   24h,	   which	  corresponds	  to	  96%	  (p<0.01)	  cell	  kill	  compared	  to	  control.	  This	  also	  represents	  an	  11%	  (p<0.01)	  increase	  in	  cell	  kill	  compared	  to	  PCI	   in	  the	  absence	  of	  BSO	  at	  72h	  SAP	  +	  BSO	  at	  72h	  produced	  10%	  (p<0.01)	   increased	  cell	  kill	   compared	   to	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24h.	   This	   corresponded	   to	   59%	   (p<0.01)	   less	   cytotoxicity	   than	   SAP-­‐PCI	   (72h)	  and	  70%	  (p<0.01)	  less	  than	  SAP-­‐PCI	  +	  BSO	  (72h).	  	  	  	  Figure	   3.20c	   illustrates	   the	   results	   for	   the	   (LA)	   protocol	   for	   PCI-­‐MTX.	   At	   72h	  MTX	   0.4	   µg/ml	   elicited	   66%	   (p<0.01)	   cell	   kill	   compared	   to	   controls,	   which	  represents	   a	   13%	   increase	   compared	   to	   24h.	   MTX-­‐PCI	   (LA)	   produced	   62%	  (p<0.01)	  cell	  kill,	  thus	  there	  was	  no	  difference	  observed	  compared	  to	  MTX	  alone	  at	   72h.	   Addition	   of	   BSO	   to	   PCI-­‐MTX	   (LA)	   resulted	   in	   85%	   cell	   kill,	   a	   14%	  (p<0.01)	   increase	   compared	   to	   PCI-­‐MTX	   +	   BSO	   at	   24h	   and	   a	   23%	   (p<0.01)	  increase	  compared	  to	  PCI-­‐MTX	  at	  72h.	  A	  15%	  rise	  in	  cytotoxicity	  was	  observed	  between	  MTX	  +	  BSO	  at	  72h	  compared	  to	  24h.	  This	  translates	  into	  32%	  increase	  compared	  to	  MTX	  alone	  at	  72h	  and	  this	  is	  equivalent	  to	  the	  level	  of	  cytotoxicity	  seen	  with	  MTX-­‐PCI	  at	  72h,	  as	  there	  is	  no	  significant	  difference.	  However,	  MTX	  +	  BSO	  (72h)	  produced	  16%	  (p<0.01)	  less	  cell	  kill	  than	  MTX-­‐PCI	  +	  BSO	  (72h).	  	  	  	  	  Figure	   3.20b	   shows	   the	   histogram	   for	   the	   light	   ‘before’	   protocol	   for	   SAP-­‐PCI.	  There	  was	  an	  8%	  (p<0.01)	  increase	  in	  cytotoxicity	  for	  SAP	  alone	  72h	  compared	  to	  24h.	  SAP-­‐PCI	  (LB,	  72h)	  achieved	  44%	  (p<0.01)	  cytotoxicity.	  This	  represents	  no	  difference	  compared	  to	  24h.	  SAP-­‐PCI	  +	  BSO	  (72h)	   increased	  cytotoxicity	  by	  12%	  (p<0.01)	  compared	  to	  SAP-­‐PCI	  (72h)	  and	  SAP-­‐PCI	  +	  BSO	  (24h).	  There	  was	  no	   difference	   in	   cytotoxicity	   between	   SAP	   +	   BSO	   (LB)	   at	   24h	   versus	   72h.	  However,	  SAP	  +	  BSO	  (LB,	  72h)	  killed	  16%	  less	  cells	  that	  SAP-­‐PCI	  (LB,	  72h)	  and	  28%	  less	  than	  SAP-­‐PCI	  +	  BSO	  (LB,	  72h)	  (p<0.01).	  	  	  Figure	  3.20d	  illustrates	  the	  difference	  in	  cytotoxicity	  at	  24h	  versus	  72h	  in	  light	  ‘before’	  MTX-­‐PCI.	  There	  was	  no	  difference	  in	  cell	  kill	  for	  MTX	  alone	  between	  24h	  and	  72h.	  MTX-­‐PCI	  (LB,	  72h)	  elicited	  10%	  (p<0.01)	  increased	  cell	  kill	  compared	  to	   MTX	   alone	   (LB,	   72h).	   MTX-­‐PCI	   (LB,	   72h)	   killed	   8%	   (p<0.01)	   less	   cells	  compared	   to	   24h	   (LB).	   MTX-­‐PCI	   +	   BSO	   (LB)	   produced	   43%	   (p<0.01)	   cell	   kill	  compared	  to	  control,	  which	  equates	   to	  an	  11%	  increase	  compared	  to	  MTX-­‐PCI	  (LB,	  72h).	  However,	  there	  is	  no	  difference	  in	  cytotoxicity	  in	  the	  MTX-­‐PCI	  +	  BSO	  groups	   at	   24h	   versus	   72h.	   MTX	   +	   BSO	   (LB,	   72h)	   produced	   11%	   (p<0.01)	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increased	   cell	   kill	   compared	   to	  24h.	  There	   is	   a	  12%	   increase	   in	   cell	   kill	   in	   the	  MTX	  +	  BSO	  (LB,	  72h)	  compared	  to	  MTX	  alone	  (LB,	  72h),	  however	  there	  is	  no	  	  difference	  between	  MTX	  +	  BSO	  and	  MTX-­‐PCI	  in	  the	  LB-­‐group	  at	  72h.	  Treatment	  of	  cells	  with	  MTX-­‐PCI	  +BSO	  resulted	  in	  9%	  (p<0.01)	  increased	  cytotoxicity	  (data	  not	  shown).	  	  	  Figure	  3.21	   illustrates	   the	  effect	  of	  waiting	  72h	  post-­‐light	  before	  assessing	  cell	  viability	   for	  Combo-­‐PCI	   for	  LA	  (fig.	  3.21a)	  and	  LB	  (fig.	  3.21b)	  protocols.	  Figure	  3.21a	  shows	  a	  19%	  (p<0.01)	  increase	  in	  cell	  kill	  for	  Combo-­‐PCI	  at	  72h	  compared	  to	   24h,	   reaching	   90%	   (p<0.01)	   overall	   cytotoxicity.	   	   However,	   there	   was	   no	  significant	  increase	  in	  cell	  kill	  compared	  to	  SAP-­‐PCI	  (72h,	  LA).	  Combo-­‐PCI	  (72h,	  LA)	  killed	  15%	  (p<0.01)	  more	  cells	  than	  SAP	  +	  MTX	  under	  the	  same	  conditions.	  However,	  at	  72h	  SAP	  +	  MTX	  (LA)	  killed	  22%	  (p<0.01)	  (74%	  in	  total)	  more	  cells	  than	  at	  24h	  (LA).	  Addition	  of	  BSO	  to	  the	  Combo-­‐PCI	  protocol	  (72h,	  LA)	  resulted	  in	  maximum	  cytotoxicity	  of	  97%	  (p<0.01)	  compared	  to	  control	  and	  8%	  (p<0.05)	  compared	   to	   Combo-­‐PCI	   alone	   (72h,	   LA).	   	   Combo-­‐PCI	   +	   BSO	   (72h,	   LA)	   killed	  21%	  more	  cells	  than	  SAP	  +	  MTX	  +	  BSO	  (B/S/M,	  72h,	  LA).	  	  Figure	  3.21b	  shows	   there	   is	  no	  significant	  difference	   in	  cell	  kill	   for	  Combo-­‐PCI	  (LB	   protocol)	   at	   72h	   compared	   to	   24h.	   This	   corresponds	   to	   reaching	   56%	  (p<0.01)	   overall	   cytotoxicity	   compared	   to	   control.	   Combo-­‐PCI	   (72h,	   LB)	   killed	  27%	  (p<0.01)	  more	  cells	  that	  SAP	  +	  MTX	  under	  the	  same	  conditions.	  However,	  at	  72h	   (LB)	  SAP	  +	  MTX	  killed	  24%	  (p<0.01)	   (29%	   in	   total)	  more	   cells	   than	  at	  24h	  (LB).	  Addition	  of	  BSO	  to	  the	  Combo-­‐PCI	  protocol	  (72h,	  LB)	  resulted	  in	  11%	  (p<0.01)	  increased	  cytotoxicity	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Figure	   3.21	   -­‐	   Investigation	   into	   the	   impact	   on	   cytotoxicity	   of	  waiting	   72h	   versus	  
24h	   post-­‐illumination	   for	   Buthionine	   Sulfoximine	   enhanced	   combination	  
Photochemical	  Internalisation	  of	  Saporin	  and	  Mitoxantrone.	  	  4T1	  breast	  cancer	  cells	  treated	  with	  different	  combinations	  of	  TPPS2a	  0.6	  µg	  ml-­‐1,	  	  SAP	  15	  nM,	  MTX	  0.4	  µg	  ml-­‐1	  and	  BSO	  1.0	  µg	  ml-­‐1.	  (a)	  Cells	  were	  treated	  with	  TP	  or	  SAP	  or	  MTX	  alone	  or	   in	  combination	  +/-­‐	  BSO	  and	   illuminated	   for	  120	  s	  at	  a	   time	  point	  4h	  after	  drugs	  were	  washed	  off	  using	  the	  light	  ‘after’	  protocol,	  MTT	  performed	  24h	  (white	  histogram)	  or	  72h	  (red	  striped)	  after	   illumination;	  (b)	  Cells	  were	   treated	  with	  TP	  +/-­‐	  BSO	  and	  illuminated	  for	  120	  s	  at	  a	  time	  point	  4h	  after	  drugs	  were	  washed	  off	  using	  the	  light	   ‘before’	   protocol,	   SAP	   and/or	   MTX	   +/-­‐	   BSO	   were	   added	   following	   illumination,	  MTT	  performed	  24h	  (white	  histogram)	  or	  72h	  (blue	  striped)	  after	  illumination;	  (c)	  cells	  were	  treated	  with	  TP	  or	  SAP	  or	  MTX	  alone	  or	  in	  combination	  +/-­‐	  BSO	  (light	  ‘after’,	  red	  striped	  histogram)	  and	  illuminated	  for	  120	  s	  at	  a	  time	  point	  4h	  after	  drugs	  were	  washed	  off	  or	  treated	  with	  TP	  +/-­‐	  BSO	  and	  illuminated	  for	  120	  s	  at	  a	  time	  point	  4h	  after	  drugs	  were	  washed	  off	  using	  the	  light	  ‘before’	  protocol,	  SAP	  and/or	  MTX	  +/-­‐	  BSO	  were	  added	  following	   illumination	   (blue	   striped	   histogram).	   Cell	   viability	   measured	   using	   MTT	  assay	  72h	  after	  illumination	  (absorbance	  read	  at	  490	  nm).	  	  compared	   to	   Combo-­‐PCI	   alone	   (72h,	   LB),	   corresponding	   to	   maximum	  cytotoxicity	  of	  67%	  (p<0.01).	  	  Combo-­‐PCI	  +	  BSO	  (72h,	  LB)	  killed	  31%	  more	  cells	  than	  B/S/M	  (72h,	  LB).	  	  Comparison	   between	   LA	   vs.	   LB	   after	   72h	   shows	   that	   overall	   LA	   achieved	  significantly	  greater	  cell	  kill	  than	  the	  LB	  protocol	  (fig	  3.21c).	  For	  SAP-­‐PCI	  +	  BSO	  the	  LA	  protocol	  achieved	  40%	  (p<0.01)	  increased	  cytotoxicity	  compared	  to	  LB.	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For	   MTX-­‐PCI	   +	   BSO	   the	   LA	   protocol	   achieved	   43%	   increased	   cytotoxicity	  compared	   LB	   (72h).	   At	   72h	   combo-­‐PCI	   +	   BSO	   using	   the	   LA	   protocol	   achieved	  97%	   cytotoxicity.	   In	   comparison,	   the	   LB	   protocol	   achieved	   67%	   cytotoxicity,	  representing	  a	  30%	  increase	  in	  cell	  kill	  using	  the	  LA	  protocol.	  	  
3.11	  Confocal	  Imaging	  –	  alexa-­‐488	  labeled	  saporin	  Confocal	  microscopy	  was	  used	   to	  assess	   the	   intracellular	   localisation	  of	  Alexa-­‐labeled	  SAP	  prior	  to	  and	  following	  ‘on-­‐stage’	  exposure	  to	  a	  405	  nm	  laser	  (15s),	  to	  excite	  TP,	  for	  4T1	  cells	  treated	  with	  SAP-­‐488	  alone	  (fig.	  3.22a-­‐c)	  and	  SAP-­‐488	  +	  TP	  0.6	  µg/ml	  (fig.	  3.23a-­‐c).	  	  The	  SAP-­‐488	  alone	  group	  is	  shown	  as	  controls	  for	  the	  any	  potential	  photobleaching	  or	  redistributive	  effects	  of	  the	  405	  nm	  laser	  on	  the	  fluorescently	  labeled	  protein.	  The	  images	  are	  a	  z-­‐stack	  of	  two	  slices	  taken	  at	  three	   different	   time	   points	   (before,	   immediately	   following	   and	   240	   s	   after	  exposure	  to	  the	  405	  nm	  laser).	  Figure	  3.22a	  shows	  the	  intracellular	  distribution	  of	  SAP-­‐488	  prior	  to	  exposure	  to	  the	  405	  nm	  laser.	  The	  image	  shows	  a	  granular	  pattern	   of	   uptake,	   28h	   after	   cells	   were	   initially	   treated	   with	   SAP-­‐488.	  Immediately	  following	  exposure	  to	  the	  laser	  there	  was	  no	  observable	  change	  in	  the	  intracellular	  distribution	  of	  SAP-­‐488	  (fig.	  3.22b).	  Figure	  3.22c	  was	  taken	  240	  s	  after	  treatment	  with	  the	  laser	  and	  again	  shows	  very	  little	  if	  any	  visual	  change	  in	  SAP-­‐488	  intensity	  or	  distribution.	  Quantitative	  analysis	  of	  the	  images	  shows	  a	  3%	  reduction	  in	  average	  signal	  intensity	  between	  fig.	  3.22a	  and	  fig.	  3.22c.	  	  
	   98	  
	  
Figure	  3.22	  –	  Confocal	  imaging	  of	  Alexa-­‐488	  labeled	  Saporin	  (alone).	  	  1	   x	   104	   4T1	   (murine)	   breast	   cancer	   cells	   were	   seeded	   on	   35	   mm	   diameter	   glass-­‐bottomed	  fluorodishes	  and	  grown	  for	  48h.	  Cells	  treated	  with	  SAP-­‐488	  400	  nM	  for	  24h	  and	   washed	   three	   times	   with	   PBS	   prior	   to	   imaging.	   (a)	   pre-­‐laser	   treatment,	   (b)	  immediately	   following	  exposure	   to	  405	  nm	   laser,	  (c)	  240	   s	   after	   exposure	   to	  405	  nm	  laser.	   Quantitative	   analysis	   of	   images	   using	   ImageJ	   revealed	   a	   3%	   reduction	   in	  intracellular	  signal	  intensity	  at	  240	  s.	  Ex	  488	  nm,	  Em	  520	  nm,	  60X	  NA:1.35	  Objective	  Lens,	  
zoom	  x1.0,	  scale	  20	  microns.	  
	  Cells	  in	  figure	  3.23	  were	  treated	  with	  both	  SAP-­‐488	  and	  TP	  prior	  to	  imaging	  and	  exposure	  to	  the	  405	  nm	  laser	  using	  the	  same	  protocol	  described	  above	  for	  figure	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3.22.	  Much	  like	  3.22a,	  figure	  3.23a	  shows	  granular	  uptake	  of	  SAP-­‐488,	  28h	  after	  drugs	  were	  initially	  added	  to	  the	  4T1	  cells.	  
	  
Figure	  3.23	  –	  Confocal	  imaging	  of	  Alexa-­‐488	  labeled	  Saporin.	  	  1	   x	   104	   4T1	   breast	   cancer	   cells	   were	   seeded	   on	   35	   mm	   diameter	   glass-­‐bottomed	  fluorodishes	  and	  grown	  for	  48h.	  Cells	  treated	  with	  TPPS2a	  0.6	  µg	  ml-­‐1	  +	  SAP-­‐488	  400	  nM	  for	  24h	  and	  washed	  three	  times	  with	  PBS	  prior	  to	  imaging.	  (a)	  pre-­‐laser	  treatment,	  (b)	  immediately	   following	  exposure	   to	  405	  nm	   laser,	  (c)	  240	   s	   after	   exposure	   to	  405	  nm	  laser.	   Quantitative	   analysis	   of	   images	   using	   ImageJ	   revealed	   a	   30%	   reduction	   in	  intracellular	   signal	   intensity	   at	   240	   s	   (p<0.01).	   Ex	   488	   nm,	   Em	   520	   nm,	   60X	   NA:1.35	  
Objective	  Lens,	  zoom	  x1.0,	  scale	  20	  microns.	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Immediately	   following	   the	   treatment	  with	   the	  405	  nm	   laser,	   little	   if	   any	  visual	  change	   in	   SAP-­‐488	   signal	   intensity	   or	   distribution	   was	   observed	   (fig.	   3.23b).	  However,	  240	  s	  following	  exposure	  to	  the	  405	  nm	  laser	  there	  was	  an	  apparent	  loss	  of	  signal	  in	  the	  2-­‐slice	  z-­‐series	  associated	  with	  phenotypic	  features	  that	  are	  consistent	  with	  a	  pre-­‐apoptotic	  state	  (seen	  in	  the	  bright	  field	  image,	  fig.	  3.23c).	  Quantitative	   analysis	   showed	   a	   30%	   reduction	   in	   SAP-­‐488	   signal	   intensity	   in	  figure	  3.23c	  compared	  to	  figure	  3.23a.	  This	  represents	  a	  10-­‐fold	  greater	  loss	  of	  signal	  intensity	  in	  cells	  treated	  with	  SAP-­‐488	  +	  TP	  compared	  to	  SAP-­‐488	  alone.	  This	  would	  be	  consistent	  with	  the	  re-­‐localisation	  of	  SAP-­‐488,	  as	  treatment	  with	  the	  405	  nm	  laser	  alone	  does	  not	  trigger	  this	  change	  in	  the	  absence	  of	  TPPS2a	  (fig.	  3.22a).	  	  
3.12	  Confocal	  Imaging	  –	  mitoxantrone	  and	  lysotracker	  green	  The	   intracellular	   localisation	   of	   the	   cytotoxin	   mitoxantrone	   (MTX,	   1.2	   µg/ml)	  was	   also	   assessed	   using	   confocal	  microscopy.	   Uptake	   into	   the	   endo-­‐lysosomal	  system	  was	   observed,	   as	   detected	   by	   co-­‐localisation	  with	   Lyso-­‐Tracker	   Green	  (50	  nM)	  (fig.	  3.24c).	  	  In	  order	  to	  make	  a	  real	  time	  assessment	  of	  the	  effect	  of	  PCI	  on	   the	   redistribution	   of	   MTX	   from	   endo-­‐lysosomal	   vesicles,	   ‘on-­‐stage’	  illumination	  of	  the	  cells	  was	  performed	  using	  the	  405	  nm	  laser.	  Prior	  to	  use	  of	  the	  laser	  (fig.	  3.24a)	  MTX	  was	  localised	  in	  discrete	  intracellular	  vesicles	  (similar	  to	  SAP-­‐488	  above).	  Following	  application	  of	  the	  405	  nm	  laser,	  the	  treated	  cells	  were	  assessed	  after	  10	  minutes	  (fig.	  3.24b).	  We	  observed	  a	  significant	  change	  in	  the	   pattern	   of	   distribution	   of	   MTX	   with	   fewer	   discrete	   vesicles,	   increased	  membrane	   uptake	   and	   mobilisation	   into	   the	   nucleus	   of	   the	   4T1	   cells	   (white	  arrows).	   This	   is	   consistent	   with	   findings	   in	   previously	   published	   data,	   which	  showed	   the	   redistribution	   and	   nuclear	   mobilisation	   of	   MTX	   following	   PCI	  treatment(25).	  	  	  
	   101	  
	  
Figure	   3.24	   -­‐	   Endolysosomal	   localization	   and	   Photo-­‐induced	   redistribution	   of	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3.13	  Confocal	  Imaging	  –	  Effect	  of	  buthionine	  sulfoximine	  on	  intracellular	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Figure	  3.25	  -­‐	  Monochlorobimane-­‐glutathione	  detection.	  	  4T1	  cells	  were	   treated	  with	  mBCl	  40	  µM	  for	  20	  minutes	  prior	   to	  confocal	  microscopy	  either	   (a)	   alone	   or	   (b)	   following	   24h	   incubation	   with	   BSO	   1.0	   µg	   ml-­‐1.	   Quantitative	  analysis	   (Image	   J)	   revealed	   a	   4-­‐fold	   reduction	   in	   the	   mBCl-­‐GSH	   signal	   in	   cells	   pre-­‐treated	  with	  BSO	  (p<0.001).	  	  20X	  NA:0.75	  Objective	  Lens,	  zoom	  x2.1,	  scale	  20	  microns	  
3.14	  Confocal	  Imaging	  –	  Lipid	  peroxidation	  studies	  This	   section	   investigates	   the	   effect	   of	   photoactivation	   and	   the	   different	  compounds	  used	  thus	  far	  in	  the	  chapter	  on	  the	  level	  of	  lipid	  peroxidation	  taking	  place	  within	  the	  intracellular	  environment.	  Cells	  were	  treated	  with	  SAP,	  TPPS2a	  and	  BSO	  either	  alone	  or	   in	  different	  combinations	  +/-­‐	   light.	  Subsequently	   they	  were	   treated	  with	  a	   lipid	  peroxide	  probe,	   Image-­‐iT®	  Peroxidation	  Kit,	  which	   is	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based	  on	  the	  BODIPY®	  581/591	  C11	  reagent, that	  has	  two	  emission	  peaks,	  one	  pre-­‐lipid	  peroxidation	  at	  ~590	  nm	  and	  the	  other	  post-­‐lipid	  peroxidation	  at	  ~610	  nm	  (figure	  3.26).	  
	  
Figure	   3.26	   -­‐	   Fluorescence	   emission	   spectra	   of	   the	   Image-­‐iT®	   Lipid	   Peroxidation	  
Sensor.	  	  Before	  and	  after	  lipid	  peroxidation(121).	  
	  Figure	  3.27	   shows	  confocal	   images	  of	  negative	   control	   groups	   (untreated	   cells	  with	  no	  lipid	  peroxide	  probe,	  fig.	  3.27a)	  and	  (untreated	  cells	  with	  lipid	  peroxide	  probe,	   fig.	   3.27b).	   	   The	   comparison	   between	   the	   two	   upper	   quadrants	   of	   fig	  3.27b	   shows	   the	   relative	   fluorescence	   of	   lipid	   peroxide	   (green)	   compared	   to	  lipid	   pre-­‐peroxidation	   (red).	   The	   ratio	   of	   green:red	   is	   1:4.7,	   indicating	   that	   in	  untreated	  cells	  there	  is	  relatively	  low	  level	  of	  lipid	  peroxidation.	  The	  bottom	  left	  quadrant	  shows	  the	  overlay	  of	  the	  two	  separate	  fluorescence	  signals,	  while	  the	  bottom	  right	  quadrant	  shows	  the	  live	  cells	  in	  a	  transmitted	  light	  view.	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Figure	  3.27	  –	  Confocal	  Microscopy	  Lipid	  Peroxidation	  Studies	  (untreated	  controls).	  1	   x	   104	   4T1	   breast	   cancer	   cells	   were	   seeded	   on	   35	   mm	   diameter	   glass-­‐bottomed	  fluorodishes	  and	  grown	  for	  48h.	  Cells	  were	  re-­‐incubated	  with	  media	  alone	  for	  a	  further	  24h.	   Cells	   were	   then	   illuminated	   for	   150	   s	   using	   the	   LumiSource®	   illuminator	   (a).	  Subsequently,	  (b)	   Image-­‐IT	   lipid	  peroxidation	  probe	  was	  added	  to	   the	  cells	   to	  make	  a	  final	  concentration	  of	  10	  µM	  and	  incubated	  at	  37°C	  for	  30	  minutes.	  Images	  then	  taken	  using	   confocal	   microscope.	   RED	   =	   reduced	   lipid,	   Ex	   581	   nm	   Em	   591	   nm;	   GREEN	   =	  oxidized	  lipid,	  Ex	  488	  nm	  Em	  510	  nm;	  ORANGE	  =	  overlaid	  image.	  60X	  NA:1.35	  Objective	  
Lens,	  zoom	  x1.0,	  scale	  20	  microns.	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Figure	   3.28	   illustrates	   the	   effects	   of	   TP	   on	   the	   level	   of	   intracellular	   lipid	  peroxidation	   both	   under	   ‘dark’	   conditions	   (fig.	   3.28a)	   and	   following	   150	   s	   of	  illumination	   using	   the	   LumiSource®	   illuminator	   (fig.	   3.28b).	   Under	   ‘dark’	  conditions,	   there	   was	   a	   three-­‐fold	   increase	   in	   the	   red	   fluorescence	   signal	  compared	   to	   the	   green	   signal.	   Interestingly	   the	  maximum	   intensity	   of	   the	   red	  signal	  is	  reduced	  compared	  to	  untreated	  cells	  (fig.	  3.27b).	  Following	  exposure	  to	  150	  seconds	  of	  light	  there	  was	  a	  shift	  in	  the	  ratio	  between	  red	  and	  green	  signal,	  reducing	   from	   1:3.4	   under	   ‘dark’	   conditions	   to	   1:0.9	   (fig.	   3.28b).	   The	   latter	  indicated	   that	   activation	   of	   the	   photosensitiser	   increased	   the	   level	   of	   lipid	  peroxidation	  compared	  to	  reduced	  lipid.	  The	  maximum	  signal	  intensity	  (green)	  increased	  2.6-­‐fold	  following	  illumination	  (fig.	  3.28b)	  compared	  to	  ‘dark’	  controls	  (fig.	   3.28a).	   The	   transmitted	   light	   image	   (fig.	   3.28b)	   showed	   features	   of	   pre-­‐apoptotic	   cells	   with	   a	   significant	   change	   in	   morphology,	   particularly	   when	  compared	  to	  untreated	  (fig.	  3.27b)	  and	  dark	  (fig.	  3.28a)	  controls.	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Figure	   3.28	   –	   Confocal	   Microscopy	   Lipid	   Peroxidation	   Studies	   (PDT	   treated	  
controls).	  	  1	   x	   104	   4T1	   breast	   cancer	   cells	   were	   seeded	   on	   35	   mm	   diameter	   glass-­‐bottomed	  fluorodishes	  and	  grown	  for	  48h.	  Cells	  were	  re-­‐incubated	  with	  TPPS2a	  0.6	  µg	  ml-­‐1	  alone	  (PDT)	   for	   a	   further	   24h.	   Cells	   in	   (b)	   were	   then	   illuminated	   for	   150	   s	   using	   the	  LumiSource®	   illuminator,	  while	   those	   in	   (a)	  were	  kept	   ‘dark’.	   Subsequently,	   Image-­‐IT	  lipid	  peroxidation	  probe	  was	  added	  to	  the	  cells	  to	  make	  a	  final	  concentration	  of	  10	  µM	  and	   incubated	   at	   37°C	   for	   30	   minutes.	   Images	   were	   then	   taken	   using	   confocal	  microscope.	  A	  2.6-­‐fold	  increase	  in	  oxidised	  lipid	  was	  observed	  in	  the	  illuminated	  group	  (b)	  compared	  to	  ‘dark’	  control	  (a).	  RED	  =	  reduced	  lipid,	  Ex	  581	  nm	  Em	  591	  nm;	  GREEN	  =	   oxidized	   lipid,	   Ex	   488	   nm	   Em	   510	   nm;	   ORANGE	   =	   overlaid	   image.	   60X	   NA:1.35	  
Objective	  Lens,	  zoom	  x1.0,	  scale	  20	  microns.	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Figure	   3.29	   –	   Confocal	   Microscopy	   Lipid	   Peroxidation	   Studies	   (Buthionine	  
Sulfoximine	  or	  Saporin	  treated	  controls).	  	  1	   x	   104	   4T1	   breast	   cancer	   cells	   were	   seeded	   on	   35	   mm	   diameter	   glass-­‐bottomed	  fluorodishes	  and	  grown	  for	  48h.	  Cells	  were	  re-­‐incubated	  with	  (a)	  BSO	  1.0	  µg	  ml-­‐1	  alone,	  
(b)	  SAP	  30	  nM	  alone,	  (c)	  BSO	  +	  SAP	  for	  a	  further	  24h.	  Cells	  in	  were	  then	  illuminated	  for	  150	   s	   using	   the	   LumiSource®	   illuminator.	   Subsequently,	   Image-­‐IT	   lipid	   peroxidation	  probe	  was	  added	  to	  the	  cells	   to	  make	  a	   final	  concentration	  of	  10	  µM	  and	  incubated	  at	  37°C	   for	   30	   minutes.	   Images	   were	   then	   taken	   using	   confocal	   microscope.	   The	  combination	   of	   BSO	   +	   SAP	   resulted	   in	   19%	   and	   31%	   increase	   in	   lipid	   peroxidation	  compared	   to	  BSO	  or	  SAP	  alone	  respectively	   (p<0.01)	  RED	  =	  reduced	   lipid,	  Ex	  581	  nm	  Em	  591	  nm;	  GREEN	  =	  oxidized	  lipid,	  Ex	  488	  nm	  Em	  510	  nm;	  ORANGE	  =	  overlaid	  image.	  
60X	  NA:1.35	  Objective	  Lens,	  zoom	  x1.0,	  scale	  20	  microns.	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  Figure	  3.29	   illustrates	   the	   effects	   of	   treating	   cells	  with	  buthionine	   sulfoximine	  1.0	  µg/ml	  (BSO,	  fig.	  3.29a),	  SAP	  30	  nM	  (fig.	  3.29b)	  and	  BSO	  +	  SAP	  (fig.	  3.29c).	  In	  cells	   treated	  with	  BSO	  alone	  (‘dark’)	  a	  ratio	  of	  1:2.8	  (green:red)	  was	  observed,	  indicating	   that	  BSO	  may	  have	   an	   effect	   on	   the	   rate	   of	   lipid-­‐peroxidation	  when	  compared	  to	  untreated	  cells	  (fig.	  3.27b).	  However,	  the	  maximum	  intensity	  of	  the	  green	  signal	  was	   less	   the	  50%	  of	   that	  observed	   in	  cells	   treated	  with	  TP	  +	   light	  (150	  s).	  	  SAP	  alone	  treatment	  resulted	  in	  a	  ratio	  of	  1:3.3	  (green:red),	  indicating	  that	   although	   SAP	   does	   appear	   to	   increase	   lipid-­‐peroxidation	   compared	   to	  untreated	   controls,	   this	   represented	   a	   14%	   relative	   reduction	   in	   green	  fluorescent	  signal.	  The	  combination	  of	  BSO	  +	  SAP	  resulted	  in	  a	  green:red	  ratio	  of	  1:1.9	   (fig.	   3.29c).	   This	   indicated	   the	   combination	   of	   these	   two	   agents	   had	   a	  greater	  positive	  effect	  on	  the	  rate	  of	  lipid-­‐peroxidation	  compared	  to	  either	  agent	  alone.	   There	   was	   a	   19%	   and	   31%	   increase	   in	   the	   maximum	   green	   signal	  intensity	   compared	   to	   BSO	   or	   SAP	   alone,	   respectively	   (p<0.01).	   There	   was	   a	  concomitant	   7%	   decrease	   in	   the	   maximum	   red	   signal	   intensity	   compared	   to	  either	  agent	  alone.	  	  	  	  	  
	  Figure	   3.30	   illustrates	   the	   effect	   treating	   cells	   with	   TP	   +	   SAP	   +	   BSO	   +	   light	  	  	  	  	  	  	  (150	  s)	  has	  on	  the	  relative	  production	  of	  lipid	  peroxides.	  Figure	  3.30a	  shows	  the	  relative	  fluorescence	  signals	  for	  peroxidised	  (green)	  and	  non-­‐peroxidised	  (red)	  lipids	  within	  a	  large	  group	  of	  4T1	  cells.	  The	  ratio	  of	  green:red	  is	  1:1.9,	  which	  is	  equivalent	  to	  that	  seen	  with	  BSO	  +	  SAP	  (fig.	  3.29c).	  However,	  it	  is	  important	  to	  note	  that	  the	  maximum	  green	  signal	  was	  36%	  greater	  than	  that	  observed	  with	  BSO	  +	  SAP	  (p<0.01).	   	  Figure	  3.30b	  shows	  a	  smaller	  group	  of	  4T1	  cells	  after	  the	  same	  treatment	  regimen	  of	  figure	  3.30a.	  The	  first	  point	  to	  note	  is	  that	  these	  cells	  appear	  to	  be	  in	  the	  early	  phases	  of	  dying.	  Second	  that	  they	  have	  a	  significantly	  greater	  intensity	  of	  both	  green	  and	  red	  signals,	  compared	  to	  the	  other	  confocal	  images.	  The	  ratio	  of	  green:red	   is	  1:1.5,	   thus	   indicating	  a	  significant	   increase	   in	  lipid	  peroxidation	  compared	  to	  untreated	  controls.	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Figure	   3.30	   –	   Confocal	   Microscopy	   Lipid	   Peroxidation	   Studies	   (Buthionine	  
Sulfoximine	  or	  Saporin	  treated	  controls).	  	  1	   x	   104	   4T1	   breast	   cancer	   cells	   were	   seeded	   on	   35	   mm	   diameter	   glass-­‐bottomed	  fluorodishes	  and	  grown	  for	  48h.	  Cells	  were	  re-­‐incubated	  with	  TPPS2a	  0.6	  µg	  ml-­‐1	  +	  SAP	  30	  nM	  +	  BSO	  1.0	  µg	  ml-­‐1	  for	  a	  further	  24h.	  Cells	  in	  were	  then	  illuminated	  for	  150	  s	  using	  the	   LumiSource®	   illuminator.	   Subsequently,	   Image-­‐IT	   lipid	   peroxidation	   probe	   was	  added	  to	  the	  cells	  to	  make	  a	  final	  concentration	  of	  10	  µM	  and	  incubated	  at	  37°C	  for	  30	  minutes.	   Images	   were	   then	   taken	   using	   confocal	   microscope.	   (a)	   cluster	   of	   cells	   (b)	  dying	   group	  of	   cells.	  RED	  =	   reduced	   lipid,	   Ex	  581	  nm	  Em	  591	  nm;	  GREEN	  =	  oxidized	  lipid,	   Ex	   488	   nm	  Em	  510	   nm;	  ORANGE	   =	   overlaid	   image.	  60X	  NA:1.35	   Objective	   Lens,	  
zoom	  x1.0,	  scale	  20	  microns.	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3.15	  Antioxidants	  and	  Reducing	  Enzymes	  This	   section	   reports	   on	   investigations	   looking	   at	   the	   potential	   impact	   of	  antioxidants	  on	  PCI.	  In	  particular,	  the	  effects	  of	  superoxide	  dismutase	  (SOD)	  and	  L-­‐histidine	  (LH).	  	  	  
	  
Figure	  3.31	  –	  Effect	  of	  antioxidants/reducing	  enzymes	  (L-­‐histidine	  and	  superoxide	  
dismutase)	  on	  Photochemical	  Internalisation	  of	  Saporin.	  	  4T1	  breast	  cancer	  cells	  treated	  with	  (a)	  TP	  0.6	  µg/ml	  +	  SAP	  30	  nM	  +	  light	  (180	  s)	  +/-­‐	  SOD	  100U,	  (b)	  TP	  0.3	  µg/ml	  +	  SAP	  15	  nM	  +	  light	  (90	  s)	  +/-­‐	  LH	  (increasing	  doses	  up	  to	  80	  µM).	  Cells	  were	  illuminated	  using	  the	  LumiSource®	  illuminator.	  (a)	  SOD	  reduced	  PCI	  cytotoxicity	   by	   43%	   (p<0.01).	   (b)	   LH	   80	   µM	   caused	   51%	   reversal	   of	   the	   PCI	   effect	  (p<0.01).	  Cell	   viability	  measured	  using	  MTT	  assay	  72h	  after	   illumination	   (absorbance	  read	  at	  490	  nm).	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DISCUSSION	  The	  ultimate	  aim	  of	   the	   studies	  performed	   in	   this	   chapter	  was	   to	   test	   the	  null	  hypothesis	   that	   the	   intracellular	   REDOX	   environment	   has	   no	   effect	   on	   the	  efficacy	  of	  PCI.	  The	  experiments	  performed	  were	  designed	  to	  initially	  determine	  whether	   or	   not	   TPPS2a	   based	   PCI	   could	   be	   used	   to	   enhance	   the	   delivery	   and	  consequently	  the	  cytotoxic	  efficacy	  of	  two	  cytotoxic	  agents	  (SAP	  and	  MTX).	  The	  balance	  between	  oxidation	  and	  reduction	  is	  vital	  to	  the	  normal	  functioning	  of	  a	  cell	   and	   abnormal	   REDOX	   states	   have	   been	   shown	   to	   confer	   resistance	   to	  cytotoxic	  agents	  in	  cancer	  chemotherapy(122).	  The	  reducing	  capacity	  of	  a	  cell	  is	  determined	  by	  the	  expression	  of	  reducing	  agents/enzymes	  including	  glutathione	  (GSH),	   glutathione	   peroxidase	   (GSHPx),	   catalase	   and	   superoxide	   dismutase	  (SOD);	   relative	   to	   the	  oxidative	   load.	  These	   reducing	  agents	  act	   to	  prevent	   the	  toxic	  and	  mutagenic	  effects	  of	  ROS,	  for	  example,	  SOD	  catalyses	  the	  conversion	  of	  the	   reactive	   O2.-­‐	   	   to	   H2O2	   +	   O2,	   the	   former	   being	   subsequently	   detoxified	   by	  catalase(123).	   Many	   clinical	   conditions	   are	   associated	   with	   imbalances	   with	  intracellular	   REDOX	   tending	   towards	   an	   oxidative	   state	   that	   can	   result	   in	   cell	  death,	   for	   example	   in	   the	   haemolytic	   anaemia’s,	   such	   as	   glucose-­‐6-­‐phosphate	  dehydrogenase	   deficiency	   and	   pyruvate	   kinase	   deficiency.	   In	   situations	  where	  overwhelming	   levels	   of	   ROS	   are	   achieved,	   including	   ionizing	   radiation	   and	  cytotoxic	   anthacycline	   antibiotics	   such	   as	   doxorubicin,	   the	   probability	   of	  observing	   increased	  DNA	  damage;	   lipid	  peroxidation	   and	  protein	  modification	  are	   enhanced(122,	   123).	   Photosensitiser	   activation	   results	   in	   the	   formation	   of	  ROS	   including	   O2.-­‐,	   1O2	   	   and	   OH-­‐.	   These	   free	   radical	   species	   can	   be	   formed	   by	  direct	  reaction	  between	  the	  excited	  photosensitiser	  and	  a	  substrate	  (Type	  I)	  or	  (Type	   II)	   energy	   transfer	   from	   the	   excited	   photosensitiser	   to	   ground	   state	  molecular	   oxygen	   (3O2)	   forming	   1O2.	   Both	  PDT	   and	  PCI	   are	   believed	   to	   favour	  Type	  II	  reactions	  whereby	  1O2	  oxidises	  substrates	  in	  close	  proximity	  e.g.	  nucleic	  acids,	   enzymes	   and	   cell	   membranes(124).	   The	   latter	   are	   rich	   in	   unsaturated	  fatty	   acids,	   which	   readily	   react	   with	   1O2.	   By	   investigating	   the	   relationship	  between	   photosensitiser	   activation	   in	   PCI	   and	   the	   intracellular	   REDOX	  environment	  of	  a	  cell	  a	  greater	  understanding	  of	   the	   influence	  reactive	  oxygen	  species	   (ROS)	   production	   had	   on	   PDT/PCI	   was	   elucidated.	   PCI	   represents	   a	  developmental	   step	   of	   PDT,	   retaining	   its	   fundamental	   properties	   of	   light,	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photosensitiser	   and	   oxygen	   dependent	   ROS	   production,	   but	   with	   the	   effect	  restricted	  to	  subcellular	  domains(28,	  125,	  126).	  In	  particular,	  the	  phospholipid	  membranes	  of	   intracellular	  vesicles	   including,	  endosomes	  and	   lysosomes.	   	  The	  most	   consistent	   observation	   in	   this	   study	   is	   that	   the	   factors	   that	   theoretically	  influence	  the	  production	  of	  ROS,	  some	  of	  which	  are	  tested	  in	  the	  current	  body	  of	  work,	   the	   photosensitiser,	   light	   dose	   and	   the	   chronological	   point	   at	  which	   the	  photosensitiser	  is	  activated	  appear	  to	  have	  a	  correlative	  effect	  on	  the	  efficacy	  of	  PCI.	  
3.16	  PCI	  	  As	   previously	   described,	   the	   ‘light-­‐after’	   (LA)	   protocol	   involved	   pre-­‐treating	  cells	   with	   photosensitiser	   (TP)	   plus	   chemotherapeutic	   (SAP	   or	   MTX)	   prior	   to	  light	   exposure.	   In	   doing	   so	   both	   the	   amphiphilic,	   TP(26,	   30),	   and	   the	   chosen	  chemotherapeutic	  will	  be	  taken	  up	  by	  the	  cell	  to	  assimilate	  in	  endosomes,	  with	  TP	   in	   the	   membrane	   and	   chemotherapeutic	   within	   the	   lumen.	   Berg	   et	   al.	  (2011)(20)	   described	   the	   endocytic	   vesicular-­‐membrane	   localisation	   of	   a	  photosensitiser	  as	  ‘a	  prerequisite’	  for	  PCI.	  Thus,	  activation	  of	  the	  photosensitiser	  leads	   to	   localised	   ROS	   production	   and	   release	   of	   the	   luminal	   toxin	   into	   the	  cytosol.	  	  	  In	  these	  experiments,	  the	  combination	  of	  the	  photosensitiser	  and	  cytotoxin	  (TP	  0.6	  µg/ml	  +	  SAP	  15	  nM)	  (PCI)	  plus	  120	  s	  illumination,	  resulted	  in	  a	  statistically	  significant	   increase	   in	   cytotoxicity,	   24h	   after	   light	   exposure,	   whereby	   PCI	  enhanced	   the	  PDT	  effect	  by	  a	   factor	  of	  1.5	   (p<0.01)	  and	   the	  chemotherapeutic	  effect	  by	  a	  factor	  of	  12.5	  (p<0.01)	  (fig.	  3.5).	  These	  observations	  support	  those	  of	  Berg	  et	  al.	  (2011)(20)	  who	  reported	  a	  significant	  increase	  in	  the	  cytotoxicity	  of	  SAP	  for	  cells	  treated	  with	  SAP	  +	  TPCS2a	  +	  light	  (PCI),	  compared	  to	  SAP	  +/-­‐	  light.	  This	   indicates	   that	   the	   combination	   of	   photosensitiser	   +	   chemotherapeutic	  enhances	  the	  cytotoxicity	  of	   the	  chosen	  photosensitiser.	  The	  12.5-­‐fold	   increase	  in	  cytotoxicity	  for	  TP	  +	  SAP	  +	  light	  (PCI)	  compared	  to	  SAP	  +	  light	  also	  supports	  the	  school	  of	  thought	  that	  despite	  lacking	  a	  B-­‐chain	  lectin-­‐based	  binding	  domain	  that	  Type	  I	  RIPs	  such	  as	  SAP	  retain	  potency	  in	  their	  enzymatically	  active	  A-­‐chain	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that	  is	  comparable	  to	  the	  Type	  II	  RIPs	  once	  they	  are	  delivered	  to	  the	  cytosol,	  as	  described	  in	  the	  Scientific	  Background	  section	  of	  this	  chapter(97,	  103,	  105).	  It	  is	  for	  this	  reason	  that	  SAP	  was	  the	  1st-­‐choice	  candidate	  for	  the	  experiments	  carried	  out	  in	  this	  chapter.	  Another	  important	  point	  of	  comparison	  is	  the	  relatively	  low	  level	  of	  cytotoxicity	  achieved	  by	  PDT	  alone	  (fig.	  3.5),	  with	  less	  than	  1	  in	  4	  cells	  killed.	  As	  will	  be	  discussed	   further	   in	   this	  chapter	   this	   low	   level	  of	  direct	  ROS-­‐induced	  death	  is	  very	  important	  for	  PCI,	  particularly	  when	  delivering	  non-­‐stable	  compounds,	  such	  as	  siRNA.	  	  	  MTX	  was	  studied	  using	  the	  same	  LA	  protocol	  for	  PCI	  (MTX	  0.4	  µg/ml	  +	  light	  +/-­‐	  TP).	   The	   dose	   of	   MTX	   chosen	   for	   experimentation	   was	   partly	   based	   on	  previously	   published	   data(25)	   and	   pilot	   experiments	   (data	   not	   shown).	   In	  comparison	   to	   SAP	   15	   nM,	  MTX	   0.4	   µg/ml	   alone	   exerted	   a	   significant	   level	   of	  cytotoxicity	   (53%,	   p<0.01).	   In	   this	   instance	   the	   addition	   of	   TP	   +	   light	   (PCI)	  yielded	   no	   significant	   additional	   cytotoxicity	   24h	   after	   illumination.	   One	  potential	   explanation	   for	   the	   apparent	   lack	   of	   effect	   is	   that	   the	   basic	   chemical	  composition	  of	  MTX	   facilitates	   its	   accumulation	  and	   ion-­‐trapping	  within	  acidic	  compartments	   such	   as	   endosomes	   and	   lysosomes.	   Lee	   and	   Tannock	  (2004)(115)	  reported	   in	  an	  abstract	   that	  by	  raising	   the	  pH	  of	  endosomes	  with	  agents	   including	   the	   antibiotic	   chloroquine	   and	   the	   proton-­‐pump	   inhibitor	  omeprazole,	  they	  were	  able	  to	  enhance	  the	  penetration	  of	  MTX	  using	  a	  multi-­‐cell	  layer	   technique.	   Given	   that	   a	   basic	   compound	  will	   be	   protonated	   in	   an	   acidic	  environment	   a	   possible	   hypothesis	   is	   that	   unless	   the	   level	   of	   ROS	   generated	  within	   the	   endo-­‐lysosomal	   membranes	   is	   sufficient,	   the	   severity	   of	   damage	  achieved	   will	   not	   permit	   the	   escape	   of	   hydrophilic	   (protonated)	   molecules	  though	  the	  phospholipid	  bilayer.	  Hence,	  the	  reduced	  potency	  of	  MTX-­‐PCI	  under	  the	  conditions	  used.	  
3.17	  Redistribution	  studies	  for	  SAP-­‐488	  and	  mitoxantrone	  The	  importance	  of	  ROS	  production	  as	  a	  rate-­‐limiting	  step	  in	  PCI	  is	  supported	  by	  the	   lack	   of	   cell	   toxicity	   in	   non-­‐illuminated	   (‘Dark	   controls’)	   and	   this	   has	   been	  described	  in	  previous	  in	  vitro	  and	  in	  vivo	  studies:	  Selbo	  et	  al.(29)	  evaluated	  the	  therapeutic	   potential	   of	   photochemical	   internalisation	   of	   gelonin	   (type	   I	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ribosome	   inactivating	   protein)	   using	   the	   photosensitiser	   aluminum	  phthalocyanine	   disulfonate	   (AlPcS2a)	   for	   the	   treatment	   of	   human	  adenocarcinoma	   (WiDr)	   in	   athymic	   female	   BALB/c	   nude	  mice.	   They	   observed	  that	  WiDr	   cells	   from	   tumours	  exposed	   to	  15	  min	  of	   light	   exposure	   in	   vivo	  had	  diffuse	  perinuclear	  fluorescence	  of	  AlPcS2a	  compared	  to	  granular	  fluorescence	  in	  ‘light-­‐protected’	   (dark	   control)	   cells.	   The	   granular	  pattern	  of	   fluorescence	  was	  hypothesized	   to	   be	   indicative	   of	   lysosomal	   uptake	   of	   the	   amphiphilic	   AlPcS2a.	  Given	  the	  light-­‐dose	  dependent	  manner	  of	  AlPcS2a	  re-­‐localisation,	  in	  addition	  to	  the	   synergistic	   cytotoxic	   effect	   of	   gelonin	   plus	   AlPcS2a,	   the	   authors	   concluded	  that	  this	  effect	  is	  consistent	  with	  PCI(43).	  	  Thus,	  it	  is	  the	  release	  of	  endocytosed	  molecules	   and	   subsequent	   redistribution	   within	   the	   cytosol	   that	   enables	   the	  therapeutic	   effect.	  The	  dynamics	   and	  photobleaching	   characteristics	  of	  AlPcS2a	  have	   been	   shown	   to	   be	   dependent	   on	   an	   aerobic	   environment(127),	   which	  further	  supports	  the	  importance	  of	  ROS	  production	  via	  type	  II	  reactions	  in	  PCI.	  The	   confocal	   study	   (figure	   3.23),	   presents	   evidence	   supporting	   the	  redistribution	   of	   SAP-­‐488,	   in	   PCI	   treated	   cells.	   Preliminary	   experiments	  performed	   using	   the	   SAP-­‐488,	   demonstrated	   that	   despite	   achieving	   a	   stable	  construct,	   only	   a	   weak	   signal	   was	   detectable	   at	   lower	   doses	   (30	   nM),	  consequently,	   a	   higher	   dose	   of	   SAP-­‐488	   was	   chosen.	   Interestingly,	   there	   was	  very	  little	  effect	  on	  cell	  viability,	  which	  supports	  pilot	  dose-­‐response	  data	  using	  SAP.	   Furthermore,	   in	   order	   to	   minimise	   any	   photobleaching	   effects,	   only	   two	  slices	   were	   taken	   for	   each	   image.	   These	  were	   subsequently	   converted	   into	   z-­‐stacks	  for	  comparison.	  The	  control	  experiment	  (figure	  3.22)	  demonstrated	  there	  was	  only	  a	  3%	  reduction	  in	  signal,	  240	  seconds	  after	  application	  of	  the	  laser.	  By	  comparison,	  there	  was	  a	  30%	  reduction	  in	  the	  signal	  for	  cells	  treated	  with	  SAP-­‐488	   +	   TPPS2a	   (fig.	   3.23),	   240	   seconds	   after	   application	   of	   the	   laser.	   This	  represented	  a	  9-­‐fold	  decrease	  in	  signal	  intensity	  for	  PCI	  compared	  to	  cytotoxin	  alone.	  The	  loss	  of	  signal	  intensity	  was	  most	  likely	  due	  to	  release	  of	  SAP-­‐488	  from	  endosomal	  stores	  into	  the	  cytoplasm	  leading	  to	  its	  spread	  and	  concurrent	  drop	  in	  signal	  intensity.	  The	  likely	  endosomal	  sequestration	  of	  SAP-­‐488	  is	  supported	  by	   work	   performed	   by	   Bolognesi	   et	   al.	   (2012)(109)	   using	   confocal-­‐based	  indirect	   immunofluorescence	   analysis	   to	   detect	   the	   intracellular	   trafficking	   of	  labeled-­‐SAP.	   They	   reported	   just	   below	   1	   in	   3	   SAP	   molecules	   end	   up	   in	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endosomes.	   This	   coupled	   with	   the	   amphiphilic	   nature	   of	   TP	   and	   the	   imaging	  observations	   (fig.	   3.2)	   supports	   the	  hypothesis	   that	   PCI	   induces	   the	   release	   of	  SAP	  from	  endosomal	  stores	  in	  to	  the	  cytoplasm.	  	  	  The	  inherent	  fluorescent	  signal	  of	  MTX	  is	  of	  benefit	  with	  regards	  to	  mapping	  out	  its	   intracellular	   localisation	   in	   cells.	   Figure	   3.24	   illustrates	   the	   intracellular	  localisation	  of	  TP-­‐MTX	  pre-­‐	  (fig.	  3.24a)	  and	  post	  (fig.	  3.24b)	  exposure	  to	  the	  405	  nm	   laser	   (15s).	   A	   longer	   laser	   exposure	   time	  was	   selected,	   compared	   to	   SAP-­‐488,	   following	   preliminary	   experiments	   that	   demonstrated	   that	   MTX	   re-­‐localisation	   required	   a	   longer	   exposure.	   The	   post	   exposure	   image	   (Fig	   3.24b)	  clearly	  demonstrated	  a	  loss	  of	  the	  granular	  pattern,	  which	  was	  present	  prior	  to	  exposure	  (fig.	  3.24a),	  to	  a	  more	  diffuse,	  membranous	  localisation	  with	  evidence	  of	  nuclear	  uptake,	  which	   is	   the	   site	  of	   action	   for	  MTX.	  The	  granular	  pattern	  of	  distribution	  pre-­‐laser	   is	   likely	   to	   represent	   endo-­‐lysosomal	   storage,	   supported	  by	   the	   evidence	   of	   co-­‐localisation	   seen	   with	   lysotracker	   (fig.	   3.24c).	   These	  findings	   are	   consistent	   with	   previously	   published	   data	   regarding	  MTX	   uptake	  into	   lysosomes	   and	   subsequent	   nuclear	   mobilisation	   following	   PCI	   treatment	  using	  hypericin	   as	   a	  photosensitiser(25).	   In	  4T1	   cells	   treated	  with	  MTX	  alone,	  there	  was	  no	  redistribution	  following	  treatment	  with	  the	  405	  nm	  laser	  (data	  not	  shown).	  This,	  as	  with	  the	  SAP-­‐488	  data	  above,	   indicated	  that	  the	  change	  in	  the	  signal	   of	   both	   compounds	   was	   less	   likely	   to	   be	   due	   to	   any	   direct	   effects	   or	  photobleaching.	  	  The	  data	  from	  the	  ‘light	  after’	  study	  along	  with	  the	  confocal	  imaging	  support	  the	  rejection	   of	   the	   null	   hypothesis	   that	   TP	   -­‐	  mediated	   PCI	   does	   not	   enhance	   the	  delivery	   and	   consequently	   the	   efficacy	   of	   SAP	   as	   a	   cytotoxin	   in	   4T1	   cells.	  However,	  under	  the	  chosen	  experimental	  conditions	  the	  null	  hypothesis	  cannot	  be	  rejected	  for	  TP-­‐mediated	  MTX-­‐PCI	  in	  4T1	  cells.	  	  
3.18	  Variable	  1:	  Photosensitiser	  Dose	  As	   described	   in	   the	   results	   section,	   in	   order	   to	   reach	   an	   excited	   state	   a	  photosensitiser	  must	  absorb	  a	  photon	  of	  light	  of	  the	  appropriate	  wavelength.	  A	  proposed	   mechanism	   is	   that	   activation	   of	   the	   photosensitiser	   generates	   ROS,	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damaging	  endosomes	  and	  liberating	  the	  endocytosed	  cytotoxin,	  thus	  enhancing	  delivery	   to	   the	   intracellular	   compartment.	   This	   is	   based	  on	   the	  understanding	  that	  the	  ground	  state	  photosensitiser	  (PS),	  prior	  to	  exposure	  to	  light,	  can	  exert	  a	  cytotoxic	  effect	   in	  dose	  dependent(25,	  128)	  and	  cell-­‐specific	  manner;	  an	  effect	  often	  referred	  to	  as	  ‘dark’	  cytotoxicity.	  Following	  absorption	  of	  a	  photon	  of	  light	  the	  PS	  can	  be	  excited	  to	  a	  number	  of	  higher-­‐energy	  states(129).	  Ultimately,	  the	  excited	  photosensitiser	  may	  go	  on	  to	  chemically	  alter	  a	  substrate	  in	  a	  time	  and	  proximity	  dependent	  manner.	  The	   formation	  of	   reactive	   oxygen	   species	   (ROS)	  may	  occur	  following	  the	  donation	  of	  an	  electron	  to	  a	  substrate	  (type	  I);	  resulting	  in	  the	  oxidation	  of	  the	  photosensitiser.	  Alternatively	  ROS,	  more	  specifically	  1O2,	  formation	   may	   be	   secondary	   to	   direct	   transfer	   of	   energy	   from	   the	   excited	  photosensitiser	  to	  ground	  state	  molecular	  oxygen,	  resulting	  in	  the	  preservation	  of	  ground-­‐state	  photosensitiser	  (type	  II)	  (fig.	  3.32).	  The	  efficiency	  of	  this	  process	  is	   often	   dependent	   on	   the	   rate	   of	   decay	   for	   the	   excited	   photosensitiser,	   the	  availability	   of	   oxygen	   and	   the	   reducing	   capacity	   of	   the	   local	   environment.	  Consequently,	   oxygen	   rich	   environments	   will	   support	   a	   type	   II	   mediated	  process,	   which	   is	   associated	   with	   increased	   decay	   of	   the	   more	   stable	   triplet	  state.	  Whereas,	  oxygen	  depleted	  environments	  will	  encourage	  a	  type	  I	  mediated	  process	   with	   formation	   of	   other	   reactive	   species,	   including	   superoxide	   and	  hydroxyl	   free	   radicals,	   associated	   with	   reduced	   decay	   of	   the	   triplet	   state.	  	  Therefore	  the	  availability	  of	  substrate	  (TP)	  may	  play	  an	  important	  role	  in	  overall	  efficacy	  of	  photoactivation.	  
	  
Figure	  3.32	  –	  The	  development	  of	  reactive	  oxygen	  species.	  Type	  I	  versus	  Type	  II	  reactions	  (129).	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  This	  section	  of	  the	  study	  was	  carried	  out	  in	  order	  to	  test	  the	  null	  hypothesis	  that	  photosensitiser	  dosing	  does	  not	  have	  a	  significant	  effect	  on	  the	  efficacy	  of	  TP	  -­‐	  mediated	  PCI	  of	  SAP	  and/or	  MTX.	  	  	  The	  results	  showed	  that	  doubling	  the	  dose	  of	  photosensitiser	  from	  0.3	  µg/ml	  to	  0.6	  µg/ml	  does	  not	  result	  in	  a	  proportionate	  rise	  in	  PDT	  or	  PCI	  efficacy	  i.e.	  these	  are	   not	   doubled	   (fig.	   3.7).	   This	   dosing	   range	  was	   chosen	   as	   pilot	   experiments	  showed	   that	   at	   0.8	   µg/ml	   the	   PDT	   effect	   of	   TP,	   for	   the	   light	   doses	   and	  experimental	   conditions	   employed,	   produced	   an	   inappropriately	   high	   level	   of	  PDT	  killing	  reducing	  the	  power	  for	  comparative	  analysis.	  As	  the	  results	  showed,	  PDT	   cytotoxicity	   (0.6	   µg/ml)	   was	   increased	   to	   18%,	   representing	   a	   12%	  (p<0.001)	   increase	   compared	   to	   0.3	   µg/ml.	   	   In	   comparison,	   an	   8%	   rise	   in	   PCI	  cytotoxicity	  (using	  SAP	  15	  nM)	  was	  observed	  over	  the	  same	  dosing	  range.	  The	  increased	   cytotoxicity	   observed	   for	   PDT	   and	   PCI	   of	   SAP	   is	   consistent	   with	  previously	   published	   work	   by	   Selbo	   et	   al.	   (2006)(120).	   Throughout	   these	  studies,	   a	   constant	   aim	   was	   to	   ensure	   that	   PDT	   based	   toxicity	   was	   kept	   to	   a	  minimum.	  The	  two	  effects	  (PDT	  and	  PCI)	  are	  on	  a	  spectrum	  and	  if	  the	  PDT	  effect	  is	   too	  great	   there	  would	  be	  an	   increased	  risk	  of	  damaging	  the	  molecule	   that	   is	  being	  internalised.	   	  Thus	  the	  relatively	  small,	  albeit	  statistically	  significant,	  rise	  in	  both	  PDT	  and	  PCI	  cytotoxicity	  in	  this	  instance	  may	  not	  justify	  the	  doubling	  of	  photosensitiser	  dose	  with	  the	  increased	  potential	  for	  unwanted	  side	  effects.	  	  	  For	   MTX	   there	   was	   no	   significant	   difference	   in	   ‘PCI’	   cytotoxicity	   between	   0.3	  µg/ml	  and	  0.6	  µg/ml	  (TP).	  	  	  Taken	   together	   these	   results	   indicate	   that	   when	   the	   illumination	   time	   is	  constant,	   a	   significant	   increase	   in	   concentration	   of	   photosensitiser	   does	   not	  produce	  a	  proportionate	  rise	  in	  PDT	  or	  PCI	  cytotoxicity.	  This	  is	  not	  to	  discount	  the	  fact	  that	  there	  was	  a	  statistically	  significant	  increase	  in	  cytotoxicity,	  which	  is	  in	   keeping	   with	   the	   reported	   results	   from	   other	   groups(120).	   	   However,	   the	  relatively	   small	   increase	   suggests	   that	   the	   rate	   and/or	   total	   amount	   of	   ROS	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produced	   upon	   activation	   of	   a	   photosensitiser	   is	   only	   partially	   limited	   by	   the	  concentration	  of	  photosensitiser	  available.	  	  
3.19	  Variable	  2:	  Light	  Dose	  The	  light	  dose	  studies	  were	  performed	  in	  order	  to	  gain	  a	  better	  understanding	  of	  what	  impact	  increasing	  duration	  (dose)	  of	  illumination	  would	  have	  on	  PDT	  and	  PCI.	   Light	   is	   an	   absolute	   requirement	   for	   photoactivation	   and	   this	   school	   of	  thought	   is	   supported	   by	   the	   significant	   decrease	   in	   cytotoxicity	   that	   was	  observed	  in	  this	  (fig.	  3.8)	  and	  previous	  studies	  on	  ‘dark	  cytotoxicity’(25).	  Figure	  3.8	   illustrates	   the	   impact	  of	   increasing	   illumination	   time	   from	  60-­‐300	  seconds	  for	  PDT	  (TP)	  and	  PCI	  (TP	  +	  SAP);	  in	  addition	  to	  non-­‐illuminated	  ‘dark’	  controls.	  There	  was	  no	  significant	  ‘dark’	  cytotoxicity	  for	  PDT.	  PCI	  did	  exhibit	  12%	  cell	  kill	  compared	  to	  control;	  however,	  when	  this	  is	  compared	  to	  the	  residual	  toxicity	  of	  SAP	   30	   nM	   no	   difference	  was	   observed.	   This	   indicates	   that	   the	   ‘dark’	   toxicity	  observed	  for	  PCI	  is	  most	  likely	  due	  to	  the	  effect	  of	  SAP.	  Thus,	  when	  comparing	  to	  other	  illumination	  times	  one	  can	  be	  confident	  that	  the	  any	  difference	  is	  at	  least	  in	  part	  related	  to	  the	  activation	  of	  the	  photosensitiser.	  	  	  For	  SAP-­‐PCI	  a	  light	  dose-­‐dependent	  increase	  in	  cytotoxicity	  was	  observed	  from	  ‘dark’	   control	   to	  a	  peak	   level	  of	   cytotoxicity	  at	  300	  s	  when	  a	  6-­‐fold	   increase	   is	  achieved	   compared	   to	   ‘dark’	   controls	   (fig.	   3.8).	   A	   similar	   trend,	   albeit	   of	  significantly	  reduced	  magnitude	  was	  observed	  for	  PDT,	  with	  peak	  cytotoxicity	  at	  300	  seconds	  (26%),	  which	  represented	  a	  12-­‐fold	  increase.	  Throughout	  all	   light	  doses,	   the	   level	   of	   cell	   kill	   achieved	   for	   PCI	  was	   significantly	   greater	   than	   for	  PDT.	  The	  mean	   increase	  was	  34%,	  with	   the	   smallest	   difference	   at	   60	   s	   (12%)	  and	  the	  greatest	  difference	  at	  240	  s	  (53%).	  Close	  analysis	  of	  the	  two	  sets	  of	  data	  showed	   that	   the	   stepwise	   rise	   in	   cytotoxicity	   tended	   to	   increase	   for	   PDT	   as	  illumination	  time	  prolonged,	  with	  the	  largest	  difference	  occurring	  between	  240	  s	  and	  300	  s	  (10%).	  Conversely,	  for	  PCI	  the	  largest	  difference	  occurred	  between	  60	  s	  and	  90	  s	  (22%)	  with	  a	  general	  trend	  of	  reducing	  difference	  as	  illumination	  time	   increased.	   Selbo	   et	   al.	   (2006)(120)	   observed	   similar	   results	   for	   PCI/PDT	  using	   the	   type	   I	   RIP	   gelonin	   +	   TPPS2a	   in	   a	   human	  multidrug-­‐resistant	   (MDR)	  uterine	  cancer	  cell	  line	  (MES-­‐SA/Dx5)	  with	  incremental	  light	  doses.	  A	  potential	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hypothesis	   for	   the	  differing	   trends	   is	   that	  at	   lower	   light	  doses/reduced	  energy	  levels,	  the	  comparatively	  modest	  level	  of	  ROS	  production	  is	  sufficient	  to	  damage	  endo-­‐lysosomal	  vesicles,	  resulting	  in	  the	  release	  of	  SAP	  and	  a	  consequent	  rate-­‐limiting	   rise	   in	   cytotoxicity;	   for	   PDT	   however,	   this	   level	   of	   ROS	   production	   is	  insufficient	   to	   kill	   the	   cell	   via	   direct	   phototoxicity.	   Conversely,	   at	   high	   light	  doses/energy	  levels,	  the	  likelihood	  that	  further	  SAP	  release	  will	  take	  place	  and	  exert	  a	  cytotoxic	  effect	  above	  and	  beyond	  that	  of	  PDT	  is	  less	  likely.	  This	  may	  go	  some	  way	   to	   explaining	  why	   the	   differential	   between	  PDT	   and	  PCI	   reduces	   at	  300	  s	  compared	  to	  240	  seconds.	  	  	  Although	  the	  overall	  trend	  for	  MTX-­‐PCI	  was	  loosely	  similar	  to	  that	  for	  SAP-­‐PCI,	  with	  the	  highest	  level	  of	  cell	  kill	  occurring	  after	  300	  s	  of	  light	  exposure	  (fig.	  3.9),	  the	   dose-­‐dependent	   effect	   only	   occurred	   for	   light	   durations	   that	  were	   greater	  than	  180	  s.	  This	  is	  illustrated	  by	  the	  following:	  
• Between	   60	   s-­‐180	   s,	   there	   was	   no	   significant	   (statistical)	   increase	   in	  cytotoxicity.	  	  
• At	  180	  s,	  MTX-­‐PCI	  toxicity	  was	  no	  different	  to	  ‘dark’	  cytotoxicity.	  
• The	  only	  significant	  rise	  occurred	  between	  180	  s-­‐300	  s	  when	  a	  30%	  rise	  in	  cytotoxicity	  was	  observed	  (p<0.01).	  	  Thus	  for	  MTX-­‐PCI	  the	  light	  dose	  progressively	  became	  a	  more	  important	  factor	  as	   it	   increased.	  Furthermore,	  a	  closer	   look	  at	  the	  differential	  between	  PDT	  and	  MTX-­‐PCI,	  with	  increasing	  light	  dose,	  reveals	  that	  the	  gap	  between	  PDT	  and	  PCI	  induced	  cytotoxicity	  widened	  with	  increasing	  light	  dose.	  At	  60	  s	  illumination	  the	  differential	  was	  22%	  in	  favour	  of	  PCI;	  there	  was	  a	  minimal	  rise	  to	  25%	  at	  150	  s	  and	   a	   peak	   differential	   of	   40%	   at	   300	   s.	   Given	   that	   the	   light	   dose-­‐dependent	  effect	  only	  occurred	  after	  180	  s,	   this	   illumination	   time	  may	  represent	   the	   true	  start	  point	  for	  MTX-­‐PCI	  as	  prior	  to	  this	  it	  is	  likely	  that	  the	  cytotoxicity	  observed	  was	  due	  to	  the	  inherent	  cytotoxicity	  of	  MTX	  1.5	  µg/ml.	  This	  would	  suggest	  that	  MTX-­‐PCI	   requires	   a	   greater	   load	   of	   ROS	   production	   compared	   to	   SAP-­‐PCI.	   A	  possible	  explanation	  is	  that	  given	  MTX	  is	  a	  weak	  base,	  therefore	  charged	  in	  the	  acidic	  environment	  of	  endosomes	  and	  lysosomes(115).	  In	  this	  charged	  state,	  the	  endo-­‐lysosomal	   membranes	   will	   provide	   both	   a	   physical	   and	   electrostatic	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barrier	  to	  MTX	  release.	  Consequently,	  whereas	  ‘minor’	  membrane	  damage	  may	  be	  sufficient	   for	  SAP	  release,	  a	  greater	   level	  of	  damage	  is	  required	   in	  order	   for	  MTX	  to	  overcome	  the	  physical	  and	  electrostatic	  resistance	  to	  its	  release.	  	  This	  is	  further	   supported	   by	   the	   fact	   that	   the	   PDT:MTX-­‐PCI	   differential	   continued	  increase;	  hence,	  it	  is	  unlikely	  that	  the	  augmented	  cytotoxicity	  was	  due	  to	  PDT.	  	  Light	  dose	  appears	  to	  play	  a	  pivotal	  role	   in	  both	  PDT	  and	  PCI.	  However,	  under	  the	  conditions	  chosen	  for	  the	  study	  described	  here,	  in	  particular	  the	  4h	  ‘chasing’	  period	   prior	   to	   illumination,	   there	   is	   a	   disproportionate	   favoring	   of	   PCI	  cytotoxicity	  compared	  to	  PDT	  for	  both	  SAP-­‐	  and	  MTX-­‐PCI.	  
3.20	  Variable	  3:	  Photosensitiser	  localisation	  The	   biochemical	   properties	   of	   a	   photosensitiser	   play	   a	   significant	   role	   in	  determining	   its	   suitability	   for	   PCI.	   Any	   photosensitiser	   that	   is	   taken	   up	   and	  retained	   by	   a	   cell	   can	   potentially	   exert	   photodynamic	   therapy	   (PDT)	   based	  cytotoxicity	   via	   site	   non-­‐specific	   generation	   of	   ROS.	   For	   example,	   the	   dye	  tetrabromorhodamine-­‐123	   selectively	   localises	   to	   mitochondria(130),	   thus	  upon	  photoactivation,	  ROS-­‐generation	  would	   be	   restricted	   to	   this	   intracellular	  compartment.	   Hypericin	   on	   the	   other	   hand	   is	   retained	   within	   endolysosomes	  (25)and	   mitochondria(131);	   the	   former	   making	   it	   a	   good	   candidate	   for	   PCI.	  Though	   it	   is	   important	   to	   note	   that	   although	   hypericin	   starts	   in	   the	  endolysosomes	   it	   can	  migrate	   to	   other	   organelles,	   hence	   a	   shorter	   incubation	  time	  is	  beneficial	  for	  hypericin-­‐mediated	  PCI.	  Newer	  photosensitisers	  have	  been	  designed	   to	   accumulate	  within	   the	  phospholipid	  bilayer	  of	   the	   cell	  membrane.	  Thus	  when	   compounds	   are	   taken	   up	   by	   endocytosis	   the	   resultant	   endosomes	  contain	   photosensitiser	   within	   their	   membrane.	   Examples	   of	   such	  photosensitisers	   include	   TPPS2a(26,	   120)	   and	   TPCS2a(20).	   The	   latter	   has	   been	  specifically	  designed	  for	  use	  as	  a	  potential	  therapeutic	  for	  clinical	  application	  for	  PCI-­‐based	  treatment	  in	  humans.	  	  	  The	  consistent	  property	  of	  general	  photosensitisers	  and	  those	  optimized	  for	  PCI	  is	   the	   generation	   of	   ROS;	   for	   example	   TPPS2a,	   has	   an	   amphiphilic	   nature	   that	  enables	   it	   to	   reside	   in	   both	   the	   cell	   membrane	   and	   endo-­‐lysosomal	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compartments.	   Consequently,	   it	   can	   potentially	   act	   as	   both	   a	   PDT	   (cell	  membrane)	  and/or	  PCI	  (endolysosomal	  membranes)	  agent.	  	  The	   location	   of	   the	   photosensitiser	   at	   the	   point	   of	   illumination	   plays	   a	  determinant	   role	   in	   PDT	   and	   PCI	   cytotoxicity.	   The	   null	   hypothesis	   is	   that	   the	  relative	  localisation	  of	  the	  photosensitiser	  at	  time	  of	  illumination	  has	  no	  bearing	  on	  the	  likelihood	  of	  achieving	  PDT	  versus	  PCI.	  It	  is	  important	  to	  consider	  this,	  as	  one	  potential	  application	  of	  PCI	  is	  to	  facilitate	  the	  intracellular	  delivery	  of	  non-­‐toxic	   therapeutics	   such	   as	   siRNA.	   In	   such	   instances,	   it	   would	   be	   beneficial	   to	  limit	  the	  proportion	  of	  ROS	  contributing	  to	  PDT	  compared	  to	  PCI.	  	  The	  two	  illumination	  protocols	  utilised	  were	  chosen	  as	  a	  means	  to	  compare	  the	  relationships	   between	   PDT	   and	   PCI	   cytotoxicity	   when	   cells	   are	   illuminated	  either	   ‘immediately’	   following	   the	   washing	   off	   of	   drugs	   (after	   a	   24	   hour	  incubation	   period)	   or	   following	   a	   further	   ‘4h’	   incubation	   period	   in	   drug-­‐free	  media.	  This	  delay	  has	  previously	  been	  described	  as	   a	   ‘chase’	  period(120).	  The	  concept	   is	   based	   on	   the	   theory	   that	   after	   a	   period	   of	   incubation	   with	   an	  amphiphilic	   photosensitiser	   such	   as	   TPPS2a	   there	   will	   be	   indiscriminate	  accumulation	   in	   lipid	   bi-­‐layers	   such	   as	   the	   cell	  membrane.	   By	  washing	   off	   the	  drug	  and	  re-­‐incubating	  cells	   in	  drug-­‐free	  media	  a	  concentration	  gradient	   is	  set	  up	   either	   side	   of	   the	   cell	   membrane	   enabling	   the	   diffusion	   of	   photosensitiser	  into	  the	  media	  and	  also	  accumulation	  within	  intracellular	  vesicular	  membranes.	  The	  former	  leads	  to	  a	  reduction	  in	  total	  photosensitiser	  load.	  Such	  an	  effect	  has	  previously	   been	   reported	   in	   2006(120)	   when	   TPPS2a	   fluorescence	   was	  measured	   in	   lysed	   cellular	  material	   that	   had	   undergone	   a	   4h	   ‘chase’	   protocol	  versus	   immediately	  after	   incubation.	  Consequently,	   the	   total	   level	  and	   location	  of	   ROS	   production	   may	   be	   significantly	   different	   between	   the	   two	   protocols.	  This	  is	  evident	  in	  the	  observations	  made	  during	  this	  study	  whereby	  for	  cells	  that	  were	   illuminated	   immediately	   after	   24h	   incubation,	   there	   is	   no	   difference	   in	  cytotoxicity	  for	  PDT	  or	  SAP-­‐PCI	  for	  illumination	  times	  ≥	  180	  s	  (fig	  3.10c).	  Using	  the	   ‘immediate’	  protocol,	   the	  greatest	  differential	  of	  PCI	  versus	  PDT	  was	  a	  2.7-­‐fold	   (42%,	  p<0.01)	   increased	  cytotoxicity,	  which	  was	  observed	   in	  cells	   treated	  with	  60	  s	  of	  illumination.	  In	  fact,	  between	  60	  s-­‐90	  s	  illumination	  the	  average	  PCI-­‐
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induced	   increase	   in	   cytotoxicity,	   compared	   to	   PDT,	  was	   36%;	   between	   120	   s-­‐150	  s	  this	  reduced	  to	  11%;	  between	  180	  s-­‐300	  s	  there	  was	  no	  difference	  (0.3%).	  This	   indicated	   that	   when	   the	   photosensitiser	   load	   was	   relatively	   high,	  immediately	   after	   incubation	   for	   example,	   the	   time	   to	   illumination	   is	   a	  major	  factor	   in	   determining	   PDT	   versus	   PCI	   induced	   cytotoxicity.	   Thus	  with	   shorter	  illumination	   times	   the	   total	   level	   of	   ROS	   production	   is	   insufficient	   to	   cause	  enough	   global	   cellular	   damage	   to	   induce	   >40%	   cytotoxicity.	   However,	   this	   is	  sufficient	  to	  trigger	  release	  of	  SAP,	  therefore	  mediate	  PCI-­‐induced	  killing.	  As	  the	  illumination	  time	  increases	  the	  level	  of	  ROS	  production	  significantly	  increases	  to	  facilitate	   PDT	   induced	   killing,	   hence	   for	   light	   durations	   ≥180	   s	   almost	   all	   the	  cytotoxicity	  can	  be	  attributed	   to	  PDT.	  The	   limited	  sensitivity	  of	   the	  MTT	  assay	  for	  cytotoxicity	  above	  90%	  makes	  it	  very	  difficult	  to	  see	  any	  true	  difference.	  This	  in	  comparison	   to	   the	  4h	  protocol	  where,	  as	  discussed	   in	   the	   light	  dose	  section	  above,	   as	   illumination	   time	   increased	   the	   difference	   between	   PDT	   and	   PCI	  induced	  cytotoxicity	  was	  divergent	  in	  favour	  of	  PCI	  with	  the	  largest	  differential	  of	  53%	  is	  observed	  at	  240	  s	  (fig.	  3.10d).	  	  	  A	  very	  similar	  trend	  was	  observed	  for	  MTX-­‐PCI	  versus	  PDT	  for	  the	  ‘immediate’	  protocol	  whereby	  between	  60	  s-­‐90	  s	   there	  was	  a	  30%	   increase	   in	   cytotoxicity	  for	   PCI;	   120	   s-­‐150	   s	   (8%);	   180	   s-­‐300	   s	   there	   was	   a	   1.3%	   reduction	   in	   PCI	  cytotoxicity	   compared	   to	   PDT,	   though	   this	   is	   unlikely	   to	   represent	   any	  significant	  difference	  (fig.	  3.11a).	  	  	  The	  effect	  of	  photosensitiser	  localisation	  on	  PDT	  is	  reinforced	  when	  ‘immediate’	  versus	   4h	   protocols	   are	   compared	   (fig.	   3.10a).	   The	   pattern	   of	   cytotoxicity	  suggests	   that	   ‘immediate’	   -­‐	  PDT	  (for	   illumination	  times	  between	  60	  s-­‐300	  s)	   is	  consistently	  more	  potent	   than	   the	  4h	  protocol.	  A	  significant	  step	   for	   increased	  effect	  appears	  to	  take	  place	  between	  90	  s-­‐120	  s	  (immediate	  group)	  when	  a	  33%	  increase	   occurs.	   This	  may	   represent	   the	   point	   at	  which	   a	   critical	   level	   of	   ROS	  production	  occurs.	  In	  comparison,	  there	  is	  no	  true	  difference	  in	  cytotoxicity,	  for	  the	   4h	   group,	   between	  90	   s-­‐120	   s.	   In	   fact,	   comparison	   of	   the	   total	   increase	   in	  cytotoxicity	   between	   60	   s-­‐300	   s	   reveals	   a	   significant	   difference	   with	   a	   71%	  increase	  for	  the	  ‘immediate’	  group	  versus	  a	  29%	  increase	  for	  the	  4h	  group.	  This	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represents	   a	   2.8-­‐fold	   (‘immediate’)	   versus	   1.9-­‐fold	   (4h)	   increase	   across	   the	  illumination	  times.	  	  	  	  	  	  The	   differential	   for	   SAP-­‐PCI	   (fig	   3.10b)	   and	   MTX-­‐PCI	   (fig.	   3.11c)	   ‘immediate’	  versus	   4h	   shows	   a	   different	   light-­‐dose	   trend	   to	   PDT	   in	   that	   despite	   the	  immediate	  group	  achieving	  greater	   cell	  kill	   at	  each	   time	  point,	   the	   two	  groups	  converge	  as	  illumination	  time	  increased	  with	  the	  major	  step	  occurring	  between	  150	  s-­‐240	  s	  for	  both	  SAP-­‐PCI	  and	  MTX-­‐PCI	  (4h	  group).	  As	  discussed	  above,	  from	  180	  s	  onwards	  the	  cytotoxicity	  observed	  was	  almost	  all	  down	  to	  PDT.	  	  Thus,	  the	  convergence	  is	  likely	  due	  to	  the	  increased	  proportion	  of	  PCI	  induced	  cytotoxicity	  occurring	  in	  the	  4h	  group.	  This	  would	  indicate	  that	  the	  4h	  protocol	   is	  superior	  when	   aiming	   to	   achieve	   the	   greatest	   PCI	   effect.	   In	   terms	   of	   photosensitiser	  localisation,	  this	  suggests	  that	  the	   ‘chase’	  period	  facilitates	  the	  accumulation	  of	  photosensitiser	   in	   endo-­‐lysosomal	   membranes	   in	   synchrony	   with	   the	   loss	   of	  photosensitiser	   from	   the	   cell	   membrane.	   Thus	   upon	   activation	   of	   the	  photosensitiser	  the	  localised	  ROS	  generation	  favours	  endo-­‐lysosomal	  disruption	  while	  preserving	  overall	   cell	   integrity.	  Consequently,	   the	  cytotoxicity	  observed	  is	  likely	  to	  be	  due	  to	  the	  mechanistic	  effects	  of	  SAP	  (RIP)	  or	  MTX	  (topoisomerase	  inhibitor).	   Therefore,	   from	   these	   results	   it	   is	   possible	   to	   conclude	   that	  photosensitiser	  location	  at	  the	  time	  of	  activation	  is	  a	  determining	  factor	  for	  PDT	  versus	  PCI	  cytotoxicity.	  	  	  
3.21	  Variable	  4:	  Intracellular	  REDOX	  Environment	  This	  section	  of	  the	  study	  aimed	  to	  test	  the	  null	  hypothesis	  that	  the	  intracellular	  REDOX	  environment	  has	  no	  effect	  on	  the	  efficacy	  of	  PCI.	  As	  described	  earlier	  in	  the	   discussion	   REDOX	   homeostasis	   is	   vital	   for	   normal	   cellular	   function	   and	   is	  believed	   to	   play	   an	   important	   role	   in	   the	   ageing	   process.	   Sandana	   et	   al.	   (132)	  performed	   studies	   to	   further	   understand	   the	   role	   of	   oxidation	   resistance-­‐1	  (OXR1)	  gene	  in	  humans	  using	  a	  homolog	  LMD-­‐3	  which	  is	  found	  in	  the	  nematode	  
Caenorhabditis	   elegans	   (C.	   elegans).	   The	   group	   concluded	   that	   in	   conjunction	  with	   mitochondrial	   superoxide	   dismutase,	   LMD-­‐3	   contributes	   to	   regulating	  oxidative	  damage	  and	  ageing	  in	  the	  C.	  elegans	  nematode.	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Buthionine	  sulfoximine	  (BSO)	   is	  an	   irreversible	   inhibitor	  of	  γ-­‐glutamylcysteine	  synthase	  that	  causes	  depletion	  of	  GSH	  in	  tumours	  and	  normal	  tissues.	  Thanislass	  et	   al.	   (133)	   	   have	  demonstrated	   that	   sustained	   treatment	   (several	   days)	   using	  BSO	   in	   male	   rats	   resulted	   in	   chronic	   suppression	   of	   GSH	   levels,	   which	   was	  associated	   with	   an	   overall	   reduction	   in	   antioxidant	   defenses	   owing	   to	  diminishing	   activity	   of	   catalase,	   superoxide	   dismutase,	   and	   glutathione	  peroxidase	  among	  other	  scavengers	  of	  ROS.	  In	  this	  chapter,	  monochlorobimane	  (mBCl)	  was	   chosen	   as	   a	   fluorescent	   probe	   for	   intracellular	   glutathione	   levels.	  However,	   it	   is	  important	  to	  state	  that	  mBCl	  will	  emit	  a	  fluorescent	  signal	  when	  conjugated	  to	  a	  range	  of	  thiols	   including	  N-­‐acetylcysteine	  and	  mercaptopurine;	  the	   glutathione	   conjugate	   of	  mBCl	   has	   a	   specific	   absorption/emission	  maxima	  ~394/490	  nm,	  which	  was	  used	  in	  this	  chapter.	  The	  4-­‐fold	  reduction	  in	  the	  mBCl	  signal	  for	  4T1	  cells	  treated	  with	  BSO	  (24h)	  versus	  untreated	  (fig.	  3.24)	  supports	  the	  findings	  of	  Thanislass	  et	  al.	  	  BSO	   appeared	   to	   have	   very	   little	   if	   any	   effect	   on	   PDT	   using	   the	   immediate	  illumination	   protocol,	   with	   the	   only	   true	   difference	   being	   observed	   at	   60	  seconds	   illumination.	   However,	   following	   the	   4h	   ‘chase’	   period	   BSO,	  significantly,	   enhanced	   PDT	   for	   illumination	   durations	   ≥150	   s.	   This	   is	  highlighted	  by	  the	  following	  observations	  whereby	  between	  60	  s-­‐90	  s	  there	  was	  no	   difference	   in	   cytotoxicity	   between	   PDT	   versus	   PDT+BSO;	   120	   s-­‐150	   s	   the	  mean	  increase	  effect	  of	  BSO	  on	  PDT	  cytotoxicity	  was	  16%;	  180	  s-­‐300	  s	  was	  57%	  with	  the	   largest	   increase	  of	  61%	  occurring	  at	  240	  s	  (fig.	  3.12b).	  The	  maximum	  level	  of	  cell	  kill	  was	  92%	  (p<0.001)	  compared	  to	  control.	  This	  is	  comparable	  to	  the	   cytotoxicity	   achieved	   using	   the	   ‘immediate’	   protocol	   for	   both	   PDT	   and	  PDT+BSO	  (fig.	  3.12a;	   fig	  3.13a).	  Another	  important	  point	  of	  note	  is	  the	  relative	  impact	   of	   BSO	   on	   PDT	   (4h	   group)	   at	   longer	   illumination	   times	   compared	   to	  shorter	  time.	  At	   longer	  illumination	  times	  BSO	  appears	  to	  have	  a	  greater	  effect	  on	   4h-­‐delayed	   PDT	   compared	   to	   ‘immediate’,	   hence	   the	   narrowing	   gap	   in	   the	  difference	   between	   their	   means	   as	   the	   light-­‐dose	   increased.	   However,	   it	   is	  important	   to	   acknowledge	   that	   this	   is	   likely	   to	  be	   confounded	  by	   the	   fact	   that	  ‘immediate’	  protocol	  PDT/PDT+BSO	  kills	  almost	  all	  the	  cells	  at	  lower	  light	  doses.	  Nevertheless,	   under	   the	   conditions	   within	   this	   set	   of	   experiments	   PDT+BSO	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produces	   greater	   cytotoxicity	   at	   illumination	   durations	   >150	   s	   than	   SAP-­‐PCI/MTX-­‐PCI.	   However	   at	   lower	   light	   doses	   60	   s-­‐150	   s,	   SAP-­‐PCI	   has	   a	   mean	  increase	   in	  cytotoxicity	  of	  24%	  compared	   to	  PDT+BSO.	   	  This	   indicates	   that	   for	  PDT	   (4h	   protocol),	   by	   impairing	   the	   ability	   of	   the	   cell	   to	   cope	  with	   increased	  oxidative	   stress	   exerted	   following	   the	   activation	   of	   a	   photosensitiser	   it	   is	  possible	  to	  achieve	  sufficient	  levels	  of	  ROS	  production	  to	  induce	  cytotoxicity	  that	  is	  comparable	  to	  ‘immediate’	  protocol	  PDT+/-­‐BSO.	  However,	  for	  the	  dose	  of	  BSO	  used	  (1.0	  µg/ml)	   in	  this	  study	  the	  effect	   is	  only	  apparent	  at	  higher	   light	  doses,	  which	  is	  in	  keeping	  with	  the	  rate-­‐limiting	  effect	  that	  light-­‐dose	  has	  on	  PDT.	  The	  overall	   enhancing	   effect	   of	   BSO	   on	   PDT	   is	   supported	   by	   findings	   in	   work	  performed	  by	   Jiang	   et	   al.	   (2003)(134)	  using	  BSO	   to	   enhance	  Photofrin	  PDT	   in	  glioma	  cells	  in	  vitro	  and	  glioma	  tumours	  in	  vivo	  (Fisher	  Rats).	  	  Unlike	  for	  ‘immediate’	  PDT,	  BSO	  appeared	  to	  have	  significantly	  enhanced	  effect	  on	   ‘immediate’	  SAP-­‐PCI	  cytotoxicity	  however	  only	  at	   light	  durations	  ≤90	  s	  (fig.	  3.14a).	   This	   suggests	   that	   at	   the	   lower	   light	   doses	   the	   attenuated	   reducing	  capacity	  of	   the	   intracellular	  environment	  does	  have	  a	  significant	  effect	  on	  ROS	  production/survival	   time,	   consequently	   enabling	   a	   greater	   degree	   of	   endo-­‐lysosomal	   disruption	   and	   release	   of	   SAP.	   	   However,	   this	   conclusion	   is	  confounded	  by	   the	  residual	   ‘dark’	   cytotoxicity	  seen	  (12%,	  data	  not	  shown)	   for	  SAP-­‐PCI+BSO.	   Thus	   at	   present	   there	   is	   not	   enough	   evidence	   to	   conclude	   that	  BSO	  enhances	  ‘immediate’	  protocol	  SAP-­‐PCI.	  The	  same	  can	  be	  said	  of	  MTX-­‐PCI	  +	  BSO	   (‘immediate’	   group)	   where	   no	   significant	   increase	   in	   cytotoxicity	   is	  observed.	   Both	   sets	   of	   results	   may	   be	   affected	   by	   the	   sensitivity	   of	   the	   MTT	  assay	   to	   delineate	   relatively	   small	   differences	   in	   cell	   viability	   accurately.	   It	   is	  likely	  that	  a	  greater	  sample	  size	  or	  alternative	  viability	  assays	  would	  be	  required	  in	  order	  to	  improve	  the	  power	  of	  this	  part	  of	  the	  study.	  	  	  The	   effect	   of	   BSO	   on	   the	   4h	   protocol	   was	   significantly	   more	   positive	   when	  compared	   to	   the	   ‘immediate’	   protocol.	   The	   mean	   increase	   in	   cytotoxicity	   for	  cells	   treated	  with	   SAP-­‐PCI	  +	  BSO	  was	  17%	  across	   all	   light	  doses.	  The	  greatest	  effect	  observed	  was	  between	  150	   s-­‐180	   s	  with	  a	  23%	   increase	   in	   cytotoxicity.	  This	   represented	   a	   0.4-­‐fold	   increase	   compared	   to	   SAP-­‐PCI	   alone.	   BSO	   had	   a	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comparable	  effect	  at	   lower	  light	  doses	  (60	  s-­‐120	  s)	  when	  a	  0.5-­‐fold	  increase	  in	  cytotoxicity	  was	  observed.	  An	  important	  point	  to	  consider	  is	  the	  effect	  of	  BSO	  on	  the	  contribution	  of	  PDT	  induced	  cytotoxicity	  to	  PCI;	  the	  question	  being	  whether	  or	   not	   the	   enhanced	   PCI	   effect	   is	   in	   fact	   due	   to	   an	   enhancement	   of	   PDT.	   For	  illumination	   times	   ≤150	   s	   PCI	   +	   BSO	   induced	   cytotoxicity	   was	   significantly	  greater	   (statistically)	   than	   for	   PDT	   +	   BSO.	   The	   mean	   increase	   in	   cell	   kill	   for	  	  	  	  	  (PCI	   +	   BSO)	   versus	   (PDT	   +	   BSO)	   between	   60	   s-­‐90	   s	   was	   43%	   (3.6-­‐fold)	   and	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  120	   s-­‐150	   s	   	   (32%,	  1-­‐fold).	  However,	   between	  180	   s-­‐300	   s	   the	  mean	   increase	  dropped	  to	  7.3%	  (p>0.05),	  which	  represented	  a	  0.1-­‐fold	  increase.	  This	  indicates	  that	   as	   light	   dose	   increases	   BSO	   acts	   to	   significantly	   increase	   ROS	   production	  and	   survival	   which	   given	   the	   increasing	   activation	   of	   photosensitiser	   tips	   the	  scales	   in	   favour	   of	   PDT.	  However,	   importantly	   at	   lower	   light	   doses	   BSO	   has	   a	  greater	  effect	  on	  ROS	  production	  favouring	  PCI	  compared	  to	  PDT.	  PCI	  appeared	  to	  have	  the	  greater	  effect.	  	  The	  effect	  of	  BSO	  on	  MTX-­‐PCI	  appeared	  to	  be	  misleading.	  Although	  comparison	  between	   MTX-­‐PCI	   versus	   MTX-­‐PCI	   +	   BSO	   showed	   that	   statistically	   significant	  increases	   in	   cytotoxicity	   are	   only	   achieved	   at	   illumination	   times	   ≥180	   s	   (fig.	  3.16b).	  However,	  when	  PDT	  +	  BSO	  was	  compared	  to	  MTX-­‐PCI	  +	  BSO,	  it	  became	  apparent	   that	   at	   illumination	   times	   ≥180	   s	   there	   was	   no	   difference	   in	  cytotoxicity	  between	  the	  two	  treatment	  groups	  (fig.	  3.16d).	  Thus,	  the	  increased	  effect	   is	   most	   likely	   due	   to	   the	   enhancement	   of	   PDT	   and	   not	   PCI.	   Another	  possible	   explanation	   is	   that	   the	   cytotoxic	   effects	   of	   mitoxantrone	   have	   been	  shown,	   in	  part,	   to	  be	  mediated	  by	  toxic	  metabolites	   formed	  via	  oxidation	  in	  by	  P450-­‐dependent	   mixed	   function	   oxidase	   (MFO)	   system(135).	   Therefore,	   the	  increased	  level	  of	  ROS	  produced	  under	  the	  conditions	  of	  suppressed	  glutathione	  levels	  may	   lead	   to	  modification	  of	  MTX,	   rendering	   it	   less	   toxic.	  Given	  MTX	  has	  been	   shown	   to	   be	   an	   effective	   candidate	   for	   PCI	   using	   hypericin	   as	   a	  photosensitiser(25),	   the	   results	   of	   this	   study	   may	   indicate	   that	   the	   choice	   of	  photosensitiser,	   beyond	   preference	   for	   amphiphilic	   structure,	   is	   of	   significant	  importance	   when	   considering	   PCI.	   If	   for	   example	   the	   structure	   of	   a	  photosensitiser	   brings	   ROS	   generation	   closer	   to	   the	   lumen	   of	   the	   endosome	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containing	   the	   internalised	   agent	   (MTX)	   then	   the	   likelihood	   of	   ROS-­‐mediated	  damage	  is	  increased.	  	  	  	  	  Overall,	   these	   results	   indicated	   that	   using	   the	   4h	   protocol,	   BSO	   effectively	  reduced	   the	  dose	  of	   light	   required	   to	  achieve	  a	  particular	   level	  of	   cytotoxicity.	  For	  example,	  at	  180	  s	  SAP-­‐PCI	  +	  BSO	  achieved	  15%	  (p<0.05)	  and	  13%	  (p<0.05)	  increase	   cytotoxicity	   compared	   to	   SAP-­‐PCI	   at	   240	   s	   and	   300	   s	   respectively.	  	  However,	  MTX-­‐PCI	  does	  not	  appear	  to	  be	  enhanced	  under	  the	  conditions	  utilised	  during	   the	   study.	   Thus,	   in	   the	   case	   of	   SAP,	   the	   addition	   of	   BSO	   creates	   an	  intracellular	  REDOX	  environment	  that	  facilitates	  the	  generation	  of	  sufficient	  ROS	  to	  enhance	  SAP	  release	  at	  a	  scale	  beyond	  that	  achieved	  with	  up	  to	  120	  seconds	  additional	   illumination.	   In	   this	   way,	   BSO	   enhances	   SAP-­‐PCI.	   Drawing	   such	   a	  conclusion	   highlights	   an	   important	   role	   of	   GSH	   in	   regulating	   the	   rate	   of	  production	   and	   survival	   time	   of	   ROS	   generated	   following	   the	   activation	   of	   a	  photosensitiser.	   Consequently,	   GSH	   levels	   within	   a	   cell	   are	   likely	   to	   have	   a	  significant	   impact	   on	   the	   success	   of	   both	  PDT	  and	  PCI;	   however,	   owing	   to	   the	  reduced	   levels	  of	  ROS	  production	   in	  PCI	   this	  effect	  will	   likely	  be	  greater	   in	   the	  latter.	   Thus,	   GSH	   modulation	   may	   be	   an	   important	   consideration	   when	  developing	  PCI	  protocols.	  	  
3.22	  Variable	  5:	  Illumination	  ‘before’	  versus	  ‘after’	  cytotoxin	  treatment.	  The	   ‘classical’	   PCI	   model	   involves	   pre-­‐treating	   cells	   with	   an	   appropriate	  photosensitiser	   prior	   to	   exposing	   them	   to	   light	   of	   a	   specific	   wavelength(26).	  Using	   this	   protocol,	   endosomes	   containing	   the	   internalized	   compound	   in	   the	  lumen	  and	  photosensitiser	  in	  the	  membrane	  will	  release	  the	  luminal	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Figure	  3.33	  –	  Diagrammatic	  representation	  of	  light	  ‘after’	  versus	  light	  ‘before’	  PCI	  
protocols.	  	  Prasmickaite	  et	  al.	  (2002)(34)	  	  compound	  following	  activation	  of	  the	  photosensitiser	  (fig.	  3.33A).	  An	  alternative	  regimen	  has	  been	  reported	  by	  Prasmickaite	  et	  al.	  (2002)(34)	  whereby	  cells	  are	  pre-­‐treated	   with	   photosensitiser	   and	   then	   exposed	   to	   light	   treatment.	  Subsequently	  they	  are	  treated	  with	  the	  compound	  to	  be	  internalised.	  The	  school	  of	  thought	  for	  the	  ‘light	  before’	  regimen	  that	  preformed	  vesicles	  (no	  drug	  within	  the	  lumen)	  will	  contain	  photosensitiser	  in	  the	  membranes	  which	  once	  activated	  will	  causes	  ROS-­‐induced	  damage,	  including	  lipid	  peroxidation.	  The	  compound	  to	  be	  internalised	  is	  given	  afterwards,	  thus	  the	  new	  endosomes	  formed	  will	   likely	  be	   of	   normal	   structure.	   However,	   these	  may	   subsequently	   come	   in	   to	   contact	  with	  pre-­‐damaged	  vesicular	  membranes	  containing	  reactive	  lipid	  peroxides	  +/-­‐	  aldehydes	  that	  can	  damage	  the	  endosomal	  membranes,	  leading	  to	  the	  release	  of	  the	  internalised	  drug.	  In	  doing	  so,	  the	  light	  before	  regimen	  may	  provide	  a	  second	  mechanism	  for	  PCI.	  	  	  	  	  	  This	  study,	  the	  light	  ‘before’	  cytotoxin	  protocol	  was	  used	  for	  both	  SAP-­‐	  and	  MTX-­‐PCI	   using	   two	   doses	   of	   TPPS2a	   (0.3	   and	   0.6	   µg/ml).	   The	   results	   indicated	   that	  when	   the	   illumination	   time	   was	   fixed	   at	   120	   seconds,	   doubling	   the	   dose	   of	  photosensitiser	   had	   a	   disproportionate	   effect	   on	   the	   light	   ‘before’	   regimen	  compared	  to	  the	  light	  ‘after’	  for	  SAP	  (15	  nM)-­‐PCI.	  When	  the	  photosensitiser	  dose	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was	   doubled	   the	   differential	   between	   light	   ‘before’	   and	   light	   ‘after’	   regimens	  reduced	  from	  20%	  (p<0.01)	  to	  8%	  (p<0.05).	  This	  represented	  a	  24-­‐fold	  increase	  in	   LB	   SAP-­‐PCI	   compared	   to	   a	   0.2-­‐fold	   increase	   in	   LA	   SAP-­‐PCI.	   BSO	   had	   a	  significant	   enhancing	   effect	   on	   the	   LB	   SAP-­‐PCI	   (TPPS2a	   0.3	   µg/ml),	   however	  almost	  all	  of	  the	  effect	  is	  likely	  to	  be	  explained	  by	  the	  enhanced	  PDT	  effect	  (fig.	  3.17).	  	  	  Using	   the	   LB	   protocol,	   an	   interesting	   observation	   was	   made	   for	   MTX	   (0.4	  µg/ml).	   There	   appeared	   to	   be	   a	   significant	   reduction	   in	   residual	   cytotoxicity	  (35%),	  which	   is	   likely	   to	   be	   due	   to	   the	   increased	   cell	   density	   and	   consequent	  reduction	   in	  doubling	   time,	  hence	  MTX	  has	   less	   access	   to	   replicating	  DNA	  and	  therefore	  a	  reduced	  therapeutic	  effect	  (fig.	  3.18b).	  This	  resulted	  in	  a	  significantly	  improved	  LB	  PCI	  effect	  of	  23%	  (p<0.01)	  improved	  cytotoxicity	  compared	  to	  LA	  PCI	  (no	  increase).	  This	  is	  in	  keeping	  with	  the	  results	  reported	  by	  Prasmickaite	  et	  al.	   (2002)(34)	   who	   found	   that	   the	   light	   ‘before	   delivery’	   protocol	   using	  Aluminium	   Phthalocyanine	   (AlPcS2a)	   “exhibited	   much	   stronger	   toxicity”	  compared	   to	   light	   after.	  Whilst	   it	   is	   correct	   to	   observe,	   in	   this	   study	   that	   the	  greatest	  cytotoxic	  effect	  was	  achieved	  using	  LA	  MTX-­‐PCI,	  the	  differential	  change	  was	   far	   greater	   for	   the	   LB	   group	   compared	   to	   the	   LA	   group.	   There	   was	   no	  increase	  in	  cytotoxicity	  upon	  addition	  of	  BSO	  for	  both	  SAP-­‐PCI	  and	  MTX-­‐PCI	  for	  the	  LB	  protocol.	  Interestingly	  there	  was	  no	  increase	  for	  PDT+BSO	  compared	  to	  PDT	  alone	  (fig.	  3.18).	  Based	  on	  the	  findings	  of	  this	  section	  of	  the	  study	  it	  would	  appear	  that	  the	  light	  ‘before’	  regimen	  does	  enhance	  drug	  delivery,	  which	  under	  conditions	   of	   increased	   photosensitiser	   dose	   appears	   to	   be	   comparable	   to	   the	  light	  after	  protocol.	  These	  observations	  are	   further	   supported	  by	  Prasmickaite	  et	  al.	   (2002)(34)	  who	  report	   from	  their	  studies	  that	  both	  the	   light	   ‘before’	  and	  light	   ‘after’	   strategies	   enhanced	   “in	   vitro	   transfection	   with	   reporter	   genes	  delivered	   by	   non-­‐viral	   and	   adenoviral	   vectors”	   by	  more	   than	   10-­‐	   and	   six-­‐fold,	  respectively.	  	  A	  possible	  explanation	  for	  this	  proposed	  mechanism	  can	  be	  found	  when	  looking	  at	  the	  propagation	  phase	  of	  lipid	  peroxidation(82)	  as	  described	  in	  the	  introduction	  to	  this	  chapter,	  whereby	  formed	  lipid	  peroxide	  radicals	  such	  as	  LOO•	  and	  LO•	  (as	  a	  result	  of	  photosensitiser	  activation	  pre-­‐cytotoxin	  treatment)	  may	   react	  with	   PUFA	  within	   newly	   formed	   endosomes	   containing	   drug.	   If	   the	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burden	  of	  lipid	  peroxides	  is	  sufficient,	  this	  will	  cause	  sufficient	  damage	  for	  drug	  release	   from	   the	   lumen	   of	   the	   endosomes.	   Lipid	   peroxidation	   appears	   to	   be	   a	  consequence	   of	   photosensitiser	   activation	   when	   the	   relative	   level	   of	   lipid	  peroxide	   compared	   to	   non-­‐oxidised	   lipid	   within	   the	   cytoplasm	   increases	   by	  60%.	  BSO	  has	  a	  significant	  effect	  on	  intracellular	  lipid	  peroxidation,	  even	  in	  the	  absence	   of	   light	   and	   photosensitiser	   (fig.	   3.29a).	   This	   indicates	   that	   impairing	  the	   reducing	   capacity	   of	   the	   intracellular	   compartment	   alone	   can	   increase	   the	  level	   of	   lipid	   peroxidation.	   However,	   in	   the	   results	   obtained	   in	   cytotoxicity	  studies,	   BSO	   alone	   did	   not	   increase	   cell	   kill	   significantly	   compared	   to	   control.	  The	   same	   can	   be	   said	   of	   BSO	   +	   SAP	   compared	   to	   SAP	   alone.	   The	  mean	   signal	  intensities	   (green/peroxide)	   for	   cells	   treated	   with	   BSO	   or	   BSO	   +	   SAP	   are	  significantly	  reduced	  compared	  to	  cells	  treated	  with	  TPPS2a	  +	   light	  or	  TPPS2a	  +	  BSO	  +	  light.	  Taken	  together	  with	  the	  increased	  level	  of	  cytotoxicity	  observed	  for	  the	   latter	  groups,	   this	   indicates	   that	   the	   level	  of	   lipid	  peroxidation	  achieved	   in	  the	   absence	   of	   photosensitiser	   activation	   may	   not	   be	   sufficient	   to	   facilitate	  cytotoxin	   release	   in	   SAP	   or	   MTX	   +	   BSO	   alone.	   This	   further	   supports	   the	  hypothesis	   that	   there	   is	   a	   critical	   load	   of	   ROS	   required	   to	   cause	   sufficient	  damage	   to	   endo-­‐lysosomal	   membranes	   and	   trigger	   the	   release	   of	   the	  endocytosed	   molecule.	   A	   potential	   confounding	   factor	   here	   is	   that	   lipid	  peroxidation	  has	  been	  reported	  as	  a	  potential	  indicator/secondary	  messenger	  of	  the	  cellular	  stress	  response,	  for	  example	  4-­‐hydroxynonenal	  (4-­‐HNE)	  is	  believed	  to	  play	  a	  role	  in	  the	  cell	  cycle	  and	  differentiation/apoptosis(136).	  Therefore,	  the	  rise	   in	   lipid	   peroxidation	   may	   in	   part	   be	   due	   to	   a	   stress	   response	   hence	   the	  increase	   in	  background	   level	   seen	  with	   the	   treatment	  of	  all	   the	  agents:	  TPPS2a	  (dark/light),	  SAP	  and	  BSO).	  	  	  	  	  The	  findings	  for	  the	  light	  ‘before’	  protocol	  are	  important	  as	  it	  may	  prove	  a	  more	  suitable	  mechanism	  for	  the	  internalisation	  of	  certain	  molecules	  such	  as	  genetic	  material	  and	  non-­‐toxic	  therapeutic	  molecules	  when	  other	  factors	  are	  taken	  into	  account	  such	  as	  the	  extinction	  coefficient	  of	  the	  photosensitiser,	  light	  dose,	  and	  stability	  of	  the	  molecule	  to	  be	  internalised.	  	  
	   133	  
The	   combination-­‐PCI	  experiments	  were	  performed	   to	   investigate	  whether	   this	  mechanism	   of	   drug	   delivery	  would	   be	   suitable	   for	   the	   internalisation	   of	  more	  than	   one	   cytotoxin.	   The	   importance	   of	   this	   is	   that	   in	   clinical	   practice,	  medical	  management	  of	  malignancy	  commonly	  requires	  the	  administration	  of	  more	  than	  on	   and	   often	   multiple	   therapeutic	   agents.	   The	   question	   to	   be	   addressed	   was	  could	  PCI	  enhance	  dual-­‐drug	  chemotherapy	  in	  4T1	  cells?	  The	  observations	  made	  during	   the	   study	   overall	   indicate	   that	   combination	   PCI	   is	   more	   effective	   than	  either	  cytotoxin-­‐PCI	  alone.	  However,	  this	  is	  only	  the	  case	  for	  the	  LA	  Combo-­‐PCI	  protocol	  where	  the	  combination	  of	  both	  agents	  resulted	  in	  a	  significant	  increase	  in	   cytotoxicity,	   compared	   to	   SAP-­‐PCI	   or	   MTX-­‐PCI	   alone	   +/-­‐	   BSO.	   In	   fact,	   LA	  Combo-­‐PCI	   produced	   cell	   kill	   equivalent	   to	   SAP-­‐PCI/MTX-­‐PCI	   +BSO.	   The	  addition	  of	  BSO	  to	  combo	  PCI	  resulted	  in	  89%	  cell	  kill.	  In	  comparison	  to	  SAP-­‐PCI	  and	  SAP-­‐PCI	  +	  BSO	   this	   represents	  an	   increase	   in	   cell	   kill	   ratio	   from	  5.7	   in	  10	  cells	   and	  7	   in	  10	   cells,	   respectively,	   to	  8.9	   in	  10	   cells	  with	  no	   increase	   in	  PDT	  toxicity.	  Whereas	  compared	  to	  MTX-­‐PCI	  and	  MTX-­‐PCI	  +	  BSO	  the	  increase	  in	  cell	  kill	  ratio	  is	  from	  5.3	  in	  10	  and	  7.1	  in	  10,	  respectively,	  to	  8.9	  in	  10.	  The	  increased	  toxicity	  in	  comparison	  to	  single	  agent	  PCI	  is	  significant,	  however	  it	  is	  important	  to	  put	  this	  into	  context	  when	  compared	  to	  SAP	  alone	  when	  a	  13.8-­‐fold	  increase	  in	  cytotoxicity	  is	  observed.	  	  	  Combination	  PCI	  is	  an	  area	  that	  certainly	  requires	  further	  evaluation	  in	  order	  to	  have	   any	   true	   relevance	   to	   clinical	   practice	   in	   cancer	   therapeutics.	   This	   study	  has	   shown	   that	   LA	   PCI	   can	   be	   used	   to	   facilitate	   the	   internalisation	   of	   two	  structurally	   and	  mechanistically	   different	   cytotoxins	   in	   unison	   and	   that	   this	   is	  significantly	   better	   than	   single-­‐agent	   PCI	   alone	   when	   the	   light	   dose	   is	   fixed.	  Furthermore,	  that	  when	  the	  REDOX	  environment	  of	  the	  cell	  is	  altered	  to	  favour	  oxidation,	   under	   the	   action	   of	   BSO,	   it	   is	   possible	   to	   see	   as	   much	   as	   an	   83%	  increase	  in	  cytotoxicity	  (compared	  to	  SAP	  alone).	  The	  benefit	  of	  such	  a	  regimen	  is	  that	  it	  is	  possible	  to	  achieve	  magnitudes	  of	  cytotoxicity	  at	  significantly	  lower	  doses	  of	  cytotoxin.	  In	  doing	  so,	  it	  is	  possible	  to	  effectively	  widen	  the	  therapeutic	  index	   of	   chemotherapeutic	   agents,	   which	   will	   be	   of	   great	   benefit	   to	   both	  clinicians	   and	  patients.	   	   The	   lack	   of	   enhanced	   killing	  with	   the	   LB	  PCI	   regimen	  further	   supports	   the	   hypothesis	   that	   LA	   and	   LB	   PCI	   have	   two	   distinct	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mechanisms.	  It	  is	  possible	  that	  when	  both	  agents	  are	  trapped	  within	  endosomes	  an	   even	   greater	   level	   of	   ROS	   production	   is	   required	   to	   cause	   sufficient	   lipid	  peroxidation,	   enabling	   adequate	   disruption	   of	   subsequently	   formed	   vesicle	  when	  they	  react.	  
3.23	  Variable	  6:	  Time	  between	  photosensitiser	  activation	  and	  survival	  assay	  The	   time	   between	   illumination	   and	   MTT	   assay	   represents	   the	   period	   during	  which	   the	   different	   phases	   of	   PCI	   will	   take	   place.	   Initially,	   photosensitiser	  activation	   and	   ROS	   generation;	   lipid	   peroxidation	   leading	   to	   endosomal	  membrane	  rupture	  and	  release	  of	  internalised	  agent	  (in	  this	  case	  cytotoxin)	  in	  to	  the	   cytoplasm;	   trafficking	   of	   the	   released	   drug	   to	   site	   of	   action	   (SAP	   to	   rough	  endoplasmic	   reticulum	   and	   MTX	   to	   nucleus);	   exerting	   cytotoxic	   effect	   (SAP	  inhibition	   of	   protein	   synthesis	   and	   MTX	   inhibition	   of	   DNA	   replication);	  apoptosis	   +/-­‐	   necrosis.	   Thus	   it	   is	   not	   without	   reason	   to	   challenge	   the	   null	  hypothesis	  that	  prolonging	  the	  time	  between	  illumination	  and	  MTT	  assay	  has	  no	  effect	  on	  overall	  cytotoxicity	  for	  PCI.	  	  	  In	   order	   to	   challenge	   the	   null	   hypothesis	   experiments	   were	   performed	   to	  evaluate	   the	  effect	  of	   increasing	   the	   time	  between	   illumination	  and	  MTT	  assay	  from	   24h	   to	   72h.	   This	   time	   period	   was	   chosen	   due	   to	   the	   practicalities	   of	  completing	   PCI-­‐based	   experiments	   in	   the	   laboratory.	   Other	   groups	   have	   been	  known	   to	  wait	   longer	   periods	   of	   up	   to	   7-­‐10	   days	   post	   illumination(137).	   The	  results	  for	  LA	  PCI	  are	  positive,	  with	  regard	  to	  an	  increased	  effect	  when	  waiting	  72h	  compared	  to	  24	  hours,	  for	  SAP,	  MTX	  and	  Combo-­‐PCI.	  SAP	  based	  PCI	  +/-­‐	  BSO	  exhibited	   the	  greatest	  magnitude	  of	   increased	  cytotoxicity	  at	  72h	  compared	   to	  24h;	  for	  SAP-­‐PCI	  there	  is	  a	  0.6-­‐fold	  increase	  in	  cytotoxicity;	  SAP-­‐PCI	  +	  BSO	  there	  is	  a	  0.8-­‐fold	  increase	  achieving	  95%	  cytotoxicity.	  Therefore,	  by	  enabling	  further	  time	   for	   the	   release	   of	   SAP	   from	  endosomal	   stores	   and/or	  prolonged	   time	   for	  cytotoxic	   effect	   to	   take	   place,	   the	   overall	   cytotoxicity	   is	   increased.	   A	   potential	  mechanism	   for	   this	   is	   that	   by	   waiting	   72h	   post-­‐illumination	   there	   is	   a	  combination	   of	   light	   ‘after’	   and	   light	   ‘before’	   PCI.	   In	   both	   protocols	  photosensitiser	  will	   initially	   become	   incorporated	   into	   the	   cell	  membrane	   and	  subsequently	   accumulate	   into	   endolysosomal	   membranes.	   In	   the	   LA	   protocol	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this	  will	  be	  accompanied	  by	  the	  random,	  non-­‐receptor	  mediated	  endocytosis	  of	  SAP	  therefore	   the	  co-­‐localisation	  of	  both	  TP	  and	  SAP	  will	  be	  dependent	  on	   the	  total	  concentration	  of	  both	  agents	  along	  with	  their	  uptake	  kinetics.	  If	  these	  are	  not	   equivalent	   then	   a	   mismatch	   may	   occur	   with	   a	   proportion	   of	   endosomes	  containing	  both;	  some	  containing	  SAP	  but	   little	  or	  no	  TP;	  others	  containing	  TP	  without	   SAP;	   and	   finally	   some	   with	   neither.	   Thus	   when	   the	   light	   (randomly)	  activates	  photosensitiser	  and	  ROS-­‐mediated	  lipid	  damage	  leads	  to	  rupture	  of	  the	  endolysosomal	   membranes	   only	   those	   cells	   with	   a	   high	   proportion	   of	   co-­‐localised	   agents	   will	   undergo	   apoptosis	   that	   can	   be	   observed	   at	   24h	   (LA	  protocol).	   However,	   waiting	   an	   extra	   48h	   enables	   those	   damaged	   endosomes	  that	  contained	  TP	  alone	  to	  react	  with	  undamaged	  vesicles	  containing	  SAP	  alone	  or	   co-­‐localised	   drugs,	   enabling	   their	   release	   and	   thus	   killing	   a	   cell	   that	   may	  otherwise	  have	  survived	  if	  assayed	  at	  24h.	  	  	  MTX	   had	   showed	   a	   slightly	   different	   trend	   in	   that	   although	   there	   was	   an	  increase	   in	   cytotoxicity	   for	   LA	  MTX-­‐PCI	   at	   72h	   compared	   to	   24h,	   this	  was	   no	  different	   to	   the	   level	   of	   cytotoxicity	   reached	   with	   MTX	   alone	   at	   72	   hours.	  However,	  in	  support	  of	  the	  hypothesis	  that	  TP	  mediated	  PCI	  of	  MTX	  requires	  a	  higher	   level	  of	  ROS	  production	  to	  facilitate	  the	  endosomal	  escape;	  the	  addition	  of	  BSO	  did	   result	   in	   a	   9%	   (p<0.05)	   and	  15%	   (p<0.01)	   increase	   in	   cytotoxicity	  compared	   to	  MTX	  and	  MTX-­‐PCI	   +	  BSO,	   respectively.	   Importantly	   this	   rise	  was	  not	  explained	  by	  an	  enhancement	  of	  the	  PDT	  effect	  alone.	  	  	  There	   was	   no	   true	   increase	   in	   PCI	   or	   PCI	   +	   BSO	   (LB),	   for	   the	   experimental	  conditions	   chosen	   (in	   particular	   cytotoxin	   and	   light	   dose).	   	   The	   LB	   protocol	  appears	  to	  suffer	  from	  what	  might	  be	  described	  as	  a	  narrow	  operating	  window.	  Pilot	   experiments	   showed	   that	   by	   increasing	   the	   illumination	   time	   it	   was	  possible	  to	  significantly	  enhance	  this	  protocol,	  however,	  this	  comes	  at	  the	  cost	  of	  an	   increased	   PDT/PDT	   +	   BSO	   effect.	   Furthermore,	   when	   the	   dose	   of	   SAP	   is	  increased	   to	  30	  nM,	   the	   level	   of	   cytotoxicity	   achieved	   is	   comparable	   to	   the	  LA	  protocol	   (fig.	   3.18a).	   Given	   that	   a	   higher	   dose	   of	   TP	   (0.6	   µg/ml)	   +	   SAP	  30	   nM	  (LB)	  at	  24h	  achieved	  a	  greater	  ultimate	   level	  of	   cytotoxicity	  and	  had	  a	  greater	  differential	  to	  PDT	  or	  SAP	  alone	  compared	  to	  TP	  (0.6	  µg/ml)	  +	  SAP	  15	  nM	  (LB)	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(same	  light	  dose,	  120	  s)	  at	  24h	  and	  72h	  suggests	  that	  the	  dose	  of	  cytotoxin	  might	  be	  the	  rate	  limiting	  step	  for	  this	  protocol.	  A	  potential	  explanation	  for	  this	  is	  that	  the	   pre-­‐treatment	   of	   the	   cell	   (TP	   +	   light)	   attenuated	   the	   efficiency	   of	  endocytosis/pinocytosis(138).	   Consequently,	   higher	   doses	   are	   required	   to	  increase	   the	   probability	   of	   endocytosis	   and	   subsequent	   cytosolic	   delivery	  following	   interaction	  between	  pre-­‐damaged	  and	  newly	  formed	  endo-­‐lysosomal	  membranes	  to	  a	  degree	  that	  supports	  significant	  enhancement	  in	  cell	  kill;	  even	  if	  more	  time	  is	  given	  for	  lipid	  peroxidation	  (i.e.	  72h).	  This	  may	  also	  explain	  why	  no	  significant	   increase	   in	   cytotoxicity,	   independent	   of	   an	   enhanced	   PDT	   effect,	   is	  observed	   following	   the	  addition	  of	  BSO.	  Such	  a	  hypothesis	   is	  supported	  by	   the	  findings	  of	  LB	  Combo-­‐PCI	  +/-­‐	  BSO	  where	  an	  overall	  greater	  level	  of	  cytotoxicity	  and	  differential	  is	  observed	  versus	  SAP	  +	  MTX	  (data	  not	  shown)	  chemotherapy	  alone	   (fig.	   3.21b).	   Therefore,	   the	   overall	   increased	   concentration	   of	   cytotoxin	  increases	   the	   likelihood	  of	   successful	   endocytosis,	   post-­‐light,	   therefore	   greater	  probability	  of	  endosomes	  containing	  drug	  reacting	  with	  pre-­‐damaged	  vesicular	  membranes	   and	   release	   into	   the	   cytoplasm.	   	   However,	   overall	   the	   light	   ‘after’	  therapy,	  using	  lower	  doses	  of	  cytotoxin	  (SAP	  15	  nM/MTX	  0.4	  µg/ml)	  appears	  to	  elicit	  a	  more	  efficacious	  PCI	  effect	  at	  both	  24h	  and	  72h	  following	  illumination.	  	  
3.24	  Effect	  of	  Antioxidants	  As	   described	   in	   the	   introduction,	   varieties	   of	   antioxidants/reducing	   enzymes	  exist	  within	   a	   cell	   to	   enable	   survival	  within	   dynamic	   REDOX	   environments.	   A	  good	   example	   of	   how	   cells	   have	   adapted	   and	   retained	   protective	   reducing	  capabilities	  can	  be	  seen	  in	  erythrocytes,	  which	  are	  exposed	  to	  both	  oxygen-­‐rich	  (pulmonary	   circulation)	   and	   oxygen-­‐deplete	   (respiring	   tissues)	   regions	   of	   the	  body.	  Enzymes	  such	  as	  G6PD	  and	  pyruvate	  kinase	  play	  a	  vital	  role	  in	  stabilizing	  the	   erythrocyte	  membrane	   and	   thus	   preventing	   oxidation	   induced	  membrane	  damage	  that	  results	  in	  inappropriate	  and	  premature	  haemolysis	  as	  a	  sequelae	  of	  their	  absence	  or	  ineffective	  function.	  The	  ability	  of	  a	  cell	  to	  enhance	  its	  reducing	  capabilities	  has	  been	  implicated	  in	  the	  development	  of	  drug	  resistance.	  Wang	  et	  al.	   (1999)(139)	   reported	   that	   multi-­‐drug	   resistant	   MCF-­‐7/ADR	   breast	   cancer	  cells,	  which	  are	  30-­‐65-­‐fold	  more	  resistant	  to	  doxorubicin	  than	  wild	  type	  and	  this	  was	   associated	   with	   23-­‐fold	   elevated	   glutathione-­‐S-­‐transferase	   (GST)	   activity	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within	  the	  cytoplasm.	  In	  addition,	  Goto	  et	  al.	  (2001)(140)	  reported	  that	  levels	  of	  nuclear-­‐targeted	   GSTπ	   are	   not	   only	   elevated	   in	   doxorubicin-­‐resistant	   cancer	  cells	   but	   dynamically	   rose	   in	   response	   to	   treatment;	   they	   conclude	   that	   GSTπ	  protects	   DNA	   from	   anticancer	   drugs.	   This	   supports	   the	   findings	   in	   this	   study	  whereby	   cells	   treated	   with	   SOD	   both	   pre-­‐	   and	   post-­‐illumination	   exhibited	  perceptible	   inhibition	   of	   the	   PCI	   effect.	   SOD	   catalyses	   the	   simultaneous	  reduction	   and	   oxidation	   of	   superoxide	   into	   oxygen	   (O2)	   +	   hydrogen	   peroxide	  (H2O2),	  and	  in	  doing	  so	  SOD	  exerts	  an	  antioxidant	  effect	  within	  a	  cell.	  Golab	  et	  al.	  (2003)(141)	  demonstrated	  that	  use	  of	  the	  MnSOD	  inhibitor	  2-­‐methoxyestradiol	  (2-­‐MeOE(2))	  potentiated	   in	  vivo	  PDT	  in	  a	  murine	  tumour	  model.	  This	  indicates	  that	  O2-­‐	  may	  play	  a	  role	  in	  mediating	  the	  ROS	  associated	  damage	  that	  is	  triggered	  by	   photosensitiser	   activation.	   Therefore,	   by	   making	   the	   intracellular	  environment	   more	   susceptible	   to	   the	   generation	   and	   persistence	   of	   O2-­‐	   by	  inhibiting	  SOD	  we	  can	  enhance	  this	  effect.	  Interestingly,	  in	  this	  study,	  under	  the	  experimental	  conditions	  used,	  SOD	  did	  not	  have	  a	  statistically	  significant	  effect	  on	  PDT	  but	  did	  for	  PCI.	  This	  is	  in	  keeping	  with	  the	  effect	  of	  BSO	  on	  PDT	  versus	  PCI,	   whereby	   under	   certain	   conditions	   it	   appears	   to	   favour	   PCI.	   This	   is	  consistent	   with	   the	   hypothesis	   that	   the	   amount	   of	   ROS	   required	   to	   liberate	  endocytosed	  drugs	   from	  their	  cytosolic	  vesicles	   in	  PCI	   is	  significantly	   less	  than	  that	   required	   for	   PDT-­‐induced	   cell	   killing;	   in	   the	   former	   the	   cytotoxic	   agent	  released	  causes	  the	  step	  in	  cytotoxicity.	  Consequently,	  a	  relatively	  small	  increase	  in	  the	  ROS-­‐quenching	  capacity	  of	  a	  cell	  using	  SOD	  may	  be	  sufficient	  to	  inhibit	  the	  low	  ROS-­‐burden	  for	  PCI	  but	  have	  little	  effect	  on	  PDT.	  	  	  A	  similar	  effect	  is	  seen	  using	  the	  amino	  acid	  L-­‐Histidine	  (LH),	  which	  is	  known	  to	  quench	  singlet	  oxygen(142).	  The	  dose-­‐dependent	  reversal	  of	  PCI	   indicates	  that	  TP	  photo-­‐activation,	  in	  part	  at	  least,	  is	  likely	  to	  involve	  the	  Type	  II	  reaction	  with	  the	  generation	  1O2.	  	  	  The	   findings	   of	   the	   ROS	   quencher	   experiments	   add	   further	   credibility	   to	   the	  importance	  of	  ROS	  generation	  and	  survival	  in	  PDT	  and	  PCI.	  In	  the	  case	  of	  LH,	  it	  is	  important	  to	  consider	  that	  a	  non-­‐enzymatic	  anti-­‐oxidant	  can	  potentially	  enhance	  ROS	  production	  and	  this	  was	  observed	  at	  higher	  doses.	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SUMMARY	  Throughout	  this	  chapter	  the	  roles	  of	  ROS	  in	  PDT	  and	  PCI,	  have	  been	  investigated	  in	   order	   to	   determine	   which	   variables	   exert	   the	   greatest	   influence	   on	   the	  relationship	   between	   the	   two	   technologies.	   The	   findings	   certainly	   do	   not	  support	   the	   theory	   that	   PDT	   and	   PCI	   are	   mutually	   exclusive.	   Rather,	   they	  highlight	  that	  certain	  variables	  play	  a	  vital	  role	  in	  determining	  what	  proportion	  of	  cell	  killing	  will	  be	  attributable	  to	  PDT	  or	  PCI.	  Furthermore,	  a	  recurrent	  theme	  throughout	   the	  results	  was	   that	  SAP-­‐PCI	   regimen	  appears	   to	  superior	   to	  MTX-­‐PCI	   despite	   the	   inherent	   toxicity	   of	   MTX.	   This	   important	   observation	  demonstrates	   the	   potential	   of	   PCI	   with	   regard	   to	   enhancing	   the	   efficacy	   of	   a	  drug.	  However,	  it	  must	  be	  noted	  that	  clearly	  in	  this	  thesis	  the	  magnitude	  of	  such	  an	  effect	  is	  dependent	  on	  the	  compound	  to	  be	  internalised.	  	  The	  process	  of	  p hotosensitiser	  activation	  is	  an	  energy	  transfer	  process,	  whereby	  visible/non-­‐visible	  light	  energy	  is	  converted	  into	  ROS	  with	  subsequent	  physical	  and	   chemical	   damage	   to	   cellular	   structures	   resulting	   in	   potential	   organelle	  disruption,	  vesicle	  rupture	  and/or	  cell	  death.	  	  	  It	  would	  appear	  that	  the	  three	  most	  important	  determinants	  for	  PDT	  versus	  PCI	  are:	  1. Light	  dose	  2. Photosensitiser	  dose	  3. Immediate	  versus	  delayed	  illumination	  (1)	  and	  (3)	  are	  of	  significant	  importance	  with	  regard	  to	   optimising	  the	  PCI	  effect.	  If	  the	  light	  dose	  is	  too	  high,	  PDT	  will	  inevitably	  predominate	  as	  the	  probability	  of	  activating	   the	   p hotosensitiser	   increases,	   and	   in	   these	   studies,	   this	   does	   not	  appear	  to	  be	  proportionate	  as	  illustrated	  by	  the	  ‘step’	  in	  cytotoxicity	  seen	  at	  180	  seconds	   illumination.	   Delaying	   the	   time	   to	   illumination	   is	   vital	   for	   PCI.	   The	  location	  and	  density	  of	   the	  p hotosensitiser	  at	   time	  of	  photo-­‐activation	   (2)	  and	  (3)	   will	   ultimately	   determine	   whether	   ROS	   production	   is	    localised	   within	  specific	   cellular	   compartments	   such	   as	   endocytic	   vesicles	   (favouring	   PCI)	   or	  indiscriminately	  throughout	  the	  cell	  (favouring	  PDT).	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Altering	   the	   REDOX	   environment	   appears	   to	   mainly	   benefit	   fine-­‐tuning	   the	  technique.	  BSO	  and	  other	  ROS	  facilitators	  may	  have	  a	  role	  to	  play	  in	  enhancing	  the	   PCI	   and/or	   PDT	   effect,	   particularly	  when	  maximum	   cell	   kill	   is	   the	   desired	  outcome.	   BSO	   is	   already	   utilized	   in	   the	   clinical	   arena	   to	   help	   reverse	   drug	  resistance	  driven	  by	  enhanced	  cellular	  robustness	  to	  oxidative	  damage.	  	  Photochemical	    internalisation	   as	   a	   tool	   for	   enhanced	   in	   vitro	   drug	   delivery	  certainly	  merits	  further	  investigation.	  By	  facilitating	  drug	  delivery	  in	  cancer,	  PCI	  has	  the	  potential	  to:	  	  1. Circumvent	   multi	   drug	   resistance:	   this	   has	   been	   demonstrated	   by	   multiple	  groups.	   The	   ‘early’	   release	   of	   endocytosed	   drug	   helps	   negate	   resistance	  mechanisms	  including	  enzymatic	  degradation	  and	  increased	  drug	  efflux.	  2. Reduced	   systemic	   toxicity:	    localised	   drug	   activation	  will	   reduce	   systemic	   side	  effects.	  3. Widen	   the	   therapeutic	   index	   of	   drugs:	   this	   is	   particularly	   important	   as	   many	  cytotoxic	  agents	  have	  very	  narrow	  therapeutic	  windows.	  By	  enabling	  clinicians	  to	  start	  drugs	  at	  lower	  doses	  (but	  with	  comparable	  therapeutic	  effect)	  PCI	  could	  have	  a	  particularly	  significant	  impact	  in	  cancer	  therapeutics.	  Strategies	  such	  as	  enhancing	  the	  oxidative	  state	  of	  the	  cell	  could	  further	  improve	  this	  effect.	  	  The	  possible	   limitations	  of	  PCI	  mainly	  centre	  on	   the	   time	  and	   labour	   intensive	  process	   of	    optimisation.	   There	   are	   significant	   variations	   in	   treatment	   success	  with	   varying	   agents	   both	   p hotosensitiser	   and	   cytotoxin.	   However,	   strategies	  such	   as	   those	   described	   in	   this	   chapter	  may	   help	   the	   development	   of	   greater	  understanding	   of	   the	   mechanisms	   that	   underpin	   PCI.	   Consequently,	   more	  reproducible	  protocols	  may	  be	  developed	  for	  PCI.	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SCIENTIFIC	  BACKGROUND	  AND	  AIMS	  Conventional	   chemotherapeutic	   agents	   have	   been	   the	   mainstay	   of	   cancer	  therapeutics	   for	   many	   years.	   	   The	   narrow	   therapeutic	   windows	   of	  mutagens/cytotoxic	   agents	   designed	   to	   induce	   DNA	   damage	   has	   limited	   the	  effectiveness	  and	  successes	  of	  such	  anticancer	  regimens.	  Consequently,	  the	  last	  20	   years	   has	   seen	   the	   advent	   of	   a	   range	   of	   targeted	   and/or	   non-­‐mutagenic	  agents,	  which	   are	   targeted	   against	   the	  underlying	   cellular	   abnormality	  driving	  the	   malignancy.	   	   The	   monoclonal	   antibody	   trastuzumab	   targets	   the	  constitutively	   active	   erbB2	   receptor	   in	   breast	   cancer;	   imatinib	   targets	   the	  constitutively	  active	  tyrosine	  kinase	  that	   is	   formed	  following	  the	  bcr-­‐abl	  fusion	  (t9:22)	  in	  chronic	  myeloid	  leukaemia.	  	  Other	  forms	  of	  targeted	  therapies	  that	  are	  being	   investigated	   in	   pre-­‐clinical	   and	   clinical	   settings	   include	   photosensitive	  compounds	  such	  as	  quantum	  dots(143).	  	  	  One	  of	   the	  major	  obstacles	   faced	  when	  developing	  novel	   therapeutic	  agents	   in	  oncology	  is	  to	  synthesize	  a	  molecule	  that	  can	  achieve	  efficient	  uptake	  within	  the	  target	   tissue.	   Therapeutic	   proteins	   and	   peptides	   are	   a	   good	   example	   of	   novel	  agents,	  which	  based	  on	  structure	  habitually	  suffer	  from	  inefficient	  transport	  into	  the	   cytoplasm	   and	   subsequently	   a	   blunted	   therapeutic	   effect.	   Mechanisms	  developed	   to	   enhance	   the	   delivery	   of	   peptides	   include	   microinjection	   and	  complexing	  with	  membrane-­‐permeablising	  agents	  such	  as	   lipids(48).	  However,	  the	   former	   is	   limited	   by	   time-­‐	   and	   labour-­‐intensity	   whereas	   the	   latter	  technologies	   are	  not	  uncommonly	   toxic	   to	   cells.	  A	  well	   known	   solution	   to	   this	  problem	   is	   the	   use	   of	   protein	   transduction	   domains	   (PTDs),	   which	   are	   short	  peptides	   that	   can	   be	   used	   for	   classical	   endocytosis-­‐independent	   ferrying	   of	  larger	  molecules	  across	  the	  cell	  membrane	  and	  into	  the	  cytoplasm(144).	  These	  PTDs	   are	   known	   to	   bind	   commonly	   expressed	   cell	   surface	   markers	   including	  Heparan	  Sulphate	  Proteoglycans,	  thus	  their	  potential	  use	  across	  many	  different	  cell	   types	  make	   them	  a	  very	  useful	  delivery	   tool.	   Some	  of	   the	  more	  commonly	  used	   PTDs	   include	   the	   basic	   region	   of	   HIV-­‐1	   Tat	   peptide,	   third	   helix	   of	  antennapedia	  homeodomain	  (penetratin)(145,	  146).	  A	  benefit	  of	  many	  PTDs	  is	  that	  that	  they	  are	  able	  to	  interact	  with	  membranes	  owing	  to	  the	  multiple	  basic	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amino	   acid	   residues	   in	   their	   structure,	   which	   affords	   them	   amphipathic	  properties.	   The	   first	  major	   PTD-­‐conjugate	  was	   the	   Tat	   fusion	   protein	   used	   to	  deliver	   β-­‐galactosidase	   to	   multiple	   organs	   in	   murine	   models(147).	   This	  demonstrated	  the	  effectiveness	  of	  PTDs,	  in	  particular	  HIV-­‐1	  Tat,	  to	  facilitate	  the	  delivery	  of	  a	  protein	  into	  cells.	  Li	  et	  al	  (2006)(148)	  have	  reported	  on	  the	  use	  of	  antennapedia	  homeodomain	  to	  facilitate	  the	  transduction	  of	  rat	  brains	  with	  the	  anti	  apoptotic	  X-­‐linked	  inhibitor	  of	  apoptosis	  protein	  (XIAP)	  to	  reduce	  cell	  death	  following	  brain	  injury	  induced	  by	  seizures.	  The	  observations	  of	  the	  group	  led	  to	  their	   conclusion	   that	  PTD-­‐XIAP	  provides	   a	  neuroprotective	   effect	   versus	  brain	  injury.	  Another	  example	  of	  the	  use	  of	  PTDs,	  in	  this	  case	  HIV-­‐1	  Tat,	  is	  shown	  by	  Choi	  et	  al.	  (2006)(149)	  who	  demonstrated	  that	  a	  wild-­‐type	  Tat-­‐alpha-­‐synuclein	  fusion	  protein	  (produced	  from	  bacteria)	  was	  able	  to	  attenuate	  paraquat	  induced	  cell	  death	  in	  astrocytes	  in	  vitro	  and	  in	  vivo.	  The	  mechanism	  is	  believed	  to	  involve	  the	  anti-­‐oxidant	  properties	  associated	  with	   increased	  expression	  of	  heat	  shock	  protein-­‐70	  (HSP70).	  This	  is	  thought	  to	  be	  of	  potential	  benefit	  for	  the	  prevention	  of	  cell	  death	  in	  the	  basal	  ganglia	  in	  Parkinson’s	  disease.	  	  In	   all	   the	   examples	   given	   above	   PTDs	   were	   able	   to	   significantly	   enhance	   the	  delivery	  of	  their	  ‘cargo’	  in	  to	  the	  cell	  and	  consequently	  to	  their	  target	  of	  action.	  	  
4.1 Small-­‐molecule	  Carriers	  (SMoCs)	  	  The	  minimal	  size	  and	  molecular	  weight	  of	  SMoCs	  affords	  them	  the	  added	  benefit	  of	  avoiding	  the	  intracellular	  biodegradation	  processes	  to	  which	  peptide	  linkers	  may	  be	  subjected.	  A	  further	  benefit	  of	  SMoCs	  is	  that	  they	  are	  able	  to	  react	  with	  native	  proteins,	  thus	  these	  can	  be	  delivered	  into	  the	  cell	  without	  need	  for	  further	  processing	  and	  without	  disruption	  of	  protein	  function	  (fig.	  4.1).	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Figure	  4.1	  –	  Molecular	  modeling	  of	  SMoCs.	  	  
A	  Molecular	  model	  of	  a	  typical	  alpha	  helix	  overlaid	  with	  a	  biphenyl	  ring	  from	  a	  SMoC.	  B	  The	   amphipathic	   nature	   of	   the	   helix	   mimic	   2G-­‐SmoC	   is	   shown	   to	   the	   alpha	   helix	   of	  antennapedia	   44-­‐57	   (penetratin).	   (Okuyama	   et	   al.,	   2007)(48).	   C	   The	   molecular	  structure	   of	   4G-­‐BfSMoC-­‐COOH	   (69)(4G-­‐SmoC).	   The	   amino	   groups	   provide	   potential	  reactive	  domains	  to	  enable	  coupling	  with,	  for	  example,	  proteins	  for	  transport.	  	  	  SMoCs	  have	  been	  shown	  to	  be	  effective	  in	  facilitating	  the	  delivery	  of	  a	  range	  of	  molecules	   including	   dyes,	   proteins(148)	   and	   siRNA(47,	   69).	   Okuyama	   et	   al.	  (2007)(48)	  complexed	  di-­‐guanidine	  (2G-­‐SmoC)	  and	  tetra-­‐guanidine	  (4G-­‐SmoC)	  with	  fluorescein	  (FITC)	  to	  assess	  uptake	  in	  U2OS	  osteosarcoma	  cells.	  Using	  Tat-­‐FITC	   and	   FITC	   alone	   as	   comparators	   the	   group	   observed	   that	   at	   low	  magnification	   SMoC-­‐FITC	   treated	   cells	   appeared	   strongly	   fluorescent	   and	   this	  was	  comparable	  to	  Tat-­‐FITC;	  cells	  treated	  with	  FITC	  alone	  were	  not	  fluorescent.	  The	  same	  group	  went	  on	  to	  demonstrate	  the	  ability	  of	  SMoCs	  to	  enhance	  uptake	  of	   protein	   based	   molecules.	   They	   coupled	   4G-­‐SmoC	   to	   the	   relatively	   large	  (23.5kDa)	   protein,	   Geminin,	   which	   blocks	   DNA	   replication	   licensing	   by	  competitively	   binding	   Cdt1(150).	   Using	   an	   Alexa-­‐fluorophore	   (488),	   they	  showed	  that	  4G-­‐SmoC	  enhanced	  the	  overall	  uptake	  of	  Geminin	  with	  perinuclear	  and	   nuclear	   accumulation.	   The	   uptake	   of	   SMoCs	   was	   assessed	   using	   reduced	  temperature	   (4°C)	   incubation	   and	   a	   range	   of	   inhibitors	   for	   differing	   endocytic	  pathways.	   The	   group	   concluded	   that	   SMoCs	   alone	   are	   taken	   up	   in	   an	   energy-­‐
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dependent	   but	   endocytosis-­‐independent	  manner.	   However	   4G-­‐SmoC-­‐Geminin-­‐Alexa	   488	   was	   dependent	   upon	   clathrin-­‐mediated	   endocytosis	   (therefore	   an	  active	  process).	  These	  findings	  demonstrate	  the	  versatility	  of	  SMoCs	  with	  regard	  to	  their	  mechanism	  of	  facilitated	  cell	  entry,	  both	  with	  and	  without	  ‘cargo’.	  SMoCs	  have	  also	  been	  used	  to	  enhance	  siRNA	  delivery	  in	  to	  cancer	  cells(69).	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RESULTS	  
4.2	  SMoC	  enhanced	  siRNA	  transfection	  observed	  using	  fluorescent	  siRNA	  
oligomers	  This	   study	   was	   performed	   to	   test	   the	   null	   hypothesis	   that	   4G-­‐BfSMoC-­‐COOH	  does	  not	  enhance	   the	  siRNA	  transfection	   in	  MCF-­‐7	  (human)	  and	  4T1	  (murine)	  breast	  cancer	  cells.	  In	  order	  to	  monitor	  the	  level	  of	  transfection	  in	  a	  manageable	  way	   within	   our	   lab,	   an	   Alexa	   Fluor®	   555-­‐labelled	   siRNA	   oligonucleotide	   was	  used,	   with	   uptake	   and	    localisation	  monitored	   using	   confocal	   microscopy.	   The	  findings	  of	  this	  study	  have	  undergone	  peer-­‐reviewed	  publication(69).	  	  Controls	   for	   SMoC	   facilitated	   uptake	   (siRNA-­‐588	   alone)	   showed	   undetectable	  uptake	  within	  the	  4T1	  cell	  line	  (fig.	  4.2a)	  and	  non-­‐significant	  uptake	  in	  the	  MCF-­‐7	   cell	   line	   (fig.	   4.2b).	   For	   negative	   controls	   with	   SMoC	   alone,	   no	   fluorescent	  signal	  was	  detected,	  suggesting	  that	  the	  background	  uptake	  of	  siRNA-­‐588,	  albeit	  not	  significant,	  seen	  with	  the	  MCF-­‐7	  cell	  line	  is	  likely	  to	  be	  a	  cell	  type-­‐dependent	  process.	  	  	  Treatment	  of	  cells	  with	  10	  μM	  4G-­‐BfSMoC-­‐COOH	  resulted	  in	  a	  4.9-­‐fold	  (p<0.01)	  increase	   in	   the	   fluorescent	   signal	   for	   the	   siRNA-­‐588	   (4T1	   cells),	   indicating	  significantly	   increased	   uptake.	   In	   addition,	   nuclear	   accumulation	   was	   also	  observed	  in	  the	  4T1	  cell	  line	  (fig.	  4.2c).	  	  There	  is	  also	  increased	  uptake	  in	  the	  MCF-­‐7	  cell	  line	  albeit,	  at	  2.6-­‐fold	  (fig.	  4.2d,	  p<0.01)	   compared	   to	   siRNA-­‐588	   alone,	   somewhat	   of	   a	   lesser	   effect	   than	  observed	   in	   the	   4T1	   cell	   line;	   indicating	   a	   that	   uptake	   of	   siRNA-­‐588	   with	   or	  without	   SMoC	   is	   likely	   to	   be	   a	   cell	   specific	   process.	   For	   the	   purpose	   of	  comparison	  the	  gold	  standard	  transfection	  reagent,	  Lipofectamine®,	  was	  used	  in	  place	  of	  SMoC.	  14.4-­‐fold	  (p<0.01)	  increased	  uptake	  of	  siRNA-­‐588	  is	  observed	  in	  the	  4T1	  cell	  line;	  a	  3.3-­‐fold	  (p<0.01)	  increase	  is	  observed	  in	  the	  MCF-­‐7	  cell	  line.	  Nuclear	  uptake	  is	  observed	  in	  both	  cells	  lines	  (white	  arrows).	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Figure	  4.2	  –	  Cellular	  uptake	  of	  fluorescent	  siRNA.	  	  Confocal	  microscopy	  of	  cells	  treated	  with	  AlexaFluor®	  Red	  Fluorescent	  Oligonucleotide	  +/-­‐	   4G-­‐BfSMoC-­‐COOH.	   Cells	   were	   treated	  with	   oligonucleotide-­‐fluorophore	   alone	   –	  A	  4T1	  and	  B	  MCF7;	  or	  treated	  with	  oligonucleotide-­‐fluorophore	  (1.0	  µM)	  –	  4G-­‐Bf-­‐SmoC-­‐COOH	  (10	  µM)	  –	  C	  4T1	  and	  D	  MCF-­‐7	  or	  oligonucleotide	  (1.0	  µM)	  plus	  Lipofectamine	  –	  E	  4T1	  and	  F	  MCF-­‐7.	  Quantitative	  analysis	  of	  the	  relative	  cellular	  uptake	  demonstrates	  that	  addition	  of	  the	  4G-­‐BfSMoC-­‐COOH,	  resulted	  in	  4.9-­‐fold	  (p<0.01)	  increased	  uptake	  of	  the	  oligonucleotide-­‐fluorophore	  (siRNA)	   in	   the	  4T1	  cells;	  and	  a	  2.6-­‐fold	   (p<0.01)	   increase	  in	  the	  MCF7	  cell	  line.	  There	  was	  evidence	  of	  nuclear	  uptake	  in	  the	  4T1	  cell	  line	  (C,	  white	  arrow).	  In	  cells	  treated	  with	  Lipofectamine	  plus	  siRNA,	  we	  observed	  14.4-­‐fold	  and	  3.3-­‐fold	   increase	   uptake	   in	   4T1	   and	   MCF-­‐7	   cell	   lines	   respectively.	   There	   was	   significant	  nuclear	   uptake	   in	   both	   cell	   lines	   following	   treatment	   with	   Lipofectamine	   (D	   and	   E,	  white	  arrows).	  The	  differing	  level	  of	  background	  uptake	  (siRNA-­‐alone)	  is	   likely	  due	  to	  the	  differing	   characteristics	   of	   the	   two	   cell	   lines	   including	  doubling	   times	   and	  uptake	  kinetics.	   Ex	   559	   nm,	   Em	   572	   nm,	   60X	   NA:1.35	   Objective	   Lens,	   zoom	   x1.0,	   scale	   20	  
microns(69).	  
	  The	  observed	   results	   showed	   that	   in	   the	  4T1	  cell	   line,	  Lipofectamine	  achieved	  1.9-­‐fold	   greater	   siRNA	   uptake	   compared	   to	   SMoC,	   which	   in	   turn	   facilitated	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significantly	   greater	   uptake	   than	   siRNA	   alone.	   In	   the	   MCF-­‐7	   cell	   line,	   this	  differential	  reduced	  to	  a	  0.3-­‐fold	  increase	  in	  uptake	  for	  Lipofectamine	  compared	  to	  SMoC.	  
4.3	  Photochemical	  Internalisation	  of	  4G-­‐BfSMoC-­‐COOH	  –	  siRNA	  
oligonucleotide	  complex.	  Given	   the	   results	   in	   the	   siRNA-­‐588	   uptake	   study	   above,	   the	   following	   set	   of	  experiments	  were	  carried	  out	  to	  determine	  if	  TPPS2a	  based	  PCI	  could	  be	  used	  to	  enhance	   the	   SMoC-­‐facilitated	   uptake	   of	   siRNA-­‐588	   in	   the	  MCF-­‐7	   cell	   line.	   The	  observations	  presented	  by	  Okuyama	  et	  al.	  (2007)(48)	  demonstrated	  that	  SMoCs	  could	  facilitate	  various	  modes	  of	  active	  uptake	  including	  endocytosis.	  Thus,	  the	  null	   hypothesis	   to	   test	   is	   PCI	   does	   not	   enhance	   the	   intracellular	   delivery	   4G-­‐BfSMoC-­‐COOH	  –	  siRNA	  complex.	  	  MCF-­‐7	   cells	  were	   treated	  with	   a	   combination	   of	  4G-­‐BfSMoC-­‐COOH	  –	   siRNA-­‐588	  
complex	  (final	  concentration	  of	  SMoC	  10	  μM	  and	  siRNA	  1	  μM)	  for	  24	  hours	  prior	  to	  washing	   and	   a	   4-­‐hour	   re-­‐incubation	   in	  media	   alone.	   Cells	   were	   given	   a	   15	  second	  exposure	  to	  a	  405	  nm	  laser	  (as	  a	  negative	  control	  for	  PCI	  to	  ensure	  the	  laser	   alone	   did	   not	   affect	   the	   signal	   intensity	   or	   distribution	   of	   cytoplasmic	  siRNA-­‐588).	   Confocal	   Images	   were	   taken	   prior	   to	   laser	   treatment	   (fig.	   4.3a),	  immediately	  after	  (fig.	  4.3b),	  300	  seconds	  after	  (fig.	  4.3c),	  and	  a	  final	  image	  600	  seconds	   after	   laser	   treatment.	   Visually	   there	   appeared	   to	   be	   little	   if	   any	  significant	  change	  in	  the	  signal	  intensity	  or	  distribution.	  	  Quantitative	  analysis	  found	  that	  there	  was	  <10%	  reduction	  in	  signal	  intensity	  at	  600	  seconds	  post	  laser	  treatment.	  This	  suggests	  that	  there	  is	  no	  significant	  effect	  exerted	   by	   laser	   alone	   on	   the	   siRNA-­‐588	   signal.	   The	   addition	   of	   TPPS2a	   (0.4	  µg/ml)	  enabled	  assessment	  of	  the	  impact	  of	  PCI	  on	  the	  overall	  cellular	  uptake	  of	  siRNA-­‐588,	  in	  the	  presence	  of	  4G-­‐BfSMoC-­‐COOH.	  The	  same	  experimental	  format	  was	  used	  as	  for	  that	  described	  in	  figure	  4.3.	  The	  first	  observation	  to	  make	  is	  that	  the	   intracellular	   localization	   of	   the	   siRNA-­‐588	   appeared	   to	   be	   different	   when	  administered	   with	    photosensitiser	   compared	   to	   without.	   In	   figure	   4.4a,	   the	  intracellular	   distribution	   appears	   to	   be	   juxta-­‐opposed	   to	   the	   membrane,	   in	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comparison	   to	   figure	   4.3a	  where	   there	   is	  more	   diffuse	   spread	   throughout	   the	  cytoplasm.	  
	  
Figure	   4.3	   –	   Intracellular	   distribution	   of	   siRNA	   Alexa-­‐555	   fluorophore	   pre-­‐	   and	  
post-­‐	  405	  nm	  laser	  treatment.	  	  Single	   slice	   confocal	  microscopy	  of	   a	   single	  MCF-­‐7	   cell	   treated	  with	  AlexaFluor®-­‐555	  Red	   Fluorescent	   Oligonucleotide	   +	   4G-­‐BfSMoC-­‐COOH.	   Cells	   were	   treated	   with	  oligonucleotide-­‐fluorophore	  (1	  µM)	  –	  4G-­‐BfSMoC-­‐COOH	  (10	  µM).	  Confocal	  images	  were	  taken	   at	   four	   different	   time	   points:	   A	   –	   Pre	   treatment	   with	   a	   405	   nm	   laser;	   B	   –	  Immediately	  after	  15s	  ‘on-­‐stage’	  exposure	  to	  the	  405	  nm	  laser;	  C	  –	  300	  s	  after	  laser;	  D	  –	  600	  s	  after	   laser.	  Quantitative	  analysis	  using	  ImageJ	  shows	  there	  was	  <10%	  reduction	  in	  the	  signal	  of	  the	  oligonucleotide-­‐fluorophore	  600	  s	  after	  treatment	  with	  the	  405	  nm	  laser.	  	  *	  N	  =	  nucleus.	  Ex	  559	  nm,	  Em	  572	  nm,	  60X	  NA:1.35	  Objective	  Lens,	  zoom	  x1.0,	  scale	  
20	  microns.	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Figure	   4.4	   –	   Intracellular	   distribution	   of	   siRNA	   Alexa-­‐588	   fluorophore	   pre-­‐	   and	  
post-­‐	  PCI	  treatment.	  	  Single	   slice	   confocal	   microscopy	   of	   two	   MCF-­‐7	   cells	   treated	   with	   AlexaFluor®	   Red	  Fluorescent	  Oligonucleotide	  –	  4G-­‐BfSMoC-­‐COOH	  complex	  +	  TPPS2a.	  Cells	  were	   treated	  with	  oligonucleotide-­‐fluorophore	   (1	  μM)	  –	  4G-­‐BfSMoC-­‐COOH	  (10	  μM)	  plus	  TPPS2a	  0.4	  µg	   ml-­‐1	   for	   24h.	   Confocal	   images	   were	   taken	   at	   four	   different	   time	   points:	   A	   –	   Pre	  treatment	  with	  a	  405	  nm	  laser;	  B	  –	  Immediately	  after	  15s	  ‘on-­‐stage’	  exposure	  to	  the	  405	  nm	  laser;	  C	  –	  300	  s	  after	  laser;	  D	  –	  600	  s	  after	  laser	  (scale	  =	  20	  microns).	  	  Quantitative	  analysis	   using	   ImageJ	   shows	   there	   was	   a	   0.5-­‐fold	   reduction	   in	   the	   signal	   of	   the	  oligonucleotide-­‐fluorophore	  and	  a	  simultaneous	  0.23-­‐fold	  rise	  in	  nuclear	  uptake,	  600	  s	  after	   treatment	   with	   the	   405	   nm	   laser.	   *	   N	   =	   nucleus.	   Ex	   559	   nm,	   Em	   572	   nm,	   60X	  
NA:1.35	  Objective	  Lens,	  zoom	  x1.0,	  scale	  20	  microns.	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However,	   what	   is	   consistent	   is	   that	   the	   internalized	   siRNA	   appear	   to	   be	  distributed	   in	  discrete	   vesicles,	  which	   is	   consistent	  with	   an	   endocytic	   process.	  Evaluation	  of	  the	  signal	  intensities	  across	  the	  four	  time	  points	  before	  and	  after	  application	  of	  the	  405	  nm	  laser,	  indicate	  the	  following:	  
• There	   was	   a	   steady	   decline	   of	   the	   mean	   signal	   intensity	   as	   time	  progressed	   following	   exposure	   to	   the	   405	   nm	   laser.	   Specifically,	   a	   0.5-­‐fold	  reduction	  was	  observed	  at	  600	  seconds	  post-­‐laser	  (fig.	  4.4b)	  compared	  to	  pre-­‐laser	  (fig.	  4.4a).	  
• There	  is	  a	  loss	  of	  signal	  from	  the	  ‘vesicular’	  structures	  that	  are	  seen	  in	  the	  cytoplasm	  (red	  arrows,	  fig.	  4.4).	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DISCUSSION	  The	  main	  aim	  of	  this	  study	  was	  to	  determine	  if	  PCI	  can	  enhance	  SMoC-­‐facilitated	  siRNA	  delivery	  in	  breast	  cancer	  cells.	  Previous	  work	  has	  demonstrated	  that	  both	  techniques	  can	  be	  used	  to	  facilitate	  in	  vitro	  delivery	  of	  genetic	  material.	  Bonsted	  et	   al.	   (2004)(151)	   used	   TPPS2a	   to	   mediate	   photochemical	    internalisation	   of	  adenovirus	   serotype	   5	   (Ad5)-­‐vectored	   gene	   transfection.	   The	   group	   reported	  that	   when	   complexed	   with	   poly-­‐L-­‐lysine	   and	   Superfect®,	   PCI-­‐mediated	   Ad5-­‐vectored	   gene	   transfection	   achieved	   “a	   substantial	   increase	   in	   reporter	   gene	  expression”	  with	   a	  maximum	  of	   75%	  positive	   cells	   (using	   flow	   cytometry).	   In	  this	   study	   PCI	   appears	   to	   have	   a	   beneficial	   effect	   on	   the	   overall	   transfection	  efficiency	  of	  the	  SMoC-­‐siRNA	  complex.	  The	  finding	  that	  the	  405	  nm	  laser-­‐alone	  does	  not	  appear	  to	  have	  a	  significant	  effect	  on	  the	  fluorescent	  signal	  of	  siRNA	  is	  important	   with	   regard	   to	   interpretation	   of	   the	   results	   for	   PCI.	   The	   vesicular	  pattern	   of	   distribution	   within	   the	   cytoplasm	   was	   promising,	   with	   regard	   to	  suitability	   for	   PCI	   as	   it	  was	   consistent	  with	   an	   endocytic	  mode	   of	   uptake	   and	  subsequent	  trafficking	  into	  the	  endo-­‐lysosomal	  pathway	  as	  described	  in	  chapter	  3.	  	  	  The	   residual	   level	   of	   background	   uptake	   for	   4G-­‐BfSMoC-­‐COOH	   –	   siRNA-­‐588	  complex	   appeared	   to	   be	   a	   cell	   specific	   process.	   This	   is	   likely	   to	   be	   a	   multi-­‐factorial	   effect.	   Overall,	   it	   appeared	   that	   the	   4T1	   cells,	   under	   the	   chosen	  experimental	   conditions	   including	  drug	  dose,	  were	   less	   able	   to	   internalize	   the	  siRNA-­‐588	   (fig.	   4.2a	   and	   4.2b).	   Consequently,	   the	   facilitating	   effect	   of	   SMoC	  appeared	  more	   pronounced	   in	   the	   4T1	   cells	   compared	   to	   the	  MCF-­‐7	   cell	   line.	  Possible	  explanations	   for	  this	  could	   include	  the	  two	  cell	   lines	  express	  different	  cell	   surface	   receptors;	   have	   differing	   preferences	   for	   modes	   of	   uptake	   for	  exogenous	  compounds;	  are	  able	  to	  degrade	  or	  efflux	  the	  siRNA	  at	  different	  rates.	  The	  second	  explanation	  is	  particularly	  interesting	  where	  SMoC-­‐assisted	  delivery	  is	   concerned	   owing	   to	   previously	   described	   evidence	   by	   Okuyama	   et	   al.	  (2007)(48)	   whereby	   SMoCs	   are	   able	   to	   support	   multiple	   forms	   of	   energy-­‐dependent	   uptake.	   If	   for	   example,	   one	   form	   of	   uptake	   is	   better	   suited	   to	   a	  particular	  SMoC	  than	  another	  then	  this	  may	  lead	  to	  a	  discrepancy	  in	  effect	  when	  comparing	  two	  separate	  cell	   lines.	  However,	   it	  could	  also	  be	  that	  the	  relatively	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good	   level	   of	   background	   uptake	   seen	   in	   the	   MCF-­‐7	   cell	   line	   means	   that	   any	  SMoC	   effect	   is	   likely	   to	   appear	   blunted	   versus	   the	   relatively	   poor	   background	  uptake	   in	   the	   4T1	   cell	   line.	   Nuclear	    	   mobilisation	   of	   siRNA	   is	   an	   important	  finding	   as	   this	   is	   where	   its	   effect	   will	   be	   exerted,	   thus	   it	   is	   relevant	   that	   4g-­‐BfSMoC-­‐COOH	  triggered	  nuclear	    mobilisation	  at	  the	  time-­‐point	  measured	  in	  the	  study	  (fig.	  4.2c	  and	  4.2d).	  Lipofectamine	  presents	  an	  interesting	  comparator	  to	  SMoC	   as	   a	   means	   to	   enhance	   gene	   transfection	   in	   both	   mechanism	   and	  efficiency.	   Lipofectamine	   comprises	   a	   cationic	   liposomal	   structure,	   which	   via	  complexing	  with	  anionic	  nucleic	  acid	  enables	  it	  to	  overcome	  the	  repulsive	  forces	  exerted	   by	   interaction	   with	   phospholipid	   bilayer(152).	   In	   doing	   so	  Lipofectamine	   achieves	   gold-­‐standard	   level	   of	   gene	   expression.	   This	   is	  supported	   by	   the	   findings	   in	   this	   study,	   whereby	   Lipofectamine	   facilitated	  increased	  uptake	  in	  4T1	  cells	  (1.9	  times)	  compared	  to	  SMoC.	  Interestingly,	  this	  differential	  was	  significantly	  reduced	  to	  0.3-­‐times	  increase	  in	  the	  MCF-­‐7	  cell	  line,	  which	  suggests	  that	  SMoC	  in	  this	  cell	  line	  may	  be	  very	  effective.	  In	  both	  cell	  lines,	  there	   was	   an	   increase	   in	   nuclear	    	   mobilisation	   and	   accumulation,	   which	   was	  particularly	   pronounced	   in	   the	   MCF-­‐7	   cell	   line.	   Overall,	   4G-­‐BfSMoC-­‐COOH	  appeared	  to	  significantly	  enhance	  the	  uptake	  of	  siRNA	  in	  both	  cell	   lines.	   In	  the	  case	  of	   the	  MCF-­‐7	  cell	   line,	   this	  appeared	   to	  be	  comparable	   to	   the	   transfection	  efficiency	  achieved	  by	  Lipofectamine.	  	  One	   of	   the	   main	   considerations	   that	   may	   limit	   the	   use	   of	   PCI	   as	   a	   means	   to	  enhance	   the	   delivery	   of	   non-­‐robust	   compounds,	   including	   genetic	   material,	   is	  the	   potential	   for	   ROS	   damage	   due	   to	   proximity	   at	   the	   time	   of	    photosensitiser	  activation.	   Although	   in	   this	   series	   of	   experiments,	   gene	   expression	   was	   not	  measured	  as	  a	  marker	  of	  successful	  transfection,	  fluorescent	  signal	  intensity	  and	   localisation	  were	   used	   as	   surrogate	  markers.	   Therefore,	   the	   lack	   of	   change	   in	  signal	   intensity	   or	   distribution	   following	   cell	   exposure	   to	   the	   405	   nm	   laser	   is	  important	  as	  it	  enables	  interpretation	  of	  gene	  delivery	  if	  the	  assumption	  is	  made	  that	   the	   siRNA	   ‘survives’	   exposure	   to	   the	   laser	  at	   the	  dose	  utilized.	  This	   is	   the	  main	   reason	   0.4	   µg/ml	   of	   TPPS2a	   was	   chosen	   for	   this	   set	   of	   experiments.	   The	  results	   from	   the	  PCI	   study	   indicate	   that	  upon	  activation	  of	   the	    photosensitiser	  there	   was	   evidence	   of	   cytoplasmic	   redistribution	   and	   increased	   nuclear	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accumulation.	   The	  mechanism	   for	   PCI	   as	   described	   by	   Adigbli	   and	  MacRobert	  (2012)(26)	  is	  supported	  in	  this	  study	  by	  the	  apparent	  loss	  of	  signal	  observed	  in	  some	   of	   the	   vesicular	   ‘clumps’	   as	   shown	   by	   the	   red	   arrows	   (fig.	   4.4).	   This	  indicated	   that	   p hotosensitiser	   activation	   might	   lead	   to	   rupture	   of	   the	   endo-­‐lysosomal	  membranes	  and	  subsequent	  release	  of	  siRNA	  into	  the	  cytoplasm	  and	  facilitation	   of	   delivery	   into	   the	   nucleus.	   One	   area	   that	   was	   not	   adequately	  investigated	   during	   this	   study	   was	   whether	   the	   presence	   of	   TPPS2a	   in	   the	  absence	   of	   light	   would	   enhance	   SMoC-­‐siRNA	   delivery.	   	   Although	   the	   level	   of	  increased	  nuclear	  uptake	  was	  not	  spectacular,	  it	  must	  be	  taken	  into	  account	  that	  the	  majority	  of	  PCI	  experiments	  in	  this	  thesis	  are	  assayed	  at	  least	  24	  hours	  after	  initial	   activation	   of	   the	    photosensitiser.	   Therefore,	   it	   would	   be	   important	   to	  follow	   this	   up	   and	   perform	   confocal	   imaging	   at	   later	   time-­‐points.	   Another	  important	   point	   of	   note	   is	   that	   cellular	   integrity	   appears	   to	   be	   preserved	  following	  405	  nm	  laser	   treatment.	  Pilot	  studies	  using	   longer	  durations	  of	   laser	  exposure	   were	   associated	   with	   cellular	   swelling	   and	   death.	   Overall,	   there	  appears	  to	  be	  insufficient	  evidence	  at	  present	  to	  justify	  the	  rejection	  of	  the	  null	  hypothesis.	  However,	  at	  the	  very	  least	  the	  evidence	  is	  consistent	  with	  PCI	  having	  an	  enhancing	  effect	  on	  SMoC-­‐facilitated	  delivery	  of	  siRNA	  in	  breast	  cancer	  cells.	  The	  findings	  also	  support	  an	  endocytic	  process	  of	  SMoC-­‐siRNA	  uptake	  and	  at	  the	  very	   least	   makes	   this	   an	   intriguing	   target	   for	   PCI	   based	   therapy.	   The	  combination	   of	   SMoC	   +	   PCI	   may	   also	   enable	   the	   adoption	   of	   less	   harsh	  conditions	   (ROS)	   as	   a	   similar	   level	   of	   transfection	   or	   drug	   delivery	   may	   be	  achieved	  with	   a	   lesser	   load	   of	   total	   ROS	   production.	   The	   benefits	   would	   be	   a	  lower	   probability	   of	   ROS-­‐mediated	   damage	   to	   the	   compound/drug	   to	   be	   internalised.	  The	  combination	  of	  the	  two	  therapies	  is	  an	  exciting	  prospect	  as	  if	  a	  true	  symbiosis	  exists	  it	  could	  further	  widen	  the	  therapeutic	  windows	  of	  multiple	  agents.	  This	  is	  further	  supported	  by	  the	  versatility	  of	  the	  two	  techniques,	  being	  amenable	   to	  a	   range	  of	   compounds	  and	  molecular	   structures.	  Further	  work	   in	  this	  area	  will	  be	  described	  in	  the	  closing	  summary.	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SCIENTIFIC	  BACKGROUND	  	  The	   tumour	   stroma	   is	   the	   basis	   upon	   which	   a	   micro-­‐collection	   of	   cells	   may	  establish	   preferential	   conditions	   to	   assist	   and	   promote	   tumour	   growth	   and	  progression.	  The	  development	  of	  hypoxia	  within	  this	  environment	  results	  in	  the	  release	   of	   hypoxia-­‐inducible	   factor	   (among	   other	   molecules),	   which	   in	   turn	  results	   in	  the	   increased	  expression	  of	  genes	  that	  will	  promote	  tumour	  survival	  and	   growth.	   These	   include	   growth	   factors	   (fibroblast	   growth-­‐factor	   (FGF),	  vascular	  endothelial	  growth	  factor	  (VEGF),	  colony-­‐stimulating	   factor	  (CSF)	  and	  inflammatory	   cytokines.	   The	   result	   is	   the	   activation	   of	   a	   host	   of	   stromal	   cells	  such	  as	  fibroblasts;	  macrophages	  and	  endothelial	  cells	  that	  can	  help	  the	  micro-­‐tumour	   proliferate,	   whilst	   supplying	   a	   route	   for	   nutrient	   delivery	   and	   waste	  excretion,	   and	   remodeling	   of	   the	   tumour	   mass	   to	   a	   point	   when	   invasion	   and	  metastasis	   become	   possible.	   The	   make	   up	   of	   the	   stroma	   is	   driven	   by	   the	  demands	  of	   the	  malignant	   cells	   and	   capabilities	  of	   the	  host	   tissue,	   resulting	   in	  varying	  ratios	  of	  non-­‐cellular	  components	  of	  the	  stroma	  including	  collagen	  and	  glycoproteins(50).	  	  	  In	   order	   to	   make	   a	   more	   representative	   analysis	   of	   cancer	   cell	   response	   to	  treatment,	   pre-­‐clinical	   researchers	   are	   often	   forced	   to	   opt	   for	   in	   vivo	   studies,	  which	  no	  doubt	  provide	  a	   far	  more	  dynamic	  and	  characteristic	   tumour	  model.	  The	  necessary	  and	  justified	  restrictions	  on	  in	  vivo	  work	  along	  with	  the	  demands	  of	   the	   Animals	   (Scientific	   Procedures)	   Act	   (ASPA)	   1986	   (revised	   2013)	   for	  researchers	   to	   look	   into	   alternative	   modes	   of	   biological	   investigations	   has	  placed	   the	  onus	  on	   scientists	   to	  develop	  new	  models	   that	   can	  at	   least	   act	   as	   a	  bridge	  between	  in	  vitro	  and	  in	  vivo	  studies.	  	  	  The	  bulk	  of	  work	   looking	   into	  alternatives	   to	  2-­‐D	  models	  has	   fallen	  under	   the	  umbrella	   of	   3-­‐D	   scaffolds,	   which	   include	   the	   development	   of	   multicellular	  tumour	   spheroids(153).	   Hirschhaeuser	   et	   al.	   (2010)(154)	   reviewed	   the	  potential	   use	   of	   spheroids,	   stating	   that	   they	   “strikingly	  mirror	   the	   3D	   cellular	  context	   and	   therapeutically	   relevant	   pathophysiological	   gradients	   of	   in	   vivo	  tumors.”	  Another	  strategy	  for	  3D	  modeling	  that	  has	  been	  employed	  is	  growing	  tumours	  in	  tissue-­‐engineered	  structures(155).	  The	  choice	  of	  natural	  or	  synthetic	  
	   156	  
constituents	  for	  the	  matrices	  is	  of	  further	  benefit	  both	  in	  terms	  of	  versatility	  in	  construction	  and	  suitability	   for	  different	  cell	   types.	  The	  non-­‐synthetic	  matrices	  typically	  comprise	  a	  structure	  rich	  in	  the	  trimeric	  glycoprotein	  laminin	  and	  Type	  I	   collagen	   or	   hyaluronic	   acid(155,	   156).	   Laminin	   is	   a	   particularly	   important	  extracellular	   matrix	   (ECM)	   component	   found	   within	   the	   basal	   lamina,	   which	  plays	   an	   important	   role	   in	   multiple	   cell	   functions	   including	   differentiation,	  adhesion,	   motility	   and	   survival(157).	   Therefore,	   a	   matrix	   rich	   in	   such	   a	  glycoprotein	   will	   possess	   many	   of	   the	   structural	   and	   biologically	   active	  characteristics	   necessary	   to	   support	   the	   growth	   of	   a	   3D	   tumour.	   The	  biocompatible	   and	   biodegrading	   polymer,	   polyethylene	   glycol	   (PEG)	   is	  commonly	   used	   in	   synthetic	   matrices(50).	   Such	   constructs	   have	   the	   added	  benefit	  of	  increased	  versatility	  with	  regards	  to	  the	  type	  of	  extra	  molecules,	  such	  as	   RGD	   (Arg-­‐Gly-­‐Asp)	   sequences(158)	   that	   can	   bind	   cell-­‐ECM	   adhesion	  molecules	   such	   as	   integrins.	   Integrins	   are	   a	   group	   of	   essential	   cell	   adhesion	  molecules	   that	  act	  as	  anchors,	   ‘wheels’	  and	  proprioceptors	   for	  cells	  and	  play	  a	  vital	   role	   in	   division,	   survival,	   invasion	   and	   metastasis.	   Such	   attributes	   and	  characteristics	  are	  of	   significant	  benefit	  when	  aiming	   to	  mimic	  or	  simulate	   the	  ‘normal’	  environment	  of	  a	  developing	  tumour.	  Another	  important	  component	  of	  the	   tumour	  stroma	  are	  catalytic	  enzymes	   that	   can	  degrade	   the	  ECM.	  The	  main	  class	   is	   a	   group	   of	   serine	   proteases	   known	   as	   matrix-­‐metalloproteinases	  (MMPs).	  A	  good	  example	  of	  the	  advantage	  of	  synthetic	  matrices	  is	  the	  inclusion	  of	   engineered	   polymers	   with	   specific	   MMP	   sites,	   which	   potentially	   can	   aid	  biodegradation	  and	  remodeling	  of	  the	  stroma(49).	  	  	  The	   different	   types	   of	   matrices	   described	   above	   highlight	   the	   potentially	  positive	   impact	   that	   3D	  models	   could	   have	   in	   the	   fields	   of	   cancer	   biology	   and	  therapeutics.	   The	   flexibility	   and	   versatility	   afforded	   by	   the	   range	   of	   different	  structures,	  in	  theory	  at	  least,	  makes	  it	  possible	  to	  mimic	  a	  small	  tumour	  stroma	  that	  can	  provide	  a	  growing	  mass	  with	  structural	  support,	  a	  reservoir	  of	  growth	  factors	   and	   the	   potential	   to	   embed	   active	   stromal	   cells	   such	   as	   fibroblasts,	  endothelial	   cells	   and	   immune	   cells.	   One	   of	   the	  more	   commonly	   used	   collagen	  matrices	   is	   the	   Type	   I	   collagen	   hydrogel,	   however	   the	   relatively	   high	   water	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content	   of	   the	   gel	   is	   not	   an	   optimal	   model	   for	   tumour	   growth,	   which	   is	  preferentially	  suited	  to	  a	  more	  densely	  packed	  collagen	  scaffold(159).	  	  	  In	  this	  chapter,	  pilot	  studies	  into	  the	  potency	  of	  TPPS2a	  and	  SAP-­‐PCI	  have	  been	  investigated	   using	   a	   3D	   tumour	   model.	   The	   model	   chosen	   was	   based	   on	   the	  plastic	   compression	   model	   first	   described	   by	   Brown	   et	   al.	   (2005)(160).	   This	  method	  is	  a	  forward	  step	  from	  previous	  hydrogel	  matrices	  that	  are	  restricted	  by	  their	   high	   water	   density,	   which	   does	   not	   closely	   mimic	   the	   denser	   collagen	  scaffold	  of	  a	  tumour	  mass.	  To	  negate	  this	  the	  hydrogel	  and	  cellular	  components	  (cancer	   cells	   +/-­‐	   stromal	   cells	   e.g.	   fibroblasts)	   are	   placed	   under	   plastic	  compression	   with	   the	   consequent	   removal	   of	   H2O	   resulting	   in	   shrinkage	  reported	   to	   be	   >100-­‐fold(160).	   This	   technique	   has	   been	   shown	   to	   have	  beneficial	  effects	  for	  closer	  tumour	  mimicking	  including:	  
• Comparable	  cell	  viability.	  
• Increased	   strength	   and	   compliance	   of	   the	   collagen	   matrix,	   associated	  with	  significantly	  increased	  collagen	  density.	  
• Spatial	  heterogeneity	  that	  better	  mimics	  a	  natural	  tumour	  stroma.	  
• Variable	  cell	  and	  matrix	  densities	  throughout	  the	  scaffold,	  which	  again	  is	  a	  closer	  fit	  to	  a	  growing	  tumour	  mass.	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RESULTS	  The	  3D	  tumour	  construct	  (fig.	  5.1)	  was	  grown	  in	  media	   for	  7	  days	  prior	  to	  the	  addition	   of	   either	   TPPS2a	   0.8	   μg/ml	   (PDT),	   SAP	   60	   nM	   (cytotoxin)	   or	   a	  combination	  of	  the	  two	  (PCI)	  and	  treated	  for	  24	  hours	  and	  subsequently	  washed	  and	   re-­‐incubated	   in	   media	   for	   4-­‐hours	   prior	   to	   illumination	   for	   180	   seconds.	  Cytotoxicity	  and	  emission	  spectra	  were	  analysed	  seven	  days	  after	   illumination	  using	  the	  AlamarBlue®	  assay.	  	  
5.1	  Spectral	  Analysis	  (AlamarBlue®)	  Analysis	   of	   cytotoxicity	   was	   also	   performed	   by	   fluorescence	   analysis	   of	  aspirated	   AlamarBlue®	   following	   a	   4-­‐hour	   incubation	   period	   with	   a	   mean	  calculated	   from	   12	   (n=3)	   100	   μL	   samples.	   PDT	   resulted	   in	   a	   21%	   increase	   in	  mean	   signal	   intensity	   compared	   to	   control	   (p<0.001),	  whereas	   treatment	  with	  SAP	  alone	  was	  associated	  with	  <10%	  increase	  in	  mean	  signal	  intensity	  (fig.	  5.2).	  	  	  Spectral	   analysis	   of	   the	   four	   experimental	   groups	   (Control,	   PDT,	   Saporin,	   PCI)	  investigated	   in	   this	   study	   was	   performed.	   Fluorescence	   intensity	   was	  normalized	   to	   enable	   a	   more	   representative	   comparison	   (fig.	   5.2).	   The	   peak	  emission	   remained	  consistent	  across	   the	   three	   treatment	  groups,	   compared	   to	  control.	   However,	   tumoroids	   treated	  with	   TPPS2a	   alone	   +	   light	   (180	   seconds)	  produced	   the	   greatest	   fluorescence	   intensity	   (40%	   increase)	   compared	   to	  control	   group.	   In	   the	   PCI	   tumoroid	   group,	   however,	   an	   85%	   reduction	   in	   the	  fluorescence	  signal	  was	  observed.	  The	   fluorescence	   intensity	  was	  proportional	  to	   the	   amount	   of	   resorufin	   produced	   via	   the	   reduction	   of	   the	   nonfluorescent	  resazurin,	  which	  is	  freely	  taken	  up	  and	  reduced	  by	  active	  cells.	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Figure	  5.1	  –	  Tumoroid	  preparation.	  	  
A	  –	  Compressed	  collagen	  scaffold	  containing	  4T1	  cells	  (5	  x	  105	  ml-­‐1),	  B	  –	  x4	  equal	  pieces	  of	  tumoroid	  cut	   from	  initial	  piece	  (A),	  C	  –	  tumoroids	   in	  media	  following	  insertion	  into	  acellular	   collagen	  hydrogel	   for	   anchorage.	  Tumoroids	  were	   subsequently	   grown	   for	  7	  days	  (media	  changed	  every	  48	  hours)	  prior	  to	  experimentation.	  	  	  	  
	  
	  
Figure	  5.2	  –	  4T1	  Tumoroids	  AlamarBlue®	  emission	  spectra.	  	  4T1	  cells	  were	  seeded	  into	  collagen	  constructs	  at	  5	  x	  105	  ml-­‐1	  and	  grown	  for	  7	  days	  at	  37°C	  prior	  to	  24h	  incubation	  with	  either	  TPPS2a	  (PDT,	  0.8	  μg	  ml-­‐1),	  SAP	  (60	  nM)	  or	  both	  (PCI).	   Cells	   were	   incubated	  with	   AlamarBlue®	   for	   4	   hours	   at	   37°C,	   7	   days	   after	   light	  exposure	  (180	  seconds).	  Peak	  emission	  at	  585	  nm.	  (n=3)	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5.2 Cytotoxicity	  Assay	  (AlamarBlue®)	  Analysis	   of	   cytotoxicity	   was	   also	   performed	   by	   fluorescence	   analysis	   of	  aspirated	   AlamarBlue®	   following	   a	   4-­‐hour	   incubation	   period	   with	   a	   mean	  calculated	   from	   12	   (n=3)	   100	   μL	   samples.	   PDT	   resulted	   in	   a	   21%	   increase	   in	  mean	   signal	   intensity	   compared	   to	   control	   (p<0.001),	  whereas	   treatment	  with	  SAP	  alone	  was	  associated	  with	  <10%	  increase	  in	  mean	  signal	  intensity	  (fig.	  5.3).	  Treatment	  with	  TPPS2a	  +	  SAP	  (PCI)	  caused	  a	  69%	  reduction	  in	  signal	  intensity,	  which	  corresponds	  to	  90%	  and	  77%	  reduction	  compared	  to	  PDT	  or	  SAP	  alone,	  respectively	  (p<0.001)	  (fig	  5.3	  and	  5.4).	  	  	  
	  
Figure	  5.3.	  4T1	  Tumoroids	  TPPS2a	  +	  SAP	  Photochemical	  Internalisation.	  	  4T1	  cells	  were	  seeded	  into	  collagen	  constructs	  at	  5	  x	  105	  ml-­‐1	  and	  grown	  for	  7	  days	  @	  37°C	  prior	  to	  24h	  incubation	  with	  either	  TPPS2a	  (PDT,	  0.8μg	  ml-­‐1),	  SAP	  (60	  nM)	  or	  both	  (PCI).	   Cells	   were	   incubated	  with	   AlamarBlue®	   for	   4	   hours	   at	   37°C,	   7	   days	   after	   light	  exposure	  (180	  seconds).	  Ex.	  570	  nm,	  Em.	  610	  nm.	  *69%	  cytotoxicity	  (p<0.001).	  n=3	  
5.3	  Histological	  Analysis	  Planned	  histological	   studies	   on	   the	   samples	   that	  had	  been	   fixed	  with	   formalin	  and	   stored	   unfortunately	   had	   to	   be	   curtailed	   as	   the	   samples	  were	  mistakenly	  destroyed	   within	   the	   multi-­‐user	   laboratory.	   Therefore,	   it	   was	   not	   possible	   to	  perform	  H&E	  staining	  to	  visually	  assess	  cytotoxicity.	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DISCUSSION	  This	  chapter	  focused	  on	  the	  development	  of	  a	  novel	  3-­‐D	  cancer	  model	  from	  4T1	  murine	  breast	  cancer	  cells,	  grown	  in	  a	  dense	  artificial	  tumour	  mass,	  surrounded	  by	   a	   non-­‐dense	   hydrogel	   in	   the	   guise	   of	   previously	   published	   data(50).	   The	  compression	  model	   utilised	  in	  this	  study	  appears	  to	  be	  a	  suitable	  method	  for	  3D	  tumour	   development	   with	   4T1	   cells	   in	   support	   of	   evidence	   in	   the	   literature	  about	   the	  versatility	  of	   this	   technique(160).	  Within	   the	  artificial	   tumour	  mass,	  the	  formation	  of	  spheroids	  could	  be	  seen	  at	  day	  7	  on	  light	  microscopy,	  with	  the	  greatest	  rate	  and	  density	  of	  growth	  at	  the	  margins	  of	  the	  mass.	  This	  may	  indicate	  more	   favourable	  growth	  conditions	  at	   the	  periphery	  and	  supports	   the	   findings	  in	  the	  literature	  where	  oxygen	  measurements	  found	  the	  centre	  of	  the	  mass	  to	  be	  hypoxic(50).	  	  	  These	  cytotoxicity	  results	  support	  the	  in	  vitro	  findings	  of	  the	  main	  PCI	  chapter,	  where	   cells	   treated	  with	   a	   combination	  of	   SAP	  and	  TPPS2a	   exhibited	   a	   greater	  level	  of	  cytotoxicity	  compared	  to	  control	  or	  either	  agent	  alone.	  This	  novel	  piece	  of	   work	   not	   only	   supports	   the	   need	   for	   further	   studies	   into	   the	   3-­‐D	   tumour	  masses	   as	   a	   platform	   for	   evaluating	   cancer	   growth	   and	   therapeutics,	   but	  supports	  the	  findings	  of	  in	  vivo	  studies	  where	  PCI	  has	  been	  shown	  to	  be	  effective	  in	   delaying	   tumour	   growth	   and	   progression(43,	   44).	   Such	   work	   using	   3-­‐D	  compressed	  collagen	  tumour	  scaffolds	   for	  PCI	  experimentation	  has	  never	  been	  investigated.	   The	   level	   of	   cell	   death	   achieved	   is	   particularly	   interesting,	  especially	  in	  the	  context	  of	  what	  appears	  to	  be	  a	  growth	  response	  to	  SAP	  or	  PDT	  alone.	  Given	  the	  cytotoxicity	  assay	  was	  performed	  7	  days	  after	  activation	  of	  the	   	  photosensitiser	  with	   light,	   the	  results	  shown	   in	   figure	  5.3	  may	  actually	  show	  a	  picture	  of	  tumour	  regrowth	  in	  all	  treatment	  groups.	  Thus,	  it	  may	  be	  possible	  that	  PCI	  in	  fact	  delayed	  regrowth	  and	  this	  has	  been	  postulated	  following	  the	  findings	  of	   previous	   in	   vivo	   data	   where	   the	   PCI	   was	   used	   to	   enhance	   the	   deliver	   of	  bleomycin	   into	   implanted	   HT1080	   tumour	   mass(44).	   Nevertheless,	   the	  regrowth	   phenomenon,	   beyond	   control,	   has	   been	   reported(25)	   and	   may	  represent	   the	   activation	   of	   survival	   and	   proliferative	   second	   messenger	  pathways	   in	   response	   to	   a	   sub-­‐lethal	   therapeutic	   ‘insult’.	   Such	   a	   response	  highlights	  the	  importance	  of	  maximizing	  drug	  delivery,	  particularly	  at	  relatively	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low	   doses	   of	   drugs	   with	   narrow	   therapeutic	   indices	   in	   order	   to	   avoid	   such	   a	  phenomenon.	  	  	  
	  
Figure	  5.4	  –	  Visualisation	  of	  AlamarBlue®	  assay.	  	  Cells	  were	  incubated	  with	  AlamarBlue®	  for	  4	  hours	  at	  37°C,	  7	  days	  after	  light	  exposure	  (180	  seconds).	  Cont	  =	  Control,	  TP	  0.8	  =	  TPPS2a	  (0.8	  µg/ml)	  +	  light	  (PDT	  group),	  SAP	  60	  =	  Saporin	  60	  nM,	  T/S	  =	  TPPS2a	  (0.8	  µg/ml)	  +	  SAP	  60	  nM	  +	  light	  (PCI	  group).	  Live	  cells	  reduce	  AlamarBlue®	   causing	  a	   shift	   in	   fluorescence	   from	  Blue	   to	   red/pink.	  Therefore,	  the	  blue	  in	  the	  T/S	  well	  indicates	  reduced	  live	  cell	  density/number.	  	  Despite	   the	   promising	   results	   from	   the	   AlamarBlue®	   assay,	   the	   lack	   of	  histological	  data	  does	  limit	  the	  impact	  of	  the	  data	  presented	  in	  this	  study.	  Figure	  5.5	   shows	   an	   example	   of	   what	   can	   be	   observed	   following	   H&E	   staining	   of	  colorectal	  cancer	  tumoroids(50).	  	  	  The	  clarity	  of	  the	  images	  obtained	  indicates	  that	  this	  might	  be	  a	  suitable	  initial	  stain	   to	   visually	   assess	   the	   impact	   of	   PCI	   treatment	   on	   tumoroid	   density	   and	  distribution	  compared	   to	  control,	  PDT	  and	  SAP	  alone.	  There	   is	  no	  dispute	   that	  further	   work	   is	   required,	   in	   particular	   the	   development	   of	   an	   active	   tumour	  stroma	   as	   this	  would	   enable	   further	   investigation	   of	   the	   impact	   of	   PCI	   on	   the	  stroma	  including	  anti-­‐tumour	  immunomodulation	  and	  angiogenesis(26).	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Figure	  5.5	  –	  Morphology	  of	  HT29	  colorectal	  cancer	  cells	  (2,000,000	  cells	  ml−1)	  in	  an	  
ACM	  situated	  within	  an	  uncompressed	  acellular	  collagen	  gel	  (H&E	  staining).	  	  Day	   1	   showing	   an	   equal	   distribution	   of	   cells	   within	   the	   ACM;	   (ii)	   day	   7	   showing	  accumulation	   of	   cells	   at	   the	   edge	   of	   the	   ACM	   (blue	   arrows);	   (iii)	   day	   14	   showing	  formation	  of	  cell	  spheroids	  (green	  arrows)	  and	  migration	  into	  the	  surrounding	  matrix	  (black	  arrows);	   (iv)	  day	  21	  showing	  escape	  of	   the	  cell	  spheroids	   into	   the	  surrounding	  matrix	  (black	  arrow).	  Scale	  bar	  400	  μm.	  Image	  and	  legend	  from	  Nyga	  et	  al.	  (2013)(50)	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SCIENTIFIC	  BACKGROUND	  	  The	  activation	  of	  photosensitisers	  following	  absorption	  of	  light	  energy	  has	  been	  described	   in	   chapter	   3	   and	  will	   only	   be	   briefly	   described	   here	   for	   the	   sake	   of	  clarity.	   Photodynamic	   therapy	   (PDT)	    utilises	   the	   unique	   properties	   of	  photosensitive	   compounds,	   which	   upon	   excitation	   with	   light	   of	   specific	  wavelengths	   in	   the	   presence	   of	   molecular	   oxygen	   results	   in	   the	   formation	   of	  reactive	  oxygen	  species.	  These	  free	  radicals,	  including	  singlet	  oxygen,	  are	  highly	  reactive	  and	  can	   trigger	  apoptosis	   following	   reactions	  with	   cellular	  organelles,	  leading	   to	   cell	   death.	   The	   photosensitisers	   tend	   to	   possess	   a	   similar	   basic	  structure	   comprising	   a	   heterocyclic	   ring	   comparable	   to	   chlorophyll	   and	  haem(161).	  Clinically,	   PDT	   has	   been	   utilised	   in	   the	   treatment	   of	   various	   conditions	  including:	    localised	   dermatological	   lesions	   (including	   tumours).	   The	  premalignant	   lesion	   actinic	   keratosis	   was	   the	   first	   approved	   dermatological	  condition	   for	   which	   PDT	   was	   indicated.	   The	   use	   of	   the	   endogenous	   photosensitiser	   protoporphyrin	   IX	   (PpIX)	   via	   administration	   of	   exogenous	   5-­‐aminolaevulinic	  acid	  (ALA)(162)	  resulted	  in	  beneficial	  effects	  seen	  at	  long-­‐term	  follow-­‐up	  with	  projected	  disease	  free	  rates	  of	  71%(163,	  164).	  PDT	  is	  currently	  one	   of	   the	   recommended	   therapeutic	   options	   (National	   Institute	   of	   Clinical	  Excellence,	   NICE)	   for	   the	   premalignant	   condition,	   Barrett’s	   oesophagus;	   for	  patients	   with	   high-­‐grade	   dysplasia(165).	   It	   is	   also	   used	   for	   the	   treatment	   of	  ophthalmological	  conditions	  (including	  proliferative	  retinopathy).	  	  	  	  Photochemical	    internalisation	   is	   an	   evolution	   of	   PDT	   that	   makes	   use	   of	   the	   localised	  toxicity	  of	  PDT	  to	  facilitate	  the	  delivery	  of	  macromolecules	  into	  cellular	  organelles.	  The	  potential	  applications	  of	  PCI	  include	  gene	  delivery	  and	  cytotoxic	  drug	  delivery;	  the	  latter	  has	  been	  demonstrated	  to	  help	  reverse	  the	  multidrug-­‐resistant	  phenotype	  in	  cancer	  cells	  in	  vitro/in	  vivo(26).	  	  A	  specific	  drawback	  of	  PDT/PCI	  is	  the	  limited	  level	  of	  tissue	  penetrance	  of	  light	  that	  can	  be	  achieved(2).	  Strategies	  that	  have	  been	  tested	  to	  reduce	  the	  limiting	  effect	   of	   this	   includes	   the	   use	   of	   fibre-­‐optic	   light	   sources	   and	   the	   use	   of	   red	  emitting	  photosensitisers	   as	   light	   >	  600	  nm	  wavelength	   enables	  deeper	   tissue	  penetration(36).	   However,	   at	   present,	   deep	   lying	   tumours	   and	   distant	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metastases	  lie	  outside	  of	  the	  therapeutic	  range	  of	  both	  PCI	  and	  PDT.	   	  Although	  strategies	   aimed	   at	   circumventing	   the	   problems	   with	   tissue	   penetrance	   have	  been	  developed,	  such	  as	  fibre	  optic	  light	  sources(2),	  technical	  limitations	  to	  their	  use	   still	   apply.	   Therefore,	   the	   challenge	   is	   to	    optimise	   the	   cytotoxic	   profile	   of	  PDT	  and	  PCI	  for	  both	  topical	  and	  deep	  lying	  tumours	  and	  distant	  metastases.	  	  
6.1	  Bioluminescence	  Firefly	  Luciferase	  (Fluc)	  is	  a	  61	  KD	  monomeric	  enzyme	  that	  catalyses	  the	  above	  reaction	  using	  D-­‐Luciferin	  as	  a	  substrate(166).	  Although	  Fluc	  is	  the	  leading	  bioluminescent	  system	   utilised	  in	  scientific	  investigations,	  particularly	  animal	  imaging	  studies,	  others	  do	  exist	  including:	  	  
• Luciferase	  produced	  by	  the	  click	  beetle	  (Pyrophorus	  plagiophthalamus)	  –	  catalyses	  D-­‐Luciferin	  emits	  green-­‐orange	  @	  540	  nm	  and	  red	  @	  611	  nm(167)	  
• Gaussia	  luciferase	  from	  the	  marine	  copepod	  and	  Renilla	  luciferase	  from	  sea	  pansy	  –	  catalyse	  coelenterazine	  to	  emit	  blue	  light	  (480	  nm)(51).	  Bioluminescent	   systems,	   particularly	   those	   based	   on	   Fluc	   have	   a	   variety	   of	  applications	   that	   have	   been	   developed	   in	   recent	   years.	   The	   use	   of	   Fluc	   as	  molecular	  probes	  has	  been	  exploited	  to	  aid	  the	    detection	  of	  toxins	  and	  bacteria	  found	   in	   the	   natural	   environment(168,	   169).	   Fluc	   has	   also	   been	   used	   for	  bioluminescence	   resonance	   energy-­‐transfer	   (BRET)	   to	   assay	   a	   range	   of	  biomolecular	   interactions	   including	   red-­‐fluorescent	   protein	   to	   monitor	  glutathione	  S-­‐tranferase(170).	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Figure	  6.1	  –	  Illustration	  of	  Bioluminescence	  Resonance	  Energy-­‐transfer.	  	  
1.	  Renilla	  luciferase.	  2.	  Green	  fluorescent	  protein	  (GFP),	  3.	  DeepBlueC	  (coelenterazine-­‐like	  luciferin),	  4.	  BRET	  process.	  In	  A.	  the	  donor	  and	  acceptor	  are	  too	  far	  apart	  for	  BRET	  to	   occur	   efficiently,	   therefore	   there	   is	   no	   activation	   of	   GFP.	   However,	   in	  B.	   the	   close	  proximity	   enables	   efficient	   energy	   transfer	   and	   subsequent	   activation	   of	   GFP.	   Image	  from	  Packard	  Bioscience	  (BioSignal	  Packard	  Inc.	  (171)	  	  	  BRET	  is	  a	  naturally	  occurring	  phenomenon(172),	  which	  has	  been	  developed	  into	  a	   biochemical	   tool	   that	   is	   based	   on	   efficient	   resonant	   energy	   transfer	   (RET)	  between	   a	   bioluminescent	   (luciferase)	   donor	   molecule	   and	   a	   fluorescent	  acceptor	  molecule	   such	   as	   green	   fluorescent	   protein	   (GFP)	   (fig.	   6.1).	   RET	   is	   a	  form	  of	  radiationless	  energy	  transfer	  from	  a	  donor	  to	  acceptor(173).	  Important	  factors	   to	  consider	  when	  aiming	  to	  enhance	  the	  efficiency	  of	  BRET	  are	  to	    limit	  the	  distance	  between	  the	  donor	  and	  acceptor	  molecule(61-­‐63)	  and	  aim	  for	  good	  donor	  emission	  and	  acceptor	  absorption	  spectral	  overlap.	  Of	  particular	  relevance	  to	  cancer	  biology,	  Fluc	  has	  been	  used	  to	  monitor	  in	  vivo	  growth(174)	   and	   metastasis(175)	   of	   tumours.	   It	   is	   the	   availability	   of	   such	  technology	  that	  led	  to	  the	  choice	  of	  the	  4T1	  (Luc1)	  breast	  cancer	  cell	  line	  for	  the	  majority	   of	   studies	   in	   this	   thesis	   as	   it	   could	   potentially	   be	   used	   to	   monitor	  tumour	  growth	  and	  treatment	  response	  in	  bioluminescent	  in	  vivo	  models.	  	  	  The	  aim	  of	  the	  studies	  in	  this	  chapter	  was	  to	  challenge	  the	  null	  hypothesis	  that	  bioluminescence	   cannot	   sufficiently	   activate	   a	   p hotosensitiser	   to	  mediate	   PDT	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or	  PCI	   in	  4T1	  (Fluc)	  and	  MCF7	  (Gluc)	  breast	  cancer	  cells.	  The	  work	  using	  Gluc	  expressing	  cells	  for	  PDT	  is	  novel.	  	  	  Initial	   work	   was	   performed	   using	   the	   Gluc	   expressing	   MCF7	   cells.	   However,	  given	   the	   blue-­‐shifted	   emission	   of	   these	   transduced	   cells	   along	   with	   the	  difficulties	  associated	  with	  using	   the	  unstable	   compound	  coelenterazine	   in	   the	  lab,	  the	  more	  suitable	  4T1	  cells	  with	  a	  stable	  Fluc	  transduction	  were	  purchased	  and	  used.	  	  	  
6.2	  Photosensitisers	  The	   chosen	   photosensitisers	   for	   bioluminescent	   studies	   in	   the	   genetically	  modified	  cell	  lines	  will	  be	  described	  below.	  
6.3	  Hypericin	  Hypericin	  is	  an	  anthraquinone,	  which	  is	    synthesised	  by	  the	  hypericum	  genus	  of	  plants(176)	  and	  is	  believed	  to	  be	  one	  of	  the	  most	  powerful	  naturally	  occurring	  photosensitisers(25).	   Agostinis	   et	   al.	   (2002)(177)	   described	   hypericin	   as	  exhibiting	   fundamental	   characteristics	   that	   are	   beneficial	   to	   its	   use	   as	   a	   photosensitiser,	   specifically	   i)	   high	   singlet	   oxygen	   yield	   following	  photoactivation,	  ii)	  intense	  fluorescence	  and	  iii)	  minimal	  dark	  cytotoxicity.	  It	   is	  important	   to	   note	   that	   it	   is	   reported	   in	   the	   literature	   that	   hypericin	   can	   also	  induce	  other	  ROS	  production	  such	  as	  superoxide(178),	  albeit	  at	  lesser	  amounts.	  Hypericin	   has	   been	   shown	   to	   be	   an	   efficacious	    photosensitiser	  when	   used	   for	  PDT	  on	  a	  range	  of	  cell	  types	  including	  fibroblasts(179),	  keratinocytes(180)	  and	  malignant	   human	   breast	   (MCF7)	   and	   bladder	   (MGHU1)	   cancer	   cells(25).	   The	  photodynamic	   efficacy	   of	   Hypericin	   was	   first	   observed	   in	   sheep	   and	   cattle	  grazing	   on	   the	   Hypericum	   species,	   which	   resulted	   in	   cutaneous	    lesi ons(180,	  181).	   Furthermore,	   it	   has	   been	   reported	   that	  much	   like	   sulfonated	   aluminium	  phthalocyanine,	  hypericin	  appears	  to	  exhibit	  lipophilic	  properties	  that	  enable	  it	  to	  become	  incorporated	  into	  cellular	  lipid	  membrane	  structures(177)	  and,	  more	  specifically,	  by	  liposomes(180).	  This	  property	  was	  exploited	  by	  Adigbli	  et	  al.(25)	  who	   demonstrated	   that	   hypericin	   can	   be	   used	   for	   PCI	   in	   breast	   and	   bladder	  cancer	   cells.	   Finally,	   hypericin	   has	   multiple	   absorption	   peaks	   at	   wavelengths	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including	  ~475	  nm,	  ~540	  nm	  and	  ~590	  nm(182),	  which	  is	  a	  good	  overlap	  with	  the	  Fluc	  emission	  to	  be	  used	  in	  this	  study.	  	  
6.4	  Tetrabromorhodamine-­‐123	  Tetrabromorhodamine-­‐123	  (TBR)	  is	  a	  halogenated	  form	  of	  the	  mitochondrial	  probe	  (dye)	  rhodamine-­‐123(130).	  Substitution	  of	  hydrogen	  with	  bromine	  results	  in	  the	  formation	  of	  a	   photosensitiser	  that	  is	  more	  likely	  to	  induce	  efficient	  formation	  of	  singlet	  oxygen(183),	  in	  terms	  of	  the	  light	  energy	  absorbed	  (also	  known	  as	  the	  ‘quantum	  yield’).	  The	  efficiency	  is	  enhanced	  by	  intersystem	  crossing,	  a	  process	  whereby	  there	  is	  non-­‐radiative	  transition	  between	  the	  excited	  singlet	  state	  and	  excited	  triplet	  state.	  Intersystem	  crossing	  is	  more	  rapid	  in	  the	  presence	  of	  a	  heavy	  atom	  such	  as	  iodine	  or	  bromine,	  thereby	  increasing	  the	  efficiency	  of	  triplet	  state	  formation(184).	  The	  efficiency	  of	  generating	  singlet	  oxygen	  and	  other	  ROS	  (such	  as	  superoxide)	  is	  in	  turn	  increased	  with	  efficient	  generation	  of	  the	  triplet	  state.	  This	  consequently	  significantly	  increases	  the	  phototoxicity	  of	  TBR	  compared	  to	  rhodamine-­‐123,	  rendering	  the	  latter	  a	  less	  suitable	  option	  for	  PDT.	  Tetrabromorhodamine	  123	  can	  be	  used	  to	  generate	  singlet	  oxygen	  (1O2)	  in	  mitochondrial	  membranes.	  The	  dye	  has	  a	  quantum	  yield	  for	  singlet	  oxygen	  generation	  of	  0.65-­‐0.7	  and	  is	  particularly	  toxic	  to	  carcinoma	  cells.	  Ex\em(MeOH)	  =	  524/550	  nm,	  ɛ	  (MeOH)	  =	  91,000(185).	  
RESULTS	  
6.5	  Flow	  cytometry	  for	  MCF7	  Luciferase	  transduction	  Following	   fluorescence-­‐activated	   cell	   sorting	   (FACS)	   of	   the	   three	   different	   cell	  samples:	   wild	   type	   MCF7,	   MCF7-­‐Fluc	   and	   MCF7-­‐Gluc,	   flow	   cytometry	   was	  performed	  in	  order	  to	  determine	  the	  transduction	  efficiency.	  The	  control	  (MCF7,	  wild-­‐type),	   were	   appropriately	   negative	   for	   Fluc	   or	   Gluc	   expression	   (fig.	   6.2).	  Those	  cells	  that	  underwent	  Fluc	  transduction	  were	  shown	  to	  be	  91%	  expressive	  for	  the	  tagged	  CD34	  biomarker	  (fig.	  6.3).	  	  The	  Gluc	  cells	  were	  found	  to	  be	  were	  found	  to	  have	  a	  transduction	  efficiency	  of	  85%.	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Unfortunately,	  due	  to	  problems	  encountered	  with	  the	  growth	  of	  the	  MCF7-­‐Fluc	  cells	  following	  transduction	  and	  FACS	  it	  was	  decided	  to	  abandon	  this	  cell	  line	  for	  further	  experimentation.	  	  	  	  
	  
Figure	  6.2	  –	  Flow	  cytometry	  of	  wild	  type	  MCF7	  (breast	  cancer)	  cells.	  	  Over	  98%	  of	   cells	  were	   identified	   as	  wild	   type.	   This	  was	  determined	  by	  positive	   bio-­‐detection	  of	  neurotensin	  with	  no	  detection	  of	  CD34	  (Fluc)	  or	  a-­‐myc-­‐FITC	  (Gluc).	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Figure	  6.4	  –	  Flow	  cytometry	  of	  wild	  type	  MCF7-­‐Gluc	  (Gaussia	  luciferase)	  cells.	  	  85%	   of	   cells	   were	   positive	   for	   the	   a-­‐myc-­‐FITC	   biomarker	   indicating	   successful	   Gluc	  transduction.	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6.6	  MCF7-­‐Gaussia	  Luciferase	  emission	  spectra	  and	  kinetics	  Following	   assessment	   of	   the	   transduction	   efficiency,	   spectral	   analysis	   was	  performed	   for	   the	   Gaussia	   luciferase.	   The	   analysis	   was	   commenced	   using	  coelenterazine	   as	   a	   substrate	   for	  Gluc.	   Two	  peaks	  were	   observed	   at	  ~460	  nm	  and	   ~490	   nm,	   which	   may	   indicate	   two	   distinct	   cell	   populations	   (fig.	   6.5).	  Analysis	  of	  the	  emission	  kinetics	  was	  also	  performed	  on	  the	  MCF-­‐Gluc	  cells.	  The	  graph	  shows	  that	  the	  intensity	  of	  the	  bioluminescent	  signal	  reduces	  by	  a	  factor	  of	  >8.5-­‐fold	  within	  the	  first	  180	  s	  (fig.	  6.6).	  	  
	  
Figure	  6.5	  –	  Gaussia	  Luciferase	  emission	  spectrum.	  	  The	   emission	   spectrum	   of	   Gaussia	   luciferase	   was	   assessed	   using	   MCF7-­‐GLuc	  (transduced	   breast	   cancer	   cell	   line).	   Spectra	   acquired	   following	   the	   addition	   of	  coelenterazine	   (25	   µg	  ml-­‐1).	   Two	   peaks:	   (1)	   at	   ~460	   nm,	   (2)	   at	   ~490	   nm	   (the	   graph	  plots	  a	  moving	  average).	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Figure	  6.6	  –	  MCF7-­‐Gluc	  emission	  kinetics.	  	  The	  emission	  kinetics	  of	  Gaussia	   luciferase	  expressing	  MCF7-­‐GLuc	   cells	  was	  assessed.	  Data	  acquired	  over	  900	  s	  following	  the	  addition	  of	  coelenterazine	  (25	  µg	  ml-­‐1).	  	  
6.7	  MCF7	  Gaussia	  luciferase	  mediated	  Photodynamic	  Therapy	  Modified	  PDT	   experiments	  were	   carried	   out	   to	   assess	   the	   level	   of	   cytotoxicity	  that	   could	   be	   elicited	   using	   the	   bioluminescent	   model.	   Cytotoxicity	   was	  calculated	   using	   the	   MTT	   assay,	   4	   hours	   after	   treatment	   with	   coelenterazine	  (light).	  	  	  
	  
Figure	  6.7	  –	  Experimental	  timeline	  for	  Gluc-­‐Hypericin	  bioluminescent	  PDT	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Two	   back-­‐to-­‐back	   15-­‐minute	   incubation	   periods	   were	   used	   to	   treat	   the	   cells	  with	  coelenterazine	  (fig.	  6.7).	  This	  was	  chosen	  following	  pilot	  experiments	  and	  based	  on	  the	  emission	  kinetics	  of	  the	  MCF7-­‐Gluc	  (fig.	  6.6).	  	  	  
	  
Figure	  6.8	  –	  MCF7	  wild	  type	  vs.	  MCF7-­‐Gluc	  –	  mediated	  PDT.	  	  Both	   cell	   lines	   were	   treated	   with	   either	   hypericin	   (‘dark’	   control,	   5µM)	   or	  coelenterazine	   (25µg/ml)	   alone	   or	   in	   combination	   (PDT).	   Combination	   of	   HYP/Coel.	  Achieved	  <2%	  cell	  kill	  (MCF7)	  compared	  to	  27%	  (MCF7-­‐Gluc,	  p<0.05).	  	  Both	   cell	   lines	   had	   no	  measurable	   cytotoxicity	   in	   response	   to	   treatment	   with	  HYP	  (4h,	  5	  µM)	  alone	  without	   light.	  There	  was	  no	  significant	  difference	   in	  cell	  kill	   following	   exposure	   to	   coelenterazine	   (2	   x	   900	   s,	   25	   µg/ml)	   with	   both	  exhibiting	   <10%	   cytotoxicity.	   The	   combination	   of	  HYP	   +	   coelenterazine	   (PDT-­‐group)	  did	  however	  result	  in	  significant	  cell	  kill	  within	  the	  Gluc	  group,	  with	  27%	  and	   25%	   increased	   cytotoxicity	   compared	   to	   MCF7-­‐Gluc	   (control)	   and	   MCF7	  respectively	  (p<0.05).	  The	  greatest	  level	  of	  cytotoxicity	  observed	  for	  MCF7-­‐Gluc	  (PDT-­‐group)	   compared	   to	   HYP	   or	   coelenterazine	   alone	   was	   not	   statistically	  significant,	   albeit	   achieving	   23%	   and	   18%	   increased	   cell	   kill	   respectively	   (fig.	  6.8).	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Despite	   repeated	   attempts	   to	    optimise	   the	   coelenterazine-­‐Gluc	   system,	   due	   to	  the	   pressures	   of	   time	   and	   the	   difficulty	   in	    limiting	   the	   oxidation	   of	  coelenterazine	  during	  experimentation	   the	  decision	  was	  made	   to	  abandon	  this	  line	   of	   investigations	   and	   search	   for	   an	   alternative	   Fluc-­‐based	   cell	  model	   that	  would	  enable	  the	  use	  of	  the	  more	  stable	  D-­‐luciferin.	  To	  this	  end,	  it	  was	  decided	  to	  purchase	  a	   stable	  Fluc	   expressing	  murine	  breast	   cancer	   cell	   line	   (4T1-­‐luc2)	  from	  Caliper	  Lifesciences.	  	  
6.8	  4T1-­‐Firefly	  Luciferase	  emission	  spectrum	  This	  was	  performed	  to	  confirm	  the	  emission	  for	  the	  4T1	  cell	  line.	  Peak	  emission	  was	  at	  ~549	  nm	  (fig.	  6.9).	  In	  order	  to	  enhance	  the	  potential	  of	  the	  4T1	  model	  a	  second	    photosensitiser,	   tetrabromorhodamine-­‐123	  (peak	  excitation	  ~514	  nm),	  was	  also	  tested	  for	  bioluminescence-­‐induced	  PDT.	  	  
	  
Figure	  6.9	  –	  4T1-­‐Firefly	  Luciferase	  emission	  spectrum.	  	  The	   emission	   spectrum	  of	   Firfly	   luciferase	   expressing	  4T1	   (stably	   transfected	  murine	  breast	   cancer	   cell	   line)	   was	   assessed.	   Spectra	   acquired	   following	   the	   addition	   of	  addition	  of	  D-­‐luciferin	  (20	  µM).	  Peak	  at	  ~549	  nm	  (the	  graph	  plots	  a	  moving	  average).	  
6.9	  Tetrabromorhodamine-­‐123	  mediated	  bioluminescent	  PDT	  in	  4T1	  cells	  PDT	  experiments	  were	  carried	  out	  using	  a	  similar	  protocol	  to	  that	  employed	  for	  Gluc-­‐coelenterazine	   protocol	   described	   above	   (fig.	   6.10).	   The	  main	   differences	  included	  the	  use	  of	  D-­‐luciferin	  and	  TBR	   in	   lieu	  of	  coelenterazine	  and	  hypericin	  respectively.	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Figure	  6.10	  –	  Experimental	  timeline	  for	  4T1-­‐TBR	  bioluminescent	  PDT.	  
	  A	   set	   of	   studies	   looking	   into	   the	   effect	   of	   increasing	   the	   concentration	   of	   TBR	  (1.0,	  3.0	  and	  5.0,	  µM)	  demonstrated	  a	  dose	  dependent	  rise	  in	  cytotoxicity	  when	  the	  concentration	  of	  D-­‐luciferin	   (D-­‐Luc)	  was	  kept	   constant	   (20	  µM)	   (fig.	  6.11).	  These	  were	  performed	  both	  in	  the	  absence	  of	  (‘dark’	  control)	  and	  the	  presence	  of	   D-­‐luciferin.	   At	   1	   µM	   TBR	   the	   addition	   of	   D-­‐Luc	   resulted	   in	   <10%	   increase	  (p>0.05)	  in	  cytotoxicity	  compared	  to	  TBR	  1	  µM	  alone.	  However,	   in	  comparison	  to	   control	   this	   represents	   14%	   cytotoxicity	   (p<0.01).	   At	   3	   µM	   TBR	   the	  cytotoxicity	  within	  the	  D-­‐Luc	  group	  increased	  to	  39%	  (p<0.01),	  which	  correlates	  to	  a	  22%	  increase	  compared	  to	  TBR	  3	  µM	  alone.	  Finally,	  at	  5µM	  TBR	  cytotoxicity	  further	  increased	  to	  69%	  (p<0.01)	  compare	  to	  control.	  This	  translates	  to	  a	  34%	  increase	   (p<0.01)	   in	   cytotoxicity	   compared	   to	  TBR	  5	  µM	  alone.	  D-­‐luciferin	   (20	  µM)	   alone	   exerted	   a	   cytotoxic	   effect	   of	   7%	   (p<0.05)	   compared	   to	   control.	   The	  importance	  of	  this	   is	   that	   it	   indicates	  that	  cytotoxicity	  seen	  at	  TBR	  3	  µM	  and	  5	  µM	  in	  the	  D-­‐Luc	  group	  is	  not	  due	  to	  D-­‐luciferin	  toxicity	  alone.	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Figure	  6.11	  –	  4T1-­‐TBR	  bioluminescence	  PDT	  dose	  response.	  	  Cells	   were	   treated	   with	   increasing	   concentrations	   of	   TBR	   for	   90	   minutes	   prior	   to	  addition	  of	  D-­‐luciferin	  (2	  x	  900	  s,	  20	  µM).	  Cell	  viability	  quantified	  using	  MTT	  assay	  2hrs	  after	  cells	  exposed	  to	  D-­‐Luciferin.	  At	  5	  µM	  TBR	  +	  20	  µM	  D-­‐luciferin	  cytotoxicity	  =	  69%	  (p<0.01).	  Background	  D-­‐luciferin	  toxicity	  =	  7%	  (p<0.05).	  
6.10	  Role	  of	  Reactive	  Oxygen	  Species	  in	  TBR-­‐mediated	  bioluminescent	  PDT	  
	  
	  
Figure	   6.12	   –	   Experimental	   timeline	   for	   4T1-­‐TBR	   bioluminescent	   PDT	   +/-­‐	  
superoxide	  dismutase.	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Work	  discussed	  within	  the	  PCI	  chapter	  of	  this	  thesis	  considered	  the	  role	  of	  ROS	  in	   PDT	   and	   PCI,	   specifically	   investigating	   the	   role	   of	   the	   REDOX	   environment	  with	   regard	   free	   radical	   potentiation	   and	   quenching.	   In	   this	   section	   of	   the	  bioluminescence	   studies,	   the	   effect	   of	   ROS	   quenching	   on	   the	   cytotoxicity	   of	  potential	  bioluminescent	  PDT	  will	  be	  assessed	  as	  a	  means	  for	  proof	  of	  principal	  (fig.	  6.12).	  	  	  The	   chosen	   antioxidant/reducing	   enzyme,	   superoxide	   dismutase	   (SOD),	   has	  previously	   been	   discussed	   in	   the	   PCI	   chapter.	   When	   SOD	   treated	   cells	  underwent	  bioluminescent	  PDT	  using	  TBR	  0.5	  µM	  +	  Luc	  25	  µM	  a	  12%	  (p<0.01)	  reduction	   in	   cytotoxicity	   was	   observed	   compared	   to	   TBR	   +	   Luc	   (PDT)	   alone,	  which	   equated	   to	   a	   2.2-­‐fold	   reduction	   (fig.	   6.13,	   p<0.01).	   This	   protection	  resulted	  in	  a	  level	  of	  cell	  kill	  that	  statistically	  was	  no	  different	  from	  control,	  TBR	  0.5	  µM	  or	  Luc	  25	  µM	  alone.	  	  
	  
Figure	  6.13	  –	  4T1	  low	  dose	  TBR	  bioluminescent	  PDT	  +/-­‐	  superoxide	  dismutase.	  Cells	   were	   treated	   with	   variable	   drug	   combinations	   to	   assess	   the	   efficiency	   of	   SOD-­‐mediated	  reduction	  of	   the	  bioluminescent	  PDT	  effect.	  Cells	   in	  the	  SOD	  or	  TBR	  +	  Luc	  +	  SOD	   (T/L/SOD)	   groups	  were	   treated	  with	   SOD	   for	   24h	   prior	   to	   addition	   of	   TBR	   and	  during	  the	  2h	  post-­‐Luc	  incubation	  time	  prior	  to	  MTT.	  2.2-­‐fold	  reduction	  was	  observed	  for	  T/L/SOD	  compared	  to	  T/L.	  *	  =	  p<0.01	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6.11	  Hypericin-­‐mediated	  bioluminescent	  PDT	  in	  4T1	  cells	  An	   identical	  protocol	   to	   the	  HYP	  study	  with	   the	  MCF7-­‐GLuc	  cells	  was	  used	   for	  the	   4T1	   cells.	   Figure	   6.14	   illustrates	   that	   upon	   combining	   HYP	   +	   Luc,	   27%	   of	  cells	  were	  killed	  (p<0.01)	  compared	  to	  control.	  Adjusted	  for	  background	  levels	  of	  toxicity	  exerted	  by	  D-­‐luciferin	  (5%,	  p>0.05),	  this	  represented	  a	  4-­‐fold	  increase	  in	  cytotoxicity.	  HYP	  alone	  (‘dark’	   control)	  killed	  <10%	  of	  cells	   (p<0.01),	  whilst	  the	   addition	   of	  D-­‐luciferin	   resulted	   in	   a	   17%	   increase	   (p<0.01)	   in	   cytotoxicity	  (fig.	  6.14).	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DISCUSSION	  PDT	   is	   a	   relatively	  well-­‐developed	   technique	  with	   a	   reasonable	   evidence	   base	  both	   in	   the	   pre-­‐clinical	   and	   clinical	   arenas(2).	   The	  mechanisms	   that	   underpin	  light-­‐activation	  of	  photosensitisers,	  which	   in	   the	  presence	  of	  molecular	  oxygen	  results	  in	  the	  formation	  of	  ROS	  that	  can	  subsequently	  cause	  oxidative	  damage	  to	  cellular	   structures	   leading	   to	   repair,	   mutation	   or	   death	   of	   a	   cell.	   In	   the	   USA,	  Porfimer	   sodium	   (Photofrin®)	   is	   licensed	   for	   the	   treatment	   and	   to	   relieve	  symptoms	  of	  oesophageal	  and	  non-­‐small	  cell	   lung	  cancer(2);	   in	  addition	  to	  the	  treatment	   of	   the	   premalignant	   lesions	   in	   Barrett’s	   oesophagus(186).	   Three	   of	  the	  most	  well	  described	  limitations	  of	  PDT	  are:	  I. Low	   tissue	   penetrance,	   with	   red	   light	   only	   able	   to	   pass	   through	  approximately	  1	  cm	  of	   tissue,	  restricting	  the	  use	  of	  PDT	  to	   luminal	  organs	  and	  the	  skin(187).	  II. Limited	   efficacy	   for	   large	   tumours,	   again	   due	   to	   inability	   of	   light	   to	  penetrate	  deep	  into	  tissue(188-­‐190).	  III. No	  indication	  for	  non-­‐focal/metastatic	  disease	  spread(190).	  	  These	  limitations	  are	  partially	  negated	  with	  the	  development	  of	  tools	  to	  enhance	  accessibility	   to	   the	   tumour	  site,	   such	  as	   fibre	  optic	   light	   sources.	  However,	   the	  potential	  of	  generating	   light	   from	  either	  within	  on	  around	  the	  target	  cell	  could	  potentially	  go	  some	  way	  to	  circumventing	  these	  limitations.	  In	  this	  study,	  MCF7	  breast	   cancer	   cells	  were	   successfully	   transduced	  with	   two	   types	  of	   Luciferase.	  This	   initial	   step	  of	   any	  gene	   therapy	   is	   fundamental	   in	  order	   to	  determine	   the	  feasibility	   such	   therapeutic	   options.	   Many	   examples	   exist	   in	   the	   literature	  including	  transfection	  of	  the	  Herpes	  Simplex	  Virus	  thymidine	  kinase	  (HSVtk),	  a	  target	  for	  antiviral	  agents	  such	  as	  ganciclovir	  to	  trigger	  death	  of	  an	  infected	  host	  cell	   in	  vitro(191).	  Such	  a	   technology	  has	  also	  been	  combined	  with	  neurotensin	  targeted	  nanoparticles	  carrying	  the	  HSVtk	  and	  ganciclovir	  for	  the	  transfection	  of	  HSVtk	   into	   adenocarcinoma	   xenografts	   grown	   in	   athymic	   mice	   where	   HSVtk	  expression	   plus	   ganciclovir	   treatment	   resulted	   55-­‐60%	   reduced	   tumour	  growth(192).	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The	  main	   difficulty	   faced	   during	   the	   planning	   phase	   for	   these	   bioluminescent	  studies	  was	   to	   find	   a	   suitable	   photosensitiser	   that	   had	   an	   absorption	   peak	   to	  match	   the	   emission	   of	   the	   transduced	   cells.	   Hypericin	   was	   chosen	   due	   to	   its	  appropriate	  absorption/emission	  overlap	  and	  evidence	  of	  its	  suitability	  for	  PDT	  in	   MCF7	   cells	   in	   previously	   published	   work(25).	   The	   failure	   of	   MCF7-­‐GLuc	   –	  coelenterazine	  model	   to	   achieve	   cytotoxicity	   that	  was	   significantly	   superior	   to	  coelenterazine	   or	   HYP	   (fig.	   6.8)	   could	   in	   part	   be	   due	   to	   the	   preparation	   of	  coelenterazine,	   which	   was	   dissolved	   in	   100%	   ethanol	   prior	   to	   dilution.	  Furthermore,	   given	   that	   GLuc	   is	   secreted	   by	   the	   cells	   into	   the	   surrounding	  media(193),	   whereas	   hypericin	   has	   been	   shown	   to	   accumulate	   within	  intracellular	   organelles	   including	   the	   endoplasmic	   reticulum	   and	   Golgi	  apparatus(194);	   this	  may	  result	   in	   inefficient	  photosensitiser	  activation,	  owing	  to	   too	   great	   a	   distance	   between	   luciferase	   and	   photosensitiser	   for	   efficient	  BRET(61-­‐63).	  To	  overcome	  this	  it	  might	  be	  advisable	  to	  repeat	  the	  experiment	  with	   hypericin	   present	   in	   the	   media,	   thus	   increasing	   the	   likelihood	   of	  photoactivation.	  	  	  The	   4T1-­‐luc2	   cell	   line	   afforded	   a	   more	   robust	   and	   reproducible	   model	   for	  bioluminescence-­‐activated	  PDT.	  The	  stable	  transfection	  in	  this	  cell	   line	  showed	  that	   this	   study	   is	   a	   step	   forward	   from	   previous	   bioluminescent	   PDT	   studies	  performed	   when	   less	   stable	   transfection	   constructs	   were	   utilised(195).	   Given	  the	   4T1-­‐luc2	   cell	   line	  was	   harvested	   from	   a	  murine	  model	   also	   presented	   the	  opportunity	  for	  using	  bioluminescence	  as	  a	  means	  for	  non-­‐invasive	  monitoring	  of	   tumour	   growth	   and	   treatment	   response.	   The	   dose-­‐dependent	   rise	   in	   TBR-­‐mediated	   –	   Fluc	   bioluminescent	   PDT	   represents	   a	   very	   promising	   finding.	   In	  addition,	   the	   dose-­‐dependent	   rise	   in	   toxicity	   appears	   to	   be	   greater	   than	   the	  effect	   of	   a	   rise	   in	   TBR	   concentration	   alone.	   This	   is	   illustrated	   by	   a	   2.9-­‐fold	  increase	   in	   ‘dark’	   toxicity	   between	   1	   µM-­‐5	   µM,	  whereas	   a	   3.9-­‐fold	   increase	   is	  observed	  between	  the	  same	  dose-­‐range	  in	  the	  presence	  of	  D-­‐luciferin.	  This	  was	  supportive	  of	  photoactivation	  of	  TBR,	  resulting	  in	  a	  disproportionate	  rise	  in	  cell	  kill	  compared	  to	  TBR	  alone.	  Of	  particular	  importance	  is	  that	  this	  cytotoxic	  effect	  appeared	   to	   be	   independent	   of	   background	   D-­‐luciferin	   cytotoxicity.	   It	   is	  important	  to	  put	  this	  finding	  in	  comparison	  with	  other	  novel	  systems	  that	  aim	  to	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overcome	   the	   challenges	   faced	   by	   conventional	   PDT.	   One	   such	   example	   is	  fluorescence	  resonance	  energy	  transfer	  (FRET)	  where	  the	  initial	  fluorescence	  of	  one	   molecule	   (donor)	   is	   used	   to	   photoactivate	   another	   (acceptor),	   a	   similar	  model	   to	  the	  BRET	  system	  explained	   in	  the	  scientific	  background	  section.	  Li	  et	  al.	  (2012)	  demonstrated	  that	  quantum	  dots	  could	  act	  as	  donors	  to	  trigger	  singlet	  oxygen	   production	   from	   sensitised	   sulfonated	   aluminium	   phthalocyanines	   for	  PDT	  in	  cancer	  cells(196).	  	  	  The	  experiment	  looking	  at	  the	  ability	  of	  SOD	  to	  reduce	  the	  apparent	  phototoxic	  effect	   of	   bioluminescence	   activated	   PDT	   was	   performed	   in	   order	   to	   obtain	  evidence	  supportive	  of	  ROS	  production	  within	  this	  bioluminescence	  PDT	  model.	  Given	  that	  these	  experiments	  were	  performed	  at	  the	  very	  beginning	  of	  the	  PhD,	  the	   L-­‐histidine	   model	   for	   ROS-­‐quenching	   had	   not	   yet	   been	   developed.	   	   As	  described	   in	   chapter	  3,	   SOD	  plays	   an	   important	   role	   in	   scavenging	   superoxide	  radicals,	   thus	   the	   inhibitory	   effects	   observed	   for	   low-­‐dose	   TBR-­‐mediated	  bioluminescent	   PDT	   support	   the	   presence	   of	   ROS	   and	   consequently	   the	  photoactivation	  of	  TBR	  via	  the	  oxidation	  of	  D-­‐luciferin	  by	  FLuc	  expressed	  within	  the	   cytoplasm	   of	   4T1	   cells	   (fig.	   6.13).	   The	   cytoplasmic	   localisation	   of	   FLuc	   to	  organelles	   including	   peroxisomes(197)	   may	   explain	   the	   improved	   cytotoxic	  efficacy	  when	  used	  with	  hypericin	  (fig.	  6.14).	  	  	  Overall,	   it	   is	   not	   possible	   to	   conclude	   from	   this	   study	   that	   bioluminescence-­‐mediated	  PDT	  is	  an	  active	  solution	  to	  the	  problems	  faced	  with	  conventional	  PDT	  but	   it	   certainly	   provides	   an	   exciting	   and	   challenging	   avenue	   that	   could	  potentially	  prove	  extremely	  useful.	  However,	   there	  have	  been	  positive	   reports	  regarding	  the	  use	  of	  bioluminescence	  to	  mediate	  PDT	  in	  cancer,	  including	  in	  vivo	  melanoma(198).	  	  	  One	  of	   the	   first	  hurdles	   that	  must	  be	  overcome	   is	   that	  of	   efficient	   transfection	  that	  does	  not	   trigger	  an	   immune	  response	   in	   the	  host,	  which	  would	  otherwise	  render	   the	   vector	   and	   genetic	   material	   inactive.	   Furthermore,	   the	  bioluminescence	  signals	  must	  be	  enhanced	  to	  boost	  tissue	  penetrance,	  though	  at	  present	  further	  red-­‐shifted	  luciferases	  are	  being	  engineered,	  for	  example	  firefly	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7.1	  CHALLENGES	  OF	  CELLULAR	  DRUG	  DELIVERY	  Inefficient	  delivery	  of	  therapeutic	  molecules	  to	  their	  site	  of	  action	  is	  a	  significant	  limiting	  factor	  in	  the	  medical	  treatment	  of	  cancer(25).	  Conventional	  anticancer	  drugs	   mainly	   exert	   their	   cytotoxic	   effect	   by	   gaining	   access	   to	   the	   nucleus	   or	  mitotic	  machinery	  of	  a	  cell,	  for	  example,	  mitoxantrone	  (anti	  topoisomerase)	  and	  docetaxel	   (anti-­‐microtubule).	   In	   order	   to	   reach	   such	   a	   target	   many	   obstacles	  must	  be	  overcome	  including	  the	  bioavailability	  and	  systemic	  metabolism	  of	  the	  therapeutic	  molecule	  and	  at	  the	  cellular	  level,	  gaining	  access	  to	  the	  intracellular	  compartment.	  Highly	  lipophilic	  agents	  including	  steroids,	  which	  do	  form	  part	  of	  many	   anti-­‐cancer	   treatment	   regimens,	   have	   excellent	   cellular	   absorption	  kinetics,	  however,	  bulky	  hydrophilic	   agents	   such	  as	   saporin	   require	  assistance	  for	   delivery(104,	   108).	   One	   such	   way	   to	   overcome	   inefficient	   delivery	   is	   to	  increase	   the	   dosage	   of	   the	   drug	   being	   administered.	   However,	   such	   practices	  lead	  to	  narrow	  therapeutic	  indices	  for	  agents	  where	  the	  difference	  between	  the	  minimum	  therapeutic	  and	  toxic	  dose	  is	  small(26).	  	  	  	  
	  
Figure	  7.1	  –	  Therapeutic	  index	  of	  drugs.	  Graphical	   representation	   of	   the	   relationship	   between	   drug	   dose,	   	   efficay,	   toxicity	   and	  the	  therapeutic	  range	  (index)(201)	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The	   consequence	   of	   this	   includes	   reduced	   patient	   tolerance	   of	   treatment	  regimens	   and	   increased	   risk	   of	   developing	   multidrug	   resistance,	   which	   is	   a	  major	   impediment	   to	   cancer	   therapy(25).	   Therefore,	   strategies	   designed	   to	  enhance	  drug	  delivery	  have	  many	  potential	  benefits,	  not	  least	  of	  all	  the	  fact	  that	  technologies	   such	   as	   PCI	   and	   SMoCs	   often	   demonstrate	   reasonable	   versatility	  when	   it	  comes	   to	  agents	   they	  can	  potentiate	   the	  delivery	  of(23,	  25,	  26,	  47,	  48,	  69,	  104,	  125,	  138).	  	  In	  this	  thesis,	  some	  of	  the	  mechanisms	  that	  mediate	  and	  factors	  that	  affect	  PCI	  have	  been	  investigated	  in	  4T1	  cells.	  PCI	  benefits	  from	  the	  fact	  that	  it	  is	  targeted	  (by	   light)	   and	   is	   based	   on	   administering	   low	   doses	   of	   agents	   for	   additive	   or	  synergistic	   effect.	   Such	   factors	   play	   a	   vital	   role	   in	   helping	   to	   widen	   the	  therapeutic	   index	   of	   a	   given	   agent.	   The	   benefits	   to	   patients	   are	   not	   limited	   to	  enhanced	   therapeutic	   effect	   but	   potentially	   include	   better	   toxicity	   profiles	  (leading	  to	  better	  compliance	  with	  treatment	  plans)	  and	  reduced	  probability	  of	  developing	  MDR	  as	  PCI	  has	  been	  shown	  to	  reverse	  MDR	  in	  previous	  studies(25).	  	  	  PCI	   is	   currently	   undergoing	  multicenter	   clinical	   trials	   in	   the	  UK/Europe	   using	  bleomycin	   for	   the	   treatment	   of	   cutaneous	   head	   and	   neck	   cancer(46),	   and	  gemcitabine/cisplatin	   for	   the	   treatment	   of	   cholangiocarcinoma(202).	   Steps	  toward	   clinical	   application	   are	   vital	   for	   the	   continued	   growth	  of	   this	   sector	   of	  cancer	  therapeutics	  and	  support	  the	  potential	  of	  PCI	  to	  make	  the	  journey	  from	  bench	   towards	   the	   bedside	   application.	   The	   findings	   from	   the	   phase	   I	   safety	  trials	  were	  encouraging(46)	  and	  the	  phase	  II	  trials	  are	  underway.	  Concurrently,	  pre-­‐clinical	   data	   continues	   to	   be	   created	   to	   help	   further	   develop	   the	  understanding	  and	  efficiency	  of	  the	  technique.	  For	  example,	  combining	  PCI	  with	  nanoparticles	   to	  enhance	   the	   intracellular	   trafficking	  and	  release	  of	  anticancer	  compounds(203).	  In	  this	  thesis,	  the	  intracellular	  REDOX	  environment	  was	  found	  to	  play	  a	  very	   important	  role	   in	  modulating	   the	  PCI	  and	  PDT	  effect.	  Given	  that	  buthionine	  sulfoximine	   is	  already	  used	   to	   reverse	  drug	  resistance,	  manifest	  by	  enhanced	   resistance	   to	   oxidative	   damage,	   it	   is	   an	   interesting	   and	   potential	  adjunct	  to	  PCI	  going	  forward.	  Many	  cancer	  clinical	  trials	  looking	  into	  BSO	  as	  an	  adjunct	  to	  established	  therapeutics	  have	  taken	  place	  such	  as	  the	  Phase	  I	  Clinical	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and	   Pharmacokinetic	   Investigation	   of	   Intravenous	   Buthionine	  
Sulfoximine/Melphalan	   in	   Patients	   with	   Refractory	   Advanced	   Solid	   Tumors	  (National	  Cancer	  Institute,	  USA).	  	  	  Another	   area	   of	   potential	   development	   in	   the	   sphere	   of	   PCI/PDT	   is	   in	  bioluminescence.	  Although	  the	  findings	  in	  this	  thesis	  are	  very	  much	  preliminary,	  the	   development	   of	   more	   suitable	   luciferases	   and	   conjugation	   with	  nanoparticles	   such	   as	   quantum	   dots	   (QDs)	   for	   BRET(204).	   Such	   technologies	  benefit	  from	  eliminating	  the	  need	  for	  fluorescent	  excitation	  and	  utilizes	  the	  blue-­‐increasing	  extinction	  coefficient	  of	  QDs.	  Further	  more	  it	  enables	  the	  exploitation	  of	  tissue-­‐penetrating	  near-­‐infrared	  wavelengths	  for	  fluorescence	  emission(205).	  Combining	   such	   technologies	   with	   PCI	   may	   help	   overcome	   two	   of	   the	   main	  limitations	   of	   PCI,	   namely	   accessing	   deep/irregularly	   shaped	   tumours	   and	  distant	  metastases.	   The	   benefit	   of	   using	   QDs	   as	   ‘transformers’	   is	   that	   it	   helps	  bridge	   the	  discrepancy	   that	  often	  exists	  between	  blue-­‐emitting	   luciferases	  and	  absorption	  maxima	  for	  porphyrin	  based	  photosensitisers.	  	  
7.2	  CONCLUSION	  In	  conclusion	  the	  options	  for	  developing	  PCI	  are	  wide	  ranging,	  however,	  in	  order	  for	  this	  technology	  to	  have	  any	  lasting,	  therapeutic	  and	  cost	  –effective	  impact	  in	  the	  clinical	  arena	  it	  must	  be	  refined	  and	  this	  requires	  a	  better	  understanding	  of	  the	  mechanics	  of	  PCI.	  This	  thesis	  aimed	  to	  address	  part	  of	   this	  and	  the	  natural	  progression	  for	  further	  work	  would	  be	  to	  test	  the	  BSO-­‐PCI	  model	  further	  in	  both	  3D	  tumoroids	  and	   in	  vivo.	  For	  the	   latter	   in	  particular,	   the	  FLuc	  expressing	  4T1	  cell	   line	  could	  be	  used	   to	  enable	  bioluminescent	  monitoring	  of	   tumour	  growth	  and	  treatment	  response.	  	  	  	  	  	  	  	  






















	   189	  
	  
PUBLISHED	  PAPERS	  
1.	   Chem	  Biol	   Drug	  Des.	   2014	   Jul;84(1):24-­‐35.	   doi:	   10.1111/cbdd.12295.	   Epub	  2014	  May	  	  	  
A	   bifurcated	   proteoglycan	   binding	   small	   molecule	   carrier	   for	   siRNA	   delivery.	  
Gooding	   M(1),	   Adigbli	   D,	   Edith	   Chan	   AW,	   Melander	   RJ,	   MacRobert	   AJ,	  
Selwood	  DL.	  	  
Author	  information:	  	  (1)The	  Wolfson	   Institute	   for	  Biomedical	  Research,	  UCL,	  Gower	  Street,	   London,	  WC1E,	  6BT,	  UK.	  
	  





	   190	  
	  
2.	   Curr	   Opin	   Pharmacol.	   2012	   Aug;12(4):434-­‐8.	   doi:	  10.1016/j.coph.2012.04.005.	  Epub	  	  2012	  May	  17.	  	  
Photochemical	   internalisation:	   the	   journey	   from	   basic	   scientific	   concept	   to	   the	  
threshold	  of	  clinical	  application.	  Adigbli	  DK(1),	  MacRobert	  AJ.	  	  
Author	  information:	  	  (1)National	  Medical	   Laser	   Center,	   UCL	   Division	   of	   Surgery	   and	   Interventional	  Science,	  University	  College	  London,	  UK.	  d.adigbli@ucl.ac.uk	  	  









	   191	  
	  
	  
3.	  Br	  J	  Cancer.	  2007	  Aug	  20;97(4):502-­‐12.	  Epub	  2007	  Jul	  31.	  	  
Photochemical	  internalisation	  of	  chemotherapy	  potentiates	  killing	  of	  
multidrug-­‐resistant	  breast	  and	  bladder	  cancer	  cells.	  Adigbli	  DK(1),	  Wilson	  DG,	  
Farooqui	  N,	  Sousi	  E,	  Risley	  P,	  Taylor	  I,	  Macrobert	  AJ,	  Loizidou	  M.	  	  
Author	  information:	  	  (1)Department	   of	   Surgery,	   Royal	   Free	   and	   University	   College	   Medical	   School,	  UCL,	  London,	  UK.	  	  
Abstract:	  Multidrug	   resistance	   (MDR)	   is	   the	  major	   confounding	   factor	   in	   adjuvant	   solid	  tumour	   chemotherapy.	   Increasing	   intracellular	   amounts	   of	   chemotherapeutics	  to	  circumvent	  MDR	  may	  be	  achieved	  by	  a	  novel	  delivery	  method,	  photochemical	  internalisation	   (PCI).	   PCI	   consists	   of	   the	   co-­‐administration	   of	   drug	   and	  photosensitiser;	  upon	  light	  activation,	  the	  latter	  induces	  intracellular	  release	  of	  organelle-­‐bound	  drug.	  We	   investigated	  whether	  co-­‐administration	  of	  hypericin	  (photosensitiser)	  with	  mitoxantrone	  (MTZ,	  chemotherapeutic)	  plus	  illumination	  potentiates	   cytotoxicity	   in	   MDR	   cancer	   cells.	   We	   mapped	   the	   extent	   of	  intracellular	   co-­‐localisation	   of	   drug/photosensitiser.	   We	   determined	   whether	  PCI	   altered	   drug-­‐excreting	   efflux	   pump	   P-­‐glycoprotein	   (Pgp)	   expression	   or	  function	   in	   MDR	   cells.	   Bladder	   and	   breast	   cancer	   cells	   and	   their	   Pgp-­‐overexpressing	   MDR	   subclones	   (MGHU1,	   MGHU1/R,	   MCF-­‐7,	   MCF-­‐7/R)	   were	  given	   hypericin/MTZ	   combinations,	  with/without	   blue-­‐light	   illumination.	   Pilot	  experiments	   determined	   appropriate	   sublethal	   doses	   for	   each.	   Viability	   was	  determined	   by	   the	   3-­‐	   [4,5-­‐dimethylthiazolyl]-­‐2,5-­‐diphenyltetrazolium	   bromide	  assay.	   Intracellular	   localisation	   was	   mapped	   by	   confocal	   microscopy.	   Pgp	  expression	  was	  detected	  by	  immunofluorescence	  and	  Pgp	  function	  investigated	  by	   Rhodamine123	   efflux	   on	   confocal	   microscopy.	   MTZ	   alone	   (0.1-­‐0.2	   microg	  ml(-­‐1))	   killed	   up	   to	   89%	   of	   drug-­‐sensitive	   cells;	   MDR	   cells	   exhibited	   less	  cytotoxicity	   (6-­‐28%).	   Hypericin	   (0.1-­‐0.2	   microM)	   effects	   were	   similar	   for	   all	  cells;	   light	   illumination	   caused	   none	   or	  minimal	   toxicity.	   In	   combination,	  MTZ	  /hypericin	  plus	  illumination,	  potentiated	  MDR	  cell	  killing,	  vs.	  hypericin	  or	  MTZ	  alone.	   (MGHU1/R:	   38.65	   and	   36.63%	   increase,	   P<0.05;	   MCF-­‐7/R:	   80.2	   and	  46.1%	   increase,	   P<0.001).	   Illumination	   of	   combined	  MTZ/hypericin	   increased	  killing	   by	   28.15%	   (P<0.05	   MGHU1/R)	   compared	   to	   dark	   controls.	  Intracytoplasmic	  vesicular	  co-­‐localisation	  of	  MTZ/hypericin	  was	  evident	  before	  illumination	   and	   at	   serial	   times	   post-­‐illumination.	   MTZ	   was	   always	   found	   in	  sensitive	  cell	  nuclei,	  but	  not	  in	  dark	  resistant	  cell	  nuclei.	  In	  illuminated	  resistant	  cells	   there	   was	   some	   mobilisation	   of	   MTZ	   into	   the	   nucleus.	   Pgp	   expression	  remained	   unchanged,	   regardless	   of	   drug	   exposure.	   Pgp	   efflux	  was	   blocked	   by	  the	  Pgp	  inhibitor	  verapamil	  (positive	  control)	  but	  not	  impeded	  by	  hypericin.	  The	  increased	  killing	  of	  MDR	  cancer	  cells	  demonstrated	  is	  consistent	  with	  PCI.	  PCI	  is	  a	  promising	  technique	  for	  enhancing	  treatment	  efficacy.	  	  PMCID:	  PMC2360354	  PMID:	  17667930	  	  	  [PubMed	  -­‐	  indexed	  for	  MEDLINE]	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   Sir	   John	   Tooke	   to	   reward	   those	   making	   an	   outstanding	  commitment	  to	  students	  and	  their	  education.	  Nominated	  by	  the	  Director	  of	  the	  Division	  of	  Medicine	  (Professor	  Raymond	  MacAllister).	  	  
November	   2012	   –	   runner	   up	   at	   UCL	   Faculty	   of	   Medical	   Sciences	   Dean’s	  Research	   Prize	   presentation	   (top	   8	   research	   students	   in	   Faculty	   of	   Medical	  Sciences.	  Oral	  presentation	  title:	  Photochemical	  Internalisation	  as	  a	  mediator	  for	  enhanced	   drug	   delivery	   in	   cancer	   cells.	   Nominated	   by	   the	   Director	   of	   the	  Division	  of	  Surgery	  and	  Interventional	  Science	  (Professor	  Mark	  Emberton).	  	  
July	   2012	   -­‐	   Poster	   Prize	   at	   the	   Third	   NIHR	   BRC/BRU/CLAHRC	   Experimental	  Medicine	  Research	  Training	  Camp	  4-­‐6	   July	  2012.	  Participants	  were	  nominated	  by	  their	  biomedical	  research	  centre	  and	  invited	  to	  the	  conference.	  70	  delegates	  submitted	   abstracts	   with	   25	   picked	   for	   a	   poster	   presentation.	   Three	   poster	  prizes	  were	  given.	  	  
July	   2012	   –	   Runner	   up	   prize	   for	   oral	   presentation	   at	   the	   Third	   NIHR	  BRC/BRU/CLAHRC	   Experimental	   Medicine	   Research	   Training	   Camp	   4-­‐6	   July	  2012.	  	  
June	   2012	   –	   awarded	   the	   Urbach	   Prize	   at	   the	   36th	   meeting	   of	   the	   American	  Society	  for	  Photobiology	  (ASP),	  Montreal,	  Canada.	  	  
April	  2012	   –	  awarded	  Winners	  Prize	  at	   the	  UCL	  Grand	  Challenge	  Studentship	  ‘Thinking	  Den’	  event.	  All	  studentship	  holders	  (21)	  were	  invited	  to	  write	  a	  one-­‐page	  proposal	  explaining	  why	  their	  project	  should	  receive	  extra	  funding.	  The	  top	  6	  proposals	  were	  selected	  to	  give	  a	  5-­‐minute	  presentation	  to	  a	  panel	  comprising	  4	  Dean’s	  from	  the	  Faculty	  of	  Medical	  Sciences,	  UCL.	  Top	  prize	  was	  awarded	  £250	  to	  assist	  with	  conference	  fees.	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September	  2010	  –	  Successfully	  applied	  for	  a	  UCL	  Grand	  Challenges	  Studentship	  for	   a	   3	   year	   PhD.	   The	   award	   provides	   me	   with	   funding	   for	   tuition	   fees,	   and	  incremental	   stipend	   starting	   at	   £18000	  p.a.	   and	   bench	   fees	   of	   £5000	   p.a.	   This	  highly	   prestigious	   award	  was	   very	   competitive	   being	   open	  Europe	  wide	   there	  were	  well	  over	  200	  applicants	  for	  21	  awards.	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